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Abstract 
The utilisation of near-infrared Raman spectroscopy for the discrimination of cancers and 
pre-cancers from normal tissue in the acro-digestive tract has been evaluated. A 
commercially available Raman microspectrometer has been modified to provide optimum 
throughput, sensitivity and fluorescence suppression for epithelial tissue measurements. 
Laser excitation at 830nm was demonstrated to be optimum. High quality (SN ratio 15-20) 
NIR-Raman spectra have been acquired from oesophageal and laryngeal tissues in time 
scales under 30 seconds. 
Pathological groupings covering the full range of normal and neoplastic tissues in the organs 
of interest have been studied. Both fresh (snap frozen) and formalin fixed tissue samples 
were investigated, firstly to indicate whether tissue-types can be distinguished in vivo and 
secondly to demonstrate the use of Raman spectroscopy as a tool for classification in the 
pathology lab. 
Results using multivariate statistical techniques to distinguish between spectra from 
specimens exhibiting different tissue pathologies have been extremely promising. Cross- 
validation of the spectral predictive models has shown that three groups of larynx tissue 
can be separated with sensitivities and specificities of between 86 and 90% and 87 and 
95% respectively. Oesophageal prediction models have demonstrated sensitivities and 
specificities of 84 to 97% and 93 to 98% respectively for a three-group consensus model 
and 73 to 100% and 92 to 100% for an eight-group consensus model. 
Epithelial tissues including stomach, tonsil, endometrium, bladder and prostate have been 
studied to identify further tissues where Raman spectroscopy may be employed for detection 
of disease. Spectra were similar to those obtained from oesophagus and larynx, although 
sufficiently different for distinct discriminant models to be required. This work has 
demonstrated the generic nature of Raman spectroscopy for the detection and classification 
of cancers and pre-cancerous lesions in many tissues. The evidence provided by this study 
indicates that utilisation of Raman spectroscopy for non-invasive detection and classification 
of disease is a distinct possibility. Potential difficulties in the transferability from in vitro to 
in vivo have been evaluated and no significant barriers have been observed. However, 
further in vivo probe development and optimisation will be required before 'optical biopsy' 
with Raman spectroscopy can become a reality. 
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1. Introduction 
1.1 Background 
The incidence of all forms of cancer is much greater than many people realise. There 
were over 219,000 new cases of cancer reported in England and Wales in 1993 alone. 1 
Moreover as many as one in three people in the UK will be struck down by the disease in 
their lifetime. Malignancy is more commonly found in older members of the community; 
with only six percent of all cancers in males and nine percent in females occurring in 
those aged under 45 years. The peak age group for presenting with cancer is between 70 
and 74 years for both males and females. ' Furthermore, with the mean age of the 
population increasing the number of cases is likely to rise markedly. Table 1.1 displays 
the survival rates for the four most common cancers in England and Wales for cases first 
diagnosed between 1991 and 1993. 
Cancer Number of natients One-vear survival M) Five-vear survival M 
Men Lung 60,300 19.8 5.0 
Prostate 41,877 79.3 48.9 
Colon 22,164 64.0 41.6 
Rectum 16,807 68.7 39.2 
Women Breast 83,912 91.8 73.7 
Lung 29,052 
1 
19.8 5.0 
Colon 24,239 60.9 40.2 
Rectum 12,281 69.4 42.5 
Table 1.1: Cancer survival rates for the four most common cancers in men and women, at one and 
five years for patients diagnosed during 1991-1993 and followed up to 31 December 19W 
The primary requirement for successful treatment of any malignancy is early detection. 
Although the pathogenesis of most malignancies is not fully understood, some cancers 
are known to develop through a pre-malignant state. Current methods of detecting early 
malignancies rely upon surveillance of at risk populations or diagnostic investigations 
following presentation with suspicious symptoms. By the time symptoms are present 
tumours are usually of a significant size, and it is often too late to facilitate a full cure. 
Over the last century there have been myriad of technological breakthroughs leading to 
improvements in medical diagnosis and therapy. These include the use of X-rays, 
magnetic resonance imaging (MRI), computer assisted tomography (CT), ultrasound, 
radio-isotope imaging, and endoscopy for diagnosis; and radiotherapy, chemotherapy, 
laser surgery and photodynamic therapy (PDT) for treatment. Most diagnostic techniques 
measure the changes in architecture and morphology of tissue that follow initiation of the 
disease process. Nuclear Medicine and selected areas of MRI are able to provide some 
functionality. However with Nuclear Medicine resolution is of the order of cms and MRI 
the order of mms. Therefore it is apparent that using current medical technology, the 
detection of malignant change at a cellular level (where a successful treatment is most 
likely) will rely upon the removal of tissue samples to enable microscopic 
histopathological analysis. 
The 'gold standard' for detection of malignancies and pre-malignancies is excisional 
biopsy followed by histopathological analysis. This technique relies upon sectioning 
tissue less than one cell thick (<10 microns) and staining with haernatoxylin and eosin (H 
& E). This provides some functional information in addition to the morphology of the 
tissue that can be viewed under a conventional light microscope. The principle of 
histology has changed little since its conception in the 19th century. 3 
In the analysis of pre-cancerous lesions there are often high levels of discrepancy 
between pathologists, due to the subjective nature of histological analysis. The variation 
in histopathological grading poses a significant problem in the classification of many pre- 
malignant abnormalities. Melville et al (1989)4 compared the grading of dysplasia in 
ulcerative colitis by five pathologists. Overall agreement between any two pathologists 
ranged from 42% to 65%. Discrepancies in the diagnosis increased with the severity of 
the dysplasia. Jensen et al (1995)5 showed similar discrepancies with the grading of 
severity of dysplasia in 194 slides of colorectal adenomas by 3 experienced pathologists. 
Reid et al (1988)6 showed that there is a substantial observer variation in the diagnosis of 
dysplasia in Barrett's oesophagus due to the subjective nature of histopathological 
analysis. The study involved the comparison of 71 sections from the oesophagus 
classified into one of 5 groups: negative for dysplasia, indefinite for dysplasia, low grade 
dysplasia, high grade dysplasia, and intra-mucosal carcinoma. The resulting agreement in 
classification by 8 gastrointestinal pathologists was between 58% and 61% over all 
groups. Blackwell et al (1995) showed agreement, in classification of laryngeal dysplasia, 
of only 54% between 2 pathologists studying a group of 148 laryngeal biopsies. 7 
A further problem associated with the gold standard involves the targeting of biopsy 
samples from microscopic abnormal lesions. It is often the case with many pre-cancerous 
lesions that they will be too small to be detected by endoscopy alone. Therefore a random 
tissue selection procedure is usually employed. This can lead to a highprobablitiy of 
missing abnormal tissue by random biopsy. Van Sandick et al (1998) followed 16 
patients undergoing surveillance for Barrett's oesophagus, a condition whereby the risk 
of developing oesophageal adenocarcinoma is increased many-fold. The patients 
underwent regular surveillance endoscopy over a number of years up until surgical 
resection was required, due to the development of high-grade dysplasia (essentially a 
localised cancerous lesion) or adenocarcinoma. Biopsies were obtained from all four 
quadrants of the oesophagus, every 2cm along the visible length of the Barrett's mucosa. 
Each biopsy was sectioned at three different levels and stained with haernatoxylin and 
eosin. The histological findings, shown in Figure 1.1, indicate either the sampling 
procedure is missing areas of abnormality, from one endoscopic procedure to the next, or 
dysplastic lesions are regressing and then reoccurring. The latter is thought to be unlikely. 
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Figure LI: duration and frequency of endoscopic surveillance with accompanying histological 
findings in 16 patients undergoing surveillance of Barrett's oesophagus. Black dots represent 
endoscopic examinations at which no biopsy specimens were obtained. Modified and reproduced 
courtesy of van Sandick et a] (1998). 8 
Biochemical changes within tissue may either initiate disease or occur as the result of the 
disease process. The qualitative analysis of such changes provides important clues in the 
search for a specific diagnosis and the quantitative analysis of biochemical abnormalities is 
important in measuring the extent of the disease process, designing therapy and evaluating 
the efficacy of treatment. The conventional method for detection of malignancy using 
histopathological examination of biopsy samples relies upon the subjective assessment of 
tissue architecture, which is likely to demonstrate abnormal changes at a later stage than 
would analysis of biochemistry. Furthermore, histopathological analysis requires tissue to be 
removed with possibly undesirable consequences. Evidently, the development of a rapid, 
non-invasive, qualitative histochernical analysis technique, enabling objective biochemical 
analysis of tissue, would be of great value. This may be possible with a variety of optical 
techniques. 
Over the past few years a number of groups have been working towards real-time, non- 
invasive techniques that utilise light to study abnormalities in tissue. 9 Recent 
technological developments have made it possible to obtain significant amounts of 
biochemical or architectural data from extremely complex biological tissue in very short 
time scales (milliseconds to seconds). Optical diagnosis relies upon measurement of the 
interaction of light photons with the constituents of biological tissue. The resultant data 
can provide an evaluation of histochernistry or morphology. This information can aid 
with the deduction of the pathological state of the tissue, and hence lead to a diagnosis. 
Light can interact with tissue in a number of ways, including elastic and inelastic 
scattering; reflection off boundary layers; and absorption, leading to fluorescence and 
phosphorescence. All of these can be utilised in some way to measure abnormal changes 
in tissue. Many authors have used the term 'Optical Biopsy' when describing these 
techniques. Optical biopsy is a misnomer because no tissue is removed in the analysis, 
however it does help to convey to the lay person the general principle of using light to 
detect cancerous transformations in tissue. 
Initial optical biopsy systems, utilising tissue fluorescence, have been used as an adjunct 
to current investigative techniques, mainly to improve targeting of blind biopsy. 10,11,12,13 
Future prospects utilising molecular-specific techniques may enable complete 
replacement of biopsy with objective optical detection providing a real-time, highly 
sensitive and specific measurement of the tissue histological state. However until its 
efficacy is proven it is most likely that optical detection will be used as a complimentary 
technique to improve targeting of biopsy selection. 
The clinical requirements for an objective, non-invasive real time probe for the accurate 
and repeatable measurement of tissue pathological state are overwhelming. There is a 
clinical need for optical diagnosis in a number of important areas: 
1. Situations where sampling errors severely restrict the effectiveness of excisional 
biopsy, such as the high failure rates associated with blind biopsies, whereby the 
clinician has to randomly select sites for sample collection. This method is used to 
screen for pre-malignant conditions such as ulcerative colitis and Barrett's 
oesophagus. 
2. Where conventional excisional biopsy is potentially hazardous, examples of 
vulnerable regions include the central nervous system, vascular system and articular 
cartilage. 
3. An immediate diagnosis during an investigative procedure would eliminate the need 
for many secondary procedures by enabling treatment to take place directly following 
diagnosis. This is especially useful with the development of treatments utilising light 
energy, such as photo-dynamic therapy and laser ablation. This is likely to improve 
patient outcomes and decrease waiting times by reducing the number of costly 
procedures required. 
4. Tumour margins could be identified during surgical resection, thus enabling a more 
accurately targeted resection to be performed. 
5. A surgeon with any doubt over a diagnosis could cross-validate a previous diagnosis 
prior to excision of an organ or lesion using a non-invasive optical probe. 
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The objective of the present research is to evaluate the potential for Raman spectroscopy, 
a highly specific optical analysis technique, to achieve the capability of in vivo detection 
of early malignant changes. Initial work has been carried out to optimise a Raman 
microspectrometer for tissue measurements; to target potential malignancies with a 
clinical need for diagnostic improvements; and to build and test spectral libraries and 
prediction algorithms for the various tissue types and pathologies. The extent of this 
thesis does not extend to cover in vivo measurements. However, the discussions outline 
the likely work required for successful implementation of an in vivo Raman probe for 
early detection of malignancy. 
1.2 Raman Spectroscopy 
Recently it has been suggested that Raman spectroscopy has the potential to identify 
markers associated with malignant change. 14,15,16 This may lead to its use as a diagnostic 
tool for the study of the evolution of pre-cancerous and cancerous lesions in vivo. The direct 
detection of biochemical tissue constituents via vibrational spectroscopy may provide a new 
methodology for non-invasive detection of disease, together with new information for 
classifying, grading and evaluating the progression of malignant neoplasms. 
Raman spectroscopy is the analysis of inelastic scattered photons following monochromatic 
laser excitation. It provides information about both the chemical and morphological 
structure of tissue in near real time 17 and can be used as a non-invasive optical method of 
tissue characterisation. Most biological molecules are Raman active with their own 
characteristic spectral fingerprint. Proteins, nucleic acids, cell membranes, single cells and 
tissues can all be studied. The Raman spectrum is a plot of scattered intensity, as a function 
of energy difference between the incident and scattered photons. The loss (or gain) in photon 
energies corresponds to the difference in the final and initial vibrational energy levels of 
molecules participating in the interaction. The observed peaks (bands) in the Raman 
spectrum are relatively narrow, easy to resolve and sensitive to molecular structure, 
conformation and environment. 
Generally biological tissues are inhomogeneous in composition and highly scattering; the 
full analysis of Raman signals thus requires an understanding of tissue optical parameters 
and photon propagation in turbid media. Raman signals are inherently weak and, in addition, 
early diagnosis of disease requires detection of tissue molecular constituents present in low 
concentrations. This is accentuated by the fact that lasers with high intensity cannot be used 
to observe weak signals from tissues because of the potential for sample damage. Thirdly, 
the complex nature of tissue composition results in absorption of light throughout the entire 
uv-visible region, and subsequent intense fluorescence emission strongly interferes with 
weak Raman signals. 
Fluorescence is one of the primary obstacles encountered in the Raman spectroscopy of 
biological tissue. A fairly recent development has been the use of near infrared (NIR) 
laser excitation and dispersive spectrometers to allow rapid detection of spectra with low 
background fluorescence. NIR radiation generally does not induce electronic absorption 
in tissue chromophores, consequently fluorescence is weak relative to the Raman signal. 
Holographic notch filters are used to filter the elastic (Rayleigh) scattered light from the 
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signal. 18 In combination with a single monochromator the throughput of the system is 
increased compared with the triple monochromators commonly used previously. The 
development of charge coupled device (CCD) detectors and solid state semiconductor 
lasers has enabled the development of portable NIR Raman systems that produce spectra 
with high signal to noise in short integration times. 16 Compatibility with fibre optics and 
the development of new probes is making in vivo diagnostics with Raman spectroscopy a 
real possibility. 
Raman spectroscopy has shown a great deal of potential for biomedical diagnosis of 
malignancy in localised sites. Techniques using ultraviolet, visible and near-infrared 
wavelengths of light have shown repeatable differences between Raman spectra from 
normal and malignant tissue. 19,14,20 There appears to be little Raman work published on the 
upper aero-digestive tract. 21 This region includes the naso-pharynx, larynx and oesophagus; 
where an increasing number of invasive adenocarcinomas are being found, often at a stage 
where the chance of successful treatment is unlikely. Raman spectroscopy has the potential 
to detect pre-malignant lesions, such as dysplasia in Barrett's oesophagus and squarnous 
dysplasia in the larynx. Use of Raman spectroscopy in vivo would potentially enhance 
targeting of the biopsy forceps to sites of abnormality, and thus would improve the 
probability of detection of abnormalities over the random biopsy currently employed for 
detection of pre-malignancies. A substantial amount of research is required to evaluate the 
sensitivity and specificity of this technique for diagnosis and to correlate specific Raman 
spectral features with histopathological data. 
1.3 Biology of Specific Malignancies 
The following sub-sections outline the current understanding of the pathogenesis of two 
particular cancers of the aero-digestive tract that have been studied in this work. The 
cancers have been selected for this study because they develop into invasive malignancies 
via a pre-malignant step. It must be noted that not all patients with pre-malignant 
abnormalities will go on to develop invasive cancers, but the probability that this will 
occur can be increased by more than 100-fold. 22,23 
1.3.1 Adenocarcinoma of the Oesophagus 
The oesophagus is a muscular, flexible tube that transports food and liquid from the 
laryngopharynx. (throat) to the stomach. It lies posterior to the trachea and is about 25cm 
long. It is made up of a number of different layers of cells, in common with other parts of 
the gastrointestinal tract, mucosa, sub-mucosa, muscularis and the serosa. See Figure 1.2. 
The inner surface, or mucosa, of a normal oesophagus is lined with stratified squamous 
epithelial cells, which form a smooth surface to aid the passage of food boluses and 
protect against wear-and-tear. The oesophagus secretes mucus and transports food to the 
stomach by the action or peristalsis. It does not produce digestive enzymes or carry out 
absorption of nutrients. At the lower end of the oesophagus there is a narrowing of the 
lumen or sphincter, which controls the entrance to the stomach. If the sphincter fails to 
close after the food has entered the stomach, the stomach contents can enter the distal 
(lower) portion of the oesophagus. This is called gastro-oesophageal reflux. Hydrochloric 
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acid and bile acid from the stomach can irritate the oesophageal mucosa and cause a 
burning sensation. 
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Figure 1.2: composite of various sections of the gastrointestinal tract seen in a three-dimensional 
drawing depicting the various layers and related structures. Reproduced from Tortora and 
Grabowski (1996). 24 
Long periods of exposure to these irritants in gastro-oesophageal reflux can lead to a 
change in the cells lining the oesophagus, whereby the squamous epithelium lining the 
distal oesophagus is replaced by columnar epithelium . 
25 This is called Barrett's 
oesophagus and is a metaplastic condition in which the cells are essentially normal but 
they do not belong in that location. Prospective studies have shown the prevalence of 
columnar lined oesophagus in patients exhibiting reflux was between II and 12%. 26.27 
Morphologically the columnar epithelium of Barrett's Oesophagus can resemble the 
mucosa of the gastric fundus, cardia, antrum, or intestine. Parietal cells are present in the 
gastric fundic-type epithelium 28 and these have been found to produce acid in the 
oesophagus . 
29 This epithelium also has chief cells which contain and secrete pepsinogens. 
The columnar-lined mucosa is more likely to be resistant to the effects of reflux than 
squamous-lined mucosa. 
Barrett's oesophagus is associated with an increased risk of oesophageal 
adenocarcinoma. 30,31,32,33,34 In recent prospective studies, Robertson et a149 reported an 
incidence of 1786 cases of Barrett's associated carcinoma per 100,000 population per 
year and Hameeteman et a, 35 reported 1920 cases per 100,000 per year. The estimated 
risk of adenocarcinoma. in Barrett's oesophagus has been shown to be between 30 and 
350 times greater than that found in the average population, depending on the figures 
7 
Esophagus Stomach Small intestine Large intestine 
35,22,23 
used. Adenocarcinomas occumng in Barrett's oesophagus make up between 54 and 
68% of all oesophageal cancers 36,37 and the rate of incidence is rising more rapidly than 
for any other cancer. 38.39 These carcinomas typically occur in older (mean age 57 years), 40 
male (male: female ratio = 5.5: 1), 40 white patients . 
32,41 
Dysplasia is the most frequently used marker of increased cancer risk in Barrett's 
oesophagus. It is an abnormal change in the maturation and development that can occur 
in all three types of Barrett's epithelia. However, it is more commonly seen in areas of 
intestinal metaplasia (IM) and it is unlikely that oesophageal adenocarcinoma occurs 
except in patients With IM. 42,43.44 Follow-up studies in patients with Barrett's oesophagus 
have shown that only patients with dysplasia progress to adenocarcinoma. 45 A number of 
studies have shown over 50% of patients operated on for high grade dysplasia will be 
found to have invasive carcinoma. 44,46,47 Circumstantial evidence suggests that dysplasia 
may not only be a marker for carcinoma, but may in itself be the early carcinomatous 
change that can progress to invasive carcinoma. 33 All grades of dysplasia appear to have 
the potential to give rise to invasive carcinoma and epithelial changes need not go 
through a recognisable carcinoma in situ phase before being associated with invasion. 33 
Although the circumstantial evidence for the dysplasia to carcinoma sequence is strong, 
the progression of dysplasia to carcinoma is still unproven and the time course 
48 unknown. Therefore, the potential benefits of removing an oesophagus exhibiting 
dysplasia must be weighed against the relatively high mortality associated with 
oesophagectomy (5 to 15%)33 and the poor outcome in patients who present with invasive 
adenocarcinorna of the oesophagus (23% survival at I year and 7% survival at 5 years in 
the England and Wales between 1986 and 1990). 2 
Robertson et al recommended that patients with Barrett's oesophagus be screened by 
endoscopy and biopsy to detect and monitor the presence and progress of dysplasia . 
41 It 
has therefore become common practice to place patients with Barrett's oesophagus in a 
cancer surveillance programme. The goal of surveillance is either prevention of 
carcinoma or the detection of carcinoma in an early and potentially curable phase. The 
current regime used for surveillance endoscopy in most UK hospitals involves the 
selection of biopsy samples from all 4 quadrants every 2cm along the entire Barrett's 
epithelium. Since the mortality and morbidity of oesophagectomy is high confirmation of 
a diagnosis of high-grade dysplasia is usually required before moving on to resect the 
organ. (A negative result is viewed with caution and initial samples are usually re- 
examined. Since dysplasia is considered neoplastic, it is unlikely to ever resolve 
spontaneously. Therefore, once true dysplasia has been identified all follow up negatives 
are likely to be the result of sampling error. 48 ) Dysplasia is relatively rare in patients with 
Barrett's oesophagus but data suggest that when biopsy specimens are positive for high- 
grade dysplasia, there is a high probability that infiltrating carcinoma will already be 
present. 30,51 
Histopathology is currently the gold standard for diagnosis of dysplastic changes in the 
oesophagus. However it can be limited by the subjective nature of biopsy interpretation 
and targetting, 6 especially in the grading of dysplasia, which has no set limits to 
progression (i. e. follows a continuum). Most patients with Barrett's oesophagus will not 
develop dysplasia or adenocarcinoma. 45,52 Reliable methods for identifying those patients 
with Barrett's oesophagus who will progress to carcinoma do not exist at present. 
Therefore, techniques that enable a greater understanding of the biological processes 
leading to carcinogenesis will be extremely valuable. 
1.3.2 Squamous Cell Carcinoma of the Larynx 
The larynx is the organ used for speech. It is the passage-way that links the 
laryngopharynx with the trachea. The wall of the larynx is made up of nine pieces of 
cartilage that influence the positions and tensions of the vocal folds (Figure 1.3). The 
epiglottis is a large piece of elastic cartilage covered with epithelium that acts as a trap 
door preventing swallowed foods and liquids from entering the trachea. The larynx rises 
during swallowing allowing the free edge of the epiglottis to close a lid over the glottis. 
The glottis is made up of a pair of folds of mucous membrane - these are the true vocal 
cords - and the space between them, the rima glottidis. The paired arytenoid cartilages 
attach to the vocal folds and intrinsic pharyngeal muscles. Contracting these muscles 
stretches the vocal cords out into the airway so that the rima glottidis is narrowed. If air is 
directed at the vocal folds they are forced to vibrate and set up sound waves in the 
column of air in the pharynx, nose and mouth. The pitch of the sound produced is 
controlled by adjusting the tension on the vocal cords. 
Epiglotfis 
ýTongue 
PoStenor Hyothyroid 1-4)aMent 
TnWW Cartilage 
HycMyroid Membrane 
Thyroid Cartilage. Superior Comu 
Comiculate Cartilage 
Thyroarytenoid (Vocal) Uganwyt 
Thyroid Cartilage, Angle 
Arytenoid Cartilage, Apex 
Aryterxicl Cartilage, Vocal Process 
Arytencid Cartilage, Muscular Process 
Cricoid Cartilage, Lama 
Posterior Cdcoarytenoid Muscle 
) Hyosd Bons 
ic Fold 
C-Uage 
Thyroid Cartlage 
-VesWxAar Fold (Faise Vocal Fold) 
-Vocal Fold 
Conus Elasticus 
CarbLage. Arch 
tarod Muscle 
ThyToid Carfilage, Inferior Comu 
Trachea 
Figure 1.3: Larynx (posterior and sagittal views). Reproduced from Palmer (1993). 53 
The mucous membrane of the larynx forms two pairs of folds: a superior pair called the 
ventricular folds (false vocal cords) and an inferior pair called simply the vocal cords 
(true vocal cords). The mucous membrane of the vocal folds is lined by nonkeratinized 
stratified squamous epithelium. Irritants such as cigarette smoke, alcohol, or respiratory 
infection can cause an inflammation of the vocal folds (laryngitis), causing hoarseness by 
interfering with the contraction of the folds or by causing them to swell so that they 
cannot vibrate freely. It has been suggested as long ago as 1960 that chronic laryngitis 
may be a pre-cursor to carcinoma of the larynx. 54,55 
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Cancer of the larynx is one of the more common malignancies with over 2000 new cases 
per year in England and Wales. Incident rates are about 8 per 100,000 per year with about 
80% of cases in men. About 45% of laryngeal turnours diagnosed during the 1980s arose 
in the glottis (endolarynx), including the vocal cords, and about 16% in the supraglottis 
(epilarynx) and four in five of these turnours were squamous carcinomas. The incidence 
of laryngeal cancer has progressively risen over the last 25 years, with the most 
significant increase occurring in women. 56 It has been estimated that there has been no 
overall improvement in the mortality from laryngeal cancer over the last three decades; 
those cancers diagnosed during 1986-90 in England and Wales having a relative survival 
of 84% at one year and 64% at five years for men and 78% at one year and 59% at five 
years for women. 57 Delayed diagnosis leading to loco-regional failure and a high 
incidence of second primary malignancy in long-term survivors are the two main reasons 
for this poor outcome. 58 In addition, laryngeal cancer has one of the greatest effects on 
quality of life of any cancer, causing devastating lifestyle changes and resulting in 
permanent cosmetic and psychosocial disability. 
The vast majority of laryngeal cancers originate in the epithelial surface. The standard 
method of detection is by inspection of the organ with endoscopy and removal of a 
sample of tissue for histopathological analysis. This can be time consuming, costly and 
due to the random nature of biopsy selection stands a chance of missing any abnormal 
cells in the organ. In addition repeated biopsy procedures increase the risk of affecting the 
quality of the voice. The transformation from the normal state to carcinoma in the larynx 
involves an intermediate step, whereby the cells in the squamous epithelial layer begin to 
grow and mature abnormally. This state is called squamous dysplasia. It is known that 
lesions exhibiting mild dysplasia have a lower potential for malignant degeneration than 
those with severe dysplasia. 7,59,60,61 Table 1.2 shows the frequency of progression to 
invasive carcinoma in patients undergoing laryngeal biopsies displaying various degrees 
of dysplasia. If the tumour can be visually detected at endoscopy it may already be too 
late to initiate a full cure. Recently, contact endoscopy has been proposed as a means of 
avoiding these problems by directly visualising the mucosa under high magnification 
following application of a tissue stain (methylene blue)'o. However, this remains very 
qualitative, time-consuming and can only, of necessity, detect abnormalities in the most 
superficial layers of cells. 
Study Grade 1 Grade 2 Grade 3 
Crissman (1979)6' 0/52 0/26 3/16 
Hellquist et al (1982)59 2/98 3/24 9/39 
Silamniku et al (1989)"u 33/808 4/23 25/90 
Blackwell et al (1995)' 3/32 5115 5/18 
Total 38/990 (3.8%) 12/88 (13.6%) 42/163 (25.8%) 
Table 1.2: Frequency of progression to Invasive carcinoma in patients undergoing laryngeal biopsies 
displaying various degrees of dysplasin. 
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The development of an automated diagnostic method allowing detection of pre-malignant 
and malignant lesions earlier, at a cellular level, would facilitate faster, more effective 
patient management and potentially further reduce mortality. 
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2. Medical and Biological Applications of Raman 
Spectroscopy: A Critical Review of Relevant Literature 
A brief discussion of Raman spectroscopy as a tool for non-invasive, real-time optical 
diagnosis of early cancers was carried out in the introduction to this thesis. This chapter is 
intended to expand on the area and to critically review the published literature for evaluation 
of the current state of play in this exciting new field. It has been explained that Raman 
spectroscopy is a technique that utilises the molecular specific inelastic scattering of light 
photons to interrogate biological tissues. By measuring the change in energy of the collected 
photons from those of the illuminating photons, the vibrational energy levels of the 
molecules present in the sample may be deduced. Raman spectroscopy is a complementary 
technique to infrared (IR) absorption spectroscopy; which is also utilised to measure 
vibrational molecular states. However, in biochemical applications the presence of water 
makes the use of IR spectroscopy difficult, whereas the Raman scattering signal of water 
is weak compared to other molecular species present in tissue. 
There are a variety of techniques employing light to analyse and/or image tissue structure or 
biochemistry. They include fluorescence spectroscopy 
11,62,63 
and fluorescence 
imaging; 12,64,13,65 elastic scatterin; spectroscopy, 
66 , 67 optical coherence tomograph Y; 
68 69 
and 
0,1,72,73.74 infrared absorption spectroscopy. Optical techniques for medical dia nosis have 
been reviewed in great detail by numerous authors9,75 including this one 17,? 6 (refer to 
Appendix 5 for copies of relevant publications by the author). Further discussion of these 
alternative approaches is beyond the scope of this thesis, other than to name and reference 
the key players in various areas. 
Optical spectroscopic methods have the potential for providing real-time 
histoPathological information and biochemical imaging of lesions. Unlike fluorescence 
(and elastic scattering) spectra, whose features are broad, Raman spectral features are 
sharp and molecular specific, thus providing an opportunity for extracting uantitative 
molecular information about tissue composition. Mahadevan et al (1995)7ý compared 
fluorescence and Raman spectroscopies for diagnosis of cervical precancers. Of 36 
cervical biopsies that were measured, 19 were normal and 17 samples exhibited various 
abnormalities. It was demonstrated that multivariate analysis using a number of Raman 
peak intensities was capable of discriminating between precancers, and cancers, and other 
tissues with 88% sensitivity and 100% specificity! This is in contrast to fluorescence 
spectroscopy which when coupled with a principal component analysis routine was only 
able to separate cancers and precancers from other tissue with 80% sensitivity and 67% 
specificity. These results indicate the problems associated with fluorescence spectroscopy 
for medical diagnosis. It was observed that samples of benign lesions such as 
* Sensitivity and specificity are used in medicine as measures of the ability of a test to correctly make a 
diagnosis. The sensitivity is the ratio of the number of true positive results to the sum of the true positives 
and false negatives, i. e. the ratio of correct to incorrect results for a particular condition. The specificity is a 
measure of the ability of the test to discriminate between two or more conditions. This is calculated by the 
ratio of true negatives to the sum of the true negatives and false positives. This is explained in greater detail 
in Appendix 3. 
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inflammation and metaplasia were commonly diagnosed falsely as precancers. It is the 
specificity of Raman spectroscopy, with each peak being specific to a particular 
molecular vibrational mode, which makes it such a valuable tool for medicine. 
There is little understanding of the pathogenesis of most cancers, although it is known that 
those originating in different tissues in the body will have distinct developmental pathways. 
Therefore it is necessary to measure and chamcterise these changes before a technique can 
be used for diagnosis or detection of a particular disease. For example normal and neoplastic 
colon tissues have distinct biochemical features that can be exploited with Raman 
spectroscopy. Measurements of excised human colon carcinoma with 13 Carbon nuclear 
magnetic resonance (NMR) have revealed that tumours exhibit decreased triacyglycerols, 
increased phospholipids, decreased saturation of lipids and increased lactate compared to 
adjacent normal tissue. 78 Raman spectroscopy has been proposed for early cancer diagnosis 
by a number of authors. 16,79,80,81 It has shown potential for early diagnosis of malignancy in 
a variety of organs (breast'82 '20 brain '83 cervix '84 oesophagus, 
21 skin, 85 and colon 86 ) by 
identifying markers associated with malignant change. Most biological molecules are 
Raman active with their own characteristic fingerprints, thus the use of Raman spectroscopy 
for studying the evolution of prc-cancerous and cancerous lesions has been suggested as a 
valuable too]. The in vivo detection of biochemical tissue constituents using vibrational 
spectroscopy has been considered by the authors to have the potential to provide a new 
methodology for non-invasive detection of disease, together with new information for 
classifying, grading and evaluating the progression of malignant neoplasms. 
The use of Raman spectroscopy to investigate tissue biochemistry has only been made 
possible in recent years by technological improvements in laser sources, spectrometer design 
and the evolution of high sensitivity multichannel detectors. A brief summary of these 
important developments is given in Section 2.1. The exploitation of medical applications of 
Raman spectroscopy has followed rapidly behind the pioneering work that has shown the 
potential of this technique (see Section 2.2). Further developments towards practical 
exploitation of biomedical Raman spectroscopy are outlined in Section 2.3 and a brief 
discussion of the future pitfalls and prospects for its utilisation for detection and 
classification of cancers and pre-cancers in vivo and in vitro is given in Section 2.4. 
2.1 Instrumentation Developments 
When CN. Raman first observed Raman scattering, in 1928, he used a very simple system; 
whereby sunlight was filtered and focussed onto a sample of liquid. Detection of the 
scattered radiation was achieved using a number of filters and polarisers placed between the 
sample and the eye of the observer. 87 The basic concept of a Raman spectroscope has 
remained the same (see Figure 2.1) as technological developments have made individual 
components more sophisticated. It was the development of the laser in 1960 by Maiman 88 
that enabled this technique to really become a practical tool in the spectroscopist's arsenal. 
Due to the relative weakness of Raman scattering compared to that of other interactions of 
light with matter, a Raman system must utilise a high intensity, monochromatic radiation 
source as well as a highly sensitive detector coupled to a high resolution wavelength 
dispersive clement having high noise rejection factor. 
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Figure 2.1, schematic diagram of apparatus to measure Raman scattering in a liquid sample, with a 
90 degree collection geometry. 
Early attempts to measure the Raman spectra of biological tissues were limited by two 
factors: (1) the inherent high fluorescence of these samples and (2) instrument sensitivity, 
which necessitated long integration times and high power densities to achieve spectra with 
good signal-to-noise ratios. The early Raman spectra of biological samples were excited 
with visible lasers; mainly with the Argon laser lines. 89,90 Detection of the Raman scattered 
light involved the use of a monochromator to frequency disperse the collected light and a 
photomultiplier tube to detect die intensity of the photons in die frequency range of interest. 
Visible Raman spectroscopy was superseded by the development of interferometers 
enabling the use of Fourier trarisform, Raman spectroscopy. 71iis technique employs infm- 
red excitation light, thereby reducing the tissue fluorescence contribution, because excitation 
of fluorophores is less likely with lower energy photons. The majority of tissue fluoropliores 
have electronic absorption levels substantially higher in energy than that provided by an IR 
photon. After modulation by the interferometer, die filtered Raman scattered light is usually 
detected by means of a high sensitivity indium-gallium-arsenide (InGaAs) detector. The 
Fourier transform IR-Raman technique produces spectra with adequate signal-to-noise- 
ratios (SNR), with moderately high incident power densities. However acquisition times of 
about 30 minutes are required to obtain the spectra of highly fluorescent tissues. 20,91 
The development of diode lasers and CCD cameras, sensitive in die near infm-red (NIR), 
has made it possible to measure Raman spectra of biological tissue with NIR excitation. The 
major advantage of this technique is that NIR radiation does not generally induce electronic 
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absorption, but it does have a greater cross-section for Raman scattering than IR photons. 
Therefore most materials, including biological tissue, exhibit extremely weak fluorescence, 
with NIR excitation, in comparison to that accompanying visible-excited Raman and 
adequate signal-to-noise mtios (SNR) can be achieved with relatively short integmtion times 
of much less than a minute. 92,93 
The advent of holographic notch filters has also played a major part in improving the 
practicality of Raman spectroscopy for medicine. The largest component of scattered light 
from tissue is the elastically (Rayleigh) scattered light. This must be filtered or suppressed 
prior to measurement. Early designs used triple monochromators to achieve this. However, 
the throughput of this type of system is very low, necessitating long acquisition times or 
high laser powers. However, with a holographic Rayleigh rejection filter only a single 
monochromator is required to separate die Raman spectra into its component energies. 
Hence a greater throughput is achieved and much shorter acquisition times or reduced laser 
powers are possible. 
The choice of the optimal excitation wavelength for measuring biological tissue must be 
balanced between the e dependence of the Raman cross-section and the fact that at higher 
photon energies, greater fluorescence signal is induced. The optimum range generally falls 
between 750 and 850nm. 94 Nevertheless, despite the relatively high SNR, the resulting 
tissue Raman spectra still contain some fluorescence background. A challenge in achieving 
a useful tissue Raman signal is the accurate subtraction of the fluorescence signal. This is 
vital because in most Raman techniques the fluorescence and weaker Raman signals lie in 
the same spectral region. 
An alternative strategy for overcoming fluorescence interference in Raman spectra is to 
resonantly excite bigh-lying electronic states with ultraviolet light, a process known as UV 
resonance Raman (UVRR) spectroscopy. In biological materials, quenching and non- 
radiative relaxation from these states often eliminates fluorescence or causes it to occur at 
much longer wavelengths, so that Raman spectra can be obtained without interference. 86 
The principle advantage of UVRR in biomedical applications is that by selecting the 
appropriate excitation wavelength, to correspond to an absorption peak of a chemical group 
of interest, Raman bands of disease markers can be enhanced by several orders of 
magnitude. 71iis enables distinct Raman peaks of low concentration constituents to be 
observed in die midst of overlapping contributions from more abundant tissue components. 
Wavelengths in the range 200-260nm selectively enhance the Raman signal from aromatic 
amino acids and purine and pyrimidine bases of nucleic acids and proteins. 86 Hence, disease 
markers present in low concentration can be potentially observed. For example nucleic acids 
make up <5% of die dry weight of tissue, therefore enhancement is required to produce a 
signal large enough to be seen above die large protein/lipid background. The use of UVRR 
and NIR-Raman methods are complementary. UV light exhibits shallow penetration in 
tissue (20-50pm), providing the ability to sample superficial lesions, such as dysplasia. NIR 
light has a relatively small extinction coefficient and hence penetrates deeply into tissues, 
providing the opportunity to sample large volumes and probe subsurface details. 
Further technological developments lead by Hendm (1988)95 have resulted in optical fibre 
probes for in situ Raman spectral measurements. Initially 514.5nm illumination and a 
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triple monochromator was used, however low Raman signals from tissue and high 
background from the probes have restricted their use in medicine and biology. Recently a 
number of groups have been working towards an in vivo fibre probe using near-infmred 
illumination, thus reducing the fibre background signals with the longer wavelength and 
by the introduction of filters into the probe head (refer to Section 2.4). 
2.2 Pioneering Research 
The advancement of laser technology enabled Raman spectroscopy to begin a renaissance in 
the late 1960s. As the sensitivity of systems using visible excitation wavelengths improved 
the study of biological samples became possible. In the 1970s pioneering work was carried 
out by Lord and Yu (1970)96 by undertaking the first laser excited (632.8nm) 
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spectroscopic measurement of native protein from lysozyme. Hartman et al (1973ý took a 
further step forward by measuring the Raman spectra of intact RNA viruses. The spectra 
were of high enough quality for many peaks, assignable to RNA and intracellular proteins, 
to be resolved. 
The majority of the work carried out in the 1970s involved the characterisation of Raman 
spectra from biological molecules and simple cellular components and tissues, excited with 
visible wavelength lasers. An excellent text outlining the findings of this work has been 
written by Carey (1982)98 and more recently by Mium and Thomas (1995). 99 Mitocliondria 
were studied using resonance Raman between the wavelengths of 442-568nm, enabling the identification of cytochromes within the organelle. 100 The first tissue samples to be investigated with Raman spectroscopy were very simple and exhibited strong Raman bands. 
Examples of these am teeth'01 102 and eye lenses. 'O' 
However, the first study to indicate the promise of Raman spectroscopy as a method for 
medical diagnosis was carried out by Larsson and Hellgren (1974). 104 Measurements 
were made of combined Raman and fluorescence spectra of human blood plasma from 
patients with various cancers, viral hepatitis and sepsis to evaluate differences between 
spectra from patients with disease. An argon ion laser was used to excite samples in a 
borosilicate capillary tube. Healthy plasma exhibited some Raman spectral peaks 
attributable to resonance enhanced carotenoids and aromatic amino acid side chains. 
However, all patients with advanced carcinomas showed a massive increase in 
fluorescence background and die sharp bands in healthy plasma were not visible. This 
technique was able to distinguish between all diseased and healthy plasma samples, 
whereas the conventional method of erythrocyte sedimentation rate was positive for 
disease in only 32 of 53 disease cases. Nevertheless, it must be noted that although the 
technique used was sensitive to disease, a positive result, i. e. high fluorescence was not 
105 specific to any particular illness. Another group, Plouvier and Huong (1984), used 
ultraviolet resonance (UVRR) Raman spectroscopy to identify blue chromophores 
observed in blood from patients with cancer and leukemia. The source of die particles is 
still unknown. 
Further instrumental developments in the 1970s by Delhaye and Dliamelincourt (1975)10' 
and others lead to the coupling of a dispersion Raman spectrometer with a microscope to 
enable study of microscopic heterogeneity within samples for the first time. This was 
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vital for the further development of Raman spectroscopy in the study of biological 
tissues, cells and constituents with the dimensions of the order of microns to tens of 
microns. Abraham and Etz (1979) 107 were the first group to utilisc this technique for the 
pathological analysis of human tissue. An argon ion laser emitting 514.5nm light was 
used to excite a deparaffinated section from a lymph node near to the site of a silicone 
fingerjoint replacement. It enabled silicone inclusions to be visualised and identified in 
tissue for the first time. Other groups have used the same techniques to study inclusions 
in silicosis lung tissue 108 and to provide microanalysis of gallstones, thus providing 
information on stone constituents. 109 
All of the studies described above have exploited Raman spectroscopy to identify the 
presence of a foreign material within human tissue. These so called 'inclusions' usually 
exhibit strong and distinctly different Raman scattering from normal tissue. It was not 
until Raman spectroscopy showed the potential to elucidate very subtle changes in 
biochemistry, that precede or accompany pathological changes, that the interest of the 
medical community was captured. These developments have lead to the prospect of 
making use of Raman spectroscopy to monitor all kinds of diseases, from those such as 
diabetes, whereby glucose levels in cells are unstable, to precancerous and cancerous 
changes, whereby the cell biochemistry undergoes subtle changes leading to neoplasia 
and cellular invasion. Early work demonstrating the use of Raman spectroscopy has been 
used to monitor ýliysiological changes in contracting muscle cells, F0 and oxygenation of 
red blood cells. ' 
It was not until the late 1980s and early 1990s that the Raman spectra obtained from 
biological tissues were of sufficient quality to enable identification of complex components 
within the tissues that induce or accompany the disease processes. This generally became a 
possibility with the development of Fr-Raman systems enabling measurements of Raman 
spectra with near-infmrcd light (1064nm), thus markedly reducing the fluorescence 
background and lience the shot noise that tended to obscure weaker Raman peaks. In 
addition, dispersion spectrometers were being developed for use in the near-infi-ared (750- 
850nm) with sensitive multichannel detectors, thus reducing acquisition times. In 1989 
McCrecry and coworkers constructed a dispersive NIR Raman spectrometer utilising a 
diode laser source (783nm), single-stage imaging spectrograph and electronically cooled 
CCD detector. ' 12 They suggested that the new system offered better sensitivity than Fr- 
Raman spectrometers. 113 Moreover, with the development of a confocal Raman 
microspcctrometer die field of investigation open to Raman spectroscopy has been 
significantly extended. Microscopically small intact biological objects such as single cells 
and chromosome bands can now be studied. ' 14,115 
2.3 In Vitro Analysis of Cancerous and Pre-cancerous Tissues 
The prospect of utilising Raman spectroscopy for the detection of cancer has been studied 
by a number of authors. Improvements in system sensitivity and source wavelength 
selection has lead to die realisation that Raman spectroscopy has the capability of 
distinguishing the extremely subtle changes that occur when normal tissues become pre- 
cancerous. It is at this stage of the disease process that treatment will be most successful. 
Early work on evaluating the differences between cancerous and normal tissue from various 
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organs did not begin until the 1990s. The first groups used Fr-Raman systems to study 
breaseo and gynaecological tUMOUrSI5 and in 1993 Alfano et al filed for a US Patent for 
cancer detection with Raman spectroscopy. 116 By the end of the 1990s a small number 
groups had initiated work on assessing the potential for Raman detection of cancer in a few 
different human tissues. This was essential to increase the understanding of various 
processes that cells undergo whilst progressing towards cancer and to enable the potential of 
Raman to be assessed for detection of each cancer type. The present work will focus on 
developing diagnostic algorithms for in vivo and in vitro cancer detection based on 
differences in spectral data from normal and cancerous cells and tissues. The most 
significant work in a number of cancer areas is outlined in the sub-sections below. 
2.3.1 Breast Cancers 
The differences in Raman scattering properties of normal and cancerous breast tissues were 
first observed using near-IR excitation with 1064nin laser jig 11t. 20 Although the results were 
encouraging the S/N ratios of the spectra in this study were poor and unacceptably long data 
acquisition times of 10 to 30 minutes were required for signal retrieval. In a later study, 
excitation at visible wavelengths (514.5 and 633nm) and detection with a more cfficient 
spectrometer system provided much better SIN ratios in a comparative data averaging 
time. 14 However, more recent studies using a laser at longer wavelengths (784nml 17 and 
83onM81,82) and single monochromator dispersion systems were found to be more efficient 
than those of the above works. A significantly lower tissue background signal was achieved 
than at visible wavelengths. It was also shown by varying excitation wavelengths that 
spectra of different tissue components could be relatively enhanced. ' 18,1 19 For example 
between 782 and 830nin spectra exhibited mainly lipid peaks in normal breast samples, 
whereas between 488 and 515nm spectra consisted largely of enhanced carotenoid peaks. 
However, it was noted that the maximum for fitiorescence from breast tissue occurred with 
530nin excitation. 119 These studies indicated that the noise contributed by the background 
tissue fluorescence was minimum at a specific excitation wavelength somewhere between 
633 and 1064nm. 
An alternative approach has utilised ultm-violet-resonance-Raman (UVRR). 19 Although 
the use of UV light is unlikely to be accepted for in vivo medical diagnosis, because of 
mutagenic effects, it has shown promise in the fact that enhancement of particular 
vibrational bands especially DNA can be achieved with 257.3nm light. 19 UVRR spectra 
of normal and malignant breast tissue have been measured with 4-5mW of 257.3nm light 
in 10 to 20 minutes. Tissue spectra consisted of mainly DNA and protein bands. The 
concentrations of the nucleic acids relative to the cell proteins were shown to increase in 
malignant cells. 
More extensive studies involving greater sample numbers and optimised excitation 
spectrometer configurations have enabled acquisition of high quality spectra with integration 
times as short as 10s. 94,120 Improvements in spectral quality made it possible to distinguish 
between pathology types using empirical peak area ratio measurements and b exploiting 
the changes in relative concentrations of lipids and proteins in the samples . 
8111 
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Empirical 
methods of analysis, utilising information in individual peaks or peak ratios, have yielded 
some separation between pathology types, but changes in biochemistry accompanying the 
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disease process are very complex. Therefore, multivariate analysis, which involves more of 
the information in the spectra, has been used to exploit this. However, until spectral S/N 
ratios improved to rival those observed in infrared absorption spectroscopy (where 
chcmometrics or multivariate analysis was first used) it was not feasible to use these 
complex methods. A very recent study, utilising 830nm excited tissue spectra integrated for 
100s, calculated four diagnostically significant principal components* for entry into a 
discrimination algorithm. The resulting 
2 
model correctly classified 14115 normal, 13/15 
benign, and 31/31 malignant specimens. ' These results appear impressive, however, it must 
be noted that this model was not tested using new data or cross-validation methods. Hence, 
the discriminant algorithm was used to predict the classification of the tissue sample from a 
spectrum that had actually been used to create the calibration. Therefore the performance of 
the algorithm would be expected to be significantly worse for the classification of new 
samples. 
2.3.2 Gynaecological Cancers 
The early work investigating the Raman scattering properties at different stages of the 
disease process in gynaccological tissue utilised near-IR (1064nm) laser light and an FT- 
Raman spectrometer. Some empirical analysis was possible by using peak intensity ratios to 
demonstrate the ability to distinguish between normal, benign and malignant cervical 
tumour tissuc. 15 However, long integration times were required and poor SNR spectra were 
obtained. Improvements in instrumentation were required to enabled high quality spectra to 
be measured at 789nm using a prototype fibre probe. 77 184 These spectra (measured in 15 
minutes) were of sufficient quality to be studied with multivariate analysis. 'Me spectra were 
compared with the histological results from two board-certified pathologists. It was shown 
that analysis using a number of Raman peak intensities was capable of discriminating 
between prccancers (and cancers) and other tissues with 88% sensitivity and 100% 
specificity. 84 In terms of medical significance, this work was an important progression 
because it investigated the facility of Raman spectroscopy to distinguish precancerous and 
cancerous tissue from normal tissue. It is the precancerous lesions that have the most 
significance medically because they are most likely to be treated successfully. It must 
however be noted that biopsies with mixed pathology were included in the analysis, but 
spectroscopic results were correlated with the most severe pathological diagnosis. This 
experimental methodology is unlikely to produce an accurate representation of the changes 
in inelastic scattering properties with pathology because heterogeneous tissue samples with 
mixed pathologies have been studied. 
The alternative approach of UVRR spectroscopy for the study of normal and malignant 
cervical tissue has been studied using 257.3nm light. 19 Spectral differences between 
normal and malignant tissue have been demonstrated to represent changes in the 
concentrations of nucleic acids relative to cell proteins. Mutagenic effects are likely to 
prevent the use of this technology in vivo. 
*A brief description of principal components and other multivariatc statistical analysis methods can be 
found in Appendix 3. 
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Ovarian tissue has been studied very recently by utilising NIR excitation at 785mn to 
produce high quality spectra of ex-frozen ovarian tissue in 30 seconds. A prototype fibre- 
probe was employed to collect the spectra. 121 Principal component analysis was performed 
and the diagnostically significant principal components were selected using a two-tailed 
Student t-test. They were entered into a Fisher's linear discriminant analysis algorithm. The 
resulting separation in the two groups (normal and endometriosis, and cystic and cancerous) 
was achieved with 93% sensitivity and 87% specificity. 121 Nevertheless, histopathological 
analysis was not performed on the samples, as a result comparisons made between tissue 
pathology and spectra are not particularly convincing. 
2.3.3 Colon Cancers 
The most extensive investigations into UVRR for the analysis of tissue pathology has been 
carried out in colon tissue by a number of workers to provide resonance enhancement of 86,122,93 
colon tissue constituents. It has been shown that at 240nm proteins and aromatic 
amino acid peaks are observed; and at 250nm selective excitation of nucleic acids is 
achieved. 122 93 The Raman cross-section of nucleic acids were calculated and demonstrated 
to be one hundred times greater with 250nin excitation than at 239.6rim. 86 A more recent 
study involving 100 samples utilised 25 lnm excitation to produce spectra with a SNR of 20 
in integration times of 100s. 123 This study enabled analysis and understanding of 
biochemical processes in the colon to be improved by modelling tissue spectra from the 
spectra of 8 likely constituents. The major contributors to colon spectra at this wavelength 
were found to be guanosine, ftWtophan and lipids. 123 UVRR has been performed on both 
bulk and microtomed specimen with similar results. 124 Once again promise has been shown 
for understanding of the disease process, but in vivo use of UV-illumination is unlikely to be 
accepted. 
Conventional approaches to Raman spectroscopy of colon tissue have utilised visible 
excitation at 406.7nm and a triple monochromator system, 118 or NIR excitation at 830nm 
with a single monochromator system . 
81 The signal-to-noise ratios of the NIR spectra were 
significantly better than those observed with visible excitation and this was possible in 
shorter integration times. The NIR spectra were made up mainly of protein bands, 
however by calculating difference spectra between normal and cancerous tissue it was 
shown to be possible to distinguish an increase in the nucleic acid peaks (at 1662,1576, 
1458,1340cm7l) and a decrease in lipid peaks in cancerous colonic mucosa. 81 
2.3.4 Hepatic Cancers 
The liver is a vital organ and any disease affecting its function can be life threatening. 
However, it is also fairly rugged and can recover in time from various assaults. It is this 
property that allows resection of areas of liver with a hot wire during keyhole surgery, 
causing little effect on the function of the remaining healthy tissue. Consequently, 
reliable non-invasive detection of abnormal lesions in the liver during laparoscopy would 
allow immediate removal of abnormal areas, thus reducing the need for secondary 
procedures. Preliminary work on the evaluation of Raman spectroscopy for the 
discrimination of liver pathologies has shown promise, although much more work needs 
to be done. Early work on Raman spectroscopy of human and rabbit livers utilised FT- 
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Raman technology. 125 This required huge integration times of between 14 hours to 
enable discrimination between normal and cirrotic liver by utilising shifts from protein to 
lipid dominated spectra respectively. Some promise has been shown in the study of 
normal and malignant hepatocytes (liver cells), in both cultured cells and human liver 
cells, using visible illumination (632.8nm) and a dispersion spectrometer. 126 It was shown 
that discrimination between the samples was possible by using the ratio of the intensities 
at 1182 and II 56cm7l. It was found to be around 0.73 for normal liver, 1.16 for cirrhotic 
liver, and 1.3 for cancer. Although the results indicate some promise, it must be noted 
that only three tissue samples and a few cell cultures were studied. 
2.3.5 Skin and Adipose Cancers 
Initial work on die skin utilised FT-Raman spectroscopy with 1064nm laser light to 
distinguish between benign and malignant skin lesions. An average of 250 scans taking a 
total of 10 minutes were required to provide adequate signal-to-noise ratios. 127,85,128,129 
However, die spectra were of sufficient quality for artificial neural networks to successfully 
discriminate between the data from normal and basal cell carcinoma tissue. Models were 
tested using leave-one-out cross-validation. Alternatively, peak-area-ratio analysis 
employing the peaks between 1290-1360 and 1220-1290cnf 1 was shown to give mean 
values of 0.67 for normal skin and 1.37 for BCC. 127 Study of malignant melanomas with the 
same technology resulted in spectra with pretty poor SNRs, although it was indicated that 
differences in protein conformation, observed by changes in the amide I, amide III and C-C 
backbone peaks, accompanies changes to malignant melanoma. 128 A significant 
improvement was demonstrated by measuring tissue samples with NIR excitation (850nm) 
and a dispersion microspectrometer. Equivalent SNRs were achieved with only a 60 second 
acquisition time. 130 
A small percentage of malignancies develop in adipose tissue (the fat layer usually 
underlying die skin) and detection relies upon presentation of symptoms and biopsy. A 
single study has demonstrated the facility of a near-infrared (830nm) dispersion system to 
measure adequate quality spectra of human adipose tissue in short timescales (15-60s). 93 
Spectra from normal adipose tissue and liposarcoma have been compared and liposarcoma 
samples were shown to contain increased polyunsaturated lipids, indicated by the 
discrimination ratio 11442/11667, which describes lipid CH bend to lipid C--C stretch peak 
intensity ratios. 93 
2.3.6 Brain Disease 
The first Raman spectra of human brain tissues and turnours were measured with a NIR 
(1064nm) FT-Raman SyStCM. 83 Acceptable quality spectra were obtained following spectral 
accumulation for 120-150 minutes. Raman spectra from the following tissue types were 
compared: normal grey and white matter, gliomas (grade H and 111), acoustic neurinomas (so 
called because they lead to hearing loss, due to their proximity to the auditory nerve), and 
central neurocytomas. Distinct differences representing biochemical changes in the tissue 
were observed. 83 
Further study of die brain for diagnosis of degenerative diseases such as Alzbeimer's, 
Parkinson's and Creutzfeldt-Jacob disease (OD) with Raman spectroscopy compared both 
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Fr-Raman and visible excitation/dispersion systems. 13 1 However, it was only possible to 
measure Raman spectra with 1064mn illumination and the resulting spectra were only of 
sufficient quality to display significant differences between grey and white brain matter. 
Samples were destroyed by thermal damage from the laser source in any attempt to acquire 
spectra with visible illumination. 131 However, recent work- utilising NIR (830nm) has 
enabled spectra of adequate quality for discrimination between Alzheimer's and normal 
tissue to be acquired in 80 seconds. Mean spectra for each sample were used in a principal 
component analysis. Two principal components provided discrimination bet, %vcen the normal 
and abnormal samples with significance of greater than 99.9%. 
2.3.7 Malignancies of the Upper Aero-digestive Tract 
Although the upper aero-digestive tract includes the tongue, soft and hard palates, pliarynx, 
epiglottis, larynx, oesophagus, stomach and trachea, to date Raman work has been published 
solely on the oesophagus (and the stomach). However, an increasing number of 
investigators are evaluating alternative optical techniques for detection of epithelial cancers 
in this region. The hollow organs enable access to endoscopic investigation and lience 
potentially Raman spectroscopic analysis. 
The pathogenesis of oesophageal adenocarcinoma is very complex. Ilie small body of work' 
investigating the application of Raman spectroscopy for the detection of early cancerous 
changes in the oesophagus has not fully taken this into account. In section 1.3.1 it was 
explained that there are potentially at least nine histopathologically different tissues present 
in a cancerous oesophagus. Although some important preliminary work has been carried out 
to indicate that Raman spectra can be used to discriminate betwcen nornial and cancerous 
tissue in the oesophagus it will also be necessary to distinguish between all the other 
pathologies also likely to be present. Following the lessons learned measuring Raman 
spectra from other tissues, the first spectra of oesophageal tissue were measured with a NIR 
(850nm) dispersion microspectrometer. 132 Spectra were measured from only three 
pathological groups of snap-frozen oesophageal mucosa (normal, Barrett's and 
adenocarcinoma). Spectra were acquired in 15 seconds with I OOmNV of laser light and five 
were averaged to achieve good quality, repeatable spectra. Difference spectra have identified 
glycogen content to be the most significant variance between normal and Barrett's 
oesophagus. Multivariate analysis was carried out using a factorial discriminant analysis 
(FDA) model (i. e. principal component analysis followed by linear discriminant analysis). 
Good separation with pathology was achieved, with 78/79 non-nal, 117/120 Barrett's and 
112/115 adenocarcinoma spectra correctly classified. 133 
Further work utilising 785nni laser excitation and a dispersion spectrometer indicated the 
possibility of measuring spectra of sufficient quality for multivariate analysis within 30 
seconds. A model constructed from 260 spectra was able to differentiate dysplasia from 
intestinal metaplasia with 77% sensitivity and 93% specificity, using artificial neural 
networks. 134 Using principal components to separate die same data enabled discrimination 
between squamous mucosa (normal) and Barrett's or dysplastic tissue, but not 
discrimination between Barrett's and dysplastic tissue, which is the most clinically 
significant for the detection of early cancerous changes. It was noted that 250mNV focussed 
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to a 5001im spot did not produce a detectable temperature (<I `C) rise in the biopsy samples 
in one minute. 134 
2.3.8 Thyroid Cancers 
Raman spectroscopy of the thyroid has been investigated recently by only one group. 
Visible Raman s ectroscopy (632.8mn) was used to study n*rotomed sections of human ý35 
thyroid turnours. Thyroid tissue from 30 patients (3 carcinomas, 16 adenomas, 11 
nodules/goiters) was collected, sectioned and Raman mapped using an automated 
microscope stage. Spectra were acquired in 30 seconds and the spectra were used to 
calculate a principal components algorithm that enabled the spectral data to be separated into 
two groups (papillary and follicular carcinomas; and micro- and macro-adenomas). 
However, nodular tissue is present in both groups. 
2.4 Conclusions 
The use of near-infmred (785-860mn) dispersion spectrometers for the measurement of 
biological samples have been shown to offer spectra with the lowest background 
fluorescence and highest SIN ratios in the shortest timescales, for most tissue types. Further 
work is required to identify optimum wavelengths for excitation within this range for each 
individual tissue. Spectrometer efficiencies are still improving with the inclusion of novel 
filters and improvements in detector sensitivity in the NIR range. In addition, illumination 
intensities can potentially be increased to reduce acquisition times. 
Small sample numbers and die lack of a thorough understanding of the shortcomings of 
histopathological analysis have restricted the accuracy of all of the tissue Raman studies 
published to date. The investigations have been limited to measuring spectral differences 
between two or three particular pathology types. Unfortunately the medical reality is more 
complex. Although the early work has proved valuable in demonstrating differences in 
Raman scattering properties that accompany pathological change, an immense amount of 
work is required to make this a functional tool. Samples covering the full spectrum of 
disease in each organ will need to be used to train spectral diagnostic models. 
Tile work of calibrating a spectroscopic diagnostic model with the current 'gold-standard' of 
histopathological analysis requires a great deal of collaboration with expert pathologists. 
Discrepancies in tissue classification can be as high as 50% from one pathologist to the 
next. 6 Therefore it is vital that a number of pathologists with expertise in the disease of 
interest work together to provide a consensus of opinion on the tissue samples used to train 
and test the spectral models. In addition, tissue samples are commonly heterogeneous. To 
enable a precise calibration of a spectral diagnostic algorithm it is essential that only tissue 
samples with a single pathology are included for measurement. Currently these important 
steps have not been undertaken by anyone. 
Many technical problems must be solved to enable routine use of Raman spectroscopy as an 
in vivo clinical tool (see Annex I). The use of fibrc-optic systems (see Annex II) based upon 
near-infmrcd diode laser illumination, filtered probes and a single spectrometer/CCD 
detector arrangement appears to be the most promising, although radical new designs may 
be necessary to eradicate the silica Raman signal. With quick integration times, due to high 
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sensitivity and low tissue fluorescence background signal the NIR system appears to offer 
the greatest benefits for use in a clinical environment. Current in vivo probe designs tend to 
sample from die first few I 00pms. However, NIR photons are highly scattered in tissue, 
therefore with improved understanding of photon migration in tissue, imaging of subsurface 
lesions may become possible. 
Studies to date have not shown any significant thermal damage to tissue from high intensity 
laser illumination for in vivo work (see Annex 111). Nevertheless, further studies into the 
effects of the excitation light on the probed tissue must be carried out Prior to routine in vivo 
work. The effect of temperature rises on die tissue or photochemical reactions caused by the 
light may have unforeseen consequences. 
In the long term it may be possible to use Raman spectroscopy to provide automated 
diagnosis for a number of conditions. This could be achieved by utilising the differences in 
spectral features with diagnostic algorithms. The simplest algorithms are based on 
empirically identified diagnostic features. These differences may be variations in intensity, 
intensity ratios and the number and location of peaks. However, it is minute changes in 
spectral shape that may indicate clinically significant biochemical changes that precede or 
accompany disease processes. Therefore high quality spectra will be required to enable use 
of multivariate techniques that analyse all die data in a spectrum and thus be more likely to 
provide the information required for detection of disease. There are a number of multivariate 
statistical techniques that are being evaluated for discrimination between diseased states and 
microbiological taxonomy. They include principal component analysis, cluster analysis, 
linear discriminant analysis and artificial neural networks. A large volume of texts discuss 
these techniques, although they have not been commonly used for spectral analysis 
(Appendix 3 discusses these further). 
The greatest obstacle to automated medical diagnosis will most likely be the transferability 
of Raman spectra acquired with different systems. If automated diagnostic algorithms are to 
be used, it must be possible to purchase an off the shelf spectral library and sort algorithm 
for a particular disease or tissue type. However this implies the need for spectra from all 
systems to be corrected to achieve the ideal that is used for calibration of these classirication 
models. 
In summary, there is such a small body of work- in the area of Raman spectroscopic 
detection of cancer and pre-cancers, that all contributions will be valuable to improve die 
understanding of biochemical processes that precede and accompany disease. Moreover 
much of the published work- has demonstrated proof-of-principle and little more at this 
stage. 
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Annex 1: Raman Spectroscopy for In Vivo Cancer Diagnostics 
The employment of Raman spectroscopy in situ for the study of most tissues necessitates the 
use of fibre optics to deliver and return the signal from the tissue site. There have been a 
number of fibre probes designs considered. 136 The most popular configuration uses a central 
excitation fibre surrounded by 6 collection fibres. The total diameter, using 200gm. diameter 
core fibres, is usually a few mm. A small reduction in size would allow the fibre probe to be 
inserted into a Imm biopsy needle. Therefore percutaneous assessment of tissues is 
theoretically possible by utilising the needle probe to sample at depth in tissue, no more 
invasively than current needle biopsy techniques. 
The major problem associated with Raman-fibre probes is that Raman signals are generated 
by the fibres themselves. The signal is proportional to the length of the fibre and to the 
excitation light intensity. It can have magnitudes equal to and often greater than that of the 
sample under study. 137 Fibre signal is generated in the delivery fibre by the excitation light. 
In addition, a background signal is also generated in the collection fibres by the elastically 
scattered excitation light returning along the collection fibre. A practical probe design must 
prevent unwanted signal generated in the delivery fibre from illuminating the sample as well 
as preventing light elastically scattered by the tissue from entering the collection fibres and 
generating unwanted signal. Practical examples use holographic notch filters to reject the 
Rayleigh scattered light from the tissue and a narrow band-pass filter to exclude the silica 
Raman before the excitation light illuminates the tissue. 
An alternative mathematical technique has been proposed to remove the silica Raman 
interference. 117 This involves acquiring a spectrum. of air, by employing the same apparatus 
as that used on tissue, and subtracting this from the tissue spectra. Although this will 
compensate for some of the probe signal, less backscattered light will enter the collection 
fibres with the air measurement, thus reducing the signal contribution in the correction 
spectrum. In addition shot noise (following the relationship Ni-VN, were N is number of 
counts) will be much greater if the fluorescence is removed post-detection and hence the 
weaker tissue Raman peaks will be obscured. 
Annex 11: In Vivo Raman Experiments with Fibre-Probes 
The earliest in vivo measurements with a Raman fibre-probe were carried out on a mt, using 
an 17-Raman spectrometer to measure the signal from leg muscle. ' 36 The fibres probes 
utilised were shown to degrade the SNR by 5-10 times relative to measurements with a 
normal FT-spectrometcr. A lower background signal from the silica fibres was observed 
with 1064nm illumination than at shorter wavelengths. Therefore a more simple probe 
design is possible for FT-Raman measurements, but the integration times required for 
adequate spectra have been shown in the above sections to be restrictively long for in vivo 
work (tens of minutes to hours). 
The first practical Raman in vivo probe for human use utilised a multi-fibre design 
coupled to a NIR-dispersion spectrometer. 138 The device was tested on human skin with 
785nm excitation light from a diode laser. The fibre-probe consisited of six collection 
fibres (NA 0.22) surrounding a single illumination fibre, with no internal filters 
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incorporated into the probe head. Evaluation of the effect of different fibres in the probe 
for reduction of fluorescence background was performed. It was shown that Low-OH 
silica fibres demonstrated the lowest contribution to the signal. 138 In the spectra of muscle 
and adipose tissue, measured ex vivo in 3 minutes, the silica Raman signal was shown to 
be 2-5 times greater than the tissue signal in the 900-1700cm" wavenumber range. Use of 
background subtraction was able to yield a poor quality tissue spectrum. In vivo 
measurements with the same probe and spectrometer indicated that spectra measured in 
30 seconds from human skin, buccal cheek epithelium, fingernail and teeth were 
possible. 138 Similar unfiltered a robes have been used to measure atherosclerotic plaques 
with 830nm laser excitation. 9 However, due to the highly scattering nature of the 
lesions, following subtraction of the fibre-background, acceptable spectra could be 
acquired in a matter of seconds. In vivo Raman spectra measured from atherosclerotic 
plaque in femoral arteries durin surgery, integrated in 3 seconds was sufficient to "ýý 
attributable to hydroxyapatite. 1 3 identify the strong peak at 960cm 9 The presence of this 
peak is clinically significant in that it demonstrates the presence of a calcified 
atherosclerotic plaque. Nevertheless, use of filterless-fibre-probes make it very difficult 
to measure normal tissue Raman spectra in acceptable timescales for in vivo use. A 
demonstration of the difficulty of employing a filter-less fibre probe was given by 
measuring pure cholesterol. With 350mW of 830nm laser light at the sample, and a 10 
second integration time, the background from the silica fibres at I OOOcm7' was more than 
30 times greater than the Raman signal from the cholesterol. 139 
A recent extensive study measured Raman spectra of biomedical samples using various fibre 
probe designs incorporating: single fibres, biffircated fibres, and filtered fibres. 140 All 
configurations used 2mW of 830nm light from a laser diode passed through a narrow 
bandpass filter, to remove the spontaneous radiation, coupled to the fibre probes using a 
lens. The output of the collection fibre/s was passed through a holographic notch filter and 
imaged onto the spectrometer slit, a single dispersion grating and CCD detector integrated 
the spectral signal distribution. It was shown that use of a single fibre (400gm diameter, 2 ft 
long) for transmission and collection produced benzene spectra totally swamped with the 
fibre background signal in integration times of 5 seconds. A bifurcated probe design with no 
internal filters employing a single illumination fibre and 6 collection fibres produced 
adequate benzene spectra but spectra from a chicken fat, a strong biological Raman 
scatterer, was swamped by the fibre background (greater than 10 times die Raman signal 
from the tissue) . 
140 An improved probe design, incorporating a narrow bandpass filter at the 
exit of the illumination fibre with die illumination fibre surrounded by 16x2OOgm collection 
fibres, was evaluated. Spectra of chicken fat measured with die narrow bandpass filtered- 
probe enabled tissue Raman peaks to be observed, however the spectrum also included silica 
Raman peaks. It was thus concluded that a narrow bandpass filter was required in the 
excitation tip and a notch or long pass filter was required to remove die elastically scattered 
signal from the tissue to reduce silica Raman signal induced in die collection fibre. 140 
Filtered probes have been shown to significantly improve die SNR and remove fluorescence 
background, although the silica Raman signal has remained. The highest collection 
efficiency can theoretically be achieved when a single fibre is used for both illumination and 
collection, giving a complete overlap between illumination and collection light cones. 
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However, multiple collection fibres reduce silica Raman signal, but have worse collection 
efficiency at short probe-sample distances-80 All of the recent work on in vivo fibre-probes 
for Raman spectroscopy has involved the development of multi-fibre, internally filtered, 
designs. 80,84,79,141,142 
Improvements in signal efficiency, background reduction and miniaturisation have been 
the key aims of the most recent studies. A fairly large 12mm. diameter fibre-probe, made 
up of a single 200grn illumination fibre and seven 100grn collection fibres, was used to 
measure cervical tissue in vivo. 143 The excitation beam was filtered in the tip of the probe 
with a bandpass filter and the collected light was passed through holographic notch filters to 
remove the signal at the laser wavelength prior to launch along the collection fibres. With 
NIR (789nm) excitation light, the time required for an acceptable spectrum to be acquired 
was 90 seconds. 143 Even with the filtered probe, silica Raman bands were still observed in 
the tissue spectra, thus obscuring tissue Raman bands below 900cm7l. However, in vivo 
spectra were shown to exhibit similar peak-intensity-mtios to those that have been used for 
discrimination between normal and cancerous cervical tissue during in vitro experiments. 84 
A similar probe design incorporating filters and beam steering optics to improve the 
collection efficiency80,141 was successfully tested on rat palate and rat oesophagus, with 
785nm illumination. 79 This improvement in collection efficiency enabled spectra to be 
obtained in 10 to 50 seconds. Subtraction of probe background was still a necessity, to 
elucidate the tissue Raman scattering peaks. In addition, the large size of the probe tip (4cm) 
was shown to be a problem for the transfer of this method to endoscopic investigation. 
Further miniaturisation enabled a 3m long bifurcated fibre-optic probe with a central 
delivery fibre (low OH-silica 400grn core and silica cladding), 7 collection fibres (300grn 
core), incorporating bandpass and longpass filters, to be used to measure in vivo Raman 
spectra during routine gastro-intestinal endoscopy. 142 The fibre-probe was passed through 
the biopsy channel of the endoscope and placed in contact with the tissue surface. 
I OOmW of NIR laser light (785nm) was used to excite the Raman spectra and a sampling 
depth of 500grn was achieved. Spectra were integrated for 5 seconds, whilst a shutter 
blocked the white light from the endoscope. Normal and diseased sites in oesophagus, 
stomach and colon were biopsied and sent for histopathological analysis following 
Raman measurement. Effects of probe tip pressure on the tissue were found to be 
insignificant. A sampling depth of approximately 100grn was achieved. Even in areas 
where blood was seen to be pooling, measured spectra were uncontaminated so long as 
the fibre tip in contact with the mucosal surface. Limited sample numbers (400 spectra 
142 from 20 patients) were used and no spectral correlation with pathology was performed . 
Even when utilising filtered probes, the Raman tissue peaks below I 100cm" were 
obscured by background signal from the silica fibres. The resulting spectra were pretty 
noisy showing only the largest four to five peaks. 134 
Finally the most recent modifications to the multi-fibre probe design have lead to in vivo 
Raman measurements in the coronary arteries of sheep and lambs. 144 A side firing probe 
design was used to measure Raman spectra with 830nm illumination in 10 to 30 seconds. 
Spectra with good SNRs were obtained when the probe was in contact with the artery 
wall. Positioning was achieved by trial and error, therefore a method of giving repeatable 
28 
contact will require development. The in vivo Raman spectra were of sufficient quality to 
define molecular composition of the examined sites. 144 However, during earlier 
discussions it was pointed out that atherosclerotic plaques exhibit high Raman scattering 
cross-sections, therefore further improvements in signal levels will be required to achieve 
in vivo diagnosis of cancerous tissues. 
Annex III: Effect of Intense Laser Radiation on Human Tissue 
A concern with any Raman technique applied to tissue is the possibility of radiation damage. 
CCD spectrometers are sufficiently sensitive that laser powers of a few milliwatts generate 
useful spectra. However, safety limits for exposure of living tissue to laser light are not fully 
established and will vary for tissue type, wavelength and spot size. It is clear that radiation 
damage will have to be evaluated if a Raman technique is to be used in vivo. 
To achieve a practical Raman signal from tissue it appears that higher intensities of light, 
than those set by the British Standard. Radiation safety of laser products, 145 will be 
necessary. (This document is currently being updated, so these limits may change in the near 
future. Additionally it must be noted that these limits are not set for medical exposure but for 
exposure limits for operators or bystanders. ) The British Standard (BS4803) defines a 
maximum permissible exposure (MPE) as the exposure causing minimum injury that can be 
observed clinically. Experimental values are provided for eyes and skin. Therefore making 
the assumption that the tissue being sampled has similar properties as skin, we may compare 
the exposure to that of the NTE for skin at that wavelength and exposure time. For example 
Alfano et al (1991)20 used IR FT Raman spectroscopy to study breast tissue in vitro with 10 
W-cm72 for 4-5 minutes. Redd et al (1993) 14 used 0.4-1.0 W. CM-2 of 514.5nm light, for a 
number of minutes to acquire adequate Raman spectra of tissue samples. The MPE to skin 
for light 400-1400nm for 10 to 30000 seconds is 0.2 W. crrf2. Therefore both authors used 
exposures between five and fifty times the MPE. 
All of the studies into Raman spectral measurements of biological tissue that have published 
illumination intensity data have exceeded the NTE limit. A number of qualitative studies 
have been carried out to assess the effect of these high intensities on tissue. Mahadevan- 
Jansen et al (1996) 16 investigated the thermal effects of laser exposures in excess of 0.3 
W. CM-2 at 789nm. A simulation calculated a rise of 5.6 'C per minute for a laser intensity of 
12.73 W. em2, which is by no means a high intensity for the excitation of Raman scattering 
in tissue. However it must be noted, the above simulation did not account for the substantial 
cooling of tissue afforded by blood flow. A study by Shim et al (2000)134 demonstrated 
this effect by carrying out in vivo temperature measurements during laser illumination of 
oesophageal tissue. Laser powers of 25OmW of 830nm light were focussed to a 500gm 
spot. It was shown that no detectable temperature rise (<I*C) occurred in the tissue in I 
minute. Shim and Wilson (1996) 146 evaluated laser heating of tissue with laser powers of 
450,250, lOOmW with a 1064nm, Nd: YAG laser source, focussed to a 0.5mm spot size. 
A thermocouple was placed on the tissue, Imm. from the beam edge, spectra were 
acquired for 30 minutes at each illumination power. Following measurement the samples 
were sectioned and histologically analysed for damage to cell viability. For adipose, 
muscle and liver tissues there was no evidence of heat damage after exposure with 
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45OmW of laser radiation for 30 minutes. In addition, there were no spectral changes 
observed over the 30 minutes with any laser power. Temperature rises measured for 
45OmW of laser power with the tissue soaked in PBS (more representative of intracellular 
fluid) were between 2.3 and 6.7"C, and in dry tissue samples between 2.3 and 261C. 
Darker tissues such as lung and liver absorbed a great deal of energy, whereas most 
others exhibited little absorption. 
In vitro measurements on porcine aorta using a multi-fibre probe to illuminate the tissue 
with I OOmW of 83 Onnilight resulted in a 2"C temperature rise over several minutes. 144 ThUS 
for short periods of illumination with NIR laser light, thermal damage should not occur in 
most tissues. However, it has been demonstrated that damage thresholds are wavelength 
dependent. 114 Sample degradation measured in single intact lymphocytes, with a confocal 
Raman microspectrometer using a x63 water immersion objective (NA 1.2) to focus I OmW 
of laser power into a 0.5pm spot (5MW cnf2) for wavelengths of 514.5,633,660nm. At 
514.5 nm, degradation occurred at 0.5-2OmW, with visible paling combined with a gradual 
reduction in Raman signal. Whereas for 660 and 632.8mn, no degradation was observed for 
under 20mW, although above this level cell death is also caused. 
Ultraviolet light has been used fairly extensively to excite the Raman bands of a number of 
biological substances in vitro. However the ideal application of Raman spectroscopy in 
medicine is for direct detection of malignancy in vivo, where the use of high-energy photons 
may cause mutagenic effects. The key parameter is the photon dose required for ultraviolet 
resonance Raman spectral data acquisition compared to that which causes a significant 
number of mutagenic alterations in the cells. There is little information available on this at 
present. Therefore the use of UVRR to study tissue in vivo is unlikely to be accepted until 
further understanding of the disruptive effect of ultraviolet light on nucleic acids can be 
achieved. However, the technique has been shown to be valuable in the study of ex vivo 
tissues, due to the enhancement of Raman scattering in constituents such as DNA that are 
present in the tissue in lower concentrations than proteins and liPids that dominate the 
non-resonant spectra. A review on the damaging effects of ultra-violet and visible light 
on DNA has been presented by Coohill et al (1987). 147 
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3. Theory of Raman Scaftering 
3.1 Introduction 
If a monochromatic beam of photons passes through a transparent medium, i. e. where 
photons of the incident energy will not be absorbed, a firaction will be scattered in all 
directions. The scattered photons will consist almost entirely of radiation of the incident 
frequency, v. This is Rayleigh scattering, an elastic process, whereby no energy is lost from 
the interacting photon. In addition, a small number of photons will emerge with discrete 
frequencies above and below that of the incident beam (v :h Avi). It is die process that leads 
to these discrete shifts that is referred to as Raman scattering. These shifts, or Raman 
frequencies, are independent of the exciting frequency, v, and are characteristic of the 
species of molecule giving rise to the scattering. 148 In effect these frequencies represent the 
vibrational frequencies of the molecules. 
Study of vibrational frequencies in fissue samples using infira-red absorption spectroscopy is 
not always possible due to strong absorption by water and other species. Raman 
spectroscopy complements infra-red spectroscopy using ultra-violet, visible, or near infira- 
red excitation. Therefore Raman spectroscopy can be used to probe the vibrational energy 
levels of molecules within many biological (and non-biological) samples. A Raman 
spectrum is a plot of scattered intensity as a function of energy difference between the 
incident and scattered photons. The unit of photon energy (E) is expressed in wavenumbers, 
the inverse of wavelength (k) in units of cm7 1 for convenience, such that; 
E=h. v= 
h-c 
Where h is Planck's constant, c is the velocity of light and v is the frequency of the radiation 
field. The loss, or gain, in photon energies corresponds to the difference in the final and 
initial vibrational energy levels of molecules participating in the interaction. A typical 
Raman peak is spectrally narrow, easy to resolve and sensitive to molecular structure and die 
Surrounding environment. Vibrational spectroscopy techniques can thus provide specific 
histochernical information from biological tissue, unparalleled by other optical methods. 
Both vibrational absorption and scattering methods are promising for biomedical 
applications. 
The Raman effect can be induced by light of all frequencies. However, the cross-scction for 
an inelastic scattering process is proportional to %ý, 4, where 4- is the wavelength of die 
incident photon. For example photons of 300nm wavelengdi have a cross-section of 
scattering sixteen times greater than photons at 600nm; assuming that there are no resonance 
effects, which may occur for incident photons having energy near an electronic absorption 
line of the molecule. 
The energy loss (or gain) of the scattered photon is constant for a particular molecular 
species no matter what frequency of excitation is used. As an example of this, die C=C 
stretching vibration of the benzene molecule always produces a Raman peak downshifted by 
1612 cnf 1 independent of the frequency of the excitation jig 11t. 86 In practice die environment 
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of the molecular species is important, as local perturbations of the electric fields around it 
will tend to slightly shift the vibrational energy levels. 
The main factors that determine the choice of excitation wavelength for tissue spectroscopy 
are: 
1. The depth of penetration of the light through tissue. 
2. The intensity of the induced fluorescence signal at that wavelength, as this can swamp 
the weaker Raman signal. 
3. The availability of an intense source and a sensitive detector at the wavelength selected. 
Raman scattering is an inherently weak process. The intensity of the Raman signal is 
typically 10-9 to 10-6 of the Rayleigh background. 149 For this reason it is difficult to observe 
without intense monochromatic excitation and a sensitive detector. There are various 
methodologies that may be utilised to obtain Raman spectra. The best technique depends 
upon the application. 
It must be noted that the Raman effect occurs without photon absorption by the molecule, 
but rather the molecule is perturbed by the photon and it is induced to undergo a vibrational 
or rotational transition. Hence the interaction N rocess between the photon and molecule is 
very fast, of the order of picoseconds (10 
-9 
s), whereas the time for absorpfion and 
fluorescence is of the order of nanoseconds (10 s). 150 
3.2 Classical Theory 
When light is incident upon a molecule, it's varying electric field, 
f 
,, 
(t) = E,, sin(2; rv,,, t) , (3.2) 
induces an oscillating dipole, which re-emits (scatters) the light at the frequency of the 
dipole oscillation. An assumption is made that the entire molecule is within a 
homogeneous incident electric field and that the incident light is monochromatic, with 
frequency vi, In practice the time-varying dipole moment, P(t), will consist of many 
different harmonic frequency components, each of which can be described by the 
following equation: 
p(t) = p. sin(2; rv,, t) (3.3) 
where v, c is the frequency (in Hertz) of the scattered light and po is the maximum induced 
dipole moment for a given frequency component. The induced dipole moment can be 
approximated by 
p(t) = af,, (t) (3.4) 
where a is the polarisability of the molecule. The polarisability describes the ease with 
which molecular orbits can be distorted by the presence of an external electric field. An 
oscillating dipole will radiate light in all directions at all frequency components of the 
dipole oscillation; the component of scattered light due to dipole oscillations at v,, = vin is 
called Rayleigh scatter. 
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If a molecule undergoes some internal motion whilst oscillating in an electric field, such 
as vibration or rotation that periodically changes the polarisability, then the oscillating 
dipole will have the vibrational or rotational oscillation superimposed on it. For example, 
we can write an expression for the time-dependent nature of the polarisability by 
performing a Taylor expansion about the equilibrium position of the atoms, Q0, expressed 
in normal coordinates, giving us 
+ Q+ Q2 +... (3.5) 
(ýQ)o 
2 ýDT)o 
It" 
where cc. is the polarisability at rest and (Dq1DQ)O, known as the derived polarisability, 
represents the rate of change of polarisability with respect to Q, the displacement from 
the equilibrium position of the vibrational mode (Q = Q0 sin(2)rv,, jbt)). If we consider the 
vibrational frequency Vvib that changes the polarisability, and neglect higher powers of Q, 
for small displacements along the normal coordinate, expression (3.5) becomes 
a=a,, 0ý)o Qo sin(22rVibl) (3.6) Qý 
Inserting (3.2) and (3.6) into expression (3.4) gives us 
+(Da) p(l)=O"EQ)== ao raQ j0 Qo sin(2zv,.,, 51) o LE,, sin(21rvi,, I)). 
Using the trigonometric expression 
sinAsinB= 
1 fcos(A-B)-cos(A+B)l 
2 
leads to 
a,, E,, sin(21rv,,, t) +I 
(aa) 
- v,, ib)t - cos 
2z(v,,, + v,, ib)tl. 2 ýaQ )OQOf,, 
jcos2ir(vj,, 
(3.7) 
Thus from expression (3.7) it can be seen that an oscillating dipole will have frequency 
components equal to Vin±Vvib as well as the exciting frequency Vin. If tile vibrational mode 
of the molecule does not alter the polarisability of the molecule then (DaIDQ)o = 0. Hence 
the components of the dipole moment, in expression (3.7), are reduced to those 
containing only the frequency of the incident radiation, vi, Therefore, for a rotational or 
vibrational mode to be Raman active it must cause some change in a component of the 
molecular polarisability. 
3.2.1 Tensor Character of Polarisability 
Scatter from isotropic molecules is characterised by the fact that the direction of p and 
are always parallel and the magnitude of 12 is independent of the orientation of the 
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molecule and E,.,,. However, when light is incident on a stationary anisotropic molecule, 
in general the induced dipole moment, p, will not be aligned with Ej.,. If we let E,,, Ey, E, 
be the components of the electric field vector relative to a cartesian coordinate system 
and consider a fixed, non-rotating molecule, then the components of the induced dipole 
moment can be written as follows 
P,, = %,, E., +cc,, yEy+%, Eý, 
Py = ay,, E., +ayyEy+ccyE7 (3.8) 
P,, = c6E., +a,, Ey+c6E,. 
It can be seen from these expressions that an incident electric field parallel to one 
cartesian axis can induce a dipole moment along a perpendicular axis, so long as the 
relevant polarisability is non-zero. 
Thus the polarisability tensor oýj is defined by 
ay., qýy qJ7 , where the first subscript denotes the 
az, Cý. Y Cý-, ý 
and the second the direction of the applied electric field. 
an array of nine components 
direction of the induced dipole, 
Thus (DaIDQ)U, the derived-polarisability tensor, the first-order term component of the 
polarisability tensor, will give rise to the inelastic Raman scattering. It should be noted 
that since a non-linear molecule of atoms has 3n-6 normal coordinates, there will also be 
3n-6 derived-polarisability terms, with each normal mode of Raman active vibration 
arising from the corresponding derived-polarisability tensor. 
3.3 Quantum Theory 
In the quantum mechanical concept molecules gain or lose sums of energy only in 
accordance with the laws of quantum physics. Thus, a molecule's change in energy, AE, 
on excitation with hvi,, must be equivalent to the difference in energy between two of its 
allowed states. AE must represent a change in the vibrational and/or rotational energy of 
the molecule. During the interaction if the molecule gains AE, the photon is scattered 
with energy (hvj,, -AE), this is called Stokes radiation. If the molecule loses AE, the photon 
is scattered with energy (hvi,, +AE), this is called anti-Stokes radiation. 
At room temperature the number of molecules in an excited vibrational state will be low. 
This can be shown by using Boltzmann's equation. 
Nv 
= cxp(_, 
Ev ) (3.9) 
No kT 
Where N, 1NO is the fraction of molecules in the vibrational state; E, is the energy of the 
vibrational state; k is Boltzmann's constant and T is the absolute temperature. For 
example the C=C stretch oscillation (1612 crn" shift) of a benzene ring requires 1.99x, 10- 
20 Joules of energy to excite the oscillation from the ground state. Using equation (3.9) 
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the fraction of benzene molecules in the excited vibrational state at 20"C is 0.0078. Hence 
it is obvious that, at room temperature, incident photons are much less likely to encounter 
molecules in an excited state. Therefore the likelyhood of Stokes' radiation, whereby the 
molecule captures a portion of the incident photon's energy is that much greater than the 
alternative anti-Stokes, since the anti-Stokes' radiation can only occur if the molecule is 
in an excited vibrational or rotational state. 
Soon after C. V. Raman's experimental discovery of the inelastic scattering of photons, 87 
Placzek, 15 1 Dirac' 52 and others developed classical, semi-classical and quantum- 
mechanical theoretical approaches. The full treatment of light scattering using quantum 
mechanics would require the incident radiation and the scattering molecule to be 
considered as quantum particles. This would call for the introduction of relativistic effects 
on the particles, which is beyond the scope of this thesis. A close approximation can be 
achieved if the incident electromagnetic wave is treated as a perturbation of the 
wavefunction of the scattering molecule. The perturbation due to the incident radiation 
produces a time-dependent virtual state. An expression can be derived for the 
polarisability of the molecule from the second-order perturbation theory. This method is 
based upon the Kramers-Heisenberg dispersion theory 153 and Dirac's second-order time- 
dependent perturbation theory. 152 It is generally known as the 'sum-over-states' method 
because the contributions to the Raman scattering intensity, arising from the coupling 
between the initial, intermediate and final states, are summed over all possible 
intermediate states. The following section outlines the derivation of an expression for the 
intensity of scattered light by a system of N molecules based upon the 'sum-over-states' 
method. 
3.3.1 Perturbation Theory 
In the quantum-mechanical description of the scattering of light photons we are interested 
in the change in the vibrational energy levels, and hence the wave functions, which will 
occur when the molecule is placed within an external electric field. The fields produced 
by the incident radiation are usually small in comparison with the internal Coulomb fields 
in the molecule. Therefore the effect of the external field may be regarded as a small 
correction to the wave function. This correction is usually referred to as a perturbation. 
Firstly we will begin by looking at the interaction between an individual molecule and the 
electric field of the incident electro-magnetic radiation. If the linear dimensions of the 
molecule are much smaller than the wavelength of the incident radiation, the phase 
change within the molecule may be neglected. Hence the field inside the molecule may 
be taken to be E= EO cos(ctx) and is the same at all points inside the molecule at a given 
time t, where co = 2; rVin is the frequency of the incident radiation and Eo is the maximum 
electric field vector of the incident radiation. 
Let the molecule be in an energy state En before the light wave is in effect 'switched on'. 
The corresponding wave function describing this state is T,, (r, 1). When the light field is 
'switched on', the state of the molecule is modified. If we suppose that this new state is 
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described by T,, (E, t)and this function must satisfy the time-dependent Schr6dinger 
equation 
ihýT-" =HOT,, +WT,, (3.10) at 
where HO is the total energy operator for the system in the absence of the light wave and 
W is the perturbation due to this wave, described simply as; 
W(r, t) = eLEO. L) cos(ca) 
which is in effect the potential energy of an electron in the oscillating electric field E; at a 
position, 1, relative to the nucleus; where e is the electric charge of an electron. Vf,, can be 
expanded as: 
0 /W I l(W. -Oi)t I(W, +W)t T. V/,, (r)e- *+U,, (r)e- + V,, (r)e- - (3.12) 
where w,, = E,,, Ih and U,, and V,, are the required corrections to the state function, T. 0, 
for the undisturbed system, to account for the cffects of the electric field on the system. In 
an undisturbed system 
HOT, O, = E,, TO,. (3.13) 
Combining expressions (3.12), (3.11) and (3.10) and, as a first approximation, neglecting 
the products W. U,, and W. V,,, since these terms are proportional to LE. 21 and therefore 
correspond to the second-order electric field approximation leads to 
elax + e-lax 0 h (w - o»U., el' + h(w + w)Ve-1" =H OUe" +H OVe-"' + eLEOr) 2 'rn - 
By equating the coefficients of corresponding tenns of Oot and e'iwt we obtain the 
following equations for U,, and V., 
0o h CO)U,, =HU,, + (3.14a) 2 
0, eLEO. r) 0 h(w,, + co)V,, =HP,, + ýý ýý V, -,. (3.14b) 2 
These equations can be solved by expanding U,, and V,, in tenns of the orthogonal 
functions V/. O. 
Un = F,, 4,,, V/10 (3.15a) 
I 
FB (3.15b) 
I nly, 
" 
By substituting expressions (3.15a) and (3.15b) into (3.14a) and (3.14b) respectively and 
remembering that for an undisturbed system H'TO, = E,, TO,, we have 
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( Eox 0= eL -) Vf'o h Y- A VI (3.16a) 
12 
eLEo-Q o h B, . (o). - oil + w) V/10 == --- - V/. - (3.16b) 2 
By multiplying both sides of these equations by V/10 * and integrating over all space, 
bearing in mind that VIkO * and V/, o are orthogonal, we have 
h (w,, - o), - w) A,, I=If Vfto LE 0. r) v/, 
O, d, r (3.17a) 2 
h (oj,, - o)k+w)B,, k= 
e io . LE 0. rE 21 -)Vf. 
od-r. (3.17b) 
The quantum-mechanical expression for the dipole moment, Dk.,,, induced by the field 
E(t) that corresponds to the transition from state k to state n is expressed as: 
2k,, = -e 
fT, '* (r, I)dr. (3.18) 
so that we may rewrite equations (3.17a) and (3.17b) as 
Ank 
fo-2kll (3.19a) 
2h (wa - o)) 
B., 
f ODI,, (3.19b) 
2h (co,, k + w) 
wbere (Onk ý-- ((N - 4) is the transition frequency between energy states n and k. 
It must be noted that the above expressions are only valid for frequencies of incident 
radiation that are not too close to one of the natural frequencies of the molecule, q'k- It is 
possible to take into account Raman scattering that occurs at or near resonance by 
introducing a damping constant into the denominator, which describes the finite lifetime 
of each molecular state. However, the quantum-meclianical treatment for resonance 
Raman is beyond the scope of this chapter, it is explained further in a number of 
teXtS. 148,154 
If we substitute the above expressions for Ank and Bnk into (3.15a) and (3.15b) and the 
expressions for Un and V,, into (3.12) we can obtain an approximation for the wave 
function of the system when the incident radiation is 'switched on'. 
fDED ý0*4:: ýLn vilo ur- vfo(r) T. (r, Ur e-", ý -- Vt. E Y, 2h j 2h 4 0)"A + 0) 
(3.20) 
If we now calculate the dipole moment Rnn(09 which is induced by the field 17 , in the state 
T, 'O,, the electric dipole moment of the new state T. (r, t) is given by 
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fnn = -efT, *, (r, l). r. T,, (r, t)dv = -eft, (r, t)l'. r. d-r. (3.21) 
The square of the modulus of the wave function can be approximated to within first-order 
terms in Eo as 
einx E Dk 0.0 E Di tyn  0.0 j!:: Lo »-- kn -1 ýý4 0 'e: Lkn - vf, - _ _ýt - V/i Vf. 
2h k wa -w k Wnk 
+W 
(3.22) 
-lag lax ýG, oý. D eZ foDkit ()*v 0- ()* () 
2h k 2h k wk 
+w 
vli Vn 
Therefore by substituting into (3.2 1) and using expression (3.18) to simplify we obtain 
tat LEOD*,, )Dk,, 
Dm -eZ 
LE w-D, n)Dn + 
2h k 0), a - 0) wnk + (11 
(3.23) 
e-lox LE o -DkX2k,, + 
(fo-2ýVh. 
2h co,, t +w 
fonk - (o 
We can see from expression (3.23) that the electric-dipole moment P"n(t) is made up of 
two components: a time independent dipole moment D. and the induced dipole moment, 
which depends linearly on the electric field strength. Dn is the mean electric dipole 
moment of the atom or molecule in the state n. The induced dipole moment is a periodic 
function of time and has a frequency equal to the frequency of the incident radiation (0. 
Tile phase of the oscillating dipole moment is directly related to the phase of the electric 
field vector in the incident radiation. This moment represents coherent scattering or 
Rayleigh scattering. 
To describe an inelastic scattering process using the above ten-ninology it is necessary to 
consider the additional dipole moment, pn, that is induced by incident radiation in a 
quantum mechanical system during its transition from state m to another state n. This can 
be described by developing expression (3.21) 
f.,, (1) = -e 
fT, *,, (r, 1). r. T,, (r, I)dv (3.24) 
State "11, (r, 1) results from V/, ' , 
(r) exp(-iw,, I) under the influence of the incident radiation 
and state T (r, I) results from yl, ',, (r)exp(-iw t)under the influence of the same 
radiation. By substituting into (3.20) we obtain 
lwt JIK-W)t ED e-I(Wý+w)t ED o*I: ýin 0 '%" -0--in 0 
2h Wnk - (0 2h k WM+W 
(3.25a) 
and 
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ei(W. --W)fj: EotDj,,, V, OU r 2h I 0). k -W 2h a Wk + 0) 
(3.25b) 
These can then be inserted into (3.24) to provide us with the following expression 
f. (1) = ý2. e"-' + D(+)e'(-")' + D(-)el('--)' (3.26) OW -MR 
where L2(+) =-I+ (3.27a) mn 2h k 
t' 
(j), a - o) 0)"k 
+ 0) 
1 
2(-) =_11: 
(EOD,,, )!?. a + 
LEO. 2,. k)2j,, 
mn 2h Af w4 +w W'a -W 
I 
(3.27b) 
The dipole moment D unction of time with a frequency (LN,, n, there are two , nn is a periodic f further dipole moments induced by the incident radiation for which the frequencies are 
given by w=oj. ±co. The dipole moment D determines the emission and absorption 
of radiation for the transitions Em, #>En. The additional dipole moments D(4, ) and D(-) are -M" HM 
responsible for the inelastic scattering of the incident radiation. The change in frequency 
is given by the sum or the difference of the frequency of the incident radiation, (0, and 
one of the natural frequencies w. = 
E,. E. 
of the system. In order to determine the h 
intensity of the scattered radiation, it is necessary to use the correspondence principle, 
which states that an atom or molecule emits and absorbs radiation as if it were a set of 
classical oscillators. 
From equation (3.26) we can see that we have three oscillators to take into account: 
mn _Mn 
Blokhintsev (1964) 155 showed that using Einstein's equation for the probability of 
absorption per second of a photon with energy, hw. = (E. -E. ), it is possible to derive 
an expression for the radiation emitted per second into a solid angle dK2 as a result of the 
transition m --> n. By taking into account 0. the angle betwecn the dipole vector D., and 
the direction of propagation of the incident radiation and integrating over the total solid 
angle Q an expression for the total radiation emitted per second can be obtained 
WJ4 dE 
=r.. 3 
IDMn 12 (3.28) 
di 32jr2EOC 
This expression can be modified to yield the following equations for the scattering 
intensity at the frequencies oj'= o),.,, +w and w' = oj.,, -w 
39 
Anti-stokes scattering: 
dE' (w +4 ID (+) 12 (3.29a) 
dl 32; r2e 0 C3 
mn 
dEff (w. n _ W) 
4 
ID(_)12 
Stokes scattering: - ; r246OC3 mn (3.29b) dt 32 
In order to determine the absolute intensity of the scattered radiation at the frequencies 
CO J. and (o, equation (3.29a) must be multiplied by the number of atoms, N. in the 
excited state m (see Figure 3.1), and equation (3.29b) by the number of atoms, N,, in the 
lower energy state n. 
Anti-Stokes scattering intensity: I'= N 
12(+)12 
32; r2COC3 mn 
Stokes scattering intensity: I" = N,, 
12(-)12 
32; r26OC3 mn 
E=hV II E=hvmk 
(a) 
E=hv E=hVnk 
En, 
ir En 
(3.30a) 
(3.30b) 
Figure 3.1 Diagram showing the energy states of a system Involved in Stokes (a) and anti-Stokes 
Raman scattering (b). 
Finally, the above expressions can be developed to yield a description of the scattering 
intensity in terms of the intensity of the incident light, 10, and the molecular polarisability, 
(x. The time-averaged value of the magnitude of the Pointing vector 156,157 
io C-0. if, o (3.31) 2 
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gives us the irradiance or energy per unit area per unit time incident upon the scattering 
molecule. By manipulating (3.27a) and (3.27b) we can obtain 
2(,. ) = 
ýEo 
--Lzf 
Din 12mk D. 
k -Din 
I) 
(3.32a) mn 2hL vni -v 
+ 
vj +v 
fj 
D(-) = 
JEOI 1 
[Dln*j2mk 
Dk. Djý, J) 
mn 2hk+v., A - 1, 
fj (3.32b). 
The components Nvithin the round-brackets in equations (3.32) are in effect components of 
the polarisability tensor of the molecule, which can be written in the more general form, to 
take into account all orientations of the molecules, 
(aij ). =-IE 
(Di),,, (Di). t + 
(DI). a (Dj)Ln (3.33) 
hk va -v 1,. k +vI 
where the Vh element represents the direction of the induced dipole moment and jh element 
represents the direction of the incident electric vector. 
Therefore by substituting (3.33) into (3.32) summing over all orientations of the scattering 
molecules and then combining with (3.31) we can develop expressions (3.30a) and (3.30b) 
to give us 
anti-Stokes scattering intensity: I'= 
r-N., 
- 10 - (v.,, + v)' - (3.34a) 4c4 E02 Y 
2 
Ijp= _. N 
I . (V _V)4. 
El( 12 Stokes scattering intensity: 0 mn 
(3.34b). 
C Ej 
These expressions can be reduced to 
I 
p=-=K- (v,,, 
n 
+V)4 . 
1: 1(ay)mnl2 (3.35a) a. 10 N. u 
a: n ==K- 
(ilmn _ V)4 (3.35b) 
10 - Nn 
to give us expressions for the cross sections for Raman scattering, a, in terms of the 
scattered intensity per molecule, per incident irradiance, for a given vibrational mode. K is a 
constant. In die situation where die excitation energy of die photons is far from that required 
to excite electronic absorption, as in die case of using near-infmrcd light, e. g. v, 'k. >> v, then 
the polarisability tensor is approximately independent of die frequency (equation 3.33). This 
allows us to understand die relationship between the Raman scattering intensity and tile 
frequency of the incident light using tile remaining function of v in expressions 3.35. For 
individual vibrational modes the frequency dependence of die scattering intensity will vary 
slightly. 
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Rearranging expression (3.35) 
07mn 
K'= (V n± V)4 (3.36) 
K 
12 
Y 
which gives us an expression for a new factor of proportionality, K and 
In K'= 4 ln(v.,, ± v) (3.37) 
when v Vmn (for vmn = 0), becomes a linear relationship and (yn, is proportional to ý, -4. 
Log-log plots of the relative scattering cross-section for two Raman lines with widely 
different values of v,, In are shown in Figure 3.2. Deviation from the 
ideal X4 dependency of 
the scattering cross-section is shown to be greater for larger values of V,,,,. For higher 
frequencies of laser excitation, where energies approach those to excite electronic absorption 
Albrecht'58-159 has provided an expression for the scattering cross-section taking into 
account the dependency of the polarisability tensor on the incident frequency (not included 
here). 
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Figure 3.2: Log-log plot of the relationship between Raman scattering cross-sections and excitation 
wavelength for two Raman scattering peaks. The relationship depends upon the fourth power of the sum 
or the difference of the excitation frequency and the vibrational frequency of the peak. See equations 
3-36. 
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4. Materials and Methods 
4.1 Materials 
The biological tissues studied in this work were selected because they exhibited the 
characteristic that the development of cancer in these tissues passes through an 
intermediate neoplastic (abnormal) step, which may be detected to allow treatment prior 
to invasion of deeper tissues. 
4.1.1 Larynx Tissue 
Thirty-five patients participated in this preliminary study. Their ages ranged from 18 to 
79 years of age, with a median of 53 years of age. Informed consent was obtained from 
each patient and the study was approved by the United Kingdom South and West Local 
Research Ethics Committee. 
Forty-one biopsy specimens (3x3x3mm3) were collected during routine surgical 
procedures (microlaryngoscopy) and snap frozen in liquid nitrogen. Histological sections 
were cut from each of the samples using a freezing-microtome (Figure 4.1) and stained 
with haematoxylin and eosin (H&E). The remaining biopsy blocks were stored at -850C 
until spectroscopic studies could be carried out. The larynx sections were classified by a 
pathologist as normal squamous epithelium; squamous dysplasia and squamous cell 
carcinoma. The procedure used for this histopathological classification is explained in 
Appendix 1. For the purpose of this study, with limited numbers of samples, mild, 
moderate and severe dysplasia were grouped together. 160 Only homogenous samples with 
clearly defined pathologies were used in this investigation and those with mixed or 
indeterminate pathologies were discarded. Twenty-five samples were retained for 
analysis with Raman spectroscopy, including fourteen histologically normal samples, five 
exhibiting dysplasia and six with squarnous cell carcinoma. Prior to carrying out spectral 
measurements, the specimens were passively warmed to room temperature and rinsed 
with phosphate buffered isotonic saline solution (pH 7.4). 
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Backing paper 
Discard 
20um slice for Raman mapping 
7um slice for histological grading 
Figure 4.1 Orientation of biopsy block for sectioning with a freezing microtome. Samples were laid 
on acetate paper prior to being snap frozen. 
4.1.2 Oesophagus Tissue 
Jumbo biopsy samples have been harvested from patients undergoing endoscopic 
surveillance for dysplasia in Barrett's oesophagus. During the endoscopic procedure 
routine biopsy samples were removed at all four quadrants, every 2 cm in the region of 
Barrett's metaplasia in addition to areas exhibiting a suspicious appearance, such as 
ulceration or polyp. The patients involved in this study have provided written consent for 
a small number of additional biopsies to be taken from normal squamous epithelial 
mucosa as well as areas of columnar epithelium (Barrett's mucosa). Ethical approval for 
this procedure has been given by the Gloucestershire Local Research Ethics Committee. 
4.1.2.1 Snap frozen tissue 
Tissue samples were removed from the biopsy forceps and orientated on acetate paper (as 
shown in Figure 4.1) to enable a depth cross-section through the tissue to be seen. The 
mounted sample was then placed in a 2ml criovial (BDH) and dropped in liquid nitrogen. 
Histological sections were cut from each of the samples using a freezing-microtome (Figure 
4.1) and stained with haernatoxylin and eosin (FI&E). The use of the acetate backing paper 
made it possible to stick the sample to the microtome using only water and thus give no 
chemical contamination to the tissue sample. 
The H&E stained sections were sent for histopathological analysis by between one and 
three gastrointestinal registry pathologists. Samples were histopathologically graded 
following the procedures outlined in Appendix 2; those samples demonstrating mixed 
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pathologies were rejected. The remaining biopsy blocks were stored at -850C until 
spectroscopic studies could be carried out. 89 homogeneous samples, collected from 45 
patients, exhibiting 9 different pathological states in the oesopliagus were retained for 
study with Raman spectroscopy. Prior to carrying out spectral measurements, the 
specimens were passively warmed to room temperature. No other sample pre-treatment 
was performed. 
4.1.2.2 Formalin fixed tissue 
Following the above protocol for sample collection and histopathological analysis, a 
random selection of homogeneous samples were placed in a buffered 10% formalin 
solution. 42 oesophageal. biopsy samples from 19 patients were used in this study. 22 
samples were stored for 18 months at room temperature, in individual criovials 
containing fixative solution, and a further 20 samples were stored for 2-3 weeks prior to 
measurement. This allowed comparison of the effects of storage time on tile Raman 
spectra and the facility of Raman spectroscopy of formalin fixed tissue to discriminate 
between pathology. 
4.1.3 Other Tissues 
The following tissues were also collected to evaluate whether NIR Raman spectroscopy 
could be used in ftiture work to study the pathogenesis of early malignant changes and 
detect abnormal lesions in vivo. Small numbers of these samples have been harvested, snap 
frozen, microtomed, histopathologically analysed and measured. 
1. Stomach. 
2. Tonsil. 
3. Endometrium. 
4. Bladder. 
5. Prostate. 
4.2 System Configuration and Characterisation 
A custom Raman spectrometer has been developed, from a commercially available 
Renishaw System 1000 microspectrometcr, to facilitate the measurement of high signal- 
to-noise Raman spectra from biological tissue in short time-scales. A schematic of tile 
customised Renishaw spectrometer is shown in figure 4.2. The following section will 
outline the system configuration and process of optimisation. 
A high power tuneable laser source was coupled to the spectrometer and a Leica DML 
polarised light microscope. Diffraction gratings (G I and G2 in Figure 4.2) were required 
to reject the spontaneous emission from the laser. A backscattering sample geometry was 
used with a laser line rejection filter restricting entry to a single monochromator and CCD 
array detector. For stability, the whole apparatus was rigidly bolted in position on a 3m x 
ImxI Ocm thick Melles-Griot optical bench. 
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The laboratory system was particularly large and required three-phase power and mains 
water cooling. Should the technique of Raman spectroscopy evolve to be used within a 
hospital environment, it would be necessary to miniaturise the system to fit upon a small 
trolley. In addition the system would have to run off 240V mains electricity with no 
external water cooling. This would be possible with the use of a single wavelength 
semiconductor laser; a miniaturised single monochromator and CCD detector; fibre-optic 
light delivery and collection; and laptop PC control. However, as an initial step towards 
this goal it was necessary to have the most flexible system available, with the ability to 
precisely visualise where in the tissue sample the spectra were being acquired. 
Ar ion laser 
Ti: Sapphire GI 
laser 
G2 
III 
PC 
Renishaw System 1000 
Control 
Raman Spectrometer CCD 
ik 
Detector 
Leica Confocal N"'N Sample 
Microscope 
Figure 4.2: Schematic diagram of customised Raman system. G1 and G2 are diffraction gratings 
used to reject spontaneous emission from the Ti: sapphire laser. 
The basic components of the Renishaw System 1000 spectrometer are shown in figure 4.3. 
They are labelled alphabetically to indicate the order that the incident light follows through 
the system. A is a steering mirror used to direct the laser light entering the spectrometer 
along the horizontal axis. B is a beam expander, usually used to fill the aperture of the 
microscope objective. This component was removed from the custom system used for this 
work, because use of the x80 ultra-long-working-distance lens for illumination and 
collection at the sample made the beam expander redundant (due to the tiny lens aperture). C 
is a further beam steering mirror to direct the laser light at the laser-line rejection apparatus. 
D/F, the laser-line rejection apparatus, reflects light at the wavelength of the laser line and 
allows light of energy with greater than 150cm-1 shift to pass through. Hence excitation light 
is reflected off the surface of the filter and directed to the microscope E. Following 
illumination of the sample, the collected light is redirected horizontally at the laser-line 
rejection filter. Light with the laser wavelength is reflected off-axis and the rest of the 
collected light is allowed to pass through to the focussing lens G. Lens G focuses the 
collected light on to the monochromator entry slit H. The slit H is used to reject scattered 
light from the out-of-focus sample volume. This improves spatial resolution and removes 
the fluorescence contribution from the out-of-focus sample volume. I is a beam expanding 
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lens. Component J is a prism mirror with two reflective surfaces that direct the light to the 
grating K and collect the dispersed light from grating K. The grating disperses the collected 
light into its constituent wavelengths. It is mounted upon a precision rotational stage to 
allow selection of the spectral range for detection. L is the CCD focussing lens and M is a 
Renishaw built CCD array detector sensitive in the near-infrared region. 
M 
-0-70 
Figure 4.3: Internal diagram of Renishaw System 1000 microspectrometer. Labels indicate the 
sequence that the incident light follows through the system (reproduced by kind permission of 
Renishaw spectrometer division). 
To enable a greater understanding of the transfer of energy through the system to a 
sample on the microscope stage, the laser power has been measured following each 
component. The losses at a few selected components is shown in Table 4.1; it can be seen 
from this data that the greatest loss of light energy occurs between the laser line rejection 
filter (on first pass) and the objective lens. The majority of this loss is due to the 
relatively small aperture at the back of the x8O ultra-long-working-distance lens and the 
large size of the laser spot in this plane. This can be observed by comparing the x80 
objective throughput/loss with that using the x20 objective, in brackets in Table 4.1. 
System component (after) Power measured / mW Loss / dB 
Ti: Sapphire Laser head' 506.7 - 
Plasma rejection gratings (G I& G2)* 388.1 0.12 
Mirror (A)' 353.3 0.04 
Mirror (Qý 330.7 0.03 
Laser line rejection filter (D)ý 181.0 0.26 
X80 ULWD objective flý 61.4 0.47 
[X20 objective (E)ý 113.3 0.20] 
Laser line reiection filter (F)4 0.0064 (Raman) - 
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Table 4.1: displaying the laser power losses at each significant component in the Raman spectrometer 
system. Components labelled with a 1*1 can be found in Figure 4.2 and those labelled with a I§Ican be 
found in Figure 4.3. 
The remainder of the System Configuration section is separated into sub-sections 
focussing on key individual components in the system. 
4.2.1 Excitation Source Selection 
The Raman excitation source chosen for the work outlined in this thesis was a Spectra- 
Physics Ti: Sapphire laser (Model 3900S), pumped with a Spectra-Physics Argon ion 
laser (Stabiliteg 2017). The pump laser produced up to six Watts of laser power using all 
emission lines. The combined laser system provided a stable high power monochromatic 
source of light with wavelength flexibility; thus enabling selection of the optimum 
wavelength of excitation to produce Raman spectra with low fluorescence and a high 
signal to noise ratio. The range of tuneability is between 750 and 950nm, with peak 
power at 790nm. The linewidth is less than 40GHz and the power is stable to less than a 
3% drift in any 2 hour period after warm-up for less than ±YC temperature change. 161 
The laser was configured with a double set of Melles Griot@ diffraction gratings (1200 
lines mm7l) to reject the spontaneous emission from the Ti: Sapphire laser. These gratings 
were positioned to enable the monochromatic radiation to be directed onto the entry 
miffor of the spectrometer (see figure 4.2). 
Selection of the optimum wavelength was achieved following measurement of tissue 
Raman spectra at selected wavelengths across the visible and NIR range. These 
wavelengths were chosen to correspond to available holographic notch filters for 
rejection of specular reflection, diffuse reflection and Rayleigh scattering at the laser 
wavelength. A Renishaw system 1000 microspectrometer was used for all measurements, 
with the entrance slit set to 100grn and incorporating a 1200 lines min-1 diffraction 
grating. Spectra of nonnal squamous mucosa from the oesophagus were acquired with 
excitation wavelengths of 514.5,633,785,830, and 860nm. Laser powers were 32mW at 
the sample through a x80 objective for measurements at 785run, 830mn and 860mn; and 
spectra were integrated for 30 seconds. Spectra acquired at 514.5 and 633mn were 
integrated for 300 seconds with 8mW of power through a x50 objective at the sample. 
The power density used in the acquisition of spectra in the NIR was approximately ten 
times that for the 514.5 and 633mn (visible) measurements. Therefore the use of a longer 
integration times for the visible wavelength Raman measurements enabled spectra with 
equivalent 'power density x integration time' products to be acquired, thus facilitating a 
more enlightening comparison between spectra at different wavelengths. The resulting 
raw spectra are shown in Figure 4.4, with the exception of that acquired at 514.5nin 
which demonstrated no visible Raman peaks within a large fluorescence background. 
Table 4.2 displays the signal-to-noise ratios (SNR) of the measured spectra at selected 
peak positions in the spectra (Figure 4.4). The SNRs were calculated by measuring the 
baseline corrected peak intensity and dividing it by the mean amplitude of the noise 
across the peak of interest. 
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Raman spectra of normal oesophagus 
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Raman spectra of normal oesophagus 
RamanSNft(cm-1) 
Figure 4.4: Plots showing differences in raw Raman spectra of normal squamous mucosa 
(oesophagus) at various excitation wavelengths. Spectra (a) at 785,830, and 860nm were recorded for 
an integration time of 30s with 32mW of power at the sample, and the spectrum (b) at 633nm was 
measured in 300s with 8mW at the sample, other spectra are included in the same intensity scale. 
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Wavelength 
/nm 620 ern-1 
Signal-to-Noise Ratio 
850 cm7l 900 crn71 
(at wavenumber shift) 
1250 cnfl 1445 cm-1 1650 cm-1 
633 1.4 1.6 3.9 4.0 9.8 7.2 
785 4.6 4.3 5.6 9.7 10.5 10.4 
830 15.1 6.8 10.9 15.0 18.5 11.0 
860 2.5 2.3 4.3 3.0 8.4 2.4 
Table 4.2: Comparison between signal-noisL, -ratios of Raman spectral peaks from normal oesophagus 
tissue at various wavelengths. 
The choice of the optimal excitation wavelength for measuring biological tissue must be 
balanced between the e dependence of the Raman cross-section and the fact that at higher 
photon energies, greater fluorescence signal is induced. The optimum range generally falls 
between 750 and 850nm. Nevertheless, despite the relatively high SIN, the resulting tissue 
Raman spectra still contain a fluorescence background. A challenge in achieving a useful 
tissue Raman signal is the accurate subtraction of the fluorescence signal. This is vital 
because in most Raman techniques the fluorescence and weaker Raman signals lie in the 
same spectral region. Among the techniques available to minimise the fluorescence 
contribution to the Raman spectrum, the best method for the current analysis appears to be 
selection of the optimum wavelength of excitation to minimise fluorescence in the fust 
place. From the spectra shown in Figure 4.4 it is evident that spectra acquired excitation 
wavelengths between 785nm and 830nm are optimum. The excitation wavelength of 830nm 
was shown to optimally balance the trade-off between the X4 Raman cross-section 
dependence, and the reducing fluorescence and detector sensitivities with increasing 
wavelength. Anecdotally, spectra acquired at 830mn also had much greater repeatability in 
terms of background fluorescence. At 785nm fluorescence was common enough to cause 
complete saturation of the detector with up to 30% of spectra due severe fluorescence, and 
large backgrounds due to moderate fluorescence in around 30% of spectra. At 633nm it was 
usually necessary to photobleach the chromophores prior to measurement, otherwise it was 
almost impossible to distinguish the Raman signal from the Shot noise. At 830nm about 1% 
of spectra were affected by severe fluorescence. 
4.2.1.1 Stability of laser output characteristics 
The Ti: sapphirc laser warm up characteristics and long term temperature stability at 
830nm were measured following power-up of the Argon ion pump laser. The laboratory 
was heated with a ccntml-hcating radiator and cooled with a Fujitsu Superwavc 
unidirectional (cooling only) air conditioning unit. 
The power output stability was measured during the first two hours after switching on the 
laser. A calibrated Newport photodiodc (detector 818-SL) fitted with neutral density filter 
(OD3) coupled to a Newport optical power meter (model 840) was used to measure the 
laser power every 15 seconds. The ambient temperature was measured with a calibrated 
thermometer at one minute intervals. Figure 4.5 shows a plot of the laser power output 
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and ambient temperature versus time from power-up. The laser power can be seen to 
change drastically in the first 30 minutes from switching on. It then tends to stabilise and 
cycle ±0.1% over 5 minute time scales, combined with a gradual drift in power of up to 
0.5% below the average over a period of a couple of hours. It can also be seen that the 
laboratory temperature changed rapidly in the first 30 minutes, followed by a more 
gradual rise to an equilibrium temperature. Thus it can be concluded that heat dissipation 
from the laser raises the ambient temperature. 
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Figure 4.5: Plot of Ti: sapphire laser output power at 830nm versus time and ambient temperature 
versus time. 
The wavelength stability of the Thsapphire laser at 830nm was evaluated by measuring 
the Raman spectrum of crystalline sulphur every minute over the wan-n up period and 
beyond. The power levels were set to those required for measurement of Raman spectra 
of biological tissue (500mW in this case). Air conditioning was set to #7 on a scale of one 
to ten. Spectra were acquired for I second. Figure 4.6 shows a typical crystalline sulphur 
spectrum measured at 830nm, with power at the sample of approximately 32mW. The 
wavenumber position of the sulphur peaks was mapped across the acquired spectra by 
utilising an Array Basic@ program written for GRAMS/320 (GalacticO). The resulting 
wavenumber positions, for the 219-220cm7l sulphur peak were plotted individually 
against time to enable visualisation of the wavenumber drift in the laser output (Figure 
4.7). 
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Figure 4.6: A typical Raman spectrum from crystalline sulphur measured at 830nm, in 1 second, 
with 32mW incident laser power. 
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Figure 4.7: Plot of peak wavenumber position of sulphur line at around 219-220cm"l versus time to 
enable visualisation of the laser wavelength drift. 
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Further adjustments were made to the laboratory and experimental apparatus to improve 
the temperature and mechanical stability of the system: 
1. The temperature stability of the laboratory was improved by installing a two-way 
feedback loop temperature control system. This relied upon the air conditioning unit 
to cool the room and a thermostatically controlled fan heater to heat the room. This 
produced ambient temperature of 23.5'C ± PC over a period of days. 
2. The cooling water flow was reduced to the minimum required to prevent automatic 
shutdown of the argon ion laser. This reduced the internal vibrations caused by 
turbulent flow through the system. 
3. The locking bolts for the focussing mirror and the Thsapphire rod were tightened to 
prevent any unwanted translations caused by vibration. 
4. The aperture of the argon ion laser was reduced to provide single mode TEMOO output 
(aperture position #5). 
5. The Thsapphire laser was realigned and peaked for 830mn. 
6. The Raman spectrometer was realigned, with Raman signal maximised. 
Following the apparatus optimisation outlined above, the warm up characteristics of the 
laser were measured again by taking consecutive sulphur spectra at one minute intervals. 
The position of the 219-220cm7l peak is plotted out in Figure 4.8. 
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Figure 4.8: Plot of peak wavenumber position of sulphur line at 219-220cnf 1 versus time to enable 
visualisation of the laser wavelength drift, showing improved wavelength stability following 
apparatus improvements. 
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Prior to installation of the two-way temperature stabilisation of the laboratory, the laser 
output drifted by between I to 2 cm7' per hour. Following the improvements outlined 
above, the laser output was found to be stable to =1: 0.15 cm-1 over many hours (up to 24), 
provided that the laser had been warmed up for in excess of one hour. 
4.2.2 Sample Presentation Configuration 
The sample presentation configuration includes the illumination and collection geometry, 
the orientation of the sample and the container or backing substrate holding the sample. The 
use of a microscope for illumination and collection of scattered light dictated the use of a 
180' backscattering geometry. This relies upon fairly complex optical system design, but the 
overlapping axes of laser and collection optics significantly simplify alignment of 
illumination and collection volumes. The excitation beam is introduced into the system via a 
beam splitter. A schematic diagram of the sample presentation configuration is shown in 
Figure 4.9. The following section outlines the assessment of the important features to 
achieve high quality spectra from an accurately defined position in the tissue sample. 
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Figure 4.9: Schematic diagram of the 180* backscattering geometry employed to measure tissue 
Raman spectra. 
4.2.2.1 Illumination/Collection Optics 
Optimum selection from the available objectives for the Leica DML polarised light 
microscope was made by evaluating the relative power density achievable; the collection 
efficiency; the practical working distance and the contribution to the signal from 
fluorescence and Raman scattering in the optics. The objectives that were available are 
listed in Table 4.3, with the inclusion of important speciflcations for illumination and 
collection efficiency calculations. 
The simplest method of increasing the Raman scattering signal is to raise the power 
density of the excitation beam. However, this may cause sample damage especially in 
biological samples. Therefore, once fluorescence is minimised by wavelength selection, 
then maximising collection and detection efficiency must be a priority for tissue Raman 
measurements. 
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The collection efficiency of Raman scattered photons is described by the fraction of the 
(4n steradian) solid angle around the sample volume that subtends the collection optics. If 
an assumption is made that the Raman scattering intensity is independent of direction, we 
can study the effect of lens characteristics upon the collection efficiency. The example of 
two typical objectives used for Raman scattering collection is outlined below. 
The solid angle collected by an optic is described by 
92=2z(l-cosO) 
where the angle 0 is the maximum angle of collection from the optical axis of the lens. 
See Figure 4.10. 
Figure 4.10: Line drawing enabling visualisation of the collection angle of a typical microscope 
objective. The angle 0 is the maximum angle of collection of the lens, the length R is the radius of the 
collection area at the distance L away from the lens aperture. 
A commonly used lens specification is the 'NA' or numerical aperture. This effectively 
describes the collection angle of the lens and follows the relation 
no sin 0 (4.2) 
where no is the refractive index of the material surrounding the outer surface of the lens, 
e. g. most commonly this is air (no; =: I). If we look at the following example of two typical 
microscope objectives it is possible to gain an understanding of their relative collection 
efficiencies. A x20 objective with a N. A. of 0.4, has a maximum collection angle, 0, of 
23.6'. This relates to a solid angle Q (equation 4.1) equal to 0.52 steradians and hence a 
collection efficiency of 4.2%; whereas a x80 objective with a N. A. of 0.75, has a 
maximum collection angle, 0, of 48.6*. This relates to a solid angle 92 equal to 2.13 
steradians and hence a collection efficiency of 16.9%. There are obvious advantages to 
collecting a greater fraction of scattered photons from the sample, but there are other 
factors to consider. Generally a lens with a large numerical aperture will have a shorter 
practical working distance. In addition lenses with larger numerical apertures will have a 
shorter depth-of-field. Therefore using a lens with a large numerical aperture will enable 
spectra to be acquired from more accurately specified sample volumes. 
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Lens 
(manufacturer/ 
magnification) 
Fabrication Numerical 
Aperture 
(NA) 
Collection 
Angle 
(degrees) 
Collection 
Efficiency 
M) 
Power 
Density* 
(KW/cM2) 
Leica x5 NPLAN 0.12 6.89 0.36 2.7 
Leica x20 NPLAN 0.4 23.58 4.17 42.4 
Leica x50 NPLAN 0.75 48.59 16.93 256.3 
Olympus x20 MDPLAN 0.4 23.58 4.17 42.4 
Olympus x80 MIRPLAN 0.75 48.59 16.93 679.1 
Table 4.3: A list of the available microscope objectives with the important specifications for use in 
illumination of the tissue sample and collection of Raman signal from the sample. * The power 
density is calculated for a power at the sample of 32mW. 
The contribution to the Raman signal of the objective lenses in the beam path was 
evaluated by measuring spectra with the laser spot focussed on a clean chromium surface. 
Spectra were acquired for either 10 or 30 seconds with a laser power of 10 or 32mW at 
the sample. Raman spectra of biological tissue will include unwanted contributions from 
any fluorescence or Raman scattering that occurs within the optics. Figures 4.11,4.12, 
and 4.13 show the resulting spectral contributions from the various microscope objectives 
available at 785,830, and 860nm respectively. It must be noted that it is not a trivial 
process to subtract the noise signal from a Raman spectrum, because the level of 
contribution will depend upon the amount of light scattering and reflecting back from the 
sample. Therefore the goal must be to reduce this contribution to a minimum. Variations 
in relative signal levels from one objective to the next are likely to be due to variable 
fluorescence excitation bands in the assorted compound optics found within each 
objective. 
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Figure 4.11: A comparision of spectral contributions from different ill u mination/collection optics. 
The spectra were excited from a clean chromium surface at 785nm excitation (IOmW) and with an 
integration time of 10s. 
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Figure 4.12: A comparision of spectral contributions from different ill u mination/collection optics. 
The spectra were excited from a clean chromium surface at 830nm excitation (32mW) and with an 
integration time of 30s. 
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Figure 4.13: A comparision of spectral contributions from different ill u mination/collection optics. 
The spectra were excited from a clean chromium surface at 860nm excitation (32mW) and with an 
integration time of 30s. 
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The effect of power density on the signal-to-noise ratio of tissue Raman spectra was 
assessed very simply by using a x80 objective, to produce a fixed elliptical laser spot of 
diameters 2 and 3gm (short and long axes respectively) at the focus, and changing the 
laser illumination power. The resulting spectra can be seen in Figure 4.14. The SIN ratios 
of the spectra versus power density are tabulated in Table 4.4. 
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Figure 4.14: Raman spectra of oesophagus tissue (with low grade dysplasia) showing the effect of 
power density on the signal-to-noise ratio. Spectra were acquired in 30 seconds using a x80 objective. 
Power / mW Power density KW/cM2 S/N Ratio 
10.3 218.6 3.8 
18.8 398.9 7.5 
37.5 795.8 17.0 
102.6 2177.2 63.0 
Table 4.4: Signal-to-noise (S/N) ratio versus power density for oesophagus spectra measured at 
830nm, in 30 seconds with a x8O objective. The S/N ratio was calculated for the 1445cm"l peak. 
The selection of the optimum microscope objective for measurement of tissue Raman 
spectra in the NIR has involved assessment of many characteristics. The x8O, MIRPLAN, 
ultra-long-working-distance lens provides the greatest collection efficiency; the smallest 
spot size and hence the greatest power density; the lowest background contributions to 
the Raman signal; and the greatest practical working distance of any of the available 
objectives. 
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4.2.2.2 Backing Substrates 
Tissue samples were mounted on a backing substrate prior to being positioned under the 
microspectrometer. Selection of the correct substrate was critical for thin tissue samples 
where the fluorescence or Raman signal from the substrate could exceed that from the 
sample. Signal contributions from a number of commonly available substrates were 
assessed by illuminating them with 60 mW of 830nm laser light and collecting the 
scattered light for 10 seconds. Figure 4.15 shows the signal contribution from uv-grade 
quartz, uv-grade calcium fluoride, glass slide and stainless steel. All the materials tested 
show some inherent Raman or fluorescence signal, however if the sample to be measured 
has spectral information at a different wavenumber position, then little interference 
should result. Calcium fluoride appears to be the ideal backing substrate for biological 
tissue measurements, with only one strong Raman peak at 323cm-1. The fingerprint 
region for most tissue Raman bands lie within the region 400 to 1800 wavenumbers. 
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Spectral contributions from backing substrates at 830nm 
Figure 4.15 spectral contributions from some typical backing substrates at 830nm, with 32mW laser 
power at the sample, x80 objective, T=10s. 
4.2.3 Spectrometer Configuration 
The spectrometer used in this work utilises a single dispersion grating coupled to a charge 
coupled device (CCD) array detector. This offers a system with the advantage of higher 
signal throughput, and one that can use higher numerical aperture collection optics that 
facilitate high collection and detection efficiencies. However, a single grating gives poor 
y light rejection. The elastic scattered light (at the laser wavelength) can equal 10-' to stra 
10- of the laser intensity at the sample. This is many orders of magnitude greater than the 
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Raman signal. Hence the first priority of a spectrometer must be to reject or separate out 
the signal at the laser frequency. 
The additional stray light rejection required by the single monochromator was achieved 
using band rejection or notch filters, with the region of rejection covering the laser 
wavelength. Dielectric notch filters constructed of alternating layers of high- and low- 
refractive index materials have been used initially by spectroscopists. However, they have 
been replaced for most applications with holographic notch filters. Holographic notch 
filters (HNF) are constructed from a gelatin film encapsulated in glass, with a refractive 
index profile varying sinusoidally with depth fixed in the gelatin. The rejection band can 
be varied in wavelength by varying the period of the oscillations in refractive index. 162 HNFs have been constructed to reject wavelengths ranging from the UV to the NIR, 
with optical densities in the rejection region of greater than 6. The attenuation band of a 
holographic notch filter shifts to shorter wavelength as the angle between the incident 
light and the normal to the surface increases. 163 In addition, the notch-filter performance 
degrades and becomes polarisation dependent as this angle increases. The transmission 
region has a very smooth profile, in contrast to dielectric interference filters, and low 
Raman shifts of the order of 50 to 100cm7l can be observed using holographic filters. 
They are currently the most common laser line rejection filters for single monochromator 
Raman spectrometers. 
The main disadvantage of the monochromator-notch filter combination is that a different 
filter is required for each wavelength, thus the flexible tuneability of triple 
monochromators is hard to achieve without multiple notch filters. 
4.2.3.1 Laser-line Rejection Filter 
A comparison was made between a pair of holographic notch filters (HNF)' and a pair of 
oxide layer edge filters b for the optimum rejection of Rayleigh scattered light from the 
Raman spectrum. A Renishaw System 1000 spectrometer fitted with a 1200 lines per min 
dispersion grating was used to take the spectral measurements with each notch filter pair 
fitted in turn. The laser line rejection filters were mounted as a pair on a Renishaw 
EASYchange replacement unit. This simplified the alignment procedure when 
interchanging filters either for different wavelengths or in this case to compare filter 
technologies. 
A white light spectrum from a tungsten-filament lamp was measured in each 
configuration to show the spectral attenuation characteristics of each filter set. The source 
was used to illuminate a barium fluoride (BaF2) disc placed under the x80 objective on 
the microscope (see Figure 4.15). The BaF2 disc causes the light to be almost completely 
difftisely scattered. This reduced the effects of beam geometry on the results. The 
measured spectra are shown in Figure 4.17 for comparison. It is evident that the HNF set 
has a smoother transmission curve than the oxide layer edge filter set, and in addition, it 
can be used to measure anti-Stokes scattering. 
" Kaiser, OD >5x2,65% transmission for the pair, cut-off -I 00cm7l. 
b Renishaw, OD >5x2,85% transmission for the pair, cut-off - 150crif 
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Figure 4.16: Illumination geometry for measurement of system energy sensitivity using a tungsten- 
filament lamp source with a known spectral profile. 
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Figure 4.17: Comparison of white light spectra measured with the spectrometer fitted either with an 
edge filter set or a holographic notch filter set. Spectra were acquired for 60 seconds. The y-axis has 
arbritary units of intensity, whereas the x-axis represents the spectral energy in cm-' relative to 
830nm (Ocm-). 
62 
Additionally, the laser-line rejection filters were evaluated by measuring spectra of 
crystalline sulphur at 830nm. The spectra were acquired for I second with a laser power 
of approximately IOmW at the sample. They are displayed in Figure 4.18. It can be seen 
that the Raman scattering measurements from sulphur using the two different rejection 
filter pairs at 830nm produce distinctly different spectra. The oxide edge filter set has a 
cut-off that extends further into the Stoke's Raman spectrum than the HNFs. In addition 
the edge filters suppress the anti-Stokes signal. However, the HNFs have a lower optical 
density at the laser line frequency. 
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Figure 4.18: Comparison of sulphur spectra measured at 830nm, with a spectrometer fitted either 
with edge filter or holographic notch filter sets. 
4.2.3.2 Dispersive Grating 
The choice of grating for use with the custom spectrometer involved the consideration of 
three significant factors: the spectral range achievable without moving the grating; the 
signal-to-noise ratio of measured tissue spectra; and the spectral resolution. Two 
holographic diffraction gratings were evaluated: a 1200 lines per mm grating' and a 300 
d lines per mm grating. For each grating Raman spectra of normal oesophageal mucosa 
were acquired in static mode (fixed grating position) to enable the spectral range and S/N 
ratio to be measured. The sample was illuminated with 32mW of 830nm light and spectra 
were integrated for 1,10 and 30 seconds. The resulting spectra are shown in Figures 4.19 
and 4.20 for comparison. Table 4.5 outlines the data on the factors described above. 
' Optometrics, 1200 lines per mm, blazed at I. Ogm, gold coated holographic grating. 
d Manufacturer confidential, 300 lines per mm, blazed at I. Ogm, custom gold grating. 
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Figure 4.19: Comparison of Raman spectra from normal oesophageal mucosa acquired at various 
integration times using a 300 lines mm-' grating coupled to a CCD array detector. Arbitrary intensity 
units. 
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Figure 4.20: Comparison of Raman spectra from normal oesophageal mucosa acquired using 1200 
lines mm" or 300 lines mm-1 gratings coupled to a CCD array detector. Arbitrary intensity units. 
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Grating 
Manufacturer 
Line density 
(mm-) 
Spectral Range 
(cuf 1) 
Spectral Resolution S/N ratio 
(caf) 
Kaiser 1200 560 3 =5 
Confidential 300 1980 12 -20 
Table 4.5: Dispersion gratings used for tissue Raman measurement. The table includes line density, 
spectral range achievable in system without rotating the grating, spectral resolution at the 
configuration used and signal to noise ratio in spectra of normal oesophagus tissue measured with the 
same parameters in 30s. 
For rapid spectral acquisition times and greater wavelength repeatability it was necessary 
to measure spectra without rotating the dispersion grating. This has been made possible 
because of the use of CCD array detectors which allowed a significant portion of the 
Raman spectral component wavelengths to be measured simultaneously, with each 
detector element measuring a separate component of the spectral range. 
The dispersion from a grating is wavelength dependent and the Raman bands become 
narrower (in nm) as the illumination wavelength decreases. The dispersion was chosen to 
yield the required spectral coverage on the detector. A spectrograph for uv-light may use 
a high density grating (e. g. 3600 lines/mm) whereas for NIR a coarse grating (e. g. 300 
lines/mm) may be adequate. For multichannel systems, the spectral range must fit onto 
the detector with a dimension of between 12 and 25mm. Hence the dispersion required 
must be low. For example in the Renishaw system 1000, the CCD detector has an active 
length of 12.7 mrn in the spectral dispersion dimension. The CCD is made up of a 
384x576 pixel array, with individual element size of 22pm. A 300 lines per mm grating 
was used to disperse Raman scattered light, using an 830nm source, to approximatel 
155cm-1 nim" across the CCD, giving a full spectral range of approximately 1980 cm- . 
The mean spectral dispersion per channel is 3.44cm". Use of gratings with a greater 
dispersion will result in a shorter spectral range projected upon the CCD. However, this 
will lead to improved spectral resolution. 
A further advantage found in systems measuring the full Raman spectrum simultaneously 
can be observed when analysing a time varying sample. The sample can degrade during a 
scan, bubbles may pass across the collection volume, and the sample may pass in and out of 
the focus. In all of these cases if all parts of the spectrum are being acquired simultaneously, 
as in the case of the spectrometer coupled to a CCD array detector, the relative peak heights 
of bands in the spectrum will be unaffected. Whereas in systems compiling Raman spectra 
from sequential discrete measurements any change to the signal returning from the sample 
will affect the relative Raman band intensity. Moreover, greater accuracy in frequency 
repeatability is achieved with fixed grating systems than with scanning monochromators. 
In array detector systems, increasing the spectral range of the measurement that can be 
achieved requires a reduction in the dispersion of the signal across the array and hence a 
reduction in the resolution of the spectrum. Alternatively the grating can be scanned to 
movp the dispersed light across the array. Sequential sections of the spectrum can be 
acquired and then attached together. Discontinuities caused by wavelength calibration 
errors, energy sensitivity variations, or a time varying background can occur at the edges 
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of the segments. These discontinuities can be reduced or removed by using scanning 
multichannel techniques to combine spectral segments that have a large amount of 
overlap, thereby averaging out variations between segments. Further detail on this 
technique can be found in a number of texts. 164,165,166,167 
Although there is a reduction in spectral resolution caused by lowering the number 
density of lines on the dispersion grating; the signal-to-noise ratio is seen to markedly 
improve (Table 4.5). 
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Figure 4.21: Spectra of neon-argon lamp source versus spectrometer entrance slit width. 
Spectrometer configuration includes a 300 lines mm-' grating and an edge-filter for laser line 
rejection. 
The apparent linewidth of narrow Ne-Ar atomic emission lines have been measured using 
the 300 lines per mm grating, an entrance slit and a CCD detector. The entrance slit width 
of the monochromator was adjusted sequentially from 10 to 100 gm. Spectra were 
acquired for 0. Is at each slit width, for a fixed grating angle. A plot showing a single 
spectral region centred on a selected peak from the resulting spectra is shown in Figure 
4.21; the Raman shift is calculated relative to 830nm. A plot of the ftill-width-half- 
maximum (FWHM) of four of the neon-argon lines versus slit width is shown in Figure 
4.22. This plot demonstrates that the apparent linewidth increases with increasing slit 
width, and hence the effective resolution of the system decreases. A balance was made 
between the stray light rejection of the monochromator entrance slit and the effective 
resolution of the system to provide sufficient signal to reach the detector. All subsequent 
measurements (unless stated otherwise) have been measured with a 50gm slit for the 300 
lines mm-1 grating and with aI OOgm slit for the 1200 lines mm-1 grating. 
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Neon-argon line widths versus spectrometer slit width 
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Figure 4.22: The full-width-half-maximum of neon-argon lines measured with the Renishaw system 
1000, with a variable entrance slit width. Error bars display wavenumbers per pixel dispersion on 
CCD. Spectrometer configuration includes a 300 lines mm71 grating and an edge-filter for laser line 
rejection. 
4.2.3.3 Detection 
A deep depletion charge-coupled-device (CCD) detector (Renishaw RenCarn), comprising 
of an array of 576x384 detector elements was used to measure the dispersed light from the 
holographic grating. Thermal noise in the CCD was minimýsed (= 0.05 photoelectrons per 
pixel per second) by cooling the silicon wafer down to -70"C with a 4-layer Peltier cooler. 
Silicon charge coupled device (CCD) arrays are the detectors of choice for most Raman 
scattering measurements where wavelengths are below 1000nm. CCI)s are manufactured 
from monolithic silicon wafers into a rectangular array of photosensitive elements or 
pixels arranged in horizontal rows and vertical columns. Most available devices have 
been developed for imaging and not spectroscopy. This is evident in their aspect ratios of 
typically 1: 1 (512x512 pixels) or 3: 2 (576x378 pixels). Charge from the absorbed light is 
produced by the photoelectric effect and stored in a capacitor. The stored charge is 
proportional to the number of photons striking the pixel. In spectroscopic applications the 
spectral or wavelength direction typically corresponds to the vertical columns and the 
row pixels are usually summed horizontally, providing intensity at each wavelength (see 
figure 4.23). Charges can be electronically summed on the chip, a process called binning. 
Adjacent rows and column elements can be binned to improve signal-to-noise ratio, 
because the electronic summing is effectively noiseless. However when these are binned 
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in the wavelength dependent direction the achievable spectral resolution will be reduced; 
so a trade off must be made depending on experimental requirements. There is a finite 
limit to the number of photoelectrons that can be stored within a pixel; exceeding this 
limit causes overflow into adjacent pixels. Raman peak distortions and intensity non- 
linearities will result. 
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Figure 4.23: diagram of spectra projected onto the CCD pixel array to show the spectral variation in 
the vertical direction and the intensities can be summed in the horizontal direction. 
The stored charges are measured sequentially by being moved across the pixels of the 
CCD to a single charge sensitive amplifier, whose output is digitised to enable Computer 
storage and manipulation. The time required to readout all the stored charge on a 
576x384 pixel CCD, at a digitising rate of IOOkHz would be 2.22 seconds. It would also 
require substantial storage space for a 16-bit digitising accuracy (512kBytes). However, 
68 
for spectroscopy a reduced band of pixels, e. g. 20 wide in the intensity direction and 576 
high in the energy dispersion direction can be used. The readout can be adjusted 
accordingly to digitise only the required pixels and discard the remainder. Therefore for a 
576x2O pixel array at lOOkHz digitisation rate, readout takes approximately 0.1 seconds. 
Binning the pixels prior to digitisation can also reduce the readout time and in addition 
reduce the read noise (see 4.2.6.4). 
The CCD dark current resulting from thermally produced electrons has been measured to 
evaluate its impact on tissue Raman spectra (typically acquired in 30 seconds). The 
measurement was obtained by closing the shutter to the CCD and integrating the counts 
for 30 seconds. The average of 10 dark current measurements was made and the resulting 
spectrum is shown in Figure 4.24. The mean dark current was found to be 4.2 ± 3.2 
counts in 30 seconds. Towards the edge of the CCD it can be seen that the dark current is 
substantially higher, due to the temperature gradient from the centre to the edge of the 
wafer. 
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Figure 4.24: Mean dark current in 30 seconds (taken by averaging ten 30 second measurements). The 
upper and lower curves show the variation in the dark current in the form of the mean plus or minus 
one standard deviation. 
The relative individual pixel sensitivity was measured by moving the narrow silicon 
Raman peak at 520.4cm-1 across the detector array, one pixel at a time (by rotating the 
dispersion grating) and measuring a spectrum. The time of acquisition was I second and 
the laser power was 18mW at 830nm. The intensity of the silicon peak measured 
sequentially by each detector element in the array was plotted against position on the 
wavelength axis on the detector. This plot is show in Figure 4.25 to enable visualisation 
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of the variability in sensitivity present in the detector. The mean intensity for the silicon 
peak was 17753.78 counts ± 8.4% for one standard deviation. 
In summary CCD detectors have very low dark noise (typically 5 electrons per pixel per 
hour) 168, low readout noise (4-7 electrons at 5OkHz) 168 and better quantum efficiency than 
the photocathodes of intensifiers or photomultipliers. Quantum efficiencies as high as 
90% can be achieved from the visible to the near-IR, out to wavelengths of around 
I 100nm. There are other detectors (indiurn gallium arsenide, germanium and indium, 
antimonide single-element and linear arrays) with quantum efficiencies around 70% from 
1000 to 2000nm, in the spectral region where there is very little tissue fluorescence. 
However these devices exhibit levels of readout noise three to four orders of magnitude 
greater than that of silicon-based CCDs at 1000nm, resulting in measurements limited by 
detector noise as opposed to shot noise. 
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Figure 4.25: Plot of the relative silicon peak scattering intensity versus CCD pixel position, 
demonstrating the variability of sensitivity between detector elements. 
4.2.4 System Calibration 
4.2.4.1 Calibration of ordinate (wave number shift) 
Wavenumber calibration of the Renishaw Raman system 1000 microspectrometer was 
achieved using a Neon-Argon standard lamp source. A number of the atomic emission 
lines were chosen to calibrate the ordinate of the spectrometer. They were selected to 
cover the spectral range required and to be sufficiently resolvable for the system to 
measure them accurately without any confusion from nearby lines. A part of the emission 
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spectrum acquired from the neon-argon lamp is shown in Figure 4.26. The absolute 
positions of these lines were defined in a text file (or line file). The line file used for the 
Neon-Argon lamp to calibrate the spectrometer in the 830nm region is displayed in Table 
4.6. Calibration was carried out over the absolute wavenumber range of 10000 to 12100 
cm The emission from the lamp was aligned with the Olympus x20 objective (N. A. 0.4) 
and the spectrometer was used to acquire a spectrum for 10 seconds (or less) at each 
spectral position. The grating was rotated to shift the spectrum in steps of 25 cm-1 and the 
measurement was repeated across the range. The entrance slit for the monochromator was 
closed down to between 10 and 20gm. Renishaw WIRE software was used to measure 
the spectrum of the lamp (or any Raman scattering source) and to fit the measured peak 
positions to the absolute spectral positions in the line file. 
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Figure 4.26: Neon-argon discharge lamp source spectrum used for calibration of energy-shift axis. 
Spectrum acquired with Renishaw system 1000 configured for 830nm excitation, with edge filter 
fitted for laser line rejection. Some discharge lines are suppressed by the laser line rejection filter. 
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Waverumber (cm-1) 
Neon-argon lamp spectrum aquired vAth 830nm edge filter 
Wavenumber 
(in air) 
Intensity 
(counts) 
13939.35 2500 
13802.30 30300 
12581.50 7840 
11936.58 3500 
11771.13 7440 
10961.35 3500 
10840.70 440 
10354.34 300 
Table 4.6: Neon-argon emission lines chosen for calibration of the Renishaw System 1000 at 830nm. 
Optimum calibration with the holographic notch filter set and a 300 lines per mm grating 
configuration was achieved with an average error of approximately 0.4 cm7l and a range 
of 1.573 to -1.237 cm7l. For the edge filter optimum calibration with the 300 lines per 
nun grating was achieved with an average error of approximately 0.56 cni" and a range 
of 2.182 to -1.949 crd'. 
Long-term drift of calibration was evaluated, for the system configured with 300 lines / 
mm grating and an edge filter laser line rejection filter set, by measuring daily Raman 
spectra of a standard of cyclohexane. This enabled shifts in peak positions caused by 
changes in calibration to be monitored. Spectra were measured with 32mW of 830nm 
laser light focussed through a uv-grade quartz cuvette contining spectroscopy-grade 
cyclohexane (Sigma). Integration times of 30 seconds were used. Figure 4.27 displays the 
relative drift of the seven most significant peaks in the Raman spectra of cyclohexane 
versus date of measurement. The last few measurments showed a reduction in relative 
drift. This was achieved by reducing the slit width from 20 to 10[im during calibration 
with the neon-argon lamp. 
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Figure 4.27: Plot of variation in wavenumber position of cyclohexane peaks (relative to mean values) 
versus date of measurement. 
Currently there is little agreement in the literature over wavelength calibration 
procedures. 169 The typical approach relies upon one of two types of standard sources: 
either a wavelength standard using atomic emission lines from a gas discharge lamp; or a 
Raman shift standard derived from standard samples. A spectrum is acquired and in the 
case of CCD spectrometers, whereby the Raman shift is not linearly dispersed across the 
detector array, the spectral lines from the standard must be fit using a polynomial 
function. It is not usually possible to calibrate the intensity axis using the same standard, 
because the instrument response can severely distort the relative intensities for standard 
samples measured with different lasers or spectrometers. 
The calibration procedure utilising atomic emission lines involves the measurement of the 
standard spectrum using the spectrometer. The position of the measured lines is then 
corrected to the true values using a second or third order polynomial. The advantages to 
this method are the high density of atomic lines across the Raman spectral range; the 
availability of accurate wavelength tables for line positions; and the repeatability and 
stability of the source. The main disadvantage with this method is the absolute nature of 
the emission lines used. If the laser wavelength for Raman excitation is changed and a 
new calibration is required then a different set of emission lines will be required for each 
of the laser wavelengths used. If the laser wavelength is not accurately known (±0.01 
nm), as in the case of tuneable lasers, then it too must be measured against the atomic line 
standard. 
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The Raman shift method relies upon acquiring spectra of Raman shift standards under the 
same conditions as the experimental sample spectra. The raw Raman shift is adjusted using 
a second or third order polynomial to the known standard shift frequencies. The positional 
geometry of the standard can affect the wavelength accuracy. It is important to reproduce the 
sample configuration for experimental samples and standards. The benefit of using this 
method is that accurate calibration of the Raman shift can be achieved without accurate 
knowledge of the laser wavelength. There are increasing numbers of Raman shift standards 
published in the literature 170,171 using common materials. The greatest inconvenience with 
using this method is caused by the low density of Raman peaks across the spectral range. it 
is therefore necessary to use a large set of standards to cover the required spectral range. The 
shift range between 1800 and 2700 cnf 1 has a deficiency of peaks for most standards. 
4.2.4.2 Calibration of abscisa (intensity) / energy sensitivity correction 
A major obstacle that prevents the acceptance of Raman spectroscopy in many fields is 
the problem associated with widely varying instrumental response. Spectrometers vary in 
transmission efficiency and detector quantum efficiency with wavelength, thus distorting 
the true spectrum of intensity against Raman shift. The vast majority of published Raman 
spectra remain uncorrected for instrumental response and are subject to large variations in 
relative peak intensities when obtained on different instruments. These variations tend to 
complicate comparison between spectra from different instruments and different sources, 
thus making library searches very complex indeed. Determination of Raman cross- 
sections requires an absolute measure of scattering intensity, so response function 
corrections are essential. 
The majority of the change in instrument sensitivity varies slowly with wavelength. This 
is mainly caused by the gradual change in quantum efficiency of the detector across the 
spectral range. A smaller contribution to the response function originates from etaloning 
in the CCD, modal interference in optical filters, and variation in the CCD pixel 
sensitivity (Figure 4.25). This can cause a rapid oscillation in the sensitivity of a Raman 
instrument with changing wavelength. 
The energy transfer function of the system was evaluated by measuring the slowly varying 
spectrum of a tungsten-filament lamp. The lamp source has been calibrated against a 
secondary standard by the National Physical Laboratory (NPL) and the user is provided with 
a spectrum of absolute intensities versus wavelength at a fixed distance from the source. 
Using the illumination geometry shown in Figure 4.16 to measure the white light spectrum 
using the Raman spectrometer it was possible to calculate the energy transfer function of the 
system by dividing the absolute spectrum of the lamp (Fig 4.28) by the measured spectrum. 
This transfer function can then be used to correct measured spectra for the energy dependent 
sensitivity of the system by multiplying the function by the measured spectrum. Figure 4.29 
shows the absolute and measured spectra of the lamp and the calculated energy sensitivity 
function. These are given as an example and the process has been repeated at regular 
intervals when spectrometer configuration changes have been made. 
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Figure 4.28: Absolute spectrum from an NPL calibrated, tungsten-filament lamp source, powered with a 
constant current supply. 
NPL Calibrated Lamp Spectrum 
Ou 
29 
28 
27 
26 
25 
24 ý1 
23 
0 1000 2000 3000 4000 
Relabve Wavenumber 1 cm- 1 
Measured Lamp Spectrum 
x 105 
2, 
1.5 
1' 0.5 
'0' ' 
5ýo 10b0 15100 2000 
Relabve wavenumber 1 cm- 1 
Transfer Functon Correction 
5X 
10-4 
4.5 
ý 
:? 
4 
3.5 
3 
. S2.5 
2 
0 500 1000 1500 2000 
Reiabve Wavenumber 1 cm- 1 
Figure 4.29: Absolute and measured spectra from the NPL calibrated W-filament lamp source and 
the resulting energy sensitivity or transfer function correction spectrum. The spectrum was 
measured with the 1200 lines per min grating and the HNF pair configured for laser line rejection. 
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A typical Raman spectrum of normal oesophagus tissue at 830nm has been corrected for 
system energy sensitivity by multiplying the spectrum by the transfer function. The raw 
and corrected spectra are shown in Figure 4.30 for comparison. 
2000- 
400 600 800 1000 1200 1400 1600 
Counts / Ramon Shift (cm-1) O%eday Y-Zoom CURSOR 
Figure 4.30: The effect of energy sensitivity correction on an 830nm Raman spectrum of normal 
oesophageal mucosa. The correction tends to flatten out the spectrum. 
4.2.6 Appraisal of Noise Contributions 
Raman spectroscopy for the measurement of biochemical changes in tissue depends as much 
upon the signal-to-noise (S/N) ratio as the magnitude of the measured Raman signal alone. 
The S/N ratio is a useful measure describing the quality of the spectrum, its inverse is the 
relative precision of the measurement, or the relative standard deviation from the true signal. 
This section aims to quantify the contributions to the Raman spectrum of each common 
component of noise or source of erroneous signal. 
Shot noise is the dominant source of noise in dispersive Raman measurements. It is 
caused by the random probabalistic nature of light and matter. If the intensity of light is 
measured with a perfect noise-free detector, the standard deviation of the number of 
detected photons will be equal to the square root of detected photons., 72 Using the 
optimised Renishaw system 1000 Raman spectrometer to measure Raman scattering in 
oesophagus biopsy samples, with 830nm light, the strong C-H stretch band intensity at 
1455 cm-1 is approximately 4500 counts in 30 seconds. Therefore the uncertainty of the 
measurement, due to shot noise, is 67 counts or ±1.5%. If the time of acquisition were 
reduced to 10s (see Figure 4.30), the measurement would yield 1500 ± 39 counts or 
±2.61/,, uncertainty; a further reduction to an integration time of Is would give 150 ± 12 
counts or ±8% uncertainty. This example shows the effect of reducing acquisition time 
leads to a reduction in the signal to noise ratio and the certainty of the measurement. 
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It must be noted that the shot noise will not only originate from the Raman scattering 
signal but also background signal such as stray light and fluorescence signal. Therefore 
even if these signals can be subtracted the shot noise contribution will remain 
superimposed on the measurement, sometimes completely obscuring the Raman 
spectrum. For example if the fluorescence background induced in a sample produces 
1000 counts per second at a particular wavenumber of a Raman scattering band that 
produces 100 counts per second, then the combined signal at the band position will be 
1100 counts ± 33 counts from shot noise. Following subtraction of the fluorescence 
signal of 1000 counts we are left with the Raman band intensity of 100 photons ± 33 
photons or ± 33% uncertainty. 
Laser-induced fluorescence is the most common source of background light encountered 
in Raman spectroscopy. Fluorescence spectral features are usually much broader than 
Raman bands, and often look like a slowly changing baseline in the Raman spectrum. 
Some fluorophores can have fluorescence cross-sections 1010 times larger than typical 
Raman scattering cross-sections. Therefore even at tiny concentrations they can produce 
a fluorescence background stronger than the Raman spectrum of the bulk material. At 
830 nm tissue fluorescence background contributes around 100 counts per second, 
whereas the Raman signal can be between 5 and 50 counts per second. 
The effects of variation in pixel sensitivity and thermal noise across the CCD detector have 
been measured in section 4.2.3.3. Both of these phenomena will superimpose a fixed pattern 
noise on the Raman spectrum. The effects of these can be reduced by binning several 
illuminated pixels in the intensity direction; or can be corrected by collecting a spectrum of 
light that changes slowly with wavelength and dividing the Raman spectrum by the source 
spectrum. (This procedure has been outlined in 4.2.4.2. ) CCI)s have an inherently low dark 
noise that will depend upon the pixel location, as there will be a temperature gradient 
from the centre to the edge of the chip, yielding fixed pattern noise plus random noise. 
The Renishaw CCD detector was cooled to -70"C to reduce thermal noise contributions 
to a minimum. 
The contribution to the signal from the CCD (Renishaw RenCam) readout noise is 
approximately 7 electrons per readout. Read noise is a random noise and therefore 
increases with the square root of the number of readouts per channel. In the case where an 
active region of 576x2O pixels was being used, when reading out 20 pixels separately 
then the read noise would be around 32 electrons per wavenumber channel (this equates 
to approximately 6 counts with the Renishaw system in high gain mode). However, if the 
20 pixels are binned and digitised together the read noise would be about 7 electrons per 
channel. 
Cosmic rays passing through the photosensitive region can produce thousands of 
photoelectrons. This effect results in a very strong sharp signal in the Raman spectrum. 
Quantification of spike noise is difficult due to the random nature of its occurrence. 
However, it is usually quite obvious to the observer when a spectrum of biological tissue 
contains a contribution from spike noise. These spikes can be erased from the spectrum or 
the whole spectrum can be discarded. 
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The effect of ambient lighting, another source of fixed pattern noise, on tissue Raman 
spectra acquired at 830nm was evaluated. Spectra of oesophageal biopsy samples were 
measured with either no ambient light in the laboratory; the overhead fluorescent light; or 
the tungsten-filament stand-lamp. Spectra were integrated for 30 seconds with a laser 
power of 32mW focussed on the sample with an Olympus x80 MIRPLAN ultra-long- 
working-distance lens. Figure 4.31 shows the resulting spectra. There appears to be little 
visible difference between them. It is therefore concluded that normal sources of ambient 
lighting have little effect on the tissue spectra at 830nm. 
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Figure 4.31: Oesophagus spectra measured at 830nm with different configurations of ambient 
lighting. 
Source noise is caused by fluctuations in the irradiance of the incident light, which 
inherently causes fluctuations in the Raman scattering. Simultaneous measurement of all 
spectral components across the CCD array reduces the effect of this noise in an individual 
spectrum. However, comparison of one spectrum to the next for quantification of 
biochemical changes is complicated by source noise. The fluctuation in intensity and 
wavelength of the Ti: sapphire source has been quantified in section 4.2.1.1. 
An often neglected source of fixed pattern noise is that caused by instrument alignment and 
calibration errors. Unwanted information about the performance of the Raman instrument is 
added to the Raman spectrum. Calibration drift errors have been assessed in section 4.2.4.1. 
In summary, a typical Raman spectrum of fresh tissue, measured at 830nm for 30 seconds 
with a laser power of 32mW at the sample, will include a C-H stretch peak at 1445cm-1. 
If the intensity at this peak is for example 4500 counts (see Figure 4.30) then a 
contribution of 67 counts will be due to Shot noise (4.2.6.1). The total signal of 4500 
counts is made up of approximately 3000 counts of fluorescence signal and 1500 counts 
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of inelastic scattering signal. The contributions from fixed pattern noise sources have 
been minimised by multiplying the spectra by correction files. Read out noise contributes 
about 6 counts and the dark current or thermal noise in the CCD contributes 
approximately 4 counts in the 30s integration time. Hence measurement repeatability due 
to quantifiable noise contributions is approximately ±5% for the 1445cm7l peak measured 
in 30 seconds. This can be converted to a quantifiable SIN ratio of 20. The theoretical 
noise contributions agree well with the measured S/N ratio at 830nm of 18.5 (see Table 
4.2). 
4.3 Experimental Methods 
4.3.1 Detection of Early Malignant Changes in the Larynx 
The goal of this study was to assess the feasibility of using NIR Raman spectroscopy for 
the early diagnosis of laryngeal malignancy originating in the squamous epithelial layer. 
Samples were collected, stored and histopathologically analysed following the procedure 
explained in section 4.1.1. Samples exhibiting mixed pathologies were rejected from this 
study. Raman spectra of normal larynx, dysplastic larynx and squamous cell carcinoma of 
the larynx were characterised in order to determine the potential of Raman spectroscopy 
to differentiate samples of distinct pathologies. The Raman scattering measurements were 
carried out in vitro with a customised Renishaw System 1000 Raman micro-spectrometer. 
The Ti: sapphire laser was tuned to provide an excitation wavelength of 830nm and a 
holographic notch filter pair (Kaiser) was used to reject unwanted light of the laser 
wavelength collected by the system. A 1200 lines per min holographic dispersion grating 
(Optometrics) was used to separate the collected light into its spectral components. To 
enable measurement of the full fingerprint region of the tissue Raman spectra (400 to 
1800cm-1) with this grating it was necessary to scan the spectrum across the CCD using 
'extended scan mode'. Otherwise the system configuration used for this experiment has 
been outlined in detail in section 4.2. 
Twenty-five laryngeal biopsy samples were measured. They were orientated so that the 
incident laser beam illuminated the epithelial surface, with a similar geometry to that that 
would be used in vivo. Tissue samples were held in position on the microscope stage 
between two calcium fluoride slides (see Figure 4.32). A x80 ultra-long-working-distance 
lens was used to focus the laser beam (power at sample of 32 ± 1.1 mW) to a spot size of 
2[im on the tissue surface and collect the scattered photons in non-confocal mode. The 
entry slit to the monochromator was set to 100gin. A minimum of five spectra were 
acquired from each sample (mean number = 7.96, range 5 to 12). The scattered Raman 
signal was integrated for 30 seconds and measured over a spectral range of 400-1800 cm7 
1 with respect to the excitation frequency. 
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Figure 4.32: Schematic diagram of the Raman microspectrometer used to measure inelastic 
scattering from biopsy samples. 
The Raman spectrometer was calibrated for wavenumber shift using a neon-argon lamp 
standard and Renishaw WIRE software (refer to Section 4.2.4.1). Tissue spectra were 
corrected for the energy dependent response of the system by multiplying the measured 
tissue spectrum by the energy transfer function measured using a tungsten-filament lamp 
with a spectral output calibrated by the National Physical Laboratory, UK (refer to 
Section 4.2.4.2). No further manipulation of the tissue spectra was performed prior to 
analysis. Intra-sample repeatability was evaluated and mean spectra for each tissue 
pathology were obtained. Any correlation between Raman spectral variations and 
histopathology was assessed using empirical and multivariate data analysis techniques. 
This involved the evaluation of absolute peak intensities or peak intensity ratios to look 
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for any correlations with pathology; in addition to developing multivariate classification 
models using principal component analysis and linear discriminant analysis methods. 
4.3.2 Detection of Early Malignant Changes in Barretts Oesophagus 
The goal of this study was to assess the feasibility of using NIR Raman spectroscopy to 
detect early malignant changes in the oesophagus and to study the pathogenesis of 
adenocarcinoma in Barrett's oesophagus. Raman spectra of 9 histopathological groups 
(normal, cardiac Barrett's, fundic Barrett's, intestinal metaplasia, low grade dysplasia, 
high grade dysplasia, adenocarcinoma, squamous dysplasia, and squamous cell 
carcinoma), defined in Appendix 2, were measured in order to determine the potential of 
Raman spectroscopy to discriminate between samples of distinct pathologies. Samples 
were collected, stored and histopathologically analysed following the procedure 
explained in section 4.1.2. Samples exhibiting mixed pathologies were rejected from this 
study. 
The Raman scattering measurements were obtained in vitro with a customised Renishaw 
System 1000 Raman micro-spectrometer. The Ti: sapphire laser was tuned to provide an 
excitation wavelength of 828run and an edge filter pair (manufacturer confidential) was 
used to reject unwanted light of the laser wavelength collected by the system. A 300 lines 
per mm holographic dispersion grating (manufacturer confidential) was used to separate 
the collected light into its spectral components. This enabled measurement of the full 
fingerprint region of the tissue Raman spectra (400 to I 800cm7l) without the need to 
move the grating. However a compromise in spectral resolution has been made. The 
procedure of optimisation of the system configuration for use in this experiment has been 
outlined in Section 4.2. 
Eighty-nine oesophageal biopsy samples were measured. Tissue samples were orientated 
in the in vivo geometry (tissue surface facing the laser beam) and placed between two 
calcium fluoride slides (Figure 4.32). A x80 ultra-long-working-distance lens was used to 
focus the laser beam (power at sample of 31 ± 0.8 mW) to a spot size of 2-3 Wn on the 
tissue surface and to collect the scattered photons in non-confocal mode. The entry slit to 
the monochromator was set to 501im. A minimum of 10 spectra were acquired from each 
sample (mean number = 14, range 10 to 20). The scattered Raman signal was integrated 
for 30 seconds and measured over a spectral range of 200-2100 cm-1 with respect to the 
excitation frequency. All other experimental procedures and data analysis methodologies 
were the same as those for the larynx samples, as described above. 
4.3.3 Detection of Early Malignant Changes in Formalin Fixed Tissue 
(Barrett's Oesophagus) 
Raman spectroscopy for the evaluation of histopathology on formalin fixed tissue is 
likely to provide a more flexible pathological tool than that using fresh or snap frozen 
tissue. The aim of this study was to assess the use of NIR Raman spectroscopy to 
measure histopathological state in formalin fixed oesophagus tissue. Raman spectra of 
eight histopathological. groups (normal, cardiac Barrett's, fundic Barrett's, intestinal 
metaplasia, low grade dysplasia, high grade dysplasia, adenocarcinoma, and squarnous 
dysplasia), defined in Appendix 2, were measured in order to determine the potential of 
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Raman spectroscopy to discriminate between samples of different pathologies. Samples 
were collected, sectioned, stored and histopathologically analysed following the 
procedure explained in section 4.1.2.2. Samples exhibiting mixed pathologies were 
rejected from this study. Approximately half of the samples were stored for 18 months in 
10% formalin (phosphate buffered) and the remainder stored for 2 to 3 weeks in the same 
fixative solution. This enabled an assessment of the effect of storage time on the 
achievable spectral discrimination between pathological types. 
The Raman scattering measurements were obtained using the procedure outlined in 
section 4.3.2 Forty-three oesophageal biopsy samples were measured. A minimum of 7 
spectra were acquired from each sample (mean number = 9.7, range 7 to 15). The 
scattered Raman signal was integrated for 30 seconds and measured over a spectral range 
of 200-2100 cm-1 with respect to the excitation frequency. Raman spectra were corrected 
for energy sensitivity of the system. However, no further manipulation of the tissue 
spectra was performed prior to analysis. Intra-sample repeatability was evaluated and 
mean spectra for each tissue pathology were obtained. Any correlation between Raman 
spectral variations and histopathology was assessed using empirical and multivariate data 
analysis techniques, as described above for the larynx samples. In addition, any 
correlation between tissue Raman spectra with time of storage in the formalin has been 
evaluated. 
4.3.4 Monitoring of Temperature Dependence of Raman Spectra 
The temperature dependence of tissue Raman spectra has been measured between 10 and 
50"C to enable evaluation of differences between measurements made at laboratory 
temperatures and those to be made in vivo. Five normal oesophagus biopsy samples were 
used in this experiment. They were collected, stored and prepared following the 
procedure laid out in 4.1.2. A Linkram. THMS600 hot/cold stage, that allowed accurate 
(±O. I'C) temperature selection in a stable nitrogen atmosphere, was used to vary the 
temperature of the tissue samples in steps of 10"C over the range 10 to 500C. The stage 
temperature was governed by a remote control unit (Linkram. TMS93) and temperatures 
were reached by using a feedback loop with resistive heating and liquid nitrogen cooling. 
Samples were allowed to equilibrate for five minutes at each new temperature prior to 
measurement with the Raman microspectrometer. Figure 4.33 shows the geometry of the 
tissue sample within the hot/cold stage. 
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Figure 4.33: Schematic diagram showing tissue sample position in hot/cold stage. 
Static spectra centred at 1150cm-1 were acquired by focussing the 828nm, 32mW, laser 
spot through the calcium fluoride windows and onto the surface of the tissue sample. It 
must be noted that reflections from refractive index boundaries substantially reduced 
signal levels compared with those achieved with direct illumination of the surface of the 
tissue. Therefore the collected signal was integrated for 60 seconds to provide adequate 
signal-to-noise ratio for analysis. The Olympus x80 ultra-long-working-distance 
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microscope objective was used in conjunction with a small monochromator slit size 
(20[tm), and a band 4 pixels wide on the CCD detector, thus minimising the contributions 
to the signal from materials found outside the focal volume. The resulting spectra at each 
temperature were compared to evaluate observable differences. 
4.3.5 Raman Depolarisation Ratio Measurements 
A schematic diagram outlining the optical illumination and collection path of the 
microspectrometer is shown in Figure 4.34. It includes polarisers (Oriel, gelatine) that 
were used to enable evaluation of the depolarisation of the Raman vibrational modes in 
the tissue, and a half-wave plate (Oriel, 850nrn) to enable an evaluation of the effect of 
illumination polarisation direction. These polarisation selection components can be 
rotated into or out of the beam. The polarisation from the Ti: sapphire laser was >1 0o: 1 in 
the horizontal direction. The arrows in the beam path show the direction of the electric 
vector component of the incident laser light. Rotating the half-waveplate into the laser 
beam caused the rotation of the polarisation of the incident light to >I 00: 1 in the vertical 
direction. The polarisers were used to analyse the direction of the polarisation of the 
collected Raman scattered signal, by rotating them into the collection path one at a time. 
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Figure 4.34: Schematic of the illumination and collection optical path of the microspectrometer used 
for polarisation sensitivity measurements. 
Raman spectra were acquired using 32mW of 828mn laser light focussed to a 2gm spot 
using a x80 objective. The Raman scattered signal was integrated for 30 seconds for each 
position of the polarisation components: all out of the beam; horizontal polariser in, 
vertical polariser out; vertical polariser in, horizontal polariser out; and a repeat of the 
above with the half-waveplate in the incident beam path. This was repeated for a number 
of positions on the tissue. The resulting spectra were used to calculate the depolarisation 
ratio of each Raman peak. 
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4.3.6 Monitoring Effects of Sampling Depth 
An investigation was made into the dependency on the depth of measurement beneath the 
mucosal surface of Raman spectra of oesophagus tissue. This was to enable evaluation of 
the possible effects of changing the depth of focus used to measure in vivo / in vitro 
tissue Raman spectra and to evaluate the possible contributions from underlying tissue 
layers. 20ýim thick sections of snap frozen oesophageal biopsy samples were cut by 
freezing microtome during preparation of samples for histopathological analysis. They 
were placed on a calcium fluoride slide, orientated to show a cross-section through the 
tissue layers and positioned under the microscope. The sample was aligned using white 
light illumination through the x5 objective. A photograph was taken of the tissue showing 
the start position for mapping at 0,0 (Figure 4.35). The objective was changed to the 
Olympus x80 ultra-long-working-distance lens and used in conjunction with a small 
monochromator slit size (20gm), and a band 4 pixels wide on the CCD detector, thus 
minimising the contributions to the signal from materials found outside the focal volume. 
Spectra were measured at 830nm, with 32mW of laser power for 60 seconds at positions 
ranging from y--O to -750gm and x=O to I OOgm by moving the laser spot in a raster 
pattern across the sample in steps of I Ogm. This was achieved by translating the PC- 
controlled XYZ motorised stage. The y-direction represented depth beneath the mucosal 
surface. Spectra were saved for future analysis. 
Surface (lumen) 
Raman spectra 
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Figure 4.35: Schematic of spectral mapping to look at the differences between Raman spectra from 
the surface and deeper tissue layers in the oesophagus. 
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4.3.7 Confounding Factors 
The effect of contamination on tissue Raman spectra from materials found in the in vivo 
environment have been evaluated. Raman spectra of these materials were measured using 
the customised Renishaw microspectrometer (outlined 4.2) with 828nm laser light 
focussed onto the sample by the x80 objective. Integration of the collected signal was 
carried out for 30 seconds with laser power levels of 32mW. 
The contaminants investigated were: 
1. Mucus 
2. Bile 
3. Blood 
4. Coffee and spittle 
5. Endoscope lubricant. 
The intensity levels of the resulting contaminant spectra were compared with those tissue 
Raman spectra obtained with the same measurement configuration (4.3.2). 
4.3.8 Other Biological Tissues 
Additional biological tissues were studied to assess the potential for future exploitation of 
Raman spectroscopy for detection of abnormalities. Raman spectra of these tissues were 
measured using the customised Renishaw microspectrometer (outlined 4.2) with 828nm 
laser light focussed onto the sample by the x80 objective. Integration of the collected 
signal was carried out for 30 seconds with laser power levels of 32mW. The tissues 
evaluated included the following: 
1. Stomach. 
2. Tonsil. 
3. Endometrium. 
4. Bladder 
5. Prostate. 
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5. Results and Analysis 
This chapter has been compiled to outline the results obtained from NIR-Raman spectral 
measurements of various epithelial tissues. The possibility of spectrally discriminating 
between tissues originating from different stages of carcinogenesis has been evaluated by 
following a logical process of spectral analysis to extract as much clinically relevant data 
from the spectra as possible. The first sub-section (5.1) describes the results obtained 
from the laryngeal tissue experiments. The pathogenesis from normal squamous mucosa 
to squamous cell carcinoma in the larynx follows a simple path. This is in contrast with 
that occuring in tissues that initially undergo a metaplastic step. The development of 
oesophageal adenocarcinoma is an example of this more complex pathogenesis. The 
results of the work on Raman spectral classification of both fresh (snap frozen) and 
formalin fixed oesophageal tissues are outlined in the second and third sub-sections of 
this chapter (5.2 and 5.3). Results from experiments to evaluate likely differences 
between in vivo and in vitro classification models have been outlined in sub-section 5.4. 
Finally investigations involving other tissues are briefly outlined in sub-section 5.5. 
5.1 Larynx 
5.1.1 Raw Spectral Data 
Following the procedures outlined in section 4.3.1 Raman spectra obtained from laryngeal 
tissue have been grouped according to the histopathological grading of the sample by a 
Consultant Pathologist at Gloucestershire Royal Hospital. This was carried out according to 
the classification protocol outlined in Appendix 1. Spectra were obtained from 25 
homogeneous samples of larynx mucosal tissue (14 normal, 5 dysplastic, 6 squamous cell 
carcinoma (SCQ. A laser beam operating at 32 ± MmW and 830nm was focussed down 
to a spot size of 2-3 gin across. An acquisition time of 30s was required to achieve 
acceptable signal to noise when using the 1200 lines per mm grating. The grating dispersed 
the spectrum over a larger collection area than that provided by the CCD therefore an 
extended scan was required to fit the spectra onto the CCD. Both I and 3 pixel binning was 
used for the larynx spectral measurements. Due to ongoing optimisation of the spectrometer 
configuration, interpolation and shift correction of the spectra were required during analysis. 
This helped reduce the effects of the varying S/N ratio and resolution from one spectrum to 
the next. Each spectrum was corrected for the wavelength sensitivity of the system by 
multiplying the spectrum by a correction file created using the procedure outlined in section 
4.2.4.2. All spectra shown in this section have been calibrated for wavelength shift using a 
standard Neon-Argon source. 
A plot of the mean of 200 spectra from normal, dysplastic and cancerous specimens is 
shown in Figure 5.1. The plot shows the intensity of the collected (Stokes) signal versus 
wavenumber shift relative to the 830 rim excitation source. The greater the wavenumber, the 
ftirther the peak is shifted from the excitation wavelength. The most significant peaks in the 
spectrum have been labelled with the corresponding wavenumber shift. Tentative peak 
assignments have been made from extensive study of the literature. These are tabulated in 
Table 5.1. Further peak assignments have been compiled in Appendix 4. 
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The spectra of normal laryngeal specimens have shown little inter- and intra-sample 
variability. Figure 5.2 shows 100 NIR-Raman spectra obtained from ten normal larynx 
tissue specimens, with the mean spectrum displayed in green. Visual inspection of the 
spectra show the peak shapes and positions to be repeatable, although overall spectral 
intensities can vary by 15% about the mean spectrum for each sample. The Raman spectra 
from normal laryngeal epithelial tissues were dominated by several peaks (see Table 5.1 and 
Figure 5.1). They have contributions from a myriad of constituents including proteins, 
lipids, carbohydrates and nucleic acids. Many of the spectral peaks overlap and thus make a 
full understanding of the biochemistry very difficult to achieve. Amide I (at 1655 cm7) and 
amide III (at 1240-1265 cm7 1) bands originate from vibrations in the peptide modes of the 
proteins and reflect the secondary structure of the proteins, arranged in three dimensions as 
a-helix, P-pleated sheet, P-tum or random coil structures. The position of these two peaks 
indicated that the majority of roteins in the normal larynx are in the a-helix conformation. 
The intense peak at 1336 cm- can be attributed to both collagen and nucleic acids (DNA) 
and more specifically to the purine bases guanine and adenine (see Table 5.1 and Appendix 
4). 
The repeatability of the wavenumber position was evaluated by measuring the position of 
the phenylalanine peak (at around 1000 cm7l) for each spectrum. The resulting wavenumber 
position for each spectruin in the data set (in order of acquisition) is plotted in Figure 5.3. 
The mean position was 1001.7 ± 3.25 cm7l. It can be seen from the plot, by the step tooth 
pattern, that consecutive spectra tend to have similar phenylalanine (PHE) peak Positions. A 
following set of spectra from a different day may have a completely different wavenumber 
position for the PHE peak. This indicates that the calibration of the spectrometer 
wavenumber position from one day to the next was not completely stable. It has been shown 
in section 4.2.1.1 that the laser wavelength stability and laser pointing stability were poor. 
Improvements were made to stabilise the laser, but these were carried out following the 
work described in this section. To compensate for the varying wavenumber position, spectra 
were shifted to align all PHE peaks to 1001.5 cm7l. 
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Mean Raman spectrum from layix tissue at 830nm (n=200) 
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Figure 5.1: Mean Raman spectrum acquired from normal, dysplastic and cancerous laryngeal tissue 
with an 830nm excitation source. T=30s. 
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Figure 5.2: 100 Raman spectra from 10 normal larynx specimens, mean spectrum plotted in green. 
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Table 5.1: Major vibrational modes identified in normal laryngeal samples. 
Peak position (cm7l) Major assignments 
622 C-C twisting mode of phenylalanine 
643 C-C twisting mode of tyrosine 
668 C-S stretching mode of cystine 
721 =C-H in-plane bending mode 
754 Symmetric breathing of tryptophan. 
780 Unassigned 
828 Out of plane ring breathing mode of tyrosine 
853 Ring breathing mode of tyrosine and C-C stretch of proline ring 
876 C-C stretch of hydroxyproline 
900 C-C stretching mode of proteins (a-helix conformation) 
920 C-C stretch of proline ring 
936 C-C stretching mode of proline and valine ((x-helix conformation) 
1001 Symmetric ring breathing mode of phenylalanine 
1029 C-H in-plane bending mode of phenylalanine 
1048 Unassigned 
1082 C-N stretching mode of proteins (and lipid mode to lesser degree) 
1125 C-N stretching mode of proteins 
1155 C-N stretching mode of proteins (also carotenoid mode) 
1172 C-H in-plane bending mode of tyrosine 
1206 Tryptophan and phenylalanine v(C-C6HS) mode 
1228 P02 antisymmetric stretching mode of polynucleotide chain (DNA) 
1240-1265 Amide III (C-N stretching mode of proteins, indicating mainly (x- 
helix conformation) 
1315 CH3CH2 twisting mode of collagen 
1336 CH3CH2 wagging mode of collagen and polynucleotide chain 
(DNA-purine bases) 
1386 Unassigned 
1446 CH2 bending mode of proteins and lipids 
1560 Tryptophan 
1579 C=C bending mode of phenylalanine 
1603 C=C in-plane bending mode of phenylalanine 
1615 C=C stretching mode of tryptophan. 
1651 Amide I (C--O stretching mode of proteins, a-helix conformation) 
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5.1.2 Empirical Spectral Analysis 
The spectra acquired from samples belonging to each of three pathological groups were 
collected together and mean spectra were calculated. A plot of the mean spectra 
normalised to the intensity at 1446 cm-1 is shown in Figure 5.4. From this plot it can be 
seen that the differences observed in the spectra from specimens at different stages of the 
cancer development process are very subtle. On first glance the spectra appear almost 
identical. However a closer study reveals miniscule changes in peak heights from one 
group to the next. One method of emphasising the variation between the spectra from 
each pathological group is to calculate difference spectra. Figures 5.5 to 5.7 display the 
resulting spectra obtained from taking the difference between mean normalised (and 
baseline subtracted) spectra from each of the groups in turn. The peaks in the difference 
plot with intensity greater than zero represent tissue constituents in excess in that 
pathology group. Conversely, those with a negative relative intensity have a lower 
concentration of that constituent relative to that found in the spectrum of the subtracted 
group. 
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Figure 5.4: Mean Raman spectra from each laryngeal histopathological group, normalised to the 
peak intensity at 1446cm". 
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Figure 5.5: Mean normalised (and baseline corrected) Raman spectrum of dysplastic larynx tissue, 
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Figure 5.6: Mean normalised (and baseline corrected) Raman spectrum of cancerous larynx tissue 
with the mean normalized (and baseline corrected) normal tissue spectrum subtracted. 
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Figure 5.7: Mean normalised (and baseline corrected) Raman spectrum from cancerous larynx tissue 
with the mean normalised (and baseline corrected) spectrum from dysplastic tissue subtracted. 
Study of the above difference spectra provides evidence for constituents in excess in 
certain pathology types and in deficit in others. Table 5.2 outlines the likely constituents 
that exhibit the greatest variation between the pathological groups. 
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600 800 low 1200 1400 1600 
Raman Shift I cm- 1 
Dy plastic vs Normal SCC vs Normal S CC vs Dysplasia 
Peak Tentative Peak Tentative Assignment Peak Tentative 
Assignment Assignment 
623 Phenylalanine (PHE) 497 ? 739 Phospholipid (P-0-P) 
643 Tyrosine (TYR) 624 PHE 752 Thymine 
827 DNA (0-P-0 stretch) 645 TYR 970 Hydoxyapatite 
900 DNA backbone 741 Phospholipid (P-0-P) 1108 Protein (C-C) stretch 
1122 Lipid (C-C stretch) 752 Thymine 1225 Heme/Am. 111: 0-sheet 
1297 Lipid (CH2 deform. ) 968 Hydroxyapatite 1248 p02 
, pl/na or 1431 Lipid (CH2) 990 ? 1370 unordered 
1497 ? 1115 Skeletal C-C unordered 1386 Porphyrins 
1631 ? 1221 Heme/Am. lll: p-sheet 1558 TRP / Porphyrins 
1250 p02 
- 
1617 Nucleic Acids 
1363 Guanine/TRP/heme 
1387 ? 
1540 TYR 
1577 Nucleic acids (G/A) 
1592 Nucleic acids (G/A) 
1614 TYR/PHE/nuc acids 
997 ? 780 Nucleotide? 1048 Lactic acid ? 
1107 Skeletal protein(C-C) 851 Glycogen/C-C collagen, 1060 ? Lipid 
1242 Am. III: unordered 935 Glycogen/C-C collagen ? Lipid (C-C) 
1265 Am. III: a-helix 1083 C-C Carotenoids 1297 CH2 Lipid 
1373 Porphyrins 1152 CH2 lipid / cc-helix 1437 CH2 Lipid 
1459 CH2/CH3 protein/lipid 1456 CH2/CH3 protein/lipid 1643 Am. 1: a-helix 
1560 Tryptophan 1663 ? Am. 1: cc-helix 
1617 Porphyrins 
1663 Am. I: a-helix 
Table 5.2: Peaks from difference spectra between normal, dysplastic and cancerous larynx spectra, 
with tentative peak assignments. (? signifies no data available on peak. ) 
5.1.2.1 Analysis of clinical significance of individual peak intensities 
A full analysis of the clinical significance of 32 selected peak intensities from the un- 
normalised spectra was carried out using analysis of variance (ANOVA). 173 The spectral 
intensities were compiled into an nxm matrix, representing n spectra and m peak 
intensity values. An algorithm written in the MATLAB computing environment, as a 
modification of a published formula, 174 was used to calculate the significance of these 
individual intensities for discrimination between the three pathological groups of interest. 
A selection of peaks with the corresponding ANOVA F-value (see below and Appendix 3 
for further explanation) is shown in Table 5.3. This method of analysis tests the 
hypothesis that means from two or more samples are equal (drawn from populations with 
the same mean). This technique expands on the tests for two means, such as the West. 
The F-value is calculated from the sum of the squares of the variance from the mean peak 
intensity between and within pathology groups. The larger the F-value the greater the 
effective grouping with pathology. Fc ,, it 
is the cut-off value for 99.9% significance, 7.19 in 
this case. The p-value is the probability that the intensities for all pathologies are 
statistically the same, i. e. that they do not correlate with histopathology of the sample. It 
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can be seen from the values in Table 5.3 that none of the individual peak intensities have 
a statistically significant (to 99.9%) difference between the groups. 
Peak Normal 
Larynx 
Mean peak intensity 
Dysplastic 
Larynx 
Cancerous 
Larynx 
ANOVA, 
F-value 
1643 0.453±0.403 0.328±0.509 0.560±0.616 3.1 
1754 0.446±0.412 0.317±0.521 0.548±0.601 3.1 
1853 0.457±0.419 0.317±0.525 0.530±0.570 4.0 
1936 0.465±0.422 0.322±0.532 0.537±0.553 4.5 
11155 0.408±0.367 0.285±0.511 0.468±0.495 4.2 
11265 0.463±0.407 0.321±0.544 0.540±0.536 4.3 
11446 0.587±0.470 0.415±0.627 0.675±0.614 5.1 
11651 0.396±0.319 0.316±0.597 0.485±0.572 4.0 
Table 5.3: Selected peak intensities, with their corresponding mean and standard deviation values for 
each group. ANOVA F-values are included to indicate significance of peak for spectral group 
separation. 
5.1.2.2 Analysis of clinical significance of peak intensity ratios 
A more rigorous technique, better able to take into account variations in overall spectral 
intensity from one measurement to the next is the calculation of peak intensity ratios. In 
simple chemical solutions it is possible to select peaks that represent known molecular 
vibrations found in constituents of interest. While in principle this is possible with 
biological samples, practical difficulties and a lack of understanding of the complex 
biochemical processes occurring in tissue make this challenging. Therefore a process of 
testing all 32 selected peaks mtioed against one another was carried out by initially 
calculating an nx (m x m) matrix containing the data for n spectra in each row, and each 
column representing the set of data for each peak ratio. Analysis of variance (ANOVA) 
was then used to evaluate the peak ratios demonstrating the most significant differences 
between groups. Considering that 1024 peak ratios were analysed (for clarity and sensible 
use of space) a selection have been recorded in Table 5.4, with the relevant mean and 
standard deviation ratios for each group. ANOVA F-values are recorded to provide 
information on the ability of each peak ratio to discriminate between pathology groups in 
the larynx. The critical F-value for 99.9% significance for this data set is 7.19. Peak ratio 
measurements with an F-value of greater than the critical value provide a high statistical 
significance (>> 99.9%) for measurement of group membership. However, it must be 
noted biological tissue is very complex in nature and although the mean and variance of 
the peak ratios indicate that discrimination is possible, in practice, sample variability 
makes it extremely difficult to achieve discrimination with only one peak ratio. The 
measurements of standard deviations from the mean values indicate the variability from 
one sample to the next. 
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Peak Ratio 
Mean 
Normal 
Larynx 
peak intensity ratio value 
Dysplastic Cancerous 
Larynx Larynx 
ANOVA, 
F-value 
1721/1754 1.006±0.028 1.020±0.032 0.983±0.031 12.57 
17544780 0.953±0.036 0.942±0.035 0.906±0.041 33.46 
1828/1754 1.035±0.038 1.035±0.061 1.076±0.045 38.15 
1936/1956 1.029±0.044 1.018±0.027 1.007±0.036 7.10 
11155/11172 1.017±0.046 0.982±0.034 0.996±0.028 3.29 
11265/11336 0.944±0.084 0.897±0.070 0.927±0.068 1.07 
11315/11336 1.001±0.031 0.998±0.029 0.994±0.027 1.17 
11603/11615 0.997±0.028 1.005±0.057 0.968±0.026 18.28 
Table 5.4: Selected peak intensity ratios, from normalised spectra, with their corresponding mean 
and standard deviation values for each group. ANOVA F-values are included to indicate significance 
of ratio for spectral group separation. 
5.1.3 Multivariate Spectral Analysis 
The use of multivariate analysis techniques enables more of the data included within the 
spectra to be utilised. A summary explanation is provided in Appendix 3. Principal 
components analysis (PCA) was performed to reduce the data to a linear combination of 
25 orthogonal variables. These variables were used in a linear discriminant model for the 
prediction of sample pathology. 
PCA was performed on the tissue spectra using a singular value decomrsition (SVD) 
algorithm in the PLS-Toolbox (Eigenvectorl) running in the MATLAB environment. 
Of the 211 spectra acquired, 12 were discarded due to extremely poor signal to noise 
ratios or an unusually large fluorescence background. The remaining spectra were 
compiled into a training data set and a variety of pre-processing routines were performed 
upon it. Initially the spectra were interpolated to a regular number of points per 
wavenumber (the Renishaw system 1000 has a variable spacing due to the polynomial 
calibration fit of wavenumber per pixel across the CCD chip). The position of the 
phenylalanine (PHE) peak at around 1000 cm7' was measured for each spectrum to 
evaluate system drift from one measurement to the next. Spectra were corrected for this 
drift by shifting the x-axis so that the PHE peak was at exactly 1001.5 cm7l (Figure 5.3). 
In the first instance unfiltered spectra were used to build a discrimination model. Then 
pre-processing based upon Savitsky-Golay filters were applied to optimise the models for 
maximum group separation. 
Following pre-processing the spectra were mean-centred; this involved calculating the 
average spectrum of all the spectra in the data set and subtracting this result from every 
spectrum. Principal component analysis was used to describe the resulting spectra as a 
sum of a small orthogonal set (25) of linear combinations of the original variables. 
Figures 5.8 a, b and c show plots of the PCs from the unfiltered data set. These principal 
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components described over 99.9% of the variance from the mean spectrum across the 
data set. 
Table 5.5 lists each PC with the corresponding percentage variance described by it. 
Multiple ANOVA was used to identify the most diagnostically significant PCs, i. e. those 
that show a significant difference in value for normal, dysplastic and cancerous larynx. In 
addition a Wilks'-Lambda test has been performed on the data (Table 5.5). The larger the 
ANOVA F-value and the smaller the Wilks' A-value, the greater the discriminating 
power of the particular principal component. 
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Figure 5.8(a): Principal components 1 to 12 representing the first 99.98% of the variance of the data 
set from the mean spectrum. 
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Figure 5.8(b): Principal components 13 to 24 representing 0.02% of the variance of the data set from 
the mean spectrum. 
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Figure 5.8(c): Principal component 25 representing 0.004% of the variance of the data set from the 
mean spectrum. 
Principal 
Component 
% Variance Cumulative 
% Variance 
Wilks' 
Lambda 
F-Value Significance 
(100-p) 
1 95.52 95.52 . 970 3.029 . 051 2 3.64 99.16 . 999 . 066 . 936 3 0.60 99.75 . 984 1.551 . 215 4 0.15 99.90 . 996 . 404 . 668 5 0.03 99.93 . 910 9.690 . 000 6 0.02 99.95 . 922 8.299 . 000 7 0.01 99.96 . 918 8.785 . 000 8 0.01 99.96 . 954 4.697 . 010 9 0.00 99.97 . 981 1.912 . 150 10 0.00 99.97 . 995 . 541 . 583 11 0.00 99.97 . 996 . 404 . 668 12 0.00 99.98 . 970 3.027 . 051 13 0.00 99.98 . 969 3.118 . 046 14 0.00 99.98 . 899 10.975 . 000 15 0.00 99.98 . 992 . 778 . 461 16 0.00 99.98 . 990 1.035 . 357 17 0.00 99.99 . 970 2.997 . 052 18 0.00 99.99 . 989 1.043 . 354 19 0.00 99.99 . 988 1.195 . 305 20 1 0.00 99.99 1 . 975 2.521 . 083 
Table 5.5: Displays the first 20 PCs with the corresponding variance of the data set described, with 
statistical significance test results for evaluation of group discrimination power. PCs with greater 
than 99.9% significance of discrimination between pathological groups are printed in bold. 
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5.1.3.1 Principal Component Discrimination 
Individual PCs were selected with greater than 99.9% significance of discrimination 
between groups. The weights of principal components 5,6,7 and 14 were plotted in Figure 
5.9. It can be seen that without any manipulation some clustering occurs within these PC 
between pathological groups. 
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Figure 5.9: Scatter plots of principal component weights from PC6 versus PC7 and PC5 versus PC14. 
Symbols represent different larynx pathological states of specimens measured. 
Note that the significant principal components describe only a small fraction (0.61%) of 
the total percentage variance in the data from larynx tissue. This indicates that changes in 
histochemistry, that accompany pathological changes in the tissue, produce quite subtle 
modifications to the Raman spectra obtained. 
5.1.3.2 Three-group Linear Discriminant Model 
The first 25 PCs (describing almost 100% of the total variance from the mean) were used 
to calculate two linear discriminant (LD) functions that maximised the variance in the 
data between the pathological groups and minimised the variance between members of 
the same pathological group. This was achieved by using a linear combination of the PCs 
to construct (n-1) discriminant ftinctions to maximally separate n groups. A diagram 
outlining the steps taken to construct a linear discriminant model is shown in Figure 5.10 
and Appendix 3. In this particular case two functions were required to separate three 
groups. The two LD ftinctions (Figure 5.11) were combined to produce a diagnostic 
prediction model. The weights of the discriminant ftinctions for each spectrum were 
plotted against each other in a scatter plot to enable visualisation of group separation. 
This is displayed in Figure 5.12. The prediction accuracy of the model was tested using a 
cross-validation procedure, whereby each measurement was held back in turn whilst all 
the others were used to calculate the discriminant functions. The held back measurement 
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then had its corresponding pathology forecast by the model. This continued until the 
pathologies of all the tissue samples measured with Raman spectroscopy had been 
predicted. The accuracy of these forecasts was compared to the 'gold standard' 
histopathological findings. Table 5.6 displays the resulting predictions versus 
histopathological grading and Table 5.7 displays the sensitivities and specificities of the 
test for each group. 
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Figure 5.10: Diagram representing the steps of construction of a linear discrimiant model to separate 
3 groups of specimens. 1. Calculate principal components from mean centred spectral data. 2. Select 
clinically significant PCs to calculate (n-1) linear discrimiant functions to maximally separate the 
groups. 
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Figure 5.11: The two linear discrimiant functions required to maximally separate the specimens into 
three clinically significant pathology groups. 
103 
4 
3 
C4 
-4 
Normal Squamous Mucosa 
Squamous Dysplasis 
a Squamous Cell Carcinoma 
C30 
63 
13 
D 
00 
a 
0 
-4-3-2-101234567 
LD 1 
Figure 5.12: Plot of linear discriminant function weights for each spectrum, when tested against the 
model using a cross-validation process. 
Classification 
Raman Predicted Group embership 
Normal Dysplasia I Carcinoma Total 
No. Normal 81 4 27 112 
Dysplasia 7 29 2 38 
Carcinoma 3 0 46 49 
M % Normal 72 4 24 100.0 2 Dysplasia 18 76 5 100.0 
Carcinoma 6 0 94 100.0 
Table 5.6: Cross-validation classification results obtained using the discriminant functions calculated 
from the first 25 principal components of the larynx spectra. Each case was classified by the 
functions derived from all cases other than that case. 78.4 % of cross-validated grouped cases are 
correctly classified using this method. 
Normal Dysplasia Carcinoma 
Sensitivity 
Specificity 
72% 
89% 
76% 
96% 
93% 
81% 
Table 5.7: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the larynx, calculated from the cross-validation classification results obtained from the linear 
discriminant model. 
5.1.3.3 Linear Discriminant Model Optimisation 
Model optimisation was achieved by applying pre-processing functions such as I" and 
2d derivative Savitsky-Golay filters, prior to calculation of PCs and linear discriminant 
functions. First and second derivative pre-processing filters removed influences from the 
overall signal level (baseline) and linear background slope respectively. A range of filters 
were applied and results were evaluated. A 95-point Savitsky-Golay fourth-order 
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polynomial, second-derivative function was shown to markedly improve the resulting 
discriminating power of the three-group larynx model. The resulting PCs and analysis are 
outlined below. Table 5.8 lists each PC with the corresponding percentage variance 
described by it. Multiple ANOVA and Wilks'-Lambda were used to identify the most 
diagnostically significant principal components, i. e. those that show a significant 
difference in value for normal, dysplastic and cancerous larynx. The larger the F-value 
and the smaller the A-value, the greater the discriminating power of the spectral principal 
component. The first 25 PCs (describing almost 100% of the total variance from the 
mean) were used to calculate two linear discriminant (LD) functions that maximised the 
variance in the data between the pathological groups and minimised the variance between 
members of the same pathological group. The weights of the discriminant functions have 
been plotted together to enable visualisation of group clustering (Figure 5.13). The 
prediction accuracy of the model was tested using a cross-validation procedure. The held 
back measurement then had its corresponding pathology forecast by the model. This 
continued until the pathologies of all the tissue samples measured with Raman 
spectroscopy had been predicted. The accuracy of these forecasts were compared to the 
'gold standard' histopathological results. Tables 5.9 and 5.10 display the breakdown of 
the resulting prediction accuracy of the optimised model. 
Principal 
Component 
% Variance Cumulative 
% Variance 
Wilks' 
Lambda 
F-Value Significance 
(100-p) 
1 47.91 47.91 . 964 3.637 . 028 2 12.87 60.78 . 989 1.136 . 323 3 6.81 67.59 . 934 6.954 . 001 4 4.74 72.33 . 784 26.990 . 000 5 3.89 76.22 . 955 4.605 . 011 6 2.53 78.75 . 997 . 300 . 741 7 2.37 81.12 . 995 . 503 . 605 8 2.13 83.25 . 996 . 417 . 659 9 1.88 85.13 . 923 8.178 . 000 10 1.67 86.80 . 983 1.675 . 190 11 1.62 88.42 . 982 1.840 . 
161 
12 1.26 89.68 . 988 1.216 . 299 13 1.22 90.90 . 951 5.067 . 
007 
14 0.98 91.88 . 978 2.208 . 113 15 0.86 92.74 . 965 3.590 . 029 16 0.78 93.52 . 975 2.509 . 084 17 0.66 94.18 . 998 . 154 . 857 18 0.54 94.71 . 996 . 
349 . 705 19 0.51 95.23 1.000 . 004 . 996 20 0.49 95.71 . 883 13.048 . 000 
Table 5.8: The first 20 PCs (from the optimised model) with the corresponding variance of the data 
set described, with statistical significance test results for evaluation of group discrimination power. 
PCs with greater than 99.9% significance of discrimination between pathological groups are printed 
in bold. 
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Figure 5.13: Plot of linear discriminant function weights for each spectrum, when tested against the 
optimised model using a cross-validation process. 
Classification 
Raman Predicted Group Me bership 
Normal Dysplasia Carcinoma Total 
No. Normal 100 5 7 112 
Dysplasia 4 34 0 38 
Carcinoma 7 0 42 49 
Normal 89 5 6 100.0 
Dysplasia 10 90 5 100.0 
Carcinoma 14 0 86 100.0 
Table 5.9: Cross-validation classification results obtained using the discriminant functions calculated 
from the first 25 principal components of the larynx spectra. Each case was classified by the 
functions derived from all cases other than that case. 88.4 % of cross-validated grouped cases are 
correctly classified using this method. 
Normal Dysplasia Carcinoma 
Sensitivity 
Specificity 
89% 
87% 
90% 
93% 
86% 
95% 
Table 5.10: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the larynx, calculated from the cross-validation classification results obtained from the linear 
discriminant model. 
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5.2 Oesophagus 
The complexity of the carcinogenesis of oesophageal adenocarcinoma has been discussed 
earlier. Due to the difficulty in achieving a reliable diagnosis with tissue histopathology 
from one pathologist, it was necessary to work with a panel of three gastro-intestinal 
registry pathologists. This increased the complexity of the analysis required. Large 
sample numbers were collected, but it can be seen from Table 5.11 and Figure 5.14 that 
many were discarded prior to analysis. Figure 5.14 is a schematic diagram of the process 
of histopathological analysis of 150 oesophageal biopsy samples. Firstly all the samples 
were histopathologically analysed by each pathologist in turn, then either a majority or 
consensus of opinion of the histopathological state in each specimen was taken. Any 
samples without this agreement were discarded from the model. Further detail on 
histopathological analysis of the oesophagus tissue is provided in Appendix 2. Grey 
circles represent unknown or mixed pathology samples; green circles are normal tissue, 
blue circles are fundic Barrett's (FB), cyan circles are cardiac Barrett's (CB), purple 
circles are intestinal metaplasia (IM), pink circles are low-grade dysplasia (LGD), red 
circles are high-grade dysplasia (HGD), black circles are adenocarcinoma, yellow circles 
are squamous dysplasia, orange circles are squamous cell carcinoma (SCC). 
From 150 biopsy samples, between 80 and 90 samples were homogeneous (depending on 
pathologist), therefore following majority selection there were 80 samples remaining and 
following consensus selection there were only 50 samples remaining. Either by looking at 
the colour coded biopsy symbols in Figure 5.14 or following the numbers in Table 5.11 it 
can be seen that there is little disagreement in normal samples, but significant 
disagreement in pre-malignant (or dysplastic) specimens. 
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Figure 5.14: Schematic diagram outlining the process of histopathological analysis by three 
consultant pathologists to achieve a consensus result for comparison with spectral measurements. 
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Reject Normal CB FB IM LGD HGD Adeno Sq 
Dys 
SCF- 
Pathologist 1 1 27 4 8 13 5 11 9 4 5 
Pathologist 2 1 25 2 5 13 10 11 11 4 5 
Pathologist 3 8 28 7 5 7 8 10 7 6 1 
Majority 7 27 2 6 11 8 10 8 4 4 
Consensus 37 25 1 4 6 0 5 7 1 1 
Table 5.11: Breakdown of results from individual pathologists and corresponding majority and 
consensus results for each pathology group in the oesophagus. Values are the number of samples 
classified to that group. 
5.2.1 Raw Spectral Data 
Raman spectra obtained from oesophagus tissue (following the procedures outlined in 
section 4.3.2) have been grouped according to the histopathological grading of the sample 
performed by a panel of three consultant pathologists. Spectra were obtained from 87 
homogeneous samples (one pathologist's grading) of oesophageal mucosal tissue (25 
normal, 2 cardiac Barrett's, 5 fundic Barrett's, 13 intestinal metaplasia, 10 low-grade. 
dysplasia, 11 high-grade dysplasia, 11 adenocarcinoma, 4 squamous dysplasia and 5 
squamous; cell carcinoma). Laser light of 830mn, 31 ± 0.8mW, was focussed to a spot 2-3 
pin across. An acquisition time of 30s was used to achieve excellent signal to noise when 
using the 300 lines per min grating. The grating dispersed the whole spectrum over the 
collection area of the CCD, therefore the grating was not required to move during 
measurements. No pixel binning was used for the oesophageal spectral measurements. Each 
spectrum was corrected for the wavelength sensitivity of the system by multiplying the 
spectrum by a correction file created using the procedure outlined in section 4.2.4.2. All 
spectra shown in this section have been calibrated for wavelength shift using a standard 
Neon-Argon source. 
A plot of the mean of 1200 spectra from normal, metaplastic, dysplastic and cancerous 
oesophagus specimens is shown in Figure 5.15. The plot shows the intensity of the collected 
(Stokes) signal versus wavenumber shift relative to the 830nin excitation source. The larger 
the wavenumber the greater the shift from the excitation wavelength. The most significant 
peaks in the spectrum have been labelled with the corresponding wavenumber shift. 
Tentative peak assignments have been made from extensive study of the literature. These are 
tabulated in Table 5.12. Further peak assignments have been compiled in Appendix 4. They 
have contributions from a myriad of constituents including proteins, lipids, carbohydrates 
and nucleic acids. Many of the spectral peaks overlap and thus make a full understanding of 
the biochemistry very difficult to achieve. 
The spectra of normal oesophageal specimens have shown little inter- and intra-sample 
variability. Figure 5.16 shows 100 NIR-Raman spectra obtained from ten normal 
oesophageal tissue specimens, with the mean spectrum displayed in green. Visual 
inspection of the spectra show the peak shapes and positions to be repeatable, although 
overall spectral intensities can vary by 10 % about the mean spectrum for each individual 
sample. Wavenumber repeatability was evaluated by measuring the position of the PHE 
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peak at around 1000 cm-'. Results have been plotted in Figure 5.17. The mean position of 
the PHE peak was shown to be 1001.8 ± 1.12 cm- I. 
Mean Raman spectrum from oesophagus tissue (all pathologies) at 830 (ný1200) 
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Table 5.12: Major vibrational modes identified in oesophageal samples. 
Peak position (crif 1) Major assignments 
490 Glycogen 
524 S-S disulfide stretch in proteins 
621 C-C twisting mode of phenylalanine 
643 C-C twisting mode of tyrosine 
669 C-S stretching mode of cystine 
719 C-N (membrane phospholipid head) / nucleotide peak 
755 Symmetric breathing of tryptophan 
781 Cytosine / uracil ring breathing (nucleotide) 
828 Out of plane ring breathing tyrosine / O-P-0 stretch DNA 
853 Ring breathing mode of tyrosine and C-C stretch of proline nng 
920 C-C stretch of proline ring / glucose / lactic acid 
935 C-C stretching mode of proline and valine and protein backbone (a- 
helix conformation) / glycogen 
1001 Symmetric ring breathing mode of phenylalanine 
1031 C-H in-plane bending mode of phenylalanine 
1083 C-N stretching mode of proteins (and lipid mode to lesser degree) 
1123 C-C stretching mode of lipids / protein C-N stretch 
1155 C-C (& C-N) stretching of proteins (also carotenoids) 
1170 C-H in-plane bending mode of tyrosine 
1209 Tryptophan and phenylalanine V(C-C6H5) mode 
1240-1265 Amide III (C-N stretching mode of proteins, indicating mainly a- 
helix conformation) 
1313 CH3CH2 twisting mode of collagen / lipids 
1335 CH3CH2 wagging mode of collagen and polynucleotide chain 
(DNA-purine bases) 
1446 CH2 bending mode of proteins and lipids 
1548 Tryptophan 
1579 Pyrimidine ring (nucleic acids) and heme protein 
1603 C=C in-plane bending mode of phenylalanine and tyrosine 
1616 C=C stretching mode of tyrosine and tryptophan 
1655 Amide I (C=O stretching mode of proteins, a-helix conformation) 
C=C lipid stretch 
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Figure 5.17: Plot of the wavenumber position of a peak assigned to phenylalanine versus acquired 
spectrum. 
5.2.2 Empirical Spectral Analysis 
The spectra acquired from samples belonging to each of nine pathological groups were 
collected together and mean spectra were calculated. A plot of the mean un-normalised 
spectra from each group is shown in Figure 5.18. From this plot it can be seen that the 
differences observed in the spectra from specimens at different stages of the cancer 
development process are very subtle. On first glance the spectra appear very similar, only 
very subtle variations in peak heights and positions can be seen from one group to the 
next. 
Initially an evaluation of NIR-Raman spectroscopy for separation of specimens into three 
clinically significant groups, as would be required for biopsy targeting was carried out. 
Empirical analysis was performed on spectra compiled into three groups: normal tissue, 
metaplastic (Barrett's) tissue, and cancerous and pre-cancerous tissue in the third group. 
One method of emphasising the variation between the spectra from the three pathological 
groups is to calculate difference spectra. Figures 5.19 to 5.21 display the resulting 
difference spectra obtained from taking the difference between mean normalised and 
baseline subtracted spectra from each of the groups in turn. 
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Figure 5.18: Mean Raman spectra from each oesophageal histopathological group. 
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Figure 5.19: Mean normalised (and baseline corrected) Raman spectrum of Barrett's oesophageal 
tissue, with the mean normalized (and baseline corrected) spectrum of normal tissue subtracted. 
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Figure 5.20: Mean normalised (and baseline corrected) Raman spectrum of dysplastic and cancerous 
oesophageal tissue with the mean (and baseline corrected) normalized normal tissue spectrum 
subtracted. 
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Figure 5.21: Mean normalised (and baseline corrected) Raman spectrum from dysplastic and 
cancerous oesophageal tissue with the mean normalized (and baseline corrected) spectrum from 
Barrett's oesophagus tissue subtracted. 
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Study of the above difference spectra provides evidence for constituents in excess in 
certain pathology types and in deficit in others. Table 5.13 outlines the likely constituents 
that exhibit the greatest variation between the pathological groups. 
Barrett's vs Normal Dysplasia & Cancer vs Dysplasia & Cancer vs 
Normal Barrett's 
Peak Tentative Peak Tentative Peak Tentative 
Assignment Assignment Assignment 
437 Ribose 439 Ribose 449 Ribose ? 
720 Nucleoticle/Phospholipid 675 Thymine / guanine 544 Protein (S-S) 
787 Cytosine/thymineluracil 718 Nucleotide/phospholipid 674 Thymine / guanine 
833 DNA (0-P-0) 761 ? 719 Nucleotide/phospholipid 
875 ? 823 DNA (0-P-0) 824 DNA (0-P-0) 
1066 Protein (C-C stretch) 878 ? 879 ? 
1092 DNA (POý) 971 Hydroxyapatite 902 ? 
1154 Carotenoids (C-C) 1006 Urea? / PHE 941 Proline/valine (C-C str) W, 1246 Am. III: unordered 1070 Protein (C-C stretch) 960 Hydroxyapatite 
1261 Am. 1: a-helix 1092 DNA (1`0ý) 1006 Urea / PHE 
1378 T/A/G bases 1258 Am. III: a-helix 1049 ? 
1437 CH2/CH3 lipid? 1307 Lipid / A/T 1070 Protein (C-C stretch) 
1523 Carotenoids (C--Q 1325 Nucleic acids 1082 Nuclear acids / lipid 
1543 ? 1443 CH2/CH3 mainly lipid? 1256 Am. III: a-helix 
1568 ? 1662 Am. 1: unordered 1306 Lipid 
1668 Am. 1: cc-helix 1670 Am. 1: a-helix 1325 Nuclear acids 
1445 CH2/CH3 mainly lipid? 
1651 UWLýý 
484 Glycogen 486 Glycogen 488 ý Glycogen 
523 Protein (S-S) ? Protein (S-S) 499 Protein (S-S) 
853 TYR / carbohydrates 741 7 737 ? 
903 Glycogen? 847 TYR / carbohydrates 772 Cytosine / Thymine 
935 Protein(C-Q/glycogen ? Glycogen 845 TYR / carbohydrate 
1130 Glucose/ (C-C)Iip/prot 930 Protein (C-C) / TRP 1016 TRP 
1300 CH2 lipid 1130 Glucose/ (C-C) lip/prot 1151 Carotenoid (C-C) 
1319 CH2 lipid 1149 Carotenoid (C-C) 1183 Carotenoid / TYR 
1341 TRP / lipid 1180 Carotenoid / TYR 1231 Am. III: P-sheet 
1646 Lipid (C=Q 1341 Lipid 1512 Carotenoid (C=Q 
1686 Am. 1: P-sheet 1409 ? 1525 ? 
1506 PHE 1626 ? 
? Carotenoid (C--Q 
1632 ? 
1641 
, 
Am. 1: ?? / lipid (C--Q 
Table 5.13: Peaks from difference spectra between normal, Barrett's and dysplastic and cancerous 
oesophagus spectra, with tentative peak assignments. (? signifies no data available for peaks) 
5.2.2.1 Analysis of clinical significance of individual peak intensities 
A full analysis of the clinical significance of 29 selected peak intensities from un- 
normalised spectra was carried out using analysis of variance (ANOVA), following the 
procedure outlined in Section 5.1.2.1. A selection of peaks with the corresponding 
ANOVA F-value is shown in Table 5.14. This method of analysis tests the hypothesis 
that means from two or more samples are equal (drawn from populations with the same 
mean). The larger the F-value the greater the effective grouping with pathology. FC,, it is 
the cut-off value for 99.9% significance. The p-value is the probability that the intensities 
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for all pathologies are statistically the same, i. e. that they do not correlate with 
histopathology of the sample. 
Mean peak intensity 
Peak Normal Barrett's Dysplasia & ANOVA, 
Oesophagus Oesophagus Cancer F-value 
1480 0.328±0.165 0.483±0.300 0.337±0.123 0.1 
1755 0.295±0.172 0.512±0.313 0.373±0.142 0.3 
1853 0.378+-+0.212 0.570±0.325 0.424±0.164 0.6 
1935 0.446±0.253 0.608±0.340 0.458±0.178 0.6 
Ilool 0.458±0.276 0.685+-+0.375 0.519±0.214 1.1 
11259 0.407±0.249 0.628±0.353 0.482±0.196 1.2 
11446 0.568±0.348 0.783±0.407 0.626±0.271 2.3 
11655 0.389±0.237 0.553±0.296 0.429±0.178 2.0 
Table 5.14: Selected peak intensities, with their corresponding mean and standard deviation values 
for each group. ANOVA F-values are included to indicate significance of peak for spectral group 
separation. F,, it = 7.05. 
5.2.2.2 Analysis of clinical significance of peak intensity ratios 
A more rigorous technique, better able to take into account variations in overall spectral 
intensity from one measurement to the next is the calculation of peak intensity ratios. A 
process of testing all 29 selected peaks ratioed against one another was carried out by 
initially calculating an nx (m x m) matrix containing the data for n spectra in each row, 
and each column representing the set of data for each peak ratio. Analysis of variance 
(ANOVA) was then used to evaluate the peak ratios demonstrating the most significant 
differences between groups. A selection of the most significant peak ratios have been 
recorded in Table 5.15, with the relevant mean and standard deviation ratios for each 
group. ANOVA F-values are recorded to provide information on the ability of each peak 
ratio to discriminate between pathology groups in the larynx. The critical F-value for 
99.9% significance for this data set is 7.05. Peak ratio measurements with an F-value of 
greater than the critical value provide a high statistical significance for measurement of 
group membership. The measurements of standard deviations from the mean values 
indicate the variability from one sample to the next. 
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Peak Ratio 
Mean 
Normal 
Oesophagus 
peak intensity ratio value 
Barrett's Dysplasia and 
Oesophagus Cancer 
ANOVA, 
F-value 
1643/11616 0.949±0.085 0.887±0.096 0.927±0.094 14.95 
11548/1669 1.345±0.207 1.261±0.104 1.241±0.133 24.12 
1935/11655 0.860±0.094 0.912±0.063 0.929±0.069 18.81 
175A80 1.197±0.334 0.946±0.054 0.916±0.073 10.48 
11155/11170 0.932±0.065 0.975±0.029 0.978±0.049 11.87 
11259/11335 1.185±0.105 1.034±0.046 1.033±0.040 4.07 
11335/11655 0.817±0.086 0.854±0.041 0.862±0.040 14.40 
11616/1755 1.191±0.087 1.248±0.086 1.238±0.079 18.71 
Table 5.15: Selected peak intensity ratios, from normalised spectra, with their corresponding mean 
and standard deviation values for each group. ANOVA F-values are included to indicate significance 
., ji=7.05. of ratio 
for spectral group separation. Fc 
5.2.3 Multivariate, Spectral Analysis 
The use of Raman spectroscopy to assist biopsy targeting is likely to require simple 
decisions between either normal or abnormal tissues, therefore three- and four-group 
models would be likely to be used in this area. However, full classification of the 
pathological state of the tissue in the oesophagus, either in the laboratory or in vivo, 
would require the discrimination between a minimum of nine groups. The ability of 
multivariate statistical techniques to separate the specimens into pathological groups was 
assessed for different scenarios and for both majority and consensus pathology results. 
Principal component analysis was performed on the oesophagus spectra using singular 
value decomposition (SVD) in PLS-Toolbox (Eigenvector) running in the MATLABO 
environment. Of the 1225 spectra acquired, 36 were discarded due to extremely poor 
signal to noise ratios or an unusually large fluorescence background. The remaining 
spectra were compiled into a training data set and some sort of pre-processing was 
performed upon it. Initially the spectra were interpolated to a regular number of points 
per wavenumber (the Renishaw system 1000 has a variable spacing due to the polynomial 
calibration fit of wavenumber per pixel across the CCD chip). The position of the 
phenylalanine (PHE) peak at around 1000 cm" was measured for each spectrum to 
evaluate system drift from one measurement to the next. Due to improvements in stability 
since laryngeal spectral measurements were taken, it was not necessary to correct spectra 
for spectrometer drift. In the first instance unfiltered spectra were used to build a 
discrimination model. Then pre-processing based upon Savitsky-Golay filters were 
applied to optimise the models for maximum group separation. 
Following pre-processing the spectra were mean-centred; this involved calculating the 
average spectrum of all the spectra in the data set and subtracting this result from every 
spectrum. Principal component analysis was used to describe the resulting spectra as a 
sum of a small orthogonal set (25) of linear combinations of the original variables. 
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Figures 5.22 a, b and c show plots of the PCs. These principal components described over 
99.9% of the variance from the mean spectrum across the data set. Each PC can represent 
a single constituent or combination of constituents that vary colinearly between samples. 
The most identifiable of these is PC 3, in this case it represents the glycogen component 
of the oesophageal. Raman spectra. Glycogen is the energy store within epithelial cells. 
Those cells rapidly dividing will use up this reserve and hence have lower concentrations 
and corresponding Raman scattering intensities. 
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Figure 5.22(a): Principal components 1 to 12 representing the first 99.98% of the variance of the data 
set from the mean spectrum. 
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Figure 5.22(b): Principal components 13 to 24 representing 0.02% of the variance of the data set 
from the mean spectrum. 
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Figure 5.22(c): Principal component 25 representing 0.004% of the variance of the data set from the 
mean spectrum. 
Table 5.16 lists each PC with the corresponding percentage variance described by it. 
Multiple ANOVA was used to identify the most diagnostically significant principal 
components, i. e. those that show a significant difference in value for normal, Barrett's, 
dysplastic and cancerous oesophagus. In addition a Wilks'-Lambda test has been 
performed on the data (Table 5.16). 
Principal 
Component 
% Variance Cumulative 
% Variance 
Wilks' 
Lambda 
F-Value Significance 
(100-P) 
1 95.98 95.98 . 864 48.162 . 000 2 2.94 98.92 . 907 31.474 . 000 3 0.46 99.38 . 969 9.686 . 000 4 0.27 99.65 . 926 24.500 . 000 5 0.16 99.80 . 864 48.377 . 000 6 0.05 99.85 . 734 111.044 . 000 7 0.03 99.88 . 850 54.212 . 000 8 0.02 99.90 . 971 9.235 . 000 9 0.02 99.91 . 980 6.394 . 002 10 0.01 99.93 . 974 8.111 . 000 11 0.01 99.94 . 984 4.840 . 008 12 0.01 99.95 . 917 27.699 . 000 13 0.01 99.95 . 988 3.855 . 022 14 0.00 99.96 . 996 1.142 . 320 15 0.00 99.96 . 986 4.307 . 014 16 0.00 99.96 . 999 . 456 . 634 17 0.00 99.96 . 995 1.440 . 238 18 0.00 99.96 . 992 2.585 . 076 19 0.00 99.96 . 994 1.986 . 138 20 0.00 99.97 1 . 999 1 . 307 1 . 736 
Table 5.16: Displays the first 20 PCs with the corresponding variance of the data set described, with 
statistical significance test results for evaluation of group discrimination power. PCs with greater 
than 99.9% significance of discrimination between pathological groups are printed in bold. 
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5.2.3.1 Principal Component Discrimination 
Individual PCs were selected with greater than 99.9% significance of discrimination 
between groups. The weights of principal components 1,6,4 and 5 were plotted in Figure 
5.23. It can be seen that without any manipulation some clustering occurs within these 
PCs between pathological groups. 
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Figure 5.23: Scatter plots of principal component weights from PCI versus PC6 and PC4 versus PC5. 
Symbols represent different oesophageal pathological states of specimens measured. 
5.2.3.2 Three-group Linear Discriminant Consensus Model 
The specimens were separated into three clinically significant pathology groups: Normal 
oesophagus, Barrett's oesophagus (Cardiac, Fundic and Intestinal Metaplasia together), 
and dysplasia and cancer (LGD, HGD and adenocarcinoma together). 
The first 25 PCs (describing almost 100% of the total variance from the mean) were used 
to calculate two linear discriminant (LD) ftinctions that maximised the variance in the 
data between the pathological groups and minimised the variance between members of 
the same pathological group. A diagram outlining the steps taken to construct a linear 
discriminant model is shown in Figure 5.24. The two LD ftinctions (Figure 5.25) were 
combined to produce a diagnostic prediction model. The prediction accuracy of the model 
was tested using a cross-validation procedure, whereby each spectrum was held back in 
turn whilst all the others were used to calculate the discriminant functions. The weights of 
the linear discriminant functions for each spectrum were plotted against each other in a 
scatter plot to enable visualisation of group separation. This is displayed in Figure 5.26. 
The held back spectrum had its corresponding pathology forecast by the model. This 
continued until the pathologies of all the tissue samples measured with Raman 
spectroscopy had been predicted. The accuracy of these forecasts was compared to the 
'gold standard' histopathological findings. Table 5.17 displays the resulting predictions 
versus histopathological grading and Table 5.18 displays the sensitivities and specificities 
of the test for each group. 
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Figure 5.24: Diagram representing the steps of construction of a linear discrimiant model to separate 
3 groups of specimens. 1. Calculate principal components from mean centred spectral data. 2. Select 
clinically significant PCs to calculate (n-1) linear discrimiant functions to maximally separate the 
groups. 
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Figure 5.25: The two linear discrimiant functions required to maximally separate the three clinically 
significant oesophageal pathology groups. 
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Figure 5.26: Plot of linear discriminant function weights for each spectrum, when tested against the 
model using a cross-validation process. 
Classification 
Raman Predi ted Group Me, bership 
Normal Barrett's Dysplasia & I 
Cancer 
Total 
No. Normal 301 1 8 310 
Barrett's 0 122 23 145 
Dys & Cancer 3 7 152 162 
% Normal 97 0 3 100.0 
Barrett's 0 84 16 100.0 
Dys & Cancer 2 4 94 100.0 
Table 5.17: Cross-validation classification results obtained using the discriminant functions 
calculated from the first 25 principal components of the oesophagus spectra. Each case was classified 
by the functions derived from all cases other than that case. 93.2% of cross-validated grouped cases 
are correctly classified using this method. 
Normal Barrett's Dysplasia & 
Cancer 
Sensitivity 97% 84% 94% 
Specificity 99% 98% 93% 
Table 5.18: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classiflcation results obtained from the linear 
discriminant model. 
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5.2.3.3 Four-group Linear Discriminant Consensus Model 
The specimens were separated into four clinically significant pathology groups: Normal 
oesophagus, Barrett's oesophagus (Cardiac, Fundic and Intestinal Metaplasia together), 
Dysplasia, and Adenocarcinoma. The same process was followed, as that in the previous 
section, to construct and test a spectral discriminant model. However this time three 
linear discriminant functions were required to optimally separate four groups. These are 
shown in Figure 5.27. The weights of the functions were plotted in against one another in 
Figure 5.28 for each spectrum in the model. Pathological group separation can be seen 
from these plots. Cross-validation of the models enabled the prediction ability to be 
tested. Results of this are shown in Tables 5.19 and 5.20 and Figure 5.29. The bar chart in 
Figure 5.29 was included to enable visualisation of the cross-over between group 
prediction within the model. Colour coding of each group is consistent throughout the 
figures. 
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Figure 5.27: Three linear discriminant functions required to maximally separate four pathology 
groups from an unfiltered spectral data set. 
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Figure 5.28: Plots of linear discriminant weights demonstrating clustering of pathology groups. 
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Classification 
Raman Predicted Group Mem rship 
Normal Barrett's Dysplasia Cancer Total 
No. Normal 295 0 13 2 310 
Barrett's I ill 26 7 145 
Dysplasia 1 2 56 9 68 
Cancer 1 1 25 67 94 
% Normal 95 0 4 1 100 
Barrett's 1 77 18 5 100 
Dysplasia 1 3 82 13 100 
L Cancer I 
1 27 71 100 
Table 5.19: Cross-validation classification results obtained using the discriminant functions 
calculated from 25 PCs of the oesophagus spectra. Each case was classified by the functions derived 
from all cases other than that case. 85.7 % of cross-validated grouped cases are correctly classified 
using this method. 
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Figure 5.29: Bar chart of prediction power of the consensus four-group discriminant model. 
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Sensitivity 
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71% 
97%! 
j 
Table 5.20: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the linear 
discriminant model. 
5.2.3.4 Eight-group Linear Discriminant Consensus Model 
The specimens were separated into eight clinically significant pathology groups: Normal 
oesophagus, cardiac Barrett's, fundic Barrett's, intestinal metaplasia, high grade 
dysplasia, adenocarcinoma, squamous dysplasia and squarnous cell carcinoma. The same 
process was followed as that section 5.2.3.2, to construct and test a spectral discriminant 
model. However this time seven linear discriminant ftinctions were required to optimally 
separate the eight groups. These are shown in Figure 5.30. The weights of the functions 
were plotted against one another in Figure 5.31 for each spectrum in the model. 
Pathological group separation can be seen from these plots, although full separation could 
only be visualised if one could plot and study seven-dimensional space. Cross-validation 
of the model enabled the prediction ability to be tested. Results of this are shown in 
Tables 5.21 and 5.22 and Figure 5.32. The bar chart in Figure 5.32 was included to enable 
visualisation of the cross-over between group prediction within in the model. Colour 
coding of each group is consistent throughout the figures. 
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Figure 5.30: Seven linear discriminant functions required to maximally separate eight pathology 
groups from an unfiltered spectral data set. 
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Figure 5.31: Two-dimensional scatter plots to enable visualisation of seven dimensional spectral 
discrimination model. 
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Figure 5.32: Bar chart of prediction power of the consensus eight-group discriminant model. 
Raman edicted Group Me bership 
Classirication Normal CB FB I IM HGD I Adeno Sq. SCC Total 
Dys 
No. Normal 292 0 1 4 9 0 4 0 310 
CB 0 12 0 0 0 0 0 0 12 
FB 0 0 45 2 0 0 0 0 47 
IM 0 0 4 66 16 0 0 0 86 
HGD 2 0 3 0 60 3 0 0 68 
Adeno 0 0 5 1 19 69 0 0 94 
Sq. Dys. 0 0 0 0 0 0 15 0 15 
Scc 0 0 0 0 0 0 0 10 10 
:; % Normal 94 0 0 1 3 0 1 0 too 
CB 0 100 0 0 0 0 0 0 100 
FB 0 0 96 4 0 0 0 0 100 
IM 0 0 5 77 19 0 0 0 100 
HGD 3 0 4 0 88 4 0 0 100 
Adeno 0 0 5 1 20 73 0 0 100 
Sq. Dys. 0 0 0 0 0 0 100 0 100 
Scc 0 0 0 0 0 0 100 100 
Table 5.21: Cross-validation classification results obtained using the discriminant functions 
calculated from the first 25 principal components of the oesophagus spectra. Each case was classified 
by the functions derived from all cases other than that case. 88.6% of cross-validated grouped cases 
are correctly classified using this method. 
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Normal CB FB IM HGD Adeno Sq. Scc 
Dys. 
Sensitivity 94% 100% 96% 77% 88% 73% 100% 100% 
Specificity 99% 100% 1 98% 1 99% 92% 1 99% 1 99% 100% 
Table 5.22: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the 
unfiltered linear discriminant model. 
5.2.3.5 Nine-group Linear Discriminant Majority Model 
The results of a model utilising the majority pathology result (agreement of 2 or 3 
pathologists) on each specimen are outlined below to enable comparison with the 
consensus models. This has also allowed the introduction of an additional group of low- 
grade dysplasia. In the consensus groupings, there was no agreement on any samples with 
a low-grade dysplasia classification. Cross-validation of the model enabled the prediction 
ability to be assessed. Results of this are shown in Tables 5.23 and 5.24 and Figure 5.33. 
The bar chart in Figure 5.33 was included to enable visualisation of the cross-over 
between group prediction within in the model. Colour coding of each group is consistent 
throughout the figures. 
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Figure 5.33: Bar chart of prediction power of the majority nine-group discriminant model. 
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Raman Predicted Grout) Membe hip 
ClaSsification Normal CB FB IM LGD HGD Adeno I Sq. SCC Total 
Dys 
No. Normal 303 0 1 5 2 2 3 14 10 340 
CB 0 24 0 0 0 0 0 0 0 24 
FB 0 0 54 2 7 5 6 1 0 75 
IM 3 0 21 87 20 3 20 1 0 155 
LGD 0 0 15 8 67 8 23 3 0 124 
HGD 2 0 9 5 12 66 34 6 0 134 
0 Adeno 4 0 6 0 12 1 85 0 0 108 
14 Sq. Dys. 3 0 
5 2 3 1 6 42 0 62 
SCC 0 0 ,0 
0 0 0 5 0 41 46 
Normal 89 0 0 1 1 1 1 4 3 100 
CB 0 100 0 0 0 0 0 0 0 100 
FB 0 0 72 3 9 7 8 1 0 too 
IM 2 0 14 56 13 2 13 1 0 100 
LGD 0 0 12 6 54 6 19 2 0 100 
HGD 1 0 7 4 9 49 25 4 0 100 
Adeno 4 0 6 0 11 1 79 0 0 too 
Sq. Dys. 5 0 8 3 5 2 10 68 0 100 
SCC 0 0 ,0 
0 0 0 11 
,0 
89 too- 
Table 5.23: Cross-validation classification results obtained using the discriminant functions 
calculated from the first 25 principal components of the oesophagus spectra. Each case was classified 
by the functions derived from all cases other than that case. 72.0% of cross-validated grouped cases 
are correctly classified using this method. 
Normal CB FB IM LGD HGD Adeno Sq. SCC 
Dys. 
Sensitivity 89% 100% 72% 56% 54% 49% 79% 68% 89% 
Specificity 98% 100% 94% 98% 94% 98% 90% 98% 99% 
Table 5.24: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the 
unfiltered linear discriminant model. 
5.2.3.6 Linear Discriminant Model Optimisation 
Model optimisation was achieved by applying pre-processing functions such as Is' and 
2 nd derivative Savitsky-Golay filters, prior to calculation of PCs and linear discriminant 
functions. First and second derivative pre-processing filters removed influences from the 
overall signal level (baseline) and linear background slope respectively. A range of filters 
were applied and results were evaluated by comparing the discriminantion achieved with 
each model. 
Optimised consensus model 
A 95-point Savitsky-Golay third-order polynomial, second-derivative function was 
shown to improve the power of the eight-group consensus model to discriminate the 
clinically significant group of adenocarcinoma. The first 25 PCs (describing almost 100% 
of the total variance from the mean) were used to calculate two linear discriminant (LD) 
functions that maximised the variance in the data between the pathological groups and 
minimised the variance between members of the same pathological group. 
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Figure 5.34: Bar chart of prediction power of the optimised consensus eight-group discriminant 
model. 
Normal CB FB IM HGD Adeno Sq. SCC 
- 
Dys. 
Sensitivity 90% 92% 89% 60% 84% 79% 93% 80% 
Specificity 99% 100% 97% 99% 92% 95% 98% 100% 
Table 5.25: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the 
optimised pre-filtered linear discriminant consensus model. 
Optimised Majority model 
A Savitsky-Golay 2 nd order polynomial, 11-point smooth provided optimum 
classification results for the nine-group majority prediction model. The prediction 
accuracy of the model was tested using a cross-validation procedure. Table 5.26 and 
Figure 5.35 display the breakdown of the resulting prediction accuracy of the optimised 
model. 
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Figure 5.35: Bar chart of prediction power of the optimised majority nine-group discriminant model. 
Normal CB FB IM LGD HGD Adeno Sq. SCC 
Dvs. 
Sensitivity 89% 100% 73% 57% 56% 50% 77% 68% 87% 
Specificity 98% 100% 94% 97% 95% 98% 90% 97% 99% 
Table 5.26: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the 
optimised pre-filtered linear discriminant majority model. 
5.2.3.7 Testing Ability of Model to Discriminate Spectra With Reduced SNR 
An evaluation of the quality of the spectra required for prediction using the consensus 
eight-group model was made by projection of a set of test spectra onto the spectral 
discrimmant model. The test spectra were acquired in 30 seconds, as were the model 
spectra, and they were downgraded by adding/subtracting increasing levels of random 
noise. The intention was to simulate the reduction in SNR that would accompany spectral 
acquisition in shorter timescales. These would be required for in vivo medical diagnosis. 
Due to the small sample numbers available only 10 adenocarcinoma. spectra were 
measured for testing the model. With no imposed signal degradation 100 percent of the 
spectra were correctly predicted by the consensus 8-group model. Figures 5.36 and 5.37 
show one test spectrum with 1% and 25% of random noise added, respectively. The 
spectrum with 25% noise is similar to those obtained in 1-2 seconds with the optimised 
spectrometer system. The results obtained from testing the consensus eight-group model 
were plotted (Figure 5.38) for spectra with noise added over the range from 0-50%. 
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Figure 5.36: Plot of Raman spectrum from adenocarcinoma of the oesophagus measured in 30s, with 
1% random noise added. 
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Figure 5.36: Plot of Raman spectrum from adenocarcinorna of the oesophagus measured in 30s, with 
25% random noise added. 
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Figure 5.37: Plot of percentage of samples correctly predicted versus the percentage of random noise 
added to the test spectra. 
5.3 Formalin fixed oesophagus models 
Formalin fixation is the most common method used in collection and preparation of 
biopsy tissue for histopathological analysis. An evaluation of Raman spectral 
discrimination of formalin fixed oesophageal tissue has been carried out to assess its 
function as a pathologist's tool in the laboratory. Sample collection procedures have been 
outlined in section 4.1.2.2, and the Raman spectral acquisition parameters described in 
section 4.3.3. It must be noted that at this time the samples used in this study were 
histopathologically graded by only one consultant gastro-intestinal pathologist. Thus 
results will be expected to be less accurate than those that could be achieved with a 
consensus of pathological opinion, utilised in the previous section. 
A plot of the mean of 418 spectra from normal, metaplastic, dysplastic and cancerous 
formalin fixed oesophagus specimens is shown in Figure 5.38. The plot shows the intensity 
of the collected (Stokes) signal versus wavenumber shift relative to the 830nm excitation 
source. The greater the wavenumber the greater the shift from the excitation wavelength. 
The most significant peaks in the spectrum have been labelled with the corresponding 
wavenumber shift. Tentative peak assignments have been made from extensive study of the 
literature. These have been compiled in Appendix 4. 
The spectra of normal oesophageal specimens have shown little inter- and intra-sample 
variability. Figure 5.39 shows 100 NIR-Raman spectra obtained from ten normal 
oesophageal tissue specimens, with the mean spectrum displayed in green. Visual 
inspection of the spectra show the peak shapes and positions to be repeatable, although 
overall spectral intensities can vary by 10-15 % about the mean spectrum for each 
individual sample. Wavenumber repeatability was evaluated by measuring the position of 
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the PHE peak at around 1000 crn". Results have been plotted in Figure 5.40. Mean PHE 
peak position was found to be 1002.2 ± 3.61 cm7l. 
Mean Raman spectrum for formalin fixed oesophagus tissue (all pathologies) at 830nm (n=418) 
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Figure 5.38: Mean Raman spectrum acquired from homogeneous formalin fixed oesophageal tissue 
samples, exhibiting eight different clinically significant pathologies, with an 830nm excitation source. 
T--30s. 
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Figure 5.39: 100 Raman spectra from 10 formalin fixed normal oesophagus specimens, mean 
spectrum in green. 
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Figure 5.40: Plot of the wavenumber position of a peak assigned to phenylalanine versus acquired 
spectrum. 
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Raman spectra from normal (formalin fixed) oesophageal biopsy tissue at 830nm 
To evaluate the effect of formalin on tissue spectra a Raman spectrum of the formalin 
fixative, used to fix and store a sample of oesophagus, was acquired and shown in Figure 
5.41. By studying Figures 5.41 and 5.38, a spectrum of normal oesophagus soaked in 
formalin, the contributions of the formalin can be assessed. Moreover, the protein cross- 
links caused by the fixation process will likely cause shifts in the Raman peak positions 
compared with those in fresh samples. 
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Figure 5.41: Plot of Raman spectrum of formalin fixative used to fix and store oesophagus samples. 
5.3.2 Multivariate Spectral Analysis 
The spectra acquired from samples belonging to each of eight pathological groups were 
collected together and mean spectra were calculated. A plot of the mean spectra from 
each group normalised to the intensity at 1445 cm-1 is shown in Figure 5.42. From this 
plot it can be seen that the differences observed in the spectra from specimens at different 
stages of the cancer development process are very subtle. 
Principal component analysis was performed on the formalin fixed oesophagus spectra 
using singular value decomposition (SVD) in PLS-Toolbox (Eigenvector') running in the 
MATLABO environment. Of the 418 spectra acquired, 7 were discarded due to extremely 
poor signal to noise ratios or an unusually large fluorescence background. The remaining 
spectra were compiled into a training data set and some pre-processing was performed 
upon it. Initially the spectra were interpolated to a regular number of points per 
wavenumber (the Renishaw system 1000 has a variable spacing due to the polynomial 
calibration fit of wavenumber per pixel across the CCD chip). The position of the 
phenylalanine (PHE) peak at around 1000 cm-1 was measured for each spectrum to 
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evaluate system drift from one measurement to the next. This value was used to correct 
spectra for spectrometer drift. In the first instance unfiltered spectra were used to build a 
discrimination model. Then pre-processing based upon Savitsky-Golay filtering was 
applied to optimise the models for maximum group separation. 
Following pre-processing the spectra were mean-Centred; this involved calculating the 
average spectrum of all the spectra in the data set and subtracting this result from every 
spectrum. Principal component analysis was used to describe the resulting spectra as a 
sum of a small orthogonal set (25) of linear combinations of the original variables. 
Figures 5.43 a, b and c show plots of the PCs. These principal components described over 
99.9% of the variance from the mean spectrum across the data set. PC 4 can be seen to 
exhibit mainly formalin peaks and PC 7 mainly glycogen peaks. Table 5.27 lists each PC 
with the corresponding percentage variance described by it. Multiple ANOVA was used 
to identify the most diagnostically significant principal components, i. e. those that show a 
significant difference in value for normal, Barrett's, dysplastic and cancerous 
oesophagus. In addition a Wilks'-Lambda test has been performed on the data (Table 
5.27). 
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Figure 5.42: Mean Raman spectra normalized to the intensity at 1445 cm-1 from each formalin fixed 
oesophageal histopathological group. 
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Figure 5.43(a): Principal components I to 12 representing the first 99.98% of the variance of the data 
set from the mean spectrum. 
. 01 
140 
PC 13 
004 0 
002 0 
0, 
-002 
-004 
-0 
-0.06 
-006 
5m lom ism 
PC la 
01 
ni 
0.1 
01 
-0 
-0. 
PC 14 
)4 
32 
0 
32 
u 
D6 
De 
rm im 
PC 17 
3.06 
304 
3.02 
a 
D02 
0.04 
0.06 
008 
-nil 
PC 15 
DOB 
006 
0.04 
002 
a 
0.02 
004 
0 OG 
0.0B 
5m lom 15m 
PC la 
0.1 
005 
500 1000 1500 Soo 1000 1500 500 1000 1500 
Raman shift I cm-1 
PC 19 PC 20 PC 21 
006 
0.04 
002 
0 
-002 
-004 
-006 
-0.08 
-0-1 
500 1000 1500 Soo 1000 1500 Soo 1000 1500 
PC 22 PC 23 PC 24 
006 0.1 008 
004 006 
002 005 004 
0 002 
-0.02 0 
.S -004 
-002 
. 006 -0.05,404 
-004 
-0.081 11. i 
500 1000 1500 Soo 1000 1500 Soo 1000 i5m 
Raman shift I cm-1 
Figure 5.43(b): Principal components 13 to 24 representing 0.02% of the variance of the data set 
from the mean spectrum. 
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Figure 5.43(c): Principal component 25 representing 0.004% of the variance of the data set from the 
mean spectrum. 
Principal 
Component 
% Variance Cumulative 
% Variance 
Wilks' 
Lambda 
F-Value Significance 
(I 00-p) 
1 99.08 99.08 . 820 12.815 . 000 2 0.68 99.76 . 792 15.383 . 000 3 0.11 99.88 . 848 10.498 . 000 4 0.03 99.91 . 896 6.814 . 000 5 0.02 99.93 . 828 12.205 . 000 6 0.02 99.95 . 916 5.394 . 000 7 0.02 99.97 . 797 14.873 . 000 8 0.01 99.97 . 825 12.435 . 000 9 0.00 99.98 . 933 4.194 . 000 10 0.00 99.98 . 763 18.242 . 000 I1 0.00 99.99 . 829 12.040 . 000 12 0.00 99.99 . 932 4.263 . 000 13 0.00 99.99 . 866 9.067 . 000 14 0.00 99.99 . 962 2.326 . 025 15 0.00 99.99 . 867 8.990 . 000 16 0.00 99.99 . 954 2.847 . 007 17 0.00 99.99 . 912 5.621 . 000 18 0.00 99.99 . 917 5.313 . 000 19 0.00 99.99 . 982 1.076 . 378 20 0.00 99.99 . 962 2.302 1 . 026 
Table 5.27: Displays the first 20 PCs with the corresponding variance of the data set described, with 
statistical significance test results for evaluation of group discrimination power. PCs with greater 
than 99.9% significance of discrimination between pathological groups are printed in bold. 
The specimens were separated into eight clinically significant pathology groups: Normal 
oesophagus, cardiac Barrett's (CB), fundic Barrett's (CB), intestinal metaplasia (IM), 
low-grade dysplasia (LGD), high-grade dysplasia (HGD), adenocarcinoma, and 
squamous dysplasia. The same process was followed as that in section 5.2.3.2, to 
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construct and test a spectral discriminant model. However this time seven linear 
discriminant functions were required to optimally separate the eight groups. These are 
shown in Figure 5.44. The weights of the functions were plotted against one another in 
Figure 5.45 for each spectrum in the model. Pathological group separation can be seen 
from these plots, although full separation would only be visualised if one could plot and 
study seven-dimensional space. Cross-validation of the model enabled the prediction 
efficiency to be tested. Results are shown in Table 5.28 and the bar chart in Figure 5.46 
was included to enable visualisation of the cross-over between group prediction within in 
the model. Colour coding of each group is consistent throughout the figures. 
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Figure 5.44: The seven linear discrimiant functions required to maximally separate the eight 
clinically significant oesophageal pathology groups using the formalin fixed sample spectral data. 
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Raman shift I crn-I 
Normal CB FB IM LGD HGD Adeno Sq 
Dys 
Sensitivity 82% 81% 86% 75% 80% 100% 93% 80% 
Specificity 92% 100% 97% 99% 94% 98% 99% 98% 
Table 5.28: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the linear 
discriminant model. (Unfiltered model) 
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Figure 5.45: Bar chart of prediction efficiency of un-optimised discriminant model tested with cross- 
validation. 
Model Optimisation 
Model optimisation was achieved by applying pre-processing ftinctions such as Ist and 
2 nd derivative Savitsky-Golay filters, prior to calculation of PCs and linear discriminant 
ftinctions. First and second derivative pre-processing filters removed influences from the 
overall signal level (baseline). A zeroth derivative, third-order polynomial, II -point 
smooth provided optimum separation of the pathological groups. A seven-dimensional 
linear discriminant model was tested using cross-validation and the results are outlined 
below. Table 5.29 displays the sensitivities and specificities achieved using the optimised 
model and Figure 5.46 displays a bar chart of the resulting model predictions. 
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Normal CB FB IM LGD HGD Adeno Sq 
Dys 
Sensitivity 76% 85% 100% 80% 88% 100% 100% 88% 
Specificity 99% 98% 98% 98% 94% 100% 99% 96% 
Table 5.29: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify pathology 
in the oesophagus, calculated from the cross-validation classification results obtained from the linear 
discriminant model. (Model optimised with pre-filtered spectra. ) 
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Figure 5.46: Bar chart of prediction efficiency of optimised, discriminant model tested with cross- 
validation. 
Effect of Time Stored in Formalin on Raman Classification of Pathology 
The principal components calculated to separate the pathological groups for formalin 
fixed oesophagus tissue were found to also include information on the time of sample 
storage in formalin. Approximately one third of the samples were stored for a number of 
weeks and the other two-thirds were stored for between 12 and 18 months. A single linear 
discriminant function was constructed from a linear combination of the PCs used in the 
un-optimised model. The linear discriminant function and the weights of the function for 
each spectrum are plotted in Figure 5.47. Table 5.30 demonstrates the separation of the 
spectra into the two groups of specimens dependent upon the time in formalin. 
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Figure 5.47: Plot of linear discriminant function calculated to maximally separate the samples by 
length of time in formalin. One set were left for over 12 months, the other set for a few weeks. 
Predicted Gro p Membership 
Time in formalin 2-3 Weeks >12 months Total 
No. 2-3 Weeks 180 2 182 
>12 Months 3 233 236 
% 2-3 Weeks 99 1 100.0 
>12 Months 1 99 100.0 
Table 5.30: Displays resulting length of time in formalin prediction model results. 
5.4 Appraisal of Factors Likely to Influence Transfer of In Vitro 
Raman Classification Models to In Vivo Spectral Discrimination 
The effect of a number of factors likely to influence the transfer of in vitro Raman 
classification models to use for in vivo spectral discrimination have been studied. Firstly 
the temperature dependence of the tissue Raman spectra over the range from room 
temperature to body temperatures has been assessed. In addition, the polarisation 
dependence of the tissue Raman spectra has been evaluated. The most significant 
differences likely to be observed in vivo are from contamination of the tissue spectra by 
so called confounding factors, such as: blood, bile and gastric juices, spittle, mucus and 
endoscope lubricant. 
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5.4.1 Temperature Dependence of Tissue Raman Spectra 
The temperature dependence of Raman spectra of oesophageal mucosa was measured 
over the range 10 to 50'C, following the procedure outlined in section 4.3.4. The most 
significant region for medical spectroscopy is between room and body temperatures. 
Figure 5.48 shows a plot of Raman spectra at 20,30 and 401C. The most significant 
changes over the investigated range appear to be increasing background luminescence 
with increased temperature. 
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Figure 5.48: Plot of Raman spectra from a sample of oesophagus tissue at 20,30 and 40"C. 
5.4.2 Polarisation Sensitivity of Tissue Raman Spectra 
Section 4.3.5 outlines the procedures carried out to study the polarisation sensitivity of 
oesophageal Raman spectra. The polarisation of the inelastic scattered light has been 
analysed and in addition the effect of the polarisation of the laser illumination has been 
evaluated. From a single point on the sample, three spectra were acquired without a 
polariser in the collection path, three spectra were acquired with a polariser parallel and 
three with a polariser perpendicular to the polarisation axis of the laser illumination. 
Figure 5.49 displays the mean resulting spectra. A depolarisation ratio has been 
calculated directly between the parallel and perpendicular polarisation spectra (Figure 
5.50), without any corrections for the polarisation orientation sensitivity of the 
spectrometer grating. When the analysing polanser was parallel to the illumination 
polarisation axis, most of the Raman peaks remained in the spectrum. However, when the 
polanser was perpendicular to the illumination polarisation axis, a significant number of 
Raman peaks were removed from the spectrum. Theoretically the most symmetric 
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vibrational modes produce the most polarised inelastically scattered light. Therefore the 
spectral peaks corresponding to these vibrational modes will be the most sensitive to the 
introduction of a polariser aligned perpendicular to the incident laser polarisation. Further 
study of this data can be used to assist in the identification of peaks for assignment to 
vibrational modes. 
An evaluation of the sensitivity of the spectra to illumination polarisation geometry was 
made by employing a half-wave plate to rotate the polarisation of the laser beam Prior to 
sample illumination. The above procedure was then repeated in the analyser/collection 
path. The resulting spectra are displayed in Figure 5.51. The half-wave plate was shown 
to rotate the polarisation orientation by 90' and to reduce the illumination intensity to 
80% of the incident irradiance. From Figure 5.51 it can be seen that the signal is 
decreased to significantly less than 80% of the scattering signal in Figure 5.49. This is 
likely to be due to the polarisation sensitivity of the optics in the spectrometer. 
Nevertheless, it can be seen that the spectral shapes are repeated when the laser 
illumination polarisation is rotated by 90'. 
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Figure 5.49: Mean Raman spectra of normal oesophageal mucosa with polarisation selection in the 
collection path. 
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Figure 5.50: Plot of depolarisation ratio of normal oesophageal mucosa, uncorrected for system 
polarisation sensitivity. 
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Figure 5.51: Mean Raman spectra of normal oesophageal mucosa with illumination polarisation 
rotated 90 degrees relative to the previous measurements and polarisation selection in the collection 
path. 
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5.4.3 Significance of Depth of Collection Volume in Oesophageal Tissue 
Section 4.3.6 describes the experimental procedures employed to measure the variation of 
the Raman spectra from oesophageal tissue with depth, by mapping transverse sections. 
Figure 5.52a shows the resulting Raman false colour map superimposed upon the white 
light image of a normal oesophageal sample from the microscope camera. Each coloured 
pixel represents an individual Raman measurement. Multivariate analysis using principal 
components on each of the pixels has been carried out. The weights of the first three PCs 
(Figure 5.52b) have been combined to construct the false colour image. This has been 
repeated for a Barrett's oesophagus tissue section (Figures 5.53a and b). The false colour 
images emphasise differences in cellular layers of the tissue, which have been 
discriminated by the differing biochemistry of the cells and surrounding stroma. 
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Figure 5.52b The PC loadings used to construct the false colour map image. Each PC represents the 
reducing variance from the mean. 
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Figure 5.52a Raman false colour map superimposed upon the white light image of a normal 
oesophageal sample. Each pixel is made up of the combined weights of the first 3 PCs. 
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Figure 5.53b shows the PC loadings used to construct the false colour map image. Each PC 
represents the reducing variance from the mean. 
5.4.4 Confounding Factors 
A selection of contaminants likely to affect Raman spectra of oesophageal tissue 
measured in vivo have been measured with the same spectrometer configuration as that 
used to measure the oesophagus spectra. See section 4.3.7 for details. The spectra have all 
been corrected for energy sensitivity of the system, and the relative intensity levels 
indicate the likely effect they will have on any spectra measured in their presence. An 
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Figure 5.53a Raman false colour map superimposed upon the white light image of a Barrett's 
oesophagus sample. 
average oesophagus spectrum has been included for comparison of relative intensity 
levels and peak positions. Figure 5.54 displays these spectra. 
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Figure 5.54: Raman spectra of possible contaminants of in vivo oesophagus spectra, measured in 30 
seconds and corrected for energy sensitivity. Average oesophagus spectrum is included for 
comparison (in red). 
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It can be seen from the spectra of potential contaminants that there are a number of these 
that exhibit sharp Raman scattering spectra, that may interfere with tissue Raman spectra. 
However, if one looks at the relative intensities, it is only the bile that has a significantly 
higher signal strength than the tissue. This appears to be mainly due to a luminescent 
background. The sample measured was of pure human bile, extracted from the bile duct. 
By the time it reaches the gastro-oesophageal junction it is likely to be markedly diluted. 
It must also be noted that all the tissue in this study has been measured without pre- 
washing of the samples, therefore it is likely that most contaminants will already be 
present on the tissue surface. 
5.5 Other Biological Tissues of Interest 
A selection of other biological tissues where Raman spectroscopy will be likely to 
contribute to the detection and classification of cancers have been studied. Spectra of 
some of these are shown in Figure 5.55. Raman spectra of these tissues were measured 
using the custornised Renishaw microspectrometer (outlined 4.2) with 828nm laser light 
focussed onto the sample by the x80 objective. Integration of the collected signal was 
carried out for 30 seconds with laser power levels of 32mW. The tissues evaluated 
included the following: 
1. Stomach. 
2. Tonsil. 
3. Endometrium. 
4. Bladder. 
5. Prostate. 
It can be seen that the epithelial spectra are visually similar, although subtle differences 
are present that would allow identification and potentially classification of pathology 
types in much the same way as those demonstrated for larynx and oesophagus tissues. 
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Figure 5.55: Raman spectra of other epithelial tissues with potential application for Raman 
spectroscopic diagnostics. 
5.6 Summary of Results 
A commercially available Raman microspectrometer (Renishaw System 1000) has been 
customized to provide optimumý signal-to-noise ratio spectra in the shortest timescales, 
with the minimum fluorescence background signal contribution from the tissue 
fluorophors. The optimisation evolved throughout the early period of experimentation. In 
the ideal world this would not have happened. However, time constraints and difficulty in 
obtaining tissue samples has meant that in the earlier larynx work spectra were measured 
with various spectrometer configurations and therefore spectra obtained have included 
fixed pattern noise from the spectrometer in addition to the tissue signal. 
The optimisation process has involved selection of the ideal excitation wavelength in the 
range available (514.5nm to 860nm). It has been demonstrated that the use of 830nm 
laser light produces the highest SIN ratio tissue spectra by providing a compromise 
between high sensitivity in the CCD detector (reducing with increasing wavelength), low 
tissue fluorescence (reducing with increasing wavelength), and the V4 dependence of the 
Raman cross-section. The most significant factor within the range of detector sensitivity 
is the background fluorescence, because high fluorescence can easily swamp weak 
Raman signals causing them to be obscured by shot noise levels (see section 4.2.6). 
Moreover, there has been no visible degradation observed in the spectral intensity when 
using 830mn excitation. However, when using 633nm excitation fluorescence bleaching 
is observed in a matter of seconds. 
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5.6.1 Raman Detection of Cancers and Pre-cancers in the Larynx 
This study was the first to demonstrate the feasibility of using Raman spectroscopy to 
measure and discriminate the pathological state of laryngeal tissue. The resulting 
sensitivities and specificities that have been achieved with the use of multivariate linear 
discriminant models indicate a high degree of discrimination is possible, even between 
samples exhibiting only very subtle morphological changes, such as between normal 
squamous mucosa and squamous dysplasia; and squamous dysplasia. and squamous cell 
carcinoma. 
The samples were snap-frozen to ideally preserve the nature and freshness of the tissue 
without introduction of any impurities likely to cause uncharacteristic spectral variations. 
In addition the spectra were acquired using an illumination/collection geometry similar to 
that that would be used for in vivo measurements. Thus confirming the feasibility of 
using Raman spectroscopy for in vivo tissue surface analysis by coupling a fibre probe to 
the spectrometer. 
Good inter- and intra- sample Raman spectral repeatability has been demonstrated. Thus 
negating the need for measurement of normal tissue as a baseline from each individual 
prior to diagnosis. There is some baseline variability that is likely to be due to a 
combination of microscopic tissue heterogeneity, a variable focus and variable laser 
powers. Wavenumber repeatability was demonstrated by calculating the standard 
deviation from the mean position. This was shown to be ±3.25 cm71 over all 200 spectra. 
This variation was likely to be due to significant drift in laser pointing and wavelength 
stability. Shift correction has been used to compensate prior to analysis. 
The spectra obtained are highly complex in nature, consisting of a superposition of 
Raman scattering peaks from a myriad of tissue constituents. There are many 
discrepancies in the literature regarding the assignment of each peak. It is likely that most 
will be made up of scattering from many biological molecules co-added, thus peak shapes 
and positions may vary. Moreover, system resolution of 3-4 cm71 will introduce some 
discrepancies. 
All spectra from laryngeal mucosal tissue are inherently similar. Any differences between 
the spectra from one pathological group to the next have required complex analytical 
procedures to exploit the subtle variations. Initially empirical peak analysis was 
evaluated. Difference spectra calculated between normalised spectra from normal, 
dysplastic and cancerous larynx enabled the more obvious variations in the Raman 
scattering properties from one group to the next to be assessed. The magnitude of the 
variation between spectra could be quantified by comparing the magnitude of the peaks 
and troughs in the difference spectra with the intensity levels shown in the individual 
mean spectra. The dysplasia versus normal difference spectrum represented about 1% 
variation from the mean spectrum. The SCC versus normal and SCC versus dysplasia 
difference spectra represented approximately 2% of the variation from the mean. These 
values indicated the small differences from one pathological group to the next. 
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Utilisation of tentative peak assignments for significant positive and negative peaks in the 
difference spectra has enabled some sense to be made of the biochemical changes that 
accompany the progress towards cancer in laryngeal mucosal tissue. Dysplastic tissue has 
been shown (tentatively) to exhibit greater DNA, lipid, phenylalanine and tyrosine peaks; 
but lower protein backbone, unordered proteins, (x-helix proteins, porphyrins, and 
tryptophan than normal tissue. Squamous cell carcinoma has been shown to demonstrate 
increased nucleic acids and DNA, hydroxyapatite, tryptophan, and P-sheet proteins and 
less glycogen, carotenoids, lipid and a-helix proteins than either normal or dysplastic 
larynx tissue. This tends to corroborate known biochemical changes leading to tumour 
develoment. These include, increased nuclear/cytoplasmic ratio, protein conformation 
changes and tissue calcification. 
The histopathology grades have been developed by pathologists utilising architectural 
and morphological differences to recognise from experience when a tissue has undergone 
a change likely to be clinically significant. However, cells are undergoing a continuum of 
change from normal to squamous dysplasia to cancer, and therefore distinguishing 
between samples, either histologically or spectroscopically will be difficult. 
The variation of peak intensities from one spectrum to the next has been shown to be 
larger than the subtle variation that represents the pathological changes within the tissue. 
The analysis of variance from the mean of 32 peak intensities from 200 un-normalised 
spectra was performed. None of the peaks were shown to vary with pathological group to 
the 99.9% significance level. Moreover, standard deviations from the mean peak intensity 
values were shown to be equivalent to the magnitude of the mean values. One method 
utilised to overcome this variation from one spectrum to the next has been peak intensity 
ratio analysis. The 32 selected peaks were ratioed with one another to produce 1024 peak 
ratio values for each spectrum. Analysis of variance from the mean (ANOVA) was 
performed on all of the values to evaluate significant differences between pathological 
groups. F-values were shown to vary from 38.15 for 1828/1754 to 1.07 for 11265/11336. These 
represent significance levels of varying from one group to the next of greater than 
99.9999% and 65.5% respectively. 
Standard deviations of peak ratios are approximately 5% of the mean values, indicating 
significantly less variation than that demonstrated by peak analysis alone. Significant 
differences in the peak ratios with pathology groups have been demonstrated. Although, 
pathological changes are the result of highly complex biochemical processes unlikely to 
be fully described by only two molecular vibrational modes. Multivariate analysis has 
enabled the most clinically significant variations from the mean spectra of the data set to 
be utilised for discrimination between the sample groups. Initially principal components 
were calculated from spectra that had been shift-corrected, interpolated to one point per 
wavenumber and mean centred. Each principal component described ever decreasing 
levels of variance from the mean spectrum of the data set. A linear combination of 
enough of the PCs would enable reconstruction of the original mean centred spectrum. 
Four principal components (5,6,7 and 14) were shown to exhibit greater than 99.9% 
significance of discrimination between the three pathological groups. The four significant 
PCs described only 0.61% of the total variance from the mean, indicating that subtle 
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modifications in biochemistry precede and accompany significant pathological changes to 
the tissue. However, by plotting the weights of the PCs in scatter plots it could be seen 
that there was a good level of clustering but some overlap from one group to the next. 
The application of linear discriminant analysis has enabled the group separation to be 
maximised by the construction of two functions from linear combinations of PCs to 
maximise the variance between groups and minimise the variance within groups. Two 
functions are necessary for discrimination between three groups. The model constructed 
from unfiltered spectra when tested with a cross-validation procedure correctly predicted 
78.4% of the spectra, with sensitivities ranging from 72 to 93% and specificities of 81 to 
96%. From scatter plots of the linear discriminant function weights it could be seen that 
group clustering was achieved successfully, although some groups appeared to cluster 
into two sub-groups. This is likely to be due to the evolving spectrometer configuration 
that was employed for measurements of larynx spectra. Raman spectra have been 
acquired with different resolutions, SIN ratios, calibration protocols and laser stabilities. 
The use of a smoothing function to pre-process the data has been shown to reduce the 
effect of these variations in the model. 
Model optimisation has involved the use of smoothing filters, likely to remove any subtle 
fluctuations in peak positions. In addition the use of V and 2 nd derivative functions would 
remove background offset and linear functions from the spectra prior to analysis, thus 
reducing the intersample variability from the sampling conditions. Optimisation of the 
linear discriminant (LD) model for the larynx tissue data was achieved by building 
multiple models with all the spectra pre-processed with Savitsky-Golay filters ranging 
from zeroth to second derivative, first- to fifth-order polynomial functions with widths 
from 7 to 105 points. The resulting discrimination was seen to vary with filter widths and 
type. It was possible to maximise the number of correctly predicted spectra for normal, 
dysplastic, or cancerous groups, or for a combination. In the case of optimisation for 
maximum number of samples correctly predicted from all groups, a 95-point, fourth- 
order polynomial, second-derivative filter, applied prior to analysis, provided an optimum 
separation for all three groups of 88.4% correctly classified. The scatter plots of the 
resulting LD weights have less overlap and sensitivities have improved to between 86 to 
90% and 87 to 95 % specificity; although the sensitivity for cancer detection has been 
shown to drop from 93 to 86%. This reduced the large number of false positives seen in 
the un-optimised model, but has introduced a few more false negatives, which will be 
likely to be more important to patient outcomes. 
5.6.2 Raman Detection of Cancers and Pre-Cancers in the Oesophagus 
Published studies have indicated high levels of discrepancy between even highly 
experienced histopathologists in the classification of oesophageal pre-cancerous lesions 
(see Chapters I and 2). Three expert gastrointestinal-registry histopathologists were used 
to judge the pathological state of all the samples used in this work. Spectral models were 
trained with majority and consensus data to evaluate the importance of a full agreement 
on the functionality of a Raman spectral diagnostic technique. Under normal 
circumstances a pathologist would classify a tissue sample by the highest or most 
clinically significant grade in a mixed sample. In this study the pathologists were given 
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the task of describing all the grades present in the tissue. Heterogeneous samples were 
discarded to remove the possibility of introducing errors from measuring different areas 
of the samples from those defined by the pathologist. Those samples with a discrepancy 
of opinion were discarded using majority or consensus selection rules. 
The results obtained in this study have been the first to demonstrate the feasibility of 
using Raman spectroscopy to measure and discriminate between large numbers (n--9) of 
pathological groups in oesophageal tissue and the first investigation to carry out a 
rigorous histopathological analysis protocol. The resulting sensitivities and specificities 
that have been achieved with the use of multivariate linear discriminant models indicate a 
high degree of discrimination is possible, even between samples exhibiting only very 
subtle morphological changes, such as between Barrett's oesophagus (intestinal 
metaplasia) and low-grade and high-grade dysplasias. 
Two separate studies were undertaken, the first with samples snap-frozen, and the second 
with the samples formalin fixed. Snap-freezing preserved the nature and freshness of the 
tissue without the introduction of any impurities likely to cause uncharacteristic spectral 
variations. Formalin is the fixative of choice for most excisional biopsies. However it is 
known to introduce cross-links between proteins and is thus likely to introduce changes to 
Raman tissue spectra, in addition to the contribution from the formalin solution itself. All 
the spectra were acquired in a geometry similar to that that would be used for in vivo 
measurements. Both studies were complimentary in that the facility of Raman 
spectroscopy to distinguish between diseased states in both fresh (live) tissue and fixed 
tissue in the pathology laboratory has been evaluated. The same spectrometer 
configuration was used throughout, 3lmW of 830nm laser light was focussed on the 
tissue surface with a x80 ultra-long-working-distance lens. A monochromator with a 
50gm entrance slit and 300 lines per mm grating was used to disperse the collected light. 
An integration time of 30 seconds was used for acquisition of high quality spectra (SNR 
>15). Use of a low dispersion grating has allowed the full spectral range of the tissue 
fingerprint region (200-2100 crn") to be acquired with a static, and hence more 
repeatable grating position. 
5.6.2.1 Snap-frozen tissue 
Initial discussion will focus on the snap-frozen oesophageal tissue models. Good inter- 
and intra- sample spectral repeatability has been demonstrated, thus negating the need for 
measurement of normal tissue as a baseline from each individual prior to diagnosis. There 
has been no visible degradation observed in the spectral intensity when using 830nm 
excitation. There is some baseline variability that is likely to be due to a combination of 
microscopic tissue heterogeneity, variable focus and variable laser powers. Wave number 
repeatability was demonstrated by calculating the standard deviation from the mean 
position. This was shown to be ±1.12 cm-1 over all 1200 spectra. This variation was likely 
to be due to a drift in laser pointing and wave length stability. Shift correction has not 
been used on the spectra prior to analysis. 
The spectra obtained are highly complex in nature, consisting of a superposition of 
Raman scattering peaks from a myriad of tissue constituents. There are many 
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discrepancies in the literature regarding the assignment of each peak. It is likely that most 
will be made up of scattering from many biological molecules co-added, thus peak shapes 
and positions may vary. Moreover, a system resolution of around 10-12 cm-1 (for the 300 
lines per min grating and 50 pm slit configuration) will introduce some discrepancies. 
All spectra from oesophageal mucosal tissue are inherently similar. Complex analytical 
procedures have been necessary to exploit the subtle variations between the spectra from 
each pathological group. Initially empirical peak analysis was evaluated for samples 
included in the three-group consensus model (normal, Barrett's and dysplasia and cancer 
combined). Difference spectra between mean normalised spectra from normal, Barrett's, 
and dysplastic and cancerous oesophagus enabled the more obvious differences between 
the Raman scattering properties from one group to the next to be assessed. The magnitude 
of the variation between spectra could be quantified by comparing the magnitude of the 
peaks and troughs in the difference spectra with the intensity levels shown in the 
individual mean spectra. The Barrett's versus normal difference spectrum represents 
about 1% variation from the mean spectrum. The dyspfasia and cancer versus normal and 
dysplasia and cancer versus Barrett's represent approximately 2% of the variation from 
the mean. These values indicate the small differences from one pathological group to the 
next. 
Utilisation of tentative peak assignments for significant positive and negative peaks in the 
difference spectra has enabled some sense to be made of the biochemical changes that 
accompany the progress towards adenocarcinoma in oesophageal tissue. Dysplastic and 
cancerous tissues have been shown (tentatively) to exhibit greater DNA, hydroxyapatite, 
urea/phenylalanine, a-helix and unordered proteins, but lower glycogen, carbohydrates, 
protein disulphide bonding, and carotenoids than normal tissue. This tends to corroborate 
known biochemical changes leading to tumour develoment such as increased energy 
consumption from cell division, increased nuclear/cytoplasmic ratio, protein 
conformation changes and tissue calcification. The histopathological groupings 
developed by pathologists utilise architectural and morphological differences to recognise 
from collective experience when a tissue has undergone a change likely to be clinically 
significant. However, cells are undergoing a continuum of change from Barrett's mucosa 
to dysplasia to adenocarcinoma, and therefore full separation, either histologically or 
spectroscopically will be difficult. 
The variation of each peak intensity across the spectral dataset has been shown to be 
larger than the subtle variation that represents the pathological changes within tissue. The 
analysis of variance from the mean of 29 peak intensities from 617 un-normalised spectra 
was performed. None of the peaks were shown to vary with pathological group to the 
99.9% significance level. Moreover, standard deviations from the mean peak intensity 
values were shown to be equivalent to approximately 30% of the magnitude of the mean 
values. One method utilised to overcome this variation from one spectrum to the next has 
been peak intensity ratio analysis. The 29 selected peaks were ratioed with one another to 
produce 841 peak ratio values for each spectrum. Analysis of variance from the mean 
(ANOVA) was performed on all of the values to evaluate significant differences between 
pathological groups. F-values were shown to vary from 24.12 for 11548/1669 to 4.07 for 
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11259/11335. These represent greater than 99.9999% and 98.25% significance of variation 
between pathology groups. 
Standard deviations of peak ratios from the mean values average approximately 7%, 
indicating significantly less variation than that demonstrated by peak analysis alone. 
Although significant differences in peak ratios have been demonstrated, pathological 
changes are the result of highly complex biochemical processes unlikely to be described 
by a pair of Raman peaks representing two molecular vibrational modes. 
Multivariate analysis has enabled the most significant variations from the mean spectra of 
the data set to be utilised for discrimination between the sample groups. Initially principal 
components were calculated from spectra that had been interpolated to one point per 
wavenumber and mean centred. Ten principal components (1,2,3,4,5,6,7,8,10 and 
12) were shown to exhibit greater than 99.9% significance of discrimination between the 
eight pathological groups designated from a consensus of opinion of three pathologists. 
The most significant PC (6) described only 0.05% of the total variance from the mean, 
indicating that subtle modifications in biochemistry precede and accompany significant 
pathological changes to the tissue. A plot of the weights of the PCs demonstrated that 
there was a good level of clustering but some overlap from one group to the next. 
Although most principal components are made up of a complex combination of tissue 
components. PC3 can be seen to represent glycogen, which is known to be the main 
energy source found in human cells. Normal cells will have this in abundance and in 
deficit in abnormal cells. This appears to be demonstrated in both difference spectra and 
principal component analyses. 
A collection of models have been assembled to discriminate between the three or four 
significant groups required for biopsy targeting in the oesophagus, and to discriminate 
between the eight or nine significant groups required for full classification of oesophageal 
tissue pathology. Models constructed from spectra classified with consensus and majority 
histopathogy have been compared. 
In the three-group consensus model the application of linear discriminant analysis has 
enabled the group separation to be maximised. This was achieved by the construction of 
two functions from linear combinations of the PCs to maximise the variance between 
groups and minimise the variance within groups. Two functions were necessary for 
discrimination between three groups, and three functions for discrimination between four 
groups, and so on. The three-group consensus discriminant model (constructed from 
unfiltered spectra) when tested with a cross-validation procedure correctly predicted 
93.2% of the spectra. Sensitivities of 97,84 and 97% and specificities of 99,98, and 93% 
were achieved for groups of normal, Barrett's and neoplasia (dysplasia and cancer) 
respectively. From scatter plots of the linear discriminant function weights it could be 
seen that group clustering was achieved extremely successfully. 
The four-group consensus discriminant model (constructed from unfiltered spectra) when 
tested with a cross-validation procedure correctly predicted 85.7% of the spectra. 
Sensitivities of 95,77,82 and 71% and specificities of 99,99,88 and 97% were achieved 
for groups of normal, Barrett's, dysplasia and cancer respectively. From the two- 
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dimensional scatter plots of the linear discriminant function weights it is difficult to fully 
visualise the model distribution in three dimensions. Nevertheless it could be seen that 
group clustering was achieved relatively successfully. 
The eight-group consensus discriminant model (constructed from unfiltered spectra) 
when tested with a cross-validation procedure correctly predicted 88.6% of the spectra. 
Sensitivities ranging from 73 to 100% and specificities ranging from 92 to 100% were 
achieved for groups including normal, cardiac Barrett's, fundic Barrett's, intestinal 
metaplasia, high-grade Barrett's dysplasia, adenocarcinoma, squamous dysplasia and 
squamous cell carcinoma. From the two-dimensional scatter plots of the linear 
discriminant function weights it is extremely difficult to fully visualise the model 
distribution in seven dimensions. Nevertheless it could be seen that group clustering was 
achieved relatively successfully. The bar chart plot of the discrimination power of the 
model indicates that the greatest cross-over between groups occurred between the 
intestinal metaplasia, high-grade dysplasia and adenocarcinoma groups. It is these that 
cause the pathologists the greatest difficulty in classification. The cross-over is likely to 
be due in part to both the difficulty in pathological discrimination between these groups 
and the fact that abnormal development of the epithelial tissue follows a continuum with 
many biochemical similarities. 
The nine-group majority discriminant model (constructed from unfiltered spectra) when 
tested with a cross-validation procedure correctly predicted 72.0% of the spectra. 
Sensitivities ranging from 49 to 100% and specificities ranging from 94 to 100% were 
achieved for groups including normal, cardiac Barrett's, fundic Barrett's, intestinal 
metaplasia, low-grade and high-grade Barrett's dysplasia, adenocarcinoma, squamous 
dysplasia and squamous cell carcinoma. From the two-dimensional scatter plots of the 
linear discriminant function weights it is extremely difficult to fully visualise the model 
distribution in eight dimensions. Nevertheless it could be seen that some group clustering 
was achieved, but significantly worse than in the consensus model. The bar chart plot of 
the discrimination power of the model indicates that once again the greatest cross-over 
between groups occurs between the intestinal metaplasia, high-grade dysplasia and 
adenocarcinoma groups. However, in the case of the majority model the cross-over is 
significant between these groups. This is almost exclusively due to discrepancies in 
pathological classification. These were introduced by including samples with an 
agreement of only two out of the three pathologists. 
Optimisation of the LD model for the oesophagus tissue data was achieved by building 
multiple models with all the spectra pre-processed with Savitsky-Golay filters ranging 
from zeroth to second derivative, first to fifth polynomial functions over 7 to 105 points. 
The resulting discrimination was seen to fluctuate with filter widths and type. It was 
possible to maximise the correctly predicted spectra for any pathological grouping, or for 
a combination. A 95-point Savitsky-Golay third-order polynomial, second-derivative 
function was shown to improve the power of the eight-group consensus model to 
discriminate the clinically significant group of adenocarcinoma. An improvement of 73% 
to 79% sensitivity for adenocarcinoma was achieved. This reduced the number of false 
negatives seen in the un-optimised model, but has introduced a few more false positives. 
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A simplistic evaluation of the effect of testing new data acquired in shorter integration 
times, or lower laser powers, has been performed by testing the model with degraded 
spectra. Varying levels of random noise have been added to the new spectra prior to 
projection onto the trained model. The resulting spectral prediction was compared with 
consensus pathology opinion. Noise levels of less than 30% of the signal, equivalent to 
those that would be achieved within 1-30 seconds with the present system, lead to 75- 
100% correct prediction of the test spectra. This indicates that so long as the training data 
is of high quality then repeatable prediction is possible with new spectra measured with 
significantly lower SIN ratios. 
5.6.2.2 Formalin fixed tissue 
The majority of biopsy samples collected for histopathological analysis are formalin fixed 
immediately following excision. This provides stablilisation of tissue properties until 
analysis can be performed. To enable evaluation of the use of Raman spectroscopy as a 
tool to aid histopathological analysis or as an automated sorting tool to remove non- 
clinically interesting samples, it was important to establish whether spectra obtained from 
formalin fixed tissue could be used for discrimination between pathology types. 
Due to time constraints only the pathological results from one gastrointestinal-registry 
pathologist were used to train the spectral models. This has inherently introduced errors 
due to the discrepancies known to exist between pathologists, however as a proof-of- 
principle study it still proves valid. The results obtained demonstrate the feasibility of 
using Raman spectroscopy to measure and discriminate between eight pathological 
groups in formalin fixed oesophageal tissue. 
Good inter- and intra- sample spectral repeatability has been demonstrated. Thus negating 
the need for measurement of normal tissue as a baseline from each individual prior to 
diagnosis. There has been no visible degradation observed in the spectral intensity when 
using 830nm excitation. There is some baseline variability that is likely to be due to a 
combination of microscopic tissue heterogeneity, variable focus and variable laser 
powers. Wave number repeatability was demonstrated by calculating the standard 
deviation from the mean position. This was shown to be ±3.61 cnf 1 over all 418 spectra. 
This variation was likely to be due to significant drift in laser pointing and wave length 
stability. Shift correction was used on the spectra prior to analysis. 
Multivariate analysis has enabled the most significant variations from the mean spectra of 
the data set to be utilised for discrimination between the sample groups. Initially principal 
components were calculated from spectra that had been shift-corrected, interpolated to 
one point per wavenumber and mean centred. 16 principal components were shown to 
exhibit greater than 99.9% significance of discrimination between the eight pathological 
groups designated from a consensus of opinion of three pathologists. The most significant 
PC (10) described less than 0.01% of the total variance from the mean, indicating that 
subtle modifications in biochemistry accompany significant pathological changes to the 
tissue. A plot of the weights of the PCs demonstrated that there was a good level of 
clustering but some overlap from one group to the next. 
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The eight-group discriminant model (constructed from unfiltered spectra) when tested 
with a cross-validation procedure correctly predicted 82.5% of the spectra. Sensitivities 
ranging from 75 to 100% and specificities ranging from 94 to 100% were achieved for 
groups including normal, cardiac Barrett's, fundic Barrett's, intestinal metaplasia, low- 
grade Barrett's dysplasia, high-grade Barrett's dysplasia, adenocarcinoma, and squamous 
dysplasia. From the two-dimensional scatter plots of the linear discriminant function 
weights it is extremely difficult to fully visualise the model distribution in seven 
dimensions. Nevertheless it could be seen that group clustering was achieved relatively 
successfully. The bar chart plot of the discrimination power of the model indicates that 
the greatest cross-over between groups occurred between the intestinal metaplasia and 
low-grade dysplasia groups. It is these that cause the pathologists the greatest difficulty in 
classification. The cross-over is likely to be due in part to both the difficulty in 
pathological discrimination between these groups and the fact that the progress through 
these groups follow a continuum with many biochemical similarities. 
Optimisation of the LD model for the oesophagus tissue data was achieved by building 
multiple models with all the spectra pre-processed with Savitsky-Golay filters ranging 
from zeroth to second derivative, first to fifth polynomial functions over 7 to 105 points. 
The resulting discrimination was seen to fluctuate with filter widths and type. It was 
possible to maximise the correctly predicted spectra for any pathological grouping, or for 
a combination. In the case of optimisation for maximum number of samples correctly 
predicted from all groups, an 11-point, third-order polynomial, zeroth-derivative filter 
provided an optimum separation of all three groups of 83.7% correctly classified. The 
scatter plots of the resulting LD weights have less overlap and sensitivities have 
improved to between 76 to 100% and 94 to 100 % specificity; although the sensitivity for 
the clinically important grades of LGD, HGD, adeno, sq dys, were all shown to increase 
from 80%, 100%, 93% and 80% to 88%, 100%, 100% and 88% respectively. Thus 
reductions in false negatives have been achieved. 
The spectra were also shown to contain information on the length of time they had been 
stored in formalin, although this didn't effect the diagnostic algorithms. Using 
multivariate analysis 98.8% of spectra were correctly predicted for time in formalin. 
However, it is not being suggested that a linear model could accurately predict time in 
formalin, just whether the sample has been immersed for short or long timescales (either 
a few weeks or many months). 
5.6.3 Factors Likely to Affect Transfer from In Vitro to In Vivo Detection 
The effect on tissue Raman spectra of changing between body- and ambient-temperatures 
has been demonstrated to change the background fluorescence levels. Nevertheless, 
Raman scattering peaks are not seen to vary over this temperature range. It is this fact that 
should allow translation of spectra measured at room temperature to diagnostic 
algorithms destined for use with in vivo measurements. 
The evaluation of the potential effects of contaminants on oesophageal spectra has 
demonstrated that substances present in the lumen of the oesophagus exhibit some degree 
of Raman scattering, although these tend to be present in low concentrations. The tissue 
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spectra measured to date from unwashed biopsy samples have not been unduly affected 
by these contaminants. Although, the strengths of the signals indicate that they should not 
be ignored from analyses altogether. Furthermore, the effects of blood now in tissue 
cannot be practically quantified in vitro. This will have to be evaluated during further 
work carried out in vivo. 
Measurement of the sensitivity of the epithelial Raman spectra to polarisation has shown 
that the orientation of the polarisation of the laser illumination does not significantly 
effect the tissue spectra. However the spectrometer is polarisation sensitive so rotation of 
the illumination polarisation will require correction to maintain the same spectral 
intensity. The polarisation of the inelastic scattering from oesophageal. tissue has been 
evaluated by use of a pair of analysers in the collection path. Measurement of the 
spectrum perpendicular to the illumination polarisation axis tends to significantly 
suppress many of the Raman peaks, most especially those spectral peaks corresponding to 
symmetric vibrational modes. The technique of polarisation analysis of scattered light 
may potentially be used as a tool to improve discrimination between normal and diseased 
tissues. Further work will be necessary to assess the facility of polarisation analysis for 
increased discrimination between pathology type. 
The effect of measuring spectra from bulk tissue versus small samples was evaluated by 
measuring spectra from both biopsy material and larger resected tissue samples. Tiny 
sample volumes of the order 200 Wn' were used throughout this study. No visible 
differences between the spectra were observed. Although it appears that the depth of field 
of the measurement is small enough to remove likely contamination to the spectra from 
deeper tissue, it is possible that more important diagnostic information may be found at 
greater depth. Moreover, it may be necessary to increase the sampling volume, by 
increasing the spot size, to enable averaging over more cells. 
Further analysis of the different oesophageal tissues at greater depth has been carried out 
by mapping transverse frozen sections. Multivariate image analysis was used to 
demonstrate the variation in chemical constituents from the surface of squarnous and 
Barrett's mucosa to deeper tissue layers. Further work is required with models built from 
measurement of larger sample volumes and larger depths before the ideal configuration 
can be fully understood. A study by Ackroyd et al. (1999) showed that the mean depth of 
columnar epithelium in 100 cases of Barrett's oesophagus was 0.5 ± 0.004mm, (range 
0.39-0.59mm) compared with a mean depth of squarnous epithelium in normal 
oesophagus of 0.49 ± 0.03mm (range 0.42-0.58mm). 
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Raman spectra of other epithelial tissues have been measured. The spectra obtained from 
stomach, bladder, prostate, endometriurn and tonsil are relatively similar. However, 
subtle differences are visible and further analysis by construction of large sample number 
multivariate models are expected to demonstrate high levels of discrimination between 
normal, pre-cancerous and cancerous tissue. 
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6. Discussion of Results 
The primary objective of this study has been to provide an appraisal of the potential use 
of Raman spectroscopy for both in vitro classification and in vivo detection of early 
malignant changes in the aero-digestive tract. 
This study was: 
" The first to demonstrate the feasibility of using Raman spectroscopy to measure 
and discriminate the pathological grade of laryngeal tissue. 
" The first to demonstrate the feasibility of using Raman spectroscopy to measure 
and discriminate between large numbers (9) of pathological groups in 
oesophageal tissue. 
" The first to demonstrate the feasibility of using Raman spectroscopy to measure 
and discriminate between eight pathological groups in formalin fixed oesophageal 
tissue. 
" The first to follow rigorous sample handling and histopathological analysis 
protocols. This included the precise orientation of samples prior to snap freezing; 
and discarding any samples likely to cause errors either from mixed pathology 
samples, or from discrepancies in histopathology opinion. 
A NIR dispersion Raman spectrometer has been optimised for measurement of the 
inelastic scattering properties of tissue. A wavelength of 830nm was demonstrated to be 
the ideal for both oesophageal and laryngeal tissue. Incident laser powers of around 
30mW were adequate when utilising a x80 ultra-long-working-distance objective (N. A. 
0.75) for illumination and collection of scattered light. A 300 lines per nun, single grating 
monochrornator coupled to a deep-depletion CCD detector provided excellent throughput 
and high signal to noise ratio spectra in timescales of seconds. An oxide layer edge filter 
set provided the required high stray light rejection. 
Raman spectra of epithelial tissues have been measured in vitro with S/N ratios of 15 to 20 
in an integration time of 30 seconds. Following illumination with a power density of l. 6kW 
mmý of 830mn laser light for over 30 minutes, spectroscopic and histopathological analysis 
demonstrated that no sample degradation was observed. With heat transfer afforded by 
blood flow, it is likely that increased power levels will be possible for in vivo measurements, 
and this will enable a significant reduction in acquisition times. Moreover, in this study 
evidence has been provided that models constructed from high quality spectra (SNRs of 10 
to 20) can be used to predict the histopathology of the sample measured with lower quality 
spectra (SNR < 5). Using the theoretical noise contributions discussed in Section 4.2.6 it can 
be estimated that employment of the same spectrometer configuration with lower acquisition 
times will result in the S/N ratios displayed in Table 6.1. Therefore in theory accurate 
prediction should still be possible with spectra measured in 2.5 seconds with a power 
density of L&W mm72 of 830nm light. Greater laser powers or further sensitivity 
improvements will reduce this time to below one second. 
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Studies published to date have not shown any significant thermal damage to tissue from high 
intensity laser illumination used during in vivo work. 16,134,146 Nevertheless, further studies 
into the effects of the excitation light on the probed tissue must be carried out prior to 
undertaking routine in vivo work. The effect of temperature rises on the tissue or 
photochemical reactions induced by the laser illumination may have unforeseen 
consequences. 
Time /s SIN Ratio 
30 20 
10 10.3 
5 6.7 
2.5 4.3 
2.3 
Table 6.1: Theoretical S/N ratios of Raman spectra from epithelial tissue using optimised spectrometer 
configuration. 
The potential of NIR Raman spectroscopy to provide automated diagnosis for a number of 
medical conditions has been established. This can be achieved by employing diagnostic 
algorithms to distinguish between the differences in spectral features found in both normal 
and abnormal tissues. The simplest algorithms are based on empirically identified diagnostic 
features. These differences may be variations in intensity, intensity ratios and the number 
and location of peaks. However, it is minute changes in spectral shape that may indicate 
clinically significant biochemical changes that precede or accompany disease processes. 
High quality spectra are required to enable use of multivariate techniques that can analyse all 
the data in a spectrum and thus be more likely to provide an accurate test for the detection of 
disease. The use of multivariate linear discriminant models appears to provide the most 
repeatable method able to utilise most of the data contained within tissue spectra. 
Assignments of Raman scattering peaks have been made tentatively from extensive study of 
the relevant literature. Glycogen has been demonstrated to be a significant component of the 
spectral variations in the Raman tissue spectra between healthy and diseased tissue. Both 
laryngeal and oesophageal tissue exhibit less glycogen peaks with increasing level of 
disease. This is likely to be due to the increased energy consumption by rapidly dividing 
neoplastic cells. This is in agreement with Raman spectral analysis in the cervix 84 and by 
other workers in the oesophagus, 132 although one investigation observed an increase in 
glycogen levels in lung cancers. 72 Distinct alterations in tissue biochemistry accompanying 
disease have been demonstrated in other principal components of the Raman spectra. 
However these changes are very complex combinations of increasing scattering from 
nucleic acids, alterations in protein secondary structure and lipid content. These 
transformations appear to be in line with current understanding of carcinogenesis in these 
tissues. 
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Low sample numbers and the lack of a thorough understanding of the shortcomings of 
histopathological analysis have restricted the accuracy of all of the tissue Raman studies 
published to date. The investigations have generally been limited to measuring spectral 
differences between two or three selected pathology types. However, it is important that 
samples covering the full spectrum of disease in each organ are studied; an achievement of 
this study. The spectral data from specimens covering all pathology types has been used to 
train the spectral diagnostic models. The work of calibrating the models with the current 
'gold-standard' of histopathological analysis has required a great deal of collaboration with 
expert pathologists. High levels of discrepancy in tissue classification has made it vital that a 
number of pathologists, with expertise in the disease of interest, work together to provide a 
consensus of opinion on the tissue samples used to train and test the spectral models. In 
addition, tissue samples are commonly heterogeneous; therefore to enable an accurate 
calibration of the spectral diagnostic algorithms it was essential that tissue samples 
exhibiting only a single pathology were included for measurement. 
The requirement for a consensus of histopathology opinion from three or more expert 
pathologists has been demonstrated in this study, not only for the calibration of 
spectroscopic diagnostic algorithms, but also for establishment of a reliable 'gold standard' 
diagnosis. Comparison of the oesophageal consensus and majority spectral discriminant 
models showed that the spectroscopic prediction of pathology was only as good as the 
training provided. This was demonstrated when samples were included in the training set 
with some discrepancy of histopathology opinion (i. e. only two out of three pathologists 
agreed on the diagnosis). The overlap in pathology groups occurred mostly between 
intestinal metaplasia, and low- and high-grade dysplasia. It is these groups that are the most 
clinically significant, but prove the most difficult for the pathologists to distinguish. The 
consensus models showed a small amount of overlap between these groups, although this 
was significantly lower than that found with the majority model where up to 50% of high- 
grade dysplasias were classified into other groups. Nevertheless, there is likely to be some 
overlap even in the best models due to the fact that the pathological groups have artificially 
defined boundaries. In fact the development of neoplastic tissue tends to follow a continuum 
of change, both biochemically and morphologically, from intestinal metaplasia to 
adenocarcinoma, and from squamous epithelium to squarnous cell carcinoma. 
6.1 Comparison with published work 
Studies published demonstrating the separation of two or three pathology groups with 
Raman spectroscopy have tended to overstate the resulting sensitivities and specificities 
of the test. When the full spectrum of pathologies found in the tissue are included these 
outcome measures are almost invariably reduced. Other workers have demonstrated 
separation of samples by histopathologically defined group in the breast, 20 cervix, 84 
colon, 86 skin85 and most recently the oesophagus . 
21 The number of spectral measurements 
used for construction of diagnostic algorithms have been between tens of measurements 
and a few hundred. These have been invariably from a restricted subset of the pathology 
groups found in the organ. 
The most extensive breast tissue study to date, investigated samples covering three 
pathology groups: normal, benign and malignant turnours in 61 samples. 82 Timescales of 
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100 seconds were required to achieve sufficient SIN ratios. A linear discriminant model 
was trained with the PCs of the spectra from all 61 samples. Use of this prediction model 
to predict the histopathology of the samples produced results of 14/15,13/15,31/31 
correctly predicted samples for normal, benign and cancerous samples respectively. 
However, the results have been significantly skewed by the fact that the same spectra 
used to train the model have been used to test it, i. e. neither cross-validation nor new 
samples have been used. 
A Raman investigation in the cervix has demonstrated much improved experimental 
techniques, by studying five pathological groups (normal, metaplasia, inflammation, human 
papilloma virus and dysplasia), using a consensus of histopathology opinion from two-board 
certified clinical pathologists and the diagnostic algorithms were tested using cross- 
validation, or the leave-one-out method. 84 However, biopsies exhibiting mixed pathologies 
were included in the study by correlating the spectral results with the most severe 
pathological diagnosis. This will have introduced discrepancies when measurements were 
made from undefined regions of the sample. Both empirical and multivariate discriminant 
algorithms were tested using cross-validation for the separation of pre-cancers and all other 
tissues. The multivariate method discriminated between the two groups with sensitivities 
and specificities of 82% and 92% respectively. However, poor system sensitivities required 
spectra to be measured for up to 15 minutes for adequate SIN ratios to be achieved. 
A number of authors have studied colon tissue samples without demonstrating the use of 
a discriminant model for separation of samples into their histopathological groups. The 
makeup of the colon, including a high lipid concentration does tend to produce spectra 
with SIN ratios of around 3 times greater than those exhibited by the oesophagus and 
larynx. 142,176 Therefore shorter acquisition times will be possible in this organ. 
Comparison between spectra has generally involved study of the visible differences 
between Raman peaks from abnormal and normal specimens from the same patient. 
interesting variations in scattering bands attributable to lipids, proteins and nucleic acids 
have been demonstrated. However more work is required to calibrate and test diagnostic 
algorithms in the colon. 
Two publications have demonstrated the use of Raman spectral models for the 
discrimination of histopathology in the oesophagus. 142,133 Both groups have used only a 
single pathologist to grade their samples and heterogeneous samples have been included 
in the studies. Shim et al included 260 biopsy samples from 17 patients in their study. 
Pathologies included normal (54), Barrett's (153), and dysplastic (53). An artificial neural 
network (ANN) was trained and used to predict the group membership of the samples. 
Differentiation between dysplasia and intestinal metaplasia was achieved with 77% 
sensitivity and 93% specificity. 142 Only three groups were included in the study and 
cross-validation testing was not mentioned. Wolthius et al measured 320 spectra (80 
normal, 120 Barrett's, 120 adenocarcinoma) of excised tissue from three patients. Cross- 
validation of an optimised linear discriminant model enabled sensitivities and 
specificities of 97% and 98% to be achieved for the separation of adenocarcinoma and 
Barrett's oesoPhagus. The difficult groups of high- and low-grade dysplasia were not 
included in the study. This compares with 96% sensitivity and 84% specificity for 
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discrimination between intestinal metaplasia and neoplastic oesophagus tissue (including 
both dysplasia and adenocarcinoma) described in this study with a dataset including 
spectra from eight pathology groupings. The results in this study indicate a high degree of 
sensitivity to neoplasia, but a slightly lower level of specificity because the introduction 
of dysplastic samples, with both biochemical and histological similarities to IM samples, 
has caused some IM to be falsely predicted as cancerous/pre-cancerous. However from a 
medical perspective a false positive result is better than a false negative, i. e. where a 
cancerous lesion is predicted as normal. 
Only one study to date has performed in vivo Raman measurements on the human 
oesophagus; and colon. 142 These have been obtained from 20 patients. However to date no 
accompanying spectral analysis has been published. S/N ratios of 3-5 and 4-17 were 
achieved for oesophagus and colon respectively using 100mW of 785nm laser light 
integrated for 5 seconds and a multi-fibre Visionexg probe. The ability to obtain spectra of 
sufficient quality in short timescales has demonstrated the feasibility of transferring models 
constructed from in vitro measurements to the prediction of pathology in vivo. 
The results - from the study outlined in this thesis - for discrimination between 
histopathology types in oesophageal and laryngeal tissue compare extremely favourably 
with those published on Raman spectroscopy in similar tissues. The number of groups 
used in this study has also provided a better representation of the tissue types likely to be 
encountered in a randomly selected biopsy sample. Furthermore, much more rigorous and 
repeatable experimental protocols have been used throughout. 
6.2 Future prospects 
In principle Raman spectroscopic classification of diseases that exhibit a significant 
biochemical modification should be feasible in any tissue of which a spectrum can be 
measured. The exploitation of this technique will require multi-disciplinary teams in many 
centres to begin work investigating the differences exhibited in diseased and normal samples 
of all relevant tissues. To enable a full understanding of the complex medical and 
technological problems a collaboration between surgeons, histopathologists, scientists and 
engineers will be necessary. 
There is significant difficulty in employment of an imperfect 'gold standard' for calibration 
of novel diagnostic techniques. Classification algorithms can only be as good as the training 
they receive. Moreover considering that histopathology is regarded as the correct diagnosis, 
it will be very difficult to demonstrate that a new technique provides a more accurate 
representation of the true diagnosis. Improvements in detection and diagnosis of cancers and 
pre-cancers using new technologies will only be possible if histopathological. results are 
carefully interpreted, with the proviso that the 'gold standard' diagnosis it not necessarily 
correct. Furthermore, future development of quantitative biochemical measurements of 
tissue state such as immunohistochemical. markers, including p53 and telomerase are likely 
to provide a more accurate, objective, and repeatable diagnosis for calibration or evaluation 
of model performance. 25 
The greatest obstacle to automated medical diagnosis will most likely be the transferability 
and repeatability of Raman spectra acquired with different systems. If automated diagnostic 
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algorithms are to be used in clinical practice, it will be necessary to provide an 'off the shelf 
spectral library and sort algorithm for a particular disease or tissue type. However this 
implies that spectra measured on all other systems will be identical. This will never be the 
case. However, variations can be minimised and spectra can be corrected to achieve the 
ideal that is used for calibration of these classification models. Methods of correction for 
spectrometer variations have been described elsewhere. 177,178 Pre-processing of spectra has 
been shown to reduce the effects caused by spectrometer variations, especially during the 
collection of the laryngeal spectral data. These include shift correction, energy sensitivity 
correction, wave number calibration and smoothing filters. 
There are some additional technical problems that need to be solved to enable routine use of 
Raman spectroscopy as an in vivo clinical tool. The use of fibre-optic systems based upon 
near-infrared diode laser illumination, filtered probes and a single spectrometer/CCD 
detector arrangement appear to be the most promising, although radical new designs may be 
necessary to eradicate the silica Raman signal. With quick integration times, due to high 
sensitivity and low tissue fluorescence background signal the NIR system appears to offer 
the greatest benefits for use in a clinical environment. Current in vivo probe designs tend to 
sample from the first few 100gms. However, NIR photons are highly scattered in tissue, 
therefore with improved understanding of photon migration in tissue, imaging of subsurface 
lesions may become possible. 
Raman spectroscopy can be applicable to many different cancers in the human body, 
including those found in solid organs. Future prospects for in vivo measurements may 
eventually enable interrogation of scattering properties using needle probes within solid 
organs, provided that probes can be miniaturised to enable insertion down a needle. 
However, the greatest impact of Raman spectroscopy will be in the assistance of biopsy 
targeting during surveillance in organs that develop cancer via pre-cancerous lesions, such 
as ulcerative colitis in the colon, Barrett's metaplasia in the oesophagus, and infection with 
human papillorna virus in the cervix. In many cancers the early cellular changes will be 
invisible and detection will rely upon a random biopsy targeting procedure. Evidently there 
will be a fair chance of missing abnormal lesions and large numbers of biopsy samples will 
be generated for histopathology departments to process. The use of a non-invasive 
spectroscopic targeting method to pre-select samples would be likely to significantly 
improve detection rates and reduce the unnecessary collection of normal tissue samples. 
Additional likely benefits of in vivo spectroscopic diagnosis include: 
op Non-invasive biopsy targeting of organs where excision biopsy would be potentially 
hazardous, such as the central nervous and vascular systems. 
The prospect of immediate diagnosis that could reduce patient anxiety, secondary 
procedures, and health service costs by enabling treatments to be performed as part of 
the same procedure. 
Validation of diagnosis prior to resection to provide a safety net for catching mis- 
diagnosed conditions prior to the irreversible removal of tissue. 
170 
Identification of tumour margins during resection, to reduce the risk of leaving 
malignant tissue behind and maximise the normal tissue remaining, thus optimising 
healing and minimising recurrence. 
Objective measurement of tissue disease state in comparison to the subjective pattern 
recognition of the current 'gold standard' technique. 
A complimentary approach may involve the use of Raman spectroscopy coupled to a 
confocal microscope as a histopathology tool. This may eventually lead to automated 
sample sorting, which could be achieved with minimal changes to the current sample 
preparation procedures. Samples could potentially be analysed prior to sectioning and 
staining for histopathological analysis to remove the huge number of normal samples 
produced in these procedures, leaving the histopathologists to deal with the samples of 
clinical significance. Moreover the most significant problem for histopathology is the high 
inter- and intra-observer discrepancy during sample classification. Provided inter-system 
repeatability is evaluated and extensive work on diagnostic algorithm training has been 
performed, then a Raman pathology tool would be likely to assist pathologists in providing a 
repeatable diagnosis from one hospital centre to the next and thus increase the chances of the 
adoption of screening and surveillance tests. Both prospects will take time for acceptance by 
the medical community and large multi-centre trials will be required to demonstrate 
efficacy. 
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7. Conclusions and Further Work 
7.1 Conclusions 
This study has demonstrated the facility of NIR-Raman spectroscopy to discriminate 
between normal and squarnous neoplasias (in the larynx and the oesophagus), and normal 
and columnar neoplasias (in the oesophagus), in both fresh and formalin fixed tissues. The 
results compare extremely favourably with those published on Raman spectroscopy in 
similar tissues. Moreover, the number of groups used in this study has also provided a better 
representation of the pathologies likely to be encountered in a randomly selected biopsy 
sample; more rigorous and repeatable experimental protocols have been used throughout. 
Cross-validation testing of spectral predictive models has demonstrated excellent results, 
although fin-ther evaluation and optimisation is required. Repeatable discrimination has been 
demonstrated between pathological groups using linear discriminant models fed with 
statistically significant principal components of the spectral data. In the larynx 100/112 
normal, 34/38 dysplastic, and 42/49 laryngeal squarnous cell carcinoma sample spectra were 
correctly predicted. In the oesophagus consensus trained models, 301/3 10 normal, 122/145 
Barrett's and 152/162 neoplastic spectra have been correctly predicted in the three group 
models. Raman spectra of other epithelial tissues studied including tonsil, stomach, bladder, 
prostate, and endometrium exhibit similar features to the spectra from the larynx and 
oesophagus. It is expected that further study of specimens from these organs will enable 
spectral separation of normal and diseased states to be demonstrated. 
There is a lack of understanding of the extremely complex biochemical processes preceding 
and accompanying carcinogenesis. Studies such as this one investigating essentially the 
differences in biochemistry between diseased and normal states can only enhance the 
knowledge base of medicine and science in this important area, as well as provide evidence 
of the potential of new tools for non-invasive optical diagnosis of cancer. Much of the work 
to date has demonstrated proof-of-principle, however the time has come for more extensive 
studies to push this exciting technology towards medical reality. The evidence provided by 
this study indicates that use of Raman spectroscopy for non-invasive detection and 
classification of disease is a distinct possibility. Potential difficulties in the transferability 
from in vitro to in vivo have been evaluated and no significant barriers have been observed. 
However, ftu-ther in vivo probe development and optimisation will be required before 
6optical biopsy' with Raman spectroscopy can become a reality. 
7.2 Further Research 
The following investigations would enhance and validate the results of the work 
performed in this thesis. A lack of time and tissue specimens has made these difficult to 
perform as part of this work. 
Validation of results with new homogeneous tissue samples with a consensus of 
histopathology opinion. 
Re-evaluation of tissue samples by histopathologists to improve consensus of 
opinion on discarded samples. 
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" Assessment of the outcome of measuring and predicting the pathology of samples 
exhibiting mixed histopathologies. 
" Evaluation of the sample numbers required for optimum model construction, by 
increasing model sizes iteratively and evaluating performance at each stage. 
" Evaluation of the effects on prediction model performance of low S/N ratio 
spectra, wavenumber shifts and changes to the spectral baseline shape. This would 
provide an understanding of the required tolerances of spectrometers for 
measurement of data for prediction against the spectral models. 
" Evaluation of inter-spectrometer repeatability and methods of correction for the 
improvement of transferability. 
Model optimisation by utilisation of 
0 Polarisation discrimination to selectively enhance or suppress spectral 
components. 
0 Weighted algorithms to enhance the importance of particular pathology 
groups, such as adenocarcinoma or high-grade dysplasia, to reduce the 
chances of falsely predicting samples from these clinically significant 
groups as something more benign. Risk analysis would be required to 
provide the weights of risk of missing a particular condition. However 
different applications will require different algorithm architectures. 
0 Staggered algorithms to reduce the reliance of the models on artificially 
created boundaries from one group to the next, which may have some 
detrimental effect on the separation. This could be achieved by making a 
decision between membership of between two to three groups at a time in 
stages to create a classification tree. For example a decision between 
squamous or columnar tissue, then if columnar, a decision between 
Barrett's or neoplasia, then if neoplasia, a decision between LGD, HGD or 
adenocarcinoma. 
0 Spectral region selection may improve discrimination by removing 
irrelevant data. This will have to be carefully performed and may be 
detrimental to model specificity. 
0 Pre-processing filtering using first and second order derivatives as well as 
smoothing functions may improve models by reducing the effects of poor 
spectrometer repeatability. This was demonstrated for the larynx model. 
Of medical interest: 
Confocal Raman spectral mapping of tissue sections from different stages of 
carcinogenesis will enable a further understanding of the biochemical disease 
processes to be achieved. Co-registration of the spectral information with an 
image captured of the haernotoxylin and eosin stained sections would facilitate the 
use of multivariate image analysis to identify biochemical regions of interest in 
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the tissue. This technique will also identify whether different sampling volumes 
and depths may facilitate further improvements in discrimination between 
pathology states by demonstrating where in the tissue the most significnat 
biochemical changes occur. 
Retrospective studies, whereby tissue spectra measured from patients that have 
gone on to develop cancer could be used to identify which biochemical changes 
precede the development of morphological and architectural changes. For 
example samples that were wrongly predicted initially (in relation to 
histopathology) may have originated in samples from patients who were 
undergoing the biochemical development of cancer. 
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Appendix 1: Histopathological Grading 
Evaluation of Frozen Laryngeal Specimens 
"1 
4ý71- 
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Figure AIA: Microscopic images of histopathological sections larynx tissue, stained with 
haematoxilin and eosin (H & E). It can be seen from the images that morphological difference 
between normal squamous mucosa, squamous dysplasia and squamous cell carcinoma are subtle and 
subjective. This can lead to high levels of discrepancy (see Chapter 1). 
Al-I 
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Squamous Dysplasia 
Squamous Cell Carcinoma 
Histopathology 
A grading system was developed for this work utilising the commonly used criterion for 
distinguishing between pathological grades of laryngeal tissue tissue. The following 
categories have been used in this study: 
1. Nonnal squamous mucosa. 
2. Squamous Dysplasia. 
3. Squamous cell carcinoma. 
The pathological markers used to distinguish between the histopathological grades are 
outlined below (see Figure Al. 1): 
Squamous Cell Dysplasia is defined as a pre-cancerous lesion of squamous epithelium 
characterised by cellular atypia and loss of normal maturation and stratification. ' In the 
larynx there are three grades of dysplasia. These are recognised on the basis of the degree 
of nuclear abnormalities and the proportion of epithelial thickness showing loss of normal 
stratification. Dysplasia and invasive carcinoma may be present in the same organ, with 
the potential for developing invasive carcinoma increasing with the severity of dysplasia. 
Mild D lasia shows the characteristics of slight nuclear abnormalities, mainly in the YSP 
basal third of the epithelial layer'. These abnormalities are minimal in the upper layers 
where the cells show normal maturation and stratification. Keratosis (the formation of a 
hard layer of keratin proteins) and chronic inflammation are usually present. 
Moderate Dysplasia demonstrates more marked nuclear abnormalities than in mild 
dysplasial. These changes are most marked in the lower two-thirds of the epithelial 
thickness. Moderate nuclear abnormalities may persist up to the surface, but cell 
maturation and stratification are evident in the upper layers. There are no abnormal 
mitoses (cell divisions). There can be associated keratosis. 
Severe Dysplasia is reached when the epithelium shows marked nuclear abnormalities 
and loss of maturation involving more than two-thirds of the epithelial thickness with 
some stratification of the most superficial layers'. Nuclear pleomorphism (occurrence of 
more than one form in a life cycle) is common, and some of the cells may have bizarre 
nuclei. Mitoses are present high up in the epithelium, these may be abnormal. The cells 
are generally not crowded as in the classic carcinoma in situ and are usually more 
differentiated with intercellular bridges between the atypical cells. The distinction is 
made between severe dysplasia and carcinoma in situ by the presence of some maturation 
and stratification of the cells. The lesion is often associated with keratosis. Severe 
dysplasia has the same high risk for developing invasive carcinoma as carcinoma in situ 
and is therefore grouped with it for clinical purposes. 
Carcinoma In Situ (Intraepithelial Carcinoma) is defined as a lesion which the full 
thickness of the squamous epithelium shows the cellular features of carcinoma without 
stromal invasion (progression below the basal membrane)'. It usually occurs with the 
epithelial cells having markedly abnormal hyperchromatic nuclei and variable 
cytoplasmic keratinisation; the appearance is very similar to severe dysplasia. In some 
AI-2 
cases the cells are found to have little cytoplasm and no evidence of squamous 
differentiation. Cell division occurs high up in the epithelium with abnormal mitoses 
often present. 
Laryngeal carcinoma in situ may occur as an isolated lesion or in association with 
invasive carcinoma; the absence of stromal. invasion should therefore be confirmed by 
sampling the entire biopsy specimen. 
Squamous Cell Carcinoma is a malignant epithelial tumour with squamous differentiation 
characterised by the formation of keratin and/or the presence of intercellular bridges. 
Squamous cell carcinomas of the upper respiratory tract produce the same range of 
histological appearances as those arising in other sites. The turnours are graded according 
to the degree of differentiation, cellular pleomorphism and mitotic activity. Well- 
differentiated carcinomas have a close resemblance to normal squarnous epithelium and 
contain varying proportions of basal-type cells and squamous cells with intercellular 
bridges and full keratinisation; mitoses are rare. Moderately differentiated carcinomas 
have less keratinisation and more nuclear pleomorphism; there are more mitoses, 
including abnormal mitoses. Keratinisation and intercellular bridges are minimal and 
barely discernible in poorly differentiated carcinomas. Grading has been found to be of 
some value for predicting patient outcomes, although the assessment of the degree of 
differentiation is essentially subjective and influenced by variations in sampling. 
1 Shanmugaratnam K, Histological typing oftumours ofthe upper respiratory tract and ear, Springer- 
Verlag, Berlin, 199 1. 
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Appendix 2: Histopathological Grading Criterion For 
Evaluation of Frozen Oesophageal Specimens 
Endoscopic Detection of Oesophageal Malignancies 
" Normal squarnous mucosa i& seen as a whitish region. 
" Barrett's mucosa is red/pink and velvety. 
" Unable to endoscopically distinguish Barrett's from dysplasia or early carcinomas. 
" Can see turnour masses above a few mrn in diameter. 
It is not possible to distinguish between Barrett's mucosa (the benign pre-cursor to 
cancer) and early neoplastic change by visual inspection during endoscopy. It is therefore 
necessary to carry out surveillance biopsy following rigourous selection protocols. The 
most commonly accepted protocol involves the selection of excisional biospy samples 
from four quadrants, every two centimetres along the Barrett's mucosal region. Figure 
A2.1 displays a pair of images captured from one patient before and after a photodynamic 
therapy (PDT) treatment. The distinct difference between the Barrett's columnar and 
normal squamous mucosa can be seen. Figure A2.2 displays captured endscopic images 
from patients with invasive adenocarcinoma of the oesophagus. Prognosis for these 
patients is extremely poor. 
A2-1 
Figure A2.1: Endoscopic images down an oesophagus exhibiting Barrett's mucosa (red). The whiter 
regions are the normal squamous epithelial regions. The image on the left is before treatment with 
photodymnamic therapy. The image on the right is post-PDT treatment. It can be seen that the 
oesophagus has healed by regrowing mainly normal squamous mucosa. 
Histopathology 
A grading system was developed for this work utilising the commonly used criterion for 
distinguishing between pathological grades of oesophageal tissue. A panel of three 
internationally renowned pathologists on the gastrointestinal Registry for Barrett's 
dysplasia were consulted and used to develop a grading system to include a measurement 
of homogeneity. The resulting diagnosis for each sample were compared and majority 
and consensus opinion was used for predictive model construction and testing. 
The following nine categories have been used in this study: 
1. Normal squamous mucosa (Normal). 
2. Cardiac type Barrett's mucosa (CB). 
3. Fundic type Barrett's mucosa (FB). 
4. Intestinal type Barrett's mucosa (IM). 
5. Low-grade Barrett's dysplasia (LGD). 
6. High-grade Barrett's dysplasia (HGD). 
7. Adenocarcinoma (Adeno). 
8. Squamous dysplasia (Sq Dys). 
9. Squamous cell carcinoma (SCC). 
The pathological markers used to distinguish between the histopathological grades are 
outlined below (see Figure A2.3): 
A2-2 
Figure A2.2: Lndoscopic images exhibiting invasive adenocarcinomas, patient prognosis is extremely 
poor once the tumour begins invading deeper tissues. 
Barrett's Oesophagus (columnar oesophageal epithelium) is defined as glandular 
metaplasia of the oesophageal mucosa, typically a sequel to chronic reflux oesophagitis. 
The Barrett's mucosa is in effect normal tissue, although it should not be in the 
oesophagus. There are three main types of glandular mucosa that are seen in Barrett's 
oesophagus: gastric, fundic and intestinal. Each type exhibits the architecture and 
biochemistry of tissue from the gastric and fundic stomach mucosa, or intestinal mucosa. 
It is the Barrett's intestinal mucosa that is known to increase the potential for developing 
adenocarcinoma by greater than 40 times. 
Dysplasia in Barrett's Oesophagus is usually graded as mild, moderate or severe, the first 
two comprising low-grade and the last, high-grade dysplasia. Distinction between the 
later, adenocarcinoma in situ and intramucosal adenocarcinoma can be especially difficult 
on small, superficial endoscopic biopsies. Dysplasia is the most reliable marker for 
assessing the risk of adenocarcinoma in the lower oesophagus. In fact, most 
adenocarcinomas of the oesophagus arise in patients with Barrett's oesophagus. 
Dysplasia is thought to develop more or less exclusively in the intestinal type of mucosa. 
in low-grade dysplasia, the abnormal nuclei are limited to the lower half of the epithelial 
layer. In high-grade dysplasia more severe cytological change and architectural 
alterations are present. Hyperchromasia (excessive colour) and pleomorphism (occurance 
of more than one form in a life cycle) are more marked. Nuclear crowding and 
stratification are often present. 
Adenocarcinoma is a malignant tumour composed of glandular epithelium, with papillary 
and/or tubular structures. The majority of oesophageal adenocarcinomas arise in 
metaplastic glandular mucosa of Barrett's oesophagus, a sequel to prolonged reflux 
oesophagitis. They occur in the lower portion of the oesophagus and may or may not be 
preceded by dysplasia. It may be difficult or impossible to determine whether an 
advanced adenocarcinoma of the lower oesophagus is the result of spread from a tumour 
of the stomach or is a true primary growth of the oesophagus. 
Squamous Dysplasia is similar to the more extensively investigated lesion encountered in 
the uterine cervix. Nuclei are enlarged and hyperchromatic and show increased mitotic 
activity. In mild dysplasia such atypical nuclei are limited to the basal zone, and there is 
evidence of cytoplasmic maturation superficially. With increasing grades of dysplasia 
there is a progressive increase in the proportion of atypical basal cells until the entire 
thickness of the mucosa is replaced. This state is often described as carcinoma in situ. 
Squamous Cell Carcinoma (SCC) is a malignant tumour composed of squamous-type 
epithelium. It is usually graded as well, moderately or poorly differentiated. Well 
differentiated tumours are those with abundant amounts of keratin, easily demonstrated 
intercellular bridges and cell layers undergoing differentiation. Poorly differentiated 
tumours are those with little or no keratin, intercellular bridges and differentiation of cell 
layers. Moderately differentiated tumours are those intermediate between well and poorly 
differentiated. 
A2-3 
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Figure A2.3: Microscopic images of histopathological sections of the oesophagus, stained with 
haematoxilin and eosin (H & E). It can be seen from the images that morphological difference 
between Barrett's intestinal metaplasia, low grade dysplasia and high grade dysplasia are very subtle 
and subjective. This leads to high levels of discrepancy (see Chapter 1). 
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Appendix 3: Multivariate Spectral Analysis 
For analysis of spectra applied to medicine a number of authors have used empirical 
methods such as peak heights, peak areas and peak ratios to glean diagnostic information 
from highly complex spectra. In a small number of cases where there is a single 
molecular species that directly accompanies any abnormality this will be sufficient. 
However in the majority of cases biochemical changes preceding and accompanying 
morphological change are extremely complex. Methods of extracting information from 
Raman spectra should use as much information as possible to facilitate the most accurate 
prediction of histopathology. Multivariate techniques have been explored to enable 
utilisation of the maximum available information for prediction of diagnosis. 
Statistical Measures 
In order to evaluate the significance of an individual variable (either peak height, peak 
area, peak height ratio or principal component) to the separation of tissue samples into 
pathological groups, it is necessary to use statistical tests. The most simple of these being 
the Student Mest. The Student t-test procedure compares means for two groups, to 
evaluate whether they originate from the same population. Analysis of variance, an 
extension of the two-sample Mest, is used to test the hypothesis that several means are 
equal (i. e. drawn from populations with the same mean). In the use of ANOVA for the 
evaluation of variable significance, if the null hypothesis is rejected then the means of the 
variable are significantly different between each group. 
ANOVA evaluates differences in group means by calculating the mean square of the 
variance between-groups and the mean square of the variance within-groups. The ratio of 
the mean squares gives the F-statistic. The greater the F-value, then the larger the 
differences between the group means. Use of look up tables for a particular level of 
significance provides us with a value for Fcit. This value is the cut-off for acceptance or 
rejection of the null hypothesis. 1,2,3 
An alternative for the evaluation of between group variable significance is the Wilks' A 
test. Wilks' A is the ratio of the within-group sum of squares to the total sum of squares. 
Where the sum of squares is the sum of the square of the variance of the variable from the 
mean value. This leads to Wilks' A values (no units) in the range of zero to one. A value 
of one means that there is no difference in the variables from one group to the next, 
whereas a value of zero means the variables tested are infinitely different from one group 
to the next. 4 
Principal Components Analysis- 
The calculation of principal components to describe the greatest variance in the spectra 
from the mean of the data set allows us to substantially reduce the number of data points 
in the analysis, thus enabling prediction algorithms to include effectively all the 
biochemical data that varies from one sample to the next. Principal components analysis 
(PCA) finds combinations of variables, called factors, which describe the major trends 
(sources of independent variation) in the data. Mathematically, PCA is an eigenvector 
decomposition of the variable correlation matrix. The principal components (PCs) are the 
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eigenvectors and the corresponding eigenvalues are the measure of the amount of spectral 
variance in the dataset (the mean of all the spectra in the -dataset), the second is 
orthogonal to the first one, and in the direction of the largest residual variance, and so on. 
The last PCs, with the smallest eigenvalues, often only represent noise and can be omitted 
in further analysis. Pre-processing of data prior to PCA, such as mean or variance 
centring removes the mean spectrum of the dataset from the analysis and the first 
principal component will then describe the greatest variance from the mean. 
PCA is an unsupervised data transformation procedure that creates new variables in the 
directions of maximal variation, but not necessarily in the directions that are most useful 
for diagnosis. In many cases further modelling is required to achieve the latter. The main 
advantages of using PCA prior to further analysis, apart from data compression, are the 
removal of all collinearity and the inherent signal averaging aspects. Because of the 
collinear nature of spectra, the amount of data reduction can be large; often a reduction of 
more than 95% can be achieved without loss of useful information. The data compression 
and the orthogonalty of the PCs can facilitate and speed up the consecutive steps in data 
analysis. 
Linear Discriminant Analysis 
Group membership for a particular spectrum can be predicted by comparing the spectrum 
to a number of reference spectra, by using some spectral distance measure, and 
classifying it to the most similar ones from a particular group. In many cases the principal 
components space is not optimal for the separation of the desired groupings. Further 
multivariate techniques can be applied that incorporate information about the origin of 
the samples in the model (supervised classification). This information can be used to find 
the directions in the spectral space that provide maximal distances between groups. The 
most often used method to achieve this is Linear Discrimant Analysis (LDA) or some 
derived form of this method. The linear discriminant function was originally derived by 
MAW as a technique for classifying an object or individual into one of two possible 
groups on the basis of a set of observations or measurements. LDA finds the direction in 
spectral space that is optimal for separating two groups. It selects the linear combination 
of vectors in spectral space that give the maximum value for the ratio between inter- 
group variance and intra-group variance. MDA is the multi-group analogue of LDA, it 
finds the (n-1) orthogonal directions that best separate n groups. LDA and MDA have the 
disadvantage that in order to obtain a reliable model the number of input variables (e. g. 
wavenumbers) should not exceed the number of samples. This problem is solved by 
performing discriminant analysis on the factors (PCs) extracted by PCA. This method has 
the advantage of the data compression and signal averaging aspects of PCA, while still 
using all the relevant information in the spectrum for the discriminant analysis. 
Figures AM and A3.2 are flow diagrams of the process of spectral diagnostic model 
building and cross-validation testing, and the process of prospective classification with a 
linear discriminant model respectively. 
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Figure A3.1: Flow diagram of the spectral diagnostic model building and cross-validation 
procedures. 
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Prospective Classification using Model 
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Figure A3.2: Flow diagram of the prospective classification procedure using the optimised linear 
discriminant model. 
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Diagnostic Outcome Measures 
There are a number of measures of the power of a medical diagnostic test to correctly 
predict whether a patient has a particular condition. The most common of these are 
sensitivity and specificity. The sensitivity of a test is the percentage of individuals with 
disease who are classified as having disease. A test is sensitive to the disease if it is 
positive for most individuals having the disease. The specificity of a test is the percentage 
of individuals without the disease who are classified as not having the disease. A test is 
specific if it is positive for a small percentage of those without the disease. ' 
An example of results obtained from the Raman spectral prediction of laryngeal sample 
pathology is shown in Table A3.1. The resulting spectral prediction is classified as a true 
positive result if both the test and the 'gold standard' histopathology for a sample agree. 
True positive results are labelled in red. In the case of the test for normal samples the true 
negatives are coloured blue, i. e. those samples that are dysplastic or cancerous and are 
predicted to be not normal. The sensitivity can be calculated for all three test groups as 
the number of true positives (in red) divided by the sum of the true positives (in red) and 
false negatives (in green). The specificity for the normal case can be calculated by 
dividing the number of true negatives (in blue) by the sum of the true negatives (in blue) 
and false positives (in pink). The resulting values of sensitivities of the Raman prediction 
model for each of the three pathological groups are shown in Table A3.2. 
Raman Predicted Group embership 
Classification Normal Dysplasia Carcinoma Total 
No. Normal 100 5 7 112 
D splasia y 4 34 0 38 
Carcinoma 7 0 42 49 
Table A3.1: Cross-validation classification results obtained using the discriminant functions 
calculated from the first 25 principal components of the larynx spectra. Each case was classified by 
the functions derived from all cases other than that case. 88.4 % of cross-validated grouped cases are 
correctly classified using this method. 
Normal Dysplasia arcinorna 
Sensitivity 
Specificity 
89% 
87% 
90% 
93% 
86% 
95% 
Table A3.2: Sensitivity and specificity of Raman spectroscopy as a diagnostic test to classify 
pathology in the larynx, calculated from the cross-validation classification results obtained from the 
linear discriminant model. 
A further useful measure is the predictive value of a positive test. This is the percentage 
of subjects with a positive result who have the condition. 
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Appendix 4: Raman Peak Assignments for Biological 
Tissue 
C 
0 
0 
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Raw Raman spe=m of normal oesophagus at 828nm, I 1OmW. 10 seconds. 
Figure A4: Typical NIR-Raman of normal oesopaphageal mucosa. 
Wavenumber 
cnfl 
Assignments (for soft mammalian tissues) Reference 
350 Ribose, cytosine 1 
385 Cytosine 1 
429 Calcium hydroxyapatite 2 
430 Cholesterol 2 
435 Ribose 1 
484 Glycogen 
500 Guanine, cytosine + disulphide (protein) 1 
500-550 Disuffide S-S stretch in proteins 3 
505 S-S stretch (Bovine serum albumen, BSA) 4 
508 Disulphide (S-S) 5 
509 S-S disulphide bridges 6 
510 Disulphide (C-S-S-C gauche-gaucbe-gauche) 3 
518 Glucose 7 
525 Disulphide (C-S-S-C gauche-gauche-trans) 3 
528 Broad -S-S- stretch (protein) 2 
533 COC deforniation (glycosidic nng 8 
540 Disulphide (C-S-S-C trans-gauche-trans) 3 
547 Cholesterol 2 
553 Glucose 9 
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556 S-S 10 
574 Tryptophan 11 
575 Cytosine, guanine + disul. (pr. ) 1 
587 Calcium hydroxyapatite 2 
607 Cholesterol 2 
622 Phenylalanine 5,12 
626 Phenylalanine 13 
620 Phenylalanine 2,14 
637 Ribose + disulphide (proteiný_ 
643 Tyrosine 2 
644-645 Tyrosine 11,12 
665 Thiamine 15 
668-669 C-S stretch (protein) 4,8 
669 Thymine 12 
670 Purine bases (A, G) 15 
670 Guanine 1 
670 Thymine and Guanine 16 
681 Guanine ring breathing 12,16 
682 Guanine 15 
692 Creatine (0-C=O deformation) 17 
700 Cholesterol 18 
701 Cholesterol 2 
710 Adenine 1 
720 Nucleotide peak 19 
720 C-N (membrane phospholipid head) 15 
722 Adenine 1 
725 C-S (Protein) 11 
725 CH2 rocking 8 
727 =C-H in plane bend (breast lipid) 20 
727 Adenine 15 
729 Adenine ring breathing 12,16 
730 Lactatic acid 21 
746 P-0-P symmetric ; tretch (phospholipds) 22 
748 Thiamine 15 
749-750 Thymine ring breathing 8,12,16 
759 Tryptophan 2,23 
760 Tryptophan (protein) 1,6,11,24 
770 Pyrimidine bases (C, T) 15 
780 Nucleotide peak 19 
780 Uracil ring 8 
782 Cytosine ring breathing 12,15 
787 Cytosine, uracil 1 
787 Cytosine, uracil, thymine 25 
788 DNA: O-P-0, cytosine, thymine 16 
790 DNAT02 symmetric stretch 12 
790 Acetone (C-C-C stretch) 17 
811 Nucleotide peak 19 
814 DNA (P02) 10 
815 Phosphate 1 
817 C-C stretch, backbone 14 
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818 Ring breathing haemoglobin ?? 13 
825-842 O-P-0 stretch (DNA) 15 
830 Tyrosine (protein) 1,23,11,24,15 
830 Lactatic acid (C-COOH stretch) 21,26 
832-833 _ T)Tosine 6,12 
832 DNA backbone 16 
833 DNAT02 asyni. stretch 12 
840-860 Polysaccharides 27,28 
840 Glucose 9 
847 Glucose 29 
850 Tyrosine 15,24 
853 Tyrosine 12,23 
855 Tyrosine 6,11 
856 Polysaccbarides (? ) 30 
856 CC stretch, COC stretcb, 1,4-glycosidic link 8 
855-856 C-C stretch collagen backbone & proline ring 14,31,32,33 
857 Tyrosine 2 
860 Collagen (? ) 34 
860 Lactate (shifted from 830cm-1 due to alkalinity 35 
865 Ribose, TRP (protein) 1 
866 Lactic acid 21 
870 Proline 36 
876 C-C stretch (hydroxyproline) 14 
879 Tryptophan 23 
880 Tryptophan 6,11 
880 Tryptophan (ring deformation and NH displacement, sensitive to H- 
bond, 883cm-1 no H-bond, 871cm-1 strong H-bond) 
24 
885 Ribose, TRP (protein) 1 
892 CH2 rock, Collagen (hydroxyproline) 31 
895-896 DNA backbone 12,16 
915 Ribose 1 
917 Deoxy-ribose (CH2 deformation) 15 
920 C-C stretch (proline ring) 14 
920 Glucose 29 
920 Lactic acid 21 
925 DNA backbone 12 
928 DNA backbone & Protein a-helix 16 
928-940 C-C proline, valine 27,28 
930 TRP (protein) 1 
931 CH3 rock, Collagen (proline) 31 
932 Skeletal C-C: cc-helix 12 
935 Collagen (? ) 34 
935-945 Skeletal C-C: a-helix 15, 
936 Hydroxyproline & C-C collagen backbone 32 
936 C-C protein backbone 11 
937-938 C-C stretch backbone 14,33 
938 Peptide backbone stretch 2 
939 C-C-N stretch 4 
941 C-C protein skeletal stretch (muscle) 6 
940 C-C stretch of proline and valine 37 
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950 Hydroxyproline 36 
955 Heavily calcified aorta 
'38 956 Hydroxyapatite (standard sample) 38 
956 Carotenoid 30 
960 Hydroxyapatite phosphate stretch (calcified plaque) 2,39 
960 Phosphate stretch in calcified aorta 40 
960 Cholesterol 18 
960 Phosphate symmetric stretch in calcified lesions, otherwise mainly 
cholesterol 
5,30 
961 P-0 stretch of underlying bone 41 
960-961 PO stretch (phosphate) 42,43 
966 Hydroxyapatite 44 
968 ? Glucid C-OH 10 
972 =C-H out of plane deformation (breast lipid) 20 
975 Ribose I 
975 Deoxy-ribose (CH2 deformation) 15 
978 Phosphorylated proteins and nucleic acids 13 
978 Phospholipids, glucose- I -phosphate 29 
1000-1150 C-C skeletal (membrane hydrophobic tail) 15 
1000-1001 Phenylalanine 10,36 
1001-1004 Phenyl ring breathing mode 27 
1002 Skeletal C-C: P-sheet 15 
1002 Phenylalanine 2,11 
1003 Urea 7,31,45 
1004 Phenylalanine 8,12,16,14 
1004 Phenylalanine & Tryptophan aromatic ring 4 
1005 PHE (protein) 1 
1005 0-carotene (breast) 20,46 
1006 Phenylalanine (breathing mode) 15,22 
1006 Carotenoids 30 
1008 Carotenoids ? 34 
1008 Urea C-N stretch ý6,35 
1010 C-N stretch 45 
1013 Urea (N-C-N stretch) 17 
1014 Tryptophan 15 
1015 TRP (protein) 1 
1016 Tryptophan 47 
1017 DNA backbone C-0 stretch 12 
1031 Proline 2 
1032 Phenylalanine 12 
1035 Ribose, PHE (protein) 1 
1035 C-C skeletal cis conformation 31 
1040 ? PHE ? increases in liver malignancy 48 
1043 Hydrox apatite (standard sample) 38 
1043 Formalin artefact 14 
1046 Lactic acid 21 
1050 CO stretch or CCC trans conformational skeletal stretch 33 
1057 DNA: backbone C-0 stretch 12 
1061-1062 Lipid (stratum comeum) 32,49 
1064 Skeletal C-C stretch 50 
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1066 C-0, C-0-C stretch (phospholipds) 22 
1066 C-C stretch 20 
1066 Lipid in crystalline form 3 
1069 Shifted hydroxyapatite band (i. e. tissue environment) 38 
1070 Collagen/elastin ?? 13,42 
1070 Phosphate/carbonate 2,40,43 
1070 Collagen, glucose- I -phosphate 29 
1074 Adipose tissue 40,51 
1078 C-N stretch 52 
1078-1090 C-C or C-0 stretch (lipid), C-C 01 P02 stretch (nucleic acids) 27 
1079 C-C stretch (lipid) 20 
1082 C-C skeletal trans conformation 31 
1082 Lipid (C-C & C-0 stretcb) 46 
1082 Nonspecified protein vibrations ? POJ in pbospholipids and nucleic 
acids ? 
37 
1083 V02- DNA-backb one? Increases in liver cancer 48 
1084 Lactic acid 21 
1085 PHE (protein) 1 
1085 Phospholipid 36 
1085 Lipid C-C stretcb 2 
1086 C-C stretch, PO" stretch (phoTpholipids) 22 
1086 Skeletal C-C stretcb 50 
1090-1091 P02- (DNA) 10,15 
1094 DNA: O-P-0- 12,16 
1095 CC stretch skeletal, COC stretch, 1,4-glycosidic link 8 
1100 Phospbate POj stretch I 
1100 ? formalin ? 18 
1100-1110 Skeletal C-C: unordered 15 
1100 Lipid (disorganised) 3 
1104 Lipid C-C stretch 2 
1119 C-C stretch (breast lipid) 20 
1122 Lipid C-C stretch 2 
1123 Glucose 29 
1125 ? 1 
1125 Glucose 7 
1126 Protein C-N stretch 12 
1127-1128 Lipids (stratum comeum) 32,49 
1128 Herne vibrational mode 53 
1128 Skeletal C-C stretch 50 
1129 C-C stretch (lipid) 33 
1129 C-N (protein) 11 
1130-1131 Glucose (C-0 stretch) 17,54 
1130 C-C stretch (lipid) 3,30 
1131 Low density lipoproteins 2 
1131 Lactic acid 21 
1150 Carotenoids 39 
1155 C-C stretch (carotenoids) 25 
1155 C-C stretch, COH deforunation 31 
1156 C-N stretch (BSA) 4 
1156 Urea 7 
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1156 Carotenoid 20,51 
1157 P-carotene 46,30 
1158 Carotenoids 34 
1158 =C-C= carotenoid 55 
1159 C-N (protein) II 
1162 Ribose 1 
1175 C-0 stretch (tyrosine/carbohydrates) 13 
1176 Tyrosine, phenylalanine 12 
1176 Carbonite substituted hydroxyapatite 38 
1180 Tyrosine (exocyclic C-H and O-H bending in plane of ring) 24,47 
1180 Cytosine, guanine, adenine . 1 
1182 ??? greater in liver cancer than normal ??? 48 
1197 Carotenoid 20 
1206 Hydoxyproline, tyrosine 14 
1207 Tyrosine 23 
1207 Tyrosine & Phenylalanine 4 
1208 Thiamine 15 
1210 TYR, PHE (protein) 1 
1211 Thymine, tyrosine, phenylalanine 12 
1227 Heme vibrational mode 53 
1227-1247 Amide III: P-sheet 15 
1230-1240 Amide III: P-sheet 56 
1230-1245 Amide III: P-sheet 24 
1230 Uracil in RNA 58 
1235-1270 Amide III: unordered 15 
1238 Uracil, cytosine, Amide 111 1 
1240 Amide III: P-sheet 18 
1240 Pyrimidine bases (C, T) 15 
1240 Thymine 12 
1240-1260 Amide III: unordered 56,30 
1243 Amide III: colIagen 18 
1245-1270 Amide III: irregular 24 
1245 Amide III: keratin, disordered collagen (CH2 wag, C-N stretch) 31 
1246 Amide III (C-N stretch) 4,13 
1246 Collagen, DNA 29 
1247 Amide III: collagen 34,14 
1247 Protein pk increases in brain sarcoma 18 
1248 Amide III (one of pair of collagen amide III peaks) 57 
1248 7 POj in phospholipids and nucleic acids ? 37 
1250 Cytosine, uracil, Amide 111 1 
1250 Cytosine 15 
1253 Amide III: random coil (mouse breast adenocarc. ) 19 
1253 Herne proteins ? (liver) 48 
1254 Adenine 16 
1255 Cytosine 12 
1258-1304 Amide III: a-helix 15 
1259 Amide III (intensity less for benign breast than malignant tissue) 14 
1260 Tyrosine (phenolic C-0 stretch, width increases with degree of 
hydrogen bond ng) 
24 
1260 Amide 111 36 
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1260-1280 Amide III (BSA) 4,27 
1260-1310 Amide III: cc-helix 10,24,49 
1261 Lipid 51 
1264-1266 =C-H in plane bending (lipid) 27 
1265 Glucose 7 
1265 =C-H in plane deformation 20 
1267 =C-H in plane deformation 18 
1267 =C-H (membmne) 15 
1267 Amide 111 14 
1268 Amide 111 1 
1271 Amide III (one of pair of collagen amide III peaks) 57 
1271 Amide III: C-N stretch, N-H deforin. ' 37 
1272 Amide III: cc-helix 22 
1265-1300 Amide III: cc-helix 56 
1296 Lipids (stmtum comeum) 32,49 
1296 CH2 deformation (cemmide, a lipid) 31 
1297 CH2 defonnation 50 
1297 Lipid 51 
1300 C-C stretch 52 
1300 Adenine, cytosine 1 
1300-1336 CH2 twisting and wagging (lipid) 27 
1301 Lipid 18 
1302 Lipid (CH2 twist and =C-H bend) 46 
1302 CH2 twist and wagging (phospholipids) 22 
1303 CH2 twist (breast lipid) 20 
1303 CH3, CH2 twisting 14 
1303 Adipose tissue 40 
1303 Adenine 16 
1303 CH2 chain defonnation (membmne) 15 
1303 CH2 deformation (lipid) 2 
1304 Adenine, cytosine 12 
1306 Lipids 34 
1309 CH2 twist/wag (lipids) 37 
1320 Guanine 1 
1320 -CH2 symmetric wagging (lipid) 2 
1322 C-H (protein sidechains) 11 
1325 Tryptophan (Alfano) /Nucleic acids (Feld) 13 
1330 Phospholipids, DNA 29 
1330 DNA nucleotide base 58 
1333 Guanine 15 
1334 CH deformation 8 
1335 Nucleic acids 5,59 
1335 Aromatic amino acids 51 
1336 UVRR Adenine & Guanine 60 
1337 Nucleic acid purine bases (Guanine and adenine) 47 
1338 Tryptophan 15 
1339-1340 Adcnine 12,15 
1340 Nucleic acid mode in colon 57 
1340 Tryptophan doublet 24 
1340 Heme vibrational mode ' 53 
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1340 -CH2 symmetric wagging (lipid) 2 
1343 CHI, CH2 wagging 14 
1343 Adenine, TRP (protein) 1 
1350 Glucose 29 
1358 Myoglobin peak in diseased breast tissue (downshifted and 
enhanced) 
46 
1358-1360 Haemoglobin Q) in liver, kidney & colon @407nm 34,18 
1360 Tryptophan doublet 24 
1361 Tryptophan 15 
1365 Guanine, TRP (protein) I 
1370 Myoglobin (heme or pophyrin) 46 
1370 -CHI symmetric deformation 2 
1372 Lipids 34 
1376-1377 Thymine, adenine, guanine 12,16 
1380 Lactate Q) 35 
1400 Uracil, adenine I 
1401 CH3 symmetric bend 13 
1421 Adenine, guanine 16 
1427 UVRR Adenine & Guanine 60 
1422 Adenine 12 
1422-1441 Tryptophan (indole N-H in plane bend) shifts from 1422 (no H- 
bonding) to 1441 (strong H-bonding) 
24 
1438-1439 CH2 deformation (lipid) 27 
1438 CH2 scissoring 50 
1439 CH2 scissoring deformation (normal breast lipid) 20,61 
1440 Lipid 51 
1440 Shoulder lipid CH2 scissor 2,31 
1441 Lipid ý4,18 
1441 CH2 in normal breast 36 
1442 Lipid (C-H bend) 46 
1442 CH2 deformation (lipids and proteins) 22 
1442 CH bend 51 
1444 Adipose tissue 40 
1445 CH2 or CH., bending 52 
1445-1452 CH2. CH3 deformation (protein) 27 
1446 CH2 or CHI bending (shifted for benign breast tumour) 14 
1448 Deoxy-ribose (CH2 deformation) 15 
1449-1450 CH2 or CH., bending (protein) 4,12,43 
1449 CH-deformation 16 
1450 C-H deformation 1,10 
1450 CH2 scissoring (shifled from 1439) (infiltrating ductal carcinoma) 61 
1451 C-H bend 2,40 
1451 CH., deform. asymmetric, CH2 defonn (protein) 31 
1452 CH2 deformation 8,36 
1452 CH2 scissor (lipid), CH2/CH3 protein 
_37 1454 CH, asymmetric bend 13 
1454 Phospholipds, collagen 29 
1455 CH2 deformation (brcast lipid) 20 
1457 CH3 deformation so 
1457 Lactic acid 21 
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1458 Nucleic acids (in colon) 57 
1462 C-H deformation 1 
1462 Deoxy-ribose (CH2 deformation) 15 
1466 Urea 7 
1474 Altered lipid component in liver carcinoma 34 
1480 Purine bases: Guanine, adenine 1,15,51,58 
1484 UVRR Adenine & Guanine 60 
1485 Nucleic acids 5,59 
1485 Nucleic acid purine bases (Guanine and adenine) 47 
1487 Guanine, adenine 12,16 
1491 Formalin artefact 14 
1509 Phenylalanine 4 
1510-1511 Adenine 12,16 
1514 C=C stretch (carotenoid, a cellular pigment) 25 
1517 Carotenoid 
1520 Carotenoid 6 
1523 -C=C- Carotenoid 55 
1523 5-carotene 46 
1524 Carotenoid 30 
1525 Low density lipoproteins 2 
1528 Carotenoid (in liposarcoma) 51 
1529 Carotenoid 34 
1538 Carotenoid 39 
1541 Typosine 11 
1547 Tryptophan 23 
1550 TRP (protein) 1,24 
1552 Amide 11 (NH deform and CN stretch) 31 
1553 Tryptophan 15 
1554 Amide 11 (coronary thrombus) 2 
1555 Amide Il 10 
1555 Tryptophan 47 
1556 Tryptophan 4 
1560 Heme vibrational mode 53 
1570 Purine bases (A, G) 15 
1573 Amide II (NH deform., CN stretch) 8 
1575 Guanine, adenine, TRP (protein) 1 
1576 Nucleic acids (colon) 57 
1577-1578 Guanine, adenine 12,16 
1578 
1578 Heme protein 48 
1579 UVRR Adenine & Guanine 60 
1580 Nucleic acids 51,58 
1585 Nucleic acids 59 
1589-1590 Porphyrin (biliverdin, liver) C=C stretch 27 
1593 Biliverdin / bilirubin 18 
1593 Nucleic acid purine bases (Guanine and adenine) 47 
1597 Urea 7 
1600 ? I 
1600 Tyrosine 24 
1601 Pyrimidine ring 62 
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1601 Phenylalanine (BSA) 4 
11 
1602 Tyrosine 47 
1606 Phenylalnine, tyrosine 12 
1610 Tyrosine (UVRR colon) 59 
1612 Proteins and nucleic acid peaks ??? 47 
1616 Tyrosine (BSA) 4 
1617 Tyrosine, phenylalanine 12 
1618 Tyrosine 24 
1618-1628 Porphyrin (lung) C--C stretch 27 
1620 Uracil, TRP, TYR, PHE (pr. ) 1 
1620 Altered lipid component in liver cancer 34 
1620 Herne vibrational mode 53 
1620 Tryptophan (UVRR colon) 59 
1622 Tryptophan 47 
1637 Amide I (? ) 14 
1640 Intermolecular bending mode of water 45 
1645-1655 Amide I: (x-heU 24 
1645-1660 Amide I: a-helix (??? ) 5Z-. 6 
1650 C=C lipid band 59 
165U-16: )l Amide I (C--U stretch): a-helix 31,52 
1651 Nucleic acid pyrimdine bases (cytosine & thymine) 47 
1651 Keratin (C=O stretch Amide 1) 33 
1652 Lipid 34 
1653 Lipid (C--C stretch) 46 
1653-1657 Amide 1 27,49 
1654-1662 Amide I: a-helix 15 
1645-1685 Amide 1: unordered 15 
1654 C=C stretch cis configuration (breast lipid) 20 
1654 C=C stretch (lipid) 27 
1655 Shoulder lipid C--C 2 
1655 C__C 18 
1655-1665 Amide I: irregular 24 
1656 Unsaturated fat (C--C) 18 
1656 Collagen 29 
1656 Amide 1: (C--O stretch) disordered, collagen triple helix 31 
1656-1657 Amide I (C=O) 14,1_3 
1657 C=C stretch (Lipids) (pre-resonance enhancement of this peak 
occurs at 250nm) 
47 
1657 Amide I (C=C lipid in normal breast) 36- 
1659 Amide I (BSA) 4- 
1660-1670 Amide I: unordered 56 
1661 Amide I (C=O stretch) 37 
1662 Nucleic acids (colon) 57 
1664 Amide I: a-helix 22 
1665 Amide 1: collagen 18 
1665 Uracil, guanine, cytosine, Am I I 
1665-1680 Amide I: P-sheet 15 
1666 Urea 7 
1667 C=C stretch (decreases with malignancy in lipoSarcoma) 51 
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1667 Amide I (disordered) 50 
1668 Amide I (keratin: P-sheet, collagen) 31 
1669 Lipid 51 
1669 Amide 1: random coil (mouse breast adenocarc. ) 19 
1665-1680 Amide 1: P-sheet 24,56 
1725 Lactate 26 
1726 Lactate 7 
1740 C--O stretch 18 
1743 C=O stretch (breast lipid) 20 
1743 C=O lipid ester 31 
1745-1746 C=O stretch (lipid) 27 
1768 COO stretch 31 
2580 
2852 CH2 sym-stretch (lipids/proteins) 37 
2857 C-H stretch (-CH2 sym) (breast lipid) 20 
2875 C-H stretch (-CH2 asym) (breast lipid) 20 
2880 Aliphatic C-H stretch I 
2885 Lactate 45 
2890 Glucose doublet 26,45 
2890 Lactate triplet 35 
2894 Lactate 7 
2895 Glucose 7 
2898 C-H stretch (-CH3 sym) (breast lipid) 20 
2929 C-H stretch (-CH3 sym) (breast lipid) 20 
2930 CH2 anti-symmetric stretch 18 
2935 C-H stretch 6 
2942 Aliphatic C-H strctch 1 
2942 CH3 as-strctch (lipids/proteins) 37 
2943 Glucosc 7 
2945 Lactate triplet 7,35,45 
2950 Glucose doublet 26,45 
2960 C-H stretch (-CH3 asym) (breast lipid) 20 
2975 Aliphatic C-H stretch 1 
2990 Lactate triplet 35 
2995 Lactate 7,45 
3006 =C-H stretch (breast lipid) 20 
3250 OH-stretch (bound and unbound water) 3 
3390 OH-stretch 6 
Proline and hydroxyproline make up 25% of the amino acids in collagen 
1650-1675: Amide I overlapping with C=C modesfrom Upids andlor ketone C=Ofrom 
DNA bases. 
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REVIEW 
Optical Spectroscopy for the Early Diagnosis of 
Gastrointestinal Malignancy 
H. Barr, T. Dix and N. Stone 
Gloucestershire Royal and Crarfield University Institute of Medical Sciences. Gloucestershire Royal Hospital, Gloucester, UK 
Abstract. The early diagnosis of gastrointertinal malignancy will allow eradication of the disease prior to 
invasivo cancer. At present, fluorescence spectroscopy offers the most realistic prospect of an early clinical 
system and is currently under evaluation. Optical coherence tomography can differentiate the layers of the 
oesophageal wall and has greater reolution than ultrasound. Although complicated, Raman spectroscopy 
offcrR the greatest information with possible development of a molecular endoacope. 
Keywords: Biopsy; Fluorescence; Optical; Raman; Spectroscopy 
INTRODUCTION 
Virtually all gastrointestinal cancers present 
with surface abnormalities prior to becoming 
invasive tumours. These changes, invisible to 
white light illumination, have to be detected 
before the development of invasive cancer if 
eradication and prevention are to be possible. 
There may be a prolonged period of some years 
from the detection of early precancer of the 
gastrointestinal tract and the development of 
invasive cancer [1). In addition there is a 
dramatic rise occurring in adenocarcinoma at 
the gastrocsophageal junction [2]. The precan- 
cerous changes arc currently detected using 
rigorous biopsy protocols [3), which are time 
consuming and cumbersome. Optical tech- 
niques may allow early diagnosis and permit 
screening protocols at endoscopy. Once 
detected there are now non-invasive endo- 
scopic eradication methods available [4-7]. 
Over the next few years we are likely to see a 
revolution in endoscopic detection, and 
already the commercial possibilities are 
exciting industry [8]. 
Spectroscopic analysis of tissue depends on 
identifying a characteristic spectral emission 
that can be used to differentiate between nor- 
Cormspondence to: Protmor Ifugh Darr, Gloucester 
Gmtrocnterology Group, Gloucestershire Royal and 
Crunfield Univervity Institute of Medical Sciences, 
Gloucestershire Royal Hospital, Great Western Road, 
Gloucemter CLI 3NN, UK. 
mal and abnormal areas in real time. Optical 
biopsy is the term commonly used to describe 
this technique, but the term biopsy is a misno- 
mer since no tissue is removed. The main goal 
in optical diagnostics is to identify early 
cancer or dysplasia [9]. Available methods 
include- fluorescence spectroscopy; elastic 
scattering spectroscopy; optical coherence 
tomography and Raman spectroscopy. 
FLUORESCENCE SPECTROSCOPY 
Irradiation of a molecule by light can lead to 
its excitation and possible fluorescence emis. 
sion. This emission is of a lower energy (longer 
wavelength) than the exciting photon. The 
ground and excited states of a molecule are 
broadened by vibrational motion and inter- 
actions with other surrounding molecules. 
Hence, the energies or wavelengths of 
light that the molecule will absorb are also 
broadened. 
Absorption of the incident radiation by the 
atoms causes the electrons to be temporarily 
raised to higher energy orbits [91 in the singlet 
state. Once in this excited state, radiationless 
relaxation occurs on a picosecond time scale to 
the bottom of the excitation band [101 where 
the molecules remain for a few nanoseconds. 
From here, several competing processes can 
take place such as the broadband light 
emission in the form of fluorescence [101 or 
phosphorescence [113 via intersystem crossing 
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[121 to the triplet state (Fig. 1). Alternatively. 
radiationless processes such as internal con- 
version and energy transfer to surrounding 
molecules can also take place. 
A fluorophore has characteristic excitation 
and emission spectra, dependent on its micro- 
environment. Detection can be performed 
using a single excitation and emission 
wavelength, although to extract further infor- 
mation several excitation-emission pairs can 
be used. Fluorescence decay lifetimes and 
depolarisation can also provide important 
additional information. 
Laser-Induced Tissue Autofluoresconce 
Naturally occurring fluorophores contribute 
to tissue autofluorescence in the near ultra- 
violet and visible region. Detailed interpret- 
ation of fluorescence signals is difficult Q because of the composite and unstructured 
nature of the spectra, their dependence on the 
microenvirorunent. and light re-absorption by 
tissue chromophores. One example is the green 
absorption band of haemoglobin. 
Intrinsic fluorophores, such as collagen and 
porphyrins, have been used to characteriso the 
physical state of many tissues including the 
colon. and upper acrodigestive tract [10-13]. 
The fluorescence signal provides information 
about the tissue microstructure and is strongly 
influenced by its chemical composition. A 
change in the state of the tissue towards 
cancer alters the nutofluorescence of the 
tissue. 
Some of the endogenous fluorophores 
responsible for tissue autofluorescence are 
listed in Table 1. Most useful are nicotinamide 
adenine dinucleotide, NADII, and the flavins 
which show changes in fluorescence spectra 
during metabolic transformation from the oxi- 
dised to the reduced state. They nre. therefore, 
an important indicator of the level of meta- 
bolic activity in particular areas of tissue. 
When cellular metabolism is slowed and the 
redox potential is allowed to fully charge there 
is an abundance of reducing equivalents. i. e. 
NADIL NADPH. F. MNH.,, FADH: j. When 
metabolism is stimulated and these reducing 
equivalents are oxidised. the redox potential is 
lowered, thus there is a shift to oxidised forms 
namely NAD*. NADP*, FININ, FAD. This 
process has been demonstrated using lactate 
to depress cellular metabolic activity and 
caffeine to increase metabolic activity [141. 
We now know that oxidative species play an 
important role in the early molecular develop- 
ment of cancer 115). The cell's defence against 
this oxidative stress includes NADIL Thus the 
fluorescence ratio or NADII to its oxidised 
form NAD* has the potential to discriminate 
between normal and precancerous tissue [14]. 
Table 1. Fluorescence lifetimes of naturally occurring fluorophores 1161 
Fluorophor 
Main 
excitation peak(s) 
(nm) 
Main 
emission peak(a) 
(nm) 
Fluoreýcencu 
lifetime 
(ns) 
Tryptophan 275 350 2.8.1.5 
Collagen . 340.270.285 295,395,310 9.9,6.0.0.8 
Elastin 460,360,425.260 520,410,490.410 6.7.1.4.7.8,2.6,0.5 
NADII 350 4GO 0.6.0.2 
FN. %l 440 520 4.7 
P-caroteno 620 9.6.2,0.0.3 
Endogenous porphyrins 400 610,675 
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This together with its high fluorescence yield 
make NADII a most promising fluorophore for 
investigation. The lack of fluorescence pro- 
duced by the oxidised NAD* means that 
reduced fluorescence is seen in tumour tissue 
compared to the surrounding normal tissue. 
As the border of the tumour is approached, 
then the fluorescence increases. The low 
fluorescing centre and 'brighter' borders indi- 
catc the'direction of the cancerous growth. 
The major exception to this rule are fibrous 
or schirrous cancers (breast) containing a 
high collagen content with high endogenous 
fluorescence. 
Although autofluorescence has the attrac- 
tion that no exogenous fluorophores are 
required, the fundamental problem is the 
broad structureless fluorescence emission 
caused by many non-specific fluorophores. This 
may be overcome by the administration of a 
specific exogenous fluorophorelphotosensitiser 
that may accumulate or be retained in differ- 
ent concentrations by neoplastic and normal 
tissue. 
Laser-induced Photosensitiser Fluorescence 
The administration of an exogenous, fluoro- 
phore is complicated by the selection of an 
appropriate non-toxic agent and delivery 
vehicle. In addition, the biodistribution in 
tumour and normal tissue will vary with time. 
Also, these fluorescent agents often have as- 
sociated photodynamic action, which restricts 
the administered patient dose. Autofluor. 
escence emission from tissue porphyrins will 
reduce the contrast between tumour and nor- 
mal tissue. One method of enhancing this 
restricted signal level is to ratio the red 
emission of the fluorophore with the blue- 
green tissue autofluorescence and thereby 
yield a dimensionless quantity [16). 
The problem of. targeting the mucosa and 
mucosal tumours directly may be achieved 
by using endogenous photosensitisation or 
immunophotodetection. The use of oral 
5-aminolaevulinic acid may be very useful in 
the gastrointestinal tract and allow mucosal 
areas of dysplasia to generate excess fluor- 
escenco from protoporphyrin IX [4,17,181. Anti. 
carcinoembryonic antigen monoclonal anti- 
bodies coupled to fluorescein have also been 
used for the immunophotodetection of human 
colon carcinomas in mice [191. 
Fluorescence Polarlsation Spectroscopy 
The dependence of absorption on the polaris- 
ation of light and the depolarisation of fluor. 
escence emission generated by polarised light 
have served as useful tools for identifying 
fluorophore electronic states and conforma. 
tional structures in diftrent environments 
(201. It has been well established that the 
polarised spectroscopic properties of the 
fluorophores are highly dependent on polarity. 
pH and viscosity. Depolarisation studies of 
known fluorophores, extrinsic and intrinsic, 
can be used as probes to investigate their 
local environment. Extrinsic fluorescent dye 
molecules with known emission properties 
have been conjugated to non-emitting protein 
molecules in order to perform polarisation. and 
lifetime studies that help elucidate protein 
structure, molecular dynamics, pathological 
state and characteristics of the local environ- 
ment. Both rotational motions and energy. 
transferring mechanisms probably participate 
in depolarising the emission from the native 
fluorophores. One problem is that multiple 
scattering in tissue will destroy a large portion 
of the light polarisation. 
All of the above techniques described have 
been based simply on the steady-state fluor- 
escence intensity at a particular wavelength. 
This can be subject to significant measurement 
errors, due to the uncontrolled variation 
in excitation/tissue-detector geometry. Ratio 
based techniques using two or more excitation/ 
emission wavelengths reduces, but cannot 
eliminate, these errors. 
Time-Resolved Fluorescence Spectroscopy 
Time-resolved detection can enhance the rela- 
tive fluorescence emission of the dye (21,22), by 
removing the undesired short-lived back. 
ground fluorescence. The simplest form of this 
is to gate the detection (introduce a time delay 
between the excitation pulse and signal detec- 
tion). Time resolved detection has been used to 
study the uptake of hacmatoporphyrin deriva. 
tive (HpD) and aluminium phthalocyanino 
(AISPc) at the cellular level in a murine 
model [23]. 
An extension of the time-resolved technique 
is to use fluorescence lifetime imaging (FLIM). 
The fluorescence lifetimes of endogenous and 
exogenous fluorophores (Table 1) have a high 
information content and are sensitive to 
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numerous chemical and physical factors 1241. 
The measurement of fluorescence lifetime is 
unaffected by intensity-based measurement 
errors. Fluorescence lifetime is independent of 
fluorophore concentration and can be used 
to distinguish between tissues with different 
microenvironments, nucleic: acid content, 
membrane permeability and enzymatic 
activity. For example, imaging of free versus 
protein bound NADII in cells is possible 
because of the differing lifetimes of the free 
and bound NIADH (0.5 and 1.5 ns, respectively) 
[25]. FLIM is intrinsically more robust than 
steady-state measurements and if the tech- 
nology can be made feasible for routine clini- 
cal use then combining spectral and lifetime 
information is likely to be very reliable. 
Fluorescence Measuring Systems 
Measurements can be performed either as a 
point by point measurement using an optical 
probe placed on or in the tissue or as a fluor- 
escence image viewing the tissue surface. Both 
techniques can be used either directly or 
through a fibreoptic endoscopc and can involve 
the postprocessing of the fluorescence signals 
(spectral ratios). Current systems vary from 
simple and relatively inexpensive fibrcoptic 
fluorometers using a filtered lamp and photo- 
diode detectors to highly complex and expen- 
sive multispectral imaging systems involving 
sophisticated laser sources, sensitive array 
detectors and computerised image processing 
to measure fluorescence decay lifetimes (26,271. 
The common goal for all measuring systems 
is to obtain the maximum discrimination of the 
tumour fluorescence signal from the back- 
ground fluorescence of normal tissue and to 
establish reliable limits for defining a positive 
fluorescent signal by comparative studies with 
histopathology. The most common technique is 
to ratio two or more fluorescence intensities. 
Bronchoscopic imaging systems are available 
for the detection of early squamous cell 
changes before the development of invasive 
lung cancer measuring the ratio of the red and 
green emission 128). Digital background sub- 
traction measuring a background level of 
autofluorescence at a shorter wavelength and 
extrapolating this to the red emission region of 
the exogenous dye [29,30], allows the contribu- 
tion of the autolluorescence in the red to be 
removed from the digitised image. The fraction 
of the green image that is subtracted from the 
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red is determined empirically by adjusting the 
video gain so that a black image is obtained 
when viewing a control site (normal tissue). 
The ratioing technique can be extended to four 
simultaneously imaged wavelengths [24,31). 
Four individually spectrally filtered images 
formed on a matrix detector are processed by a 
computer pixel by pixel to produce an opti- 
mised contrast image. Another method of 
avoiding problems with intensity measure- 
ments is differential normalised fluorescence 
(DNF) which uses the difference in the normal- 
ised fluorescence spectra between the malig- 
nant and normal tissue [10,121. Identification 
of an area of normal tissue in the patient is 
used to set a 'baseline curve'. 
To utilise more of the spectral information 
and thus detect the early subtle changes in 
tissue a multivariate linear regression analysis 
(NIVLR) technique has been developed 1321. 
Multiple excitation wavelengths were used 
and the resulting emission spectra were sam. 
pled at set intervals. By dividing the data into 
groups such as normal, dysplastic. and early 
carcinoma; the most 'diagnostic' excitation- 
emission pairs were selected. The encouraging 
results obtained could possibly be enhanced by 
the application of a neural network type learn- 
ing system on fully sampled spectra. 
Fluorescence lifetime measurements afrLr 
the most information for the detection of early 
precanccrous changes. Unfortunately, the 
costly and complicated equipment required for 
these measurements does not lend itselfto easy 
clinical use. In vitro measurements have been 
completed using the high frequency gain 
modulation of an image intensifier to preserve 
phase information with respect to an incident 
light source which is also intensity modulated 
at a high frequency 125). To calculate the fluor- 
escence lifetime a series of measurements were 
required to examine the detector phase angle 
dependence of the emission. Alternative sys- 
tems have been used to complete measurements 
using a pulsed light source provided by either a 
mode-locked argon ion or nitrogen pumped dye 
laser 122,23). The spectral and temporal content 
of the signal was preserved by using a streak 
camera as a detector coupled to a spectrograph. 
Clinical Applications of Fluorescence 
Spectroscopy 
For some time it has been known that turnours 
of the upper aerodigestive tract contained 
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endogenous porphyrins which allowed dis- 
crimination from the normal mucosa by 
autofluorescence [10,34]. Thus, most tech- 
niques are at present concentrating on laser 
induced fluorescence (LJF). 
Panjepour et al. [101 have successfully ident- 
ified high-grade dysplasia in Barrett's ocsoph- 
agus using this technique. Thirty-six patients 
were studied and the area of Barrett's oesoph- 
agus interrogated using a nitrogen-pumped 
dye laser emitting 410 nm light in 6 ns pulses. 
This was used to excite tissue autofluorescence 
which was collected by a fibre bundle and 
analysed by a spectrograph. Both emitting and 
collecting fibres were included in a flexible 
fibreoptic probe (1.7 mm). The endoscopist 
passed this through the biopsy channel of the 
endoscope and placed the end touching the 
tissue. It must be noted that the fluorescence 
intensity is strongly affected by the probe 
placement against the tissue. Multiple 
measurements were taken and histological 
biopsy taken from the sites of spectral 
measurement. A mathematical model on differ- 
ential normaliscd fluorescence was developed. 
Using this method, seven patients were 
detected to have high-grade dysplasia and all 
correlated completely with the biopsy samples. 
All patients with low-grade dysplasia were 
also correctly identified (six patients). Non 
dysplastic Barrett's mucosa was identified in 
16 of 23 patients (70%). An accompanying 
editorial [351 puts this paper in context, and 
suggests that a more user-friendly system is 
required. It would be preferable if it was incor. 
porated directly into the endoscope with 
real-time imaging. 
Another study of laser induced fluorescence 
for the detection of adenocarcinoma in Bar. 
rett's oesophagus adopted a different approach 
[36]. Patients with adenocarcinoma were pre- 
treated with an intravenous photosensitiser 
and measurements performed immediately 
after resection of the ocsophagus. Measure- 
ments were also taken during endoscopy in five 
patients to assess how applicable the tech- 
nique wag to clinical use. Fluorescence was 
excited using a nitrogen pumped dye laser 
connected to a 600 jun optical fibre. This fibre 
was used to collect light emitted from the 
tissue and connected to a charged coupled 
device camera. The fluorescence spectra from 
460 to 750 run were analysed. A tumour demar- 
cation function was established in the form of 
a fluorescence ratio: the quotient of porphyrin 
fluorescence at 630 nm divided by autofluores. 
cence at 500 nm. Normal oesophageal mucosa 
had a fluorescence ratio of 0.1 :h0.058, gastric 
mucosa 0.1610.073, Barrett's oesophagus 
0.205: 1: 0.17, severe dysplasia 0.79±-0.54 and 
adenocarcinoma 0.78: EO. 56. Thus, this tech. 
nique can characterise ditrerent histologicnl 
changes in the oesophagus, which were not 
macroscopically evident. Others have used 
hypercin for the fluorescence detection of 
stomach cancer [37]. 
Most work has concentrated on distinguish. 
ing between neoplastic and normal tissue in 
the colon (38-41]. This seems to be a proving 
ground for new detection techniques and 
systems. Fluorescence endoscope imaging of 
colonic adenomas has also been useful in 
identifying dysplasia in adenomatous polyps in 
the resected colons of three patients with 
familial adenomatous polyposis [421. Although 
these techniques have concentrated on 
malignant disease, some inflammatory pro- 
cesses such as recurrent Crohn's disease, not 
evident macroscopically, can be detected 
using fluorescence endoscopy 143]. The ability 
of fluorescence techniques to distinguish 
between inflammation and neoplasia is there- 
fore of current concern and a major challenge. 
ELASTIC SCATTERING SPECTROSCOPY 
In tissue the most likely mechanism of inter- 
action for light photons is elastic scattering. 
Thus, the elastic scattering signal intensity 
is greater than all other signals'and can be 
used to probe tissue characteristics 19,441. 
Selected wavelengths of light, or white light, 
may be used to irradiate the tissue. The 
scattered light is collected by an optical fibre 
and an intensity spectrum is constructed. This 
comprises data from the elastic scattering and 
absorption of the tissue the light has passed 
through. 
Light scattering is wavelength dependent, 
the greatest degree occurring in photons of 
wavelength similar to the size of the particles 
scattering them. This is predicted by Mic 
theory. Thus, the different morphological char- 
acteristics of precancer and cancer cells, as 
well as changes in tissue microstructure may 
be probed by this method. The depth to which 
the tissue can be probed is dependent on the 
penetration of the light and the geometry of 
the illuminating and collecting fibres. All the 
important scattering components of tissue 
have yet to be fully identified. 
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Its use for gastrointestinal neoplasia has 
been explored by the Los Alamos group [451. 
Their approach has been to use different col. 
lecting and irradiating fibres in direct contact 
with the tissue to avoid specular reflectance. 
The advantages of elastic scattering are that 
the signals are large and information can 
be gathered rapidly and the equipment is 
relatively inexpensive. The diagnostic algo- 
rithms have yet to be fully evaluated and 
developed. 
RAMAN SPECTROSCOPY 
Raman spectroscopy is a very powerful tech- 
nique, which has the potential to identify early 
molecular markers of malignant change. It can 
be used to probe the vibrational energy levels 
of tissue molecules. The detection of biocbemi- 
cal tissue changes via vibrational spectroscopy 
may provide a now methodology for the 
development of the molecular endoscope. 
OPTICAL COHERENCE TOMOGRAPHY 
Optical coherence tomography (OCT) exam- 
ines fine tissue structure using light elastically 
backscattered from tissue layers and bound. 
aries. Light from a monochromatic low coher- 
ence source (usually a superhuninescent diode) 
is evenly split into two fibres. One fibre directs 
light to the tissue to be investigated and the 
other to a reference mirror. When the signals 
from the mirror and the tissue are recombined 
constructive interference occurs when the 
path lengths match to within the coherence 
length of the light. Thus, the optical path 
length of the reference arm controls the depth 
of measurement in the sample. Accurate cross- 
sectional images can be obtained from the 
backscattered light giving a two-dimensional 
image which can be displayed with false 
colour. The depth resolution depends on the 
light sources used and can vary from 50 pm 
to 2-4 gm if ultrashort pulsed lasers are 
used (46,47]. 
The use of this technique has been initially 
in vascular imaging [48] and skin diagnostics. 
It is analogous to ultrasound imaging, but with 
up to 10 times improved depth resolution OCT 
will give more detailed morphological informa- 
tion for the detection of early cancer. Both 
these techniques can be adapted for endo- 
scopic use. The depth for OCT imaging in 
tissues is limited by the power of the super- 
luminescent diode source. Images have been 
obtained in the gastrointestinal tract to a 
depth of 200-300 jim [491. 
The most likely use for OCT will be to stage 
gastrointestinal neoplasms after they are dis- 
covered using other methods. This could be 
achieved using the technique to measure the 
depth of abnormal growth at a particular posi. 
tion within the gastrointestinal tract. A scan 
covering all regions would be likely to be too 
time consuming. 
Raman Theory 
If a monochromatic beam of photons passes 
through any medium a proportion will be scat- 
tered in all directions. These scattered photons 
will consist almost entirely of radiation of the 
incident frequency, v. This is Rayleigh scatter- 
ing, an elastic process, whereby no energy is 
lost from the interacting photon. However, 
a small number of photons will emerge with 
discrete frequencies above and below that of 
the incident beam (v I Avi). This is Raman 
scattering, and the energy shift is independent 
of the exciting frequency, v, and is character- 
istic of the species of scattering molecule [50]. 
A Raman spectrum is a plot of scattered 
intensity as a function of energy difference 
between the incident and scattered photons. 
The units of energy are displayed in wavenum- 
bers (11wavelength). The loss (or gain) in pho- 
ton energies corresponds to the difference in 
the final and initial vibrational energy levels 
of molecules participating in the interaction. 
A typical Raman peak is spectrally narrow, 
easy to resolve and sensitive to molecular 
structure and the surrounding environment. 
Vibrational spectroscopy techniques can thus 
provide specific histochemical information 
unparalleled by other optical methods. 
The Raman effect can be induced by all 
frequencies of incident light. The energy 
change of the scattered photon is constant for 
a particular molecular species. As an example 
of this, the C=C stretching vibration of the 
benzene molecule always produces a Raman 
peak downshifted by 1612 cm -' independent 
of the frequency of the excitation light (511. 
The main factors that determine the choice 
of excitation wavelength are, the depth of 
penetration of the light through tissue; the 
intensity of the induced fluorescence signal 
at that wavelength; the availability of an 
intense source and a sensitive detector at the 
wavelength selected. 
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Raman scattering is an inherently weak 
process. The intensity of the Raman signal is 
typically 10' to 10' of the Rayleigh back- 
ground [521. Therefore, it is difficult to observe 
without intense monochromatic excitation and 
a sensitive detector. The Raman effect occurs 
without photon absorption by the molecule, 
but rather the molecule is perturbed by the 
photon and it is induced to undergo a vibra- 
Lional or, rotational transition. Hence the 
interaction process between the photon and 
molecule is very fast; of the order of picosec- 
onds, whereas the time for absorption and 
fluorescence is of the order of 10 ns 153,541. 
Raman Techniques 
Visible 
Early aitempts to measure the Raman spectra 
of tissues were limited by two factors, the 
highly fluorescent nature of biological samples 
and the long integration times and high power 
densities required. The early Raman spectra of 
tissue were measured using visible laser exci. 
tation light; mainly from argon-ion laser lines 
[55,561. Detection of the Raman scattered light 
involved u3ing a monochromator to frequency 
disperse the collected light and a photomulti. 
plier tube to detect the intensity of the photons 
in the frequency range of interest. 
Infra-red Raman 
Visible Raman spectroscopy has been super- 
seded by the development of interferometers 
using Fourier transform Raman spectroscopy. 
This technique using infra-red excitation light, 
reduces tissue fluorescence. After modulation 
by the interforometer, the filtered Raman- 
scattered light is detected by means of a high 
sensitivity InGaAs detector. The Fourier trans- 
form IR-Raman technique produces adequate 
signal-to-noise, with moderately high power 
densities. However, acquisition times of about 
30 min were required to obtain the spectra of 
highly fluorescent tissues [57,58). 
Near Infra-red Raman 
The development of diode lasers and CCD 
cameras, sensitive in the near infra-red, has 
made it possible to measure the tissue Raman 
spectra with near-infra-red (NIR) excitation. 
The major advantage of this technique is that 
NIR radiation does not generally induce elec- 
tronic absorption. Therefore, most materials, 
including biological tissue, exhibit extremely 
weak fluorescence relative to visible excited 
Raman and relatively short integrations are 
possible [59,60]. 
The development of holographic notch 
filters has also played a major part in improv. 
ing the practicality of Raman spectroscopy for 
medicine, The largest component of scattered 
light from tissue is the elastically scattered 
(Rayleigh) light. This must be filtered out 
before measurement. This was originally 
achieved with triple monochromators. How- 
ever, the throughput of this type of system is 
very low, necessitating long acquisition times 
or high laser powers. However, with a holo- 
graphic Rayleigh rejection filter, a single 
monochromator is required to separate the 
Raman spectra into its separate energies. 
Hence, a much greater throughput is achieved 
and much shorter acquisition times or reduced 
laser powers are possible. 
Removal of Background Fluorescence 
For biological tissue samples the optimal exci- 
tation wavelength range generally falls 
between 750 and 850 run. The resulting tissue 
Raman spectra contain a large fluorescence 
background and they lie in the same spectral 
region. 
A simple method to remove the fluorescence 
is polynomial subtraction; whereby the spec. 
trum containing both Raman and fluorescence 
information is fit to a polynomial of high 
enough order to describe the fluorescence line 
shape but not the higher frequency Raman line 
shape. A fifth-order polynomial was found to 
be optimal by Mahadevan et al. [611. The best 
fit polynomial was then subtracted from the 
spectrum to yield the Raman signal alone. 
An alternative method is to vary the 
frequency of the excitation light over a narrow 
range (10-30 cm '). The Raman band positions 
vary directly with the excitation frequency, 
whereas the fluorescence emission remains 
fairly constant with such small changes 
in excitation frequency, allowing it to be 
efficiently subtracted out [601, 
Time gating is another method to remove the 
fluorescence signal. This technique takes 
advantage of the short lifetimes of Raman 
scattering events (10-11-10-l's) compared 
with fluorescence lifetimes (10-ý-10`s) in 
biological samples to temporally differentiate 
between Raman and fluorescence signals. 
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Using a pulsed laser source. a time gate can be 
used to synchronise the detector with the laser 
pulse so that all the Raman signal is collected, 
while the majority of the fluorescence is 
rejected [541. 
Resonance Raman Spectroscopy 
An alternative strategy is to resonantly excite 
high-lying electronic states with ultraviolet 
light, a process known as UV resonance 
Raman spectroscopy (UVRR). In biological 
materials, quenching and non-radiative relax. 
ation from these states often eliminates fluor- 
escence or causes it to occur at much longer 
wavelengths, so that Raman spectra can be 
obtained without interference [511. 
The principal advantage of UVRR in bio. 
medical applications is that by selecting the 
appropriate excitation wavelength, Raman 
bands of disease markers can be selectively 
enhanced in the midst of overlapping vibra. 
tions from more abundant tissue components. 
LTV excitation results in a tremendous increase 
in Raman intensity due to the Raman cross- 
section being proportional to the fourth power 
of the excitation frequency (0). Hence, disease 
markers present in low concentration can be 
potentially observed. For example, nucleic 
acids are selectively enhanced with 251 run 
laser light 151]. 
UVRR and NIR methods are complementary. 
UV light exhibits shallow penetration in tissue 
(20-50 jun), providing the ability to sample 
superficial lesions, such as dysplasia. NIR light 
has a relatively small extinction coefficient 
and hence penetrates deeply into tissues, 
providing the opportunity to sample large 
volumes and probe subsurface details. 
Current Applications of Raman 
Spectroscopy 
The majority of the work on Raman detection 
of malignancy has been for the detection of 
breast, brain, gynaecological and bladder 
cancer and some sarcomas [61-65]. There are 
some data on gastrointestinal cancer. 
Redd ct al. [641 produced Raman spectra of a 
number of normal and malignant colonic tis. 
sue samples in vitro. They demonstrated that 
Raman lines attributable to carotenoids and 
lipids have much greater intensities in adene- 
carcinoma. At an excitation wavelength of 
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514.5 ma carotenoid resonance enhancement 
is achieved. Whereas if near-IR excitation is 
used lipids provide the greater Raman com- 
ponent. They proposed an optical fibre probe 
design to measure the Raman spectra of tissues 
in situ. 
Manoharan et al. (51,66) showed that the 
distinct biochemical differences between nor. 
mal and neoplastic colonic tissues may be 
exploited spectrally using the technique of 
ultraviolet resonance Raman spectroscopy. In 
the histocbernical detection of procancerous 
cells pathologists look for increases in the 
nuclear-to-cytoplasmic ratio. The study evalu- 
ated the use of UVRR to detect nucleic acid 
and protein changes in human colon adenocar- 
cinema and the surrounding normal colonic 
mucosa. The authors were the first to demon- 
strate Raman spectra from biological tissue 
using UV excitation light (239.6 nm). They 
showed that the ratio of nucleic acid to cyto. 
plasmic content in the cells of colonic mucosa 
can be quantitatively determined from the 
intensity ratio of the nucloic acid bands to 
protein bands in the Raman spectra. 
Feld et al. [631 used 830 nm excited CCD 
Raman spectroscopy to collect spectra from 
normal colon and colonic adenocarcinoma. 
Tissue samples from three patients were 
excited with 100 mW of laser power. Spectra 
were obtained with a collection time of 50 s. A 
comparison between the spectra of normal 
colonic mucosa and adenocarcinoma was 
made. Although the spectra were similar, small 
but significant differences were present. These 
were enhanced by producing difference spectra 
between normal and malignant tissue. Peaks 
were observed on the difference spectra at 
1662,1576,1458 and 1340 cm - '. These corre- 
spond to nucleic acid modes, indicating the 
nucleic acid content is higher in adenocarci- 
noma than in normal mucosa. This agrees with 
the histological method of grading malignancy 
by the nucleic acid to cytoplasmic ratio. 
The majority of Raman studies have been 
carried out on excised samples. An unpub. 
lished study by Richards-Kortum et al. (1994), 
described by MahadevanJansen et al. [54], 
showed that variations in Raman spectra 
between fixed and fresh tissues appeared to be 
minimal. Hence measurements in vitro should 
not affect the potential diagnostic capability of 
the spectra obtained. However, if the in vitro 
measurements are to be extrapolated to an in 
vivo tissue geometry, the biopsy specimens 
should be large enough to include all the layers 
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of tissue present in vivo that provide com- 
ponents of the Raman signal. Each tissue type 
will produce a different Raman signal due 
to its own biochemical and physiological 
makeup. Thus, in vitro measurements on thin 
samples of tissue may not provide the whole 
picture. 
A number of authors have worked on the 
detection of metabolites in aqueous solution. 
This may have application in early detection of 
malignancy, as changes in cell biochemistry 
occur before any structural change. Examples 
of metabolites that have potential diagnostic 
significance include citrate in prostatic adeno- 
carcinomas, glycogen in renal cell carcinomas, 
N-acetylaspartate in brain turnours, lactate 
and phospholipid metabolites in carcinomas of 
the prostate, colon and lung [631. Cassanas 
et al. [671 demonstrated that lactic acid 
concentration could be measured, in aqueous 
solution, using Raman spectroscopy. Measur- 
ing lactate concentration in tissue using a 
Raman technique may be a useful diagnostic 
indicator for malignancy. Goetz et al. [681 and 
Berger et al. [691 also measured various 
metabolites using visible and NIR excitation 
Raman, respectively. 
Practical Problems 
Tissue is inhomogenous in composition and 
also highly scattering; the full analysis of 
Raman signals thus requires an understanding 
of tissue optical parameters and photon propa- 
gation in turbid media. Raman signals are 
inherently weak and, in addition, early diag- 
nosis of disease requires detection of tissue 
molecular constituents present in low concen- 
trations. This is accentuated by the fact that 
lasers with high intensity cannot be used to 
observe weak signals from tissues because of 
the potential for sample damage. Thirdly, the 
complex nature of tissue composition results in 
absorption of light throughout the entire 
UV-visible region, and subsequent intense 
fluorescence emission strongly interferes with 
weak Raman signals. 
The major problem associated with Raman- 
fibre probes is that Raman signals are gener. 
ated by the fibres themselves. The signal is 
proportional to the length of the fibre and to 
the excitation light intensity and can have 
magnitudes equal to and sometimes greater 
than that of the sample under study. 
CONCLUSION 
Clinical fluorescence detection of early precan- 
cer is still in its infancy. More and more work is 
concentrating on intrinsic fluorophores within 
the tissue rather than solely relying on the 
characteristic signal of an exogenous fluoro- 
phore. The technique which is expected to hold 
the most promise is the fluorescence lifetime 
imaging of the tissue's natural fluorophores, 
since this should yield most information. 
Elastic scattering spectroscopy is possibly 
the cheapest and most accessible technique, 
but its lack of specificity may restrict its use 
for detecting precancerous lesions. 
Optical coherence tomography has the 
potential to detect subtle structural changes 
within tissue. However, for the early detection 
of premalignancy, the measurement of bio- 
chemical rather than structural abnormalities 
may be necessary. The main potential in OCT 
lies in staging gastrointestinal neoplasms after 
they are discovered using other methods. 
Raman spectroscopy has shown potential for 
the biomedical diagnosis of malignancy in 
localised sites. The most promising gastro- 
intestinal malignancy for Raman detection is 
colon adenocarcinoma, where most work has 
been done. Techniques using ultraviolet, vis- 
ible and near-infrared wavelengths of light 
have shown repeatable differences between 
normal and malignant Raman spectra in vitro. 
However, there arc still a number of technical 
problems to be overcome to enable routine in 
vivo measurements. 
More work is still required to understand 
how the various optical signatures of tissue 
are influenced by the local microenvironment 
and this then needs to be correlated with early 
pathological changes that the precancer 
undergoes. 
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Beyond white light endoscopy - the prospect for endoscopic optical 
biopsy 
C. Fulijames, N. Stonc. D. Bennett, H. Barr 
The most importanifactor in the successful treatment ofcan- 
cer is early detection. 7his will be mom likely to facilitate 
eradication of abnormal cells prior to systemic invasion. 
White light entloscolry hiss been an essential loot in medical 
diagnosisfor a number ofyears. Direct endoscopic inTection 
ofgastrointeminal argaris has rrvolutioniseddiagnoslic tech. 
niques, improving the targeting of biopsies of macroscopic 
morphological abnormalities. Recent technological develop- 
ments are threatening a further m volution enabling the in- 
stantancous and non-invasive diagnosis ofmicroscopic tissue 
ubnoniudifies in vivo. This is made possible by improving the 
level of information that can be obtainedfivm the tissue. As 
well as the nvo-dimensional sujlhce morphology image. 
which the traditional endoscope can vim new techniques en- 
able structure at depth, Le, the Mird-dimension, to be imaged 
in high resolution. Other advances enable the detection of 
biochemical changes in tissue that precede any changes in 
morphology, thus enabling earlier diagnosis of tissue abnor- 
malities. 77sis review details recent advances that have the 
gremem potential, for u%e inpartnership with endoscopy. for 
the diagnosis ofmalignancy and pre-malignancy. 
Ila] I Ga, trocntenal Hepatof 1999ý31: 695-704 
Key words: fluorescence; Raman; speciroscopy 
Introduction 
The identification of many diseases and cancers in the 
gastrointestinal tract is by visual inspection at cn- 
doscopy, the diagnosis being confirmed by pathologi- 
cal analysis after biopsy. By the time a cancer is visi- 
ble to white light cndoscopy, it is often advanced. and 
when morphological pathological changes have oc- 
curred the disease is often invasivc. Yet, almost all can- 
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cers in the gastrointestinal tract start as a subtle invisi- 
ble mucosal change. In order to bring forward the di- 
agnosis, interrogation of the surface changes prior to 
gross morphological transition is vital. There is great 
interest in optical techniques to go beyond our visual 
receptors (eyes) and detect (he earliest transition to dis- 
ease, prior to invasion. This would allow cndoscopic 
minimally invasive destruction of these pre-invasive le- 
sions. 
'Me diagnosis ofdisease states and measurement ofthe 
extent of the disease process is often given by qua] ita- 
tivc analysis of the biochemical changes within the tis- 
sue. For the detection of malignancy. however. tissue is 
removed as biopsy samples and examined histopatho- 
logically, looking for morphological changes rather 
than biochemical changes. There is delay in the diag- 
nosis and the precise area in the tissue of a subtle 
change may not be evident when looked for at a sub- 
sequent endescopy. Therefore. targeted local treatment 
may not be possible. The ideal would be to detect and 
treat at the same endoscopic examination. Non-inva- 
sive, rapid, histochcmical and/or morphological analy- 
sis, potentially used in vivo, is possible using optical 
techniques. Biochemical information is obtained from 
fluorescence. absorption and Raman spectra. whereas 
morphological and structural information, such as nu- 
clear size and density, is obtained from the elastic scat- 
tering properties of the tissue and optical coherence to- 
mography measurements. 
Light with wavelengths from 650 to 950 nm can prop- 
agate several millimetres through ti,. sue, outside of this 
optical window absorption by haemoglobin and water 
predominate and the penetration is limited. Optical 
Spectroscopy involves the excitation of tissue with pho- 
tons and the identification of characteristic spectra. Tis- 
sue spectroscopy can, therefore, be used for the detec- 
tion of ischaernia or inflammation but most interest in 
the technique lies in its ability to detect malignancy 1. 
This has potential benerits for premalignant diseases of 
the gastrointestinal tract, such as Barrett's oesophagus, 
which have significant risks of developing into adcno- 
carcinoma, through the development of high-grade 
dysplasia. At present. surveillance is carried out by tak- 
ing random biopsies according to a rigorous protocol 2. 
Tissue spectroscopy has advantages over more conven- 
tional methods used in histology and pathology in that 
A5-13 
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Table 1. Major techniques for endoscopic optical biopsy (listed according to predominant information that will be elicited). 
Morphology BiGchemicalMorphology Molecular/Biochemical 
Optical-coherence tomography Laser-induced Fluorescence (Autofluor=cncc) Raman 
Elastic scattering Lascr-induccd Fluorescence (Photosensitiser) Resonance Raman 
Multi-photon excitation Infrared bpectroscopy 
it is non-invasive, allows rapid measurement and diag- 
nosis, and guides the targeting of biopsies. The rapidi- 
ty of spectroscopic measurements means that many 
more sites can be investigated than with pinch biop- 
sies, thereby reducing sampling error. Also due to the 
non-invasive nature of spectroscopy multiple measure- 
ments can be taken without bleeding and tissue disrup- 
tion with the potential for seeding abnormal cells. The 
subjective nature and the variation in the interpretation 
of morphological changes, so evident in the interpreta- 
tion of gastrointestinal cancer 3, can be overcome by 
using standard mathematical techniques for interpreta- 
tion of the data 4. T'licre arc a number of spectroscopic 
methods available for the early diagnosis of gastroin- 
testinal malignancy (Table 1). 
Fluorescence Spectroscopy 
Scientific background 
Light radiation absorbed by a molecule causes its ex- 
citation to a higher energy level. The molecule can re- 
turn to its original energy level by emitting light of 
lower energy than the excitation light (longer wave- 
length). This is called fluorescence. The light wave- 
lengths absorbed and emitted by a molecule are called 
the absorption and emission spectra and arc highly 
specific of that species. Analysis of these spectra 
(spectroscopy) can indicate the molecules present. In 
complex biological tissue, there are many confound- 
ing factors related to the absorption, interaction with 
other molecules, distortion of the signal due to scat- 
tering in the tissue -1 and reabsorption by tissue other 
than chromophores (light absorbing molecules). Poli- 
card first studied fluorescence measurement,; for the 
detection of cancer and showed some cancers pro- 
duccd a bright red fluorescence 1. This was later 
shown to be due to prophyrins produced by bacteria in 
necrotic areas of turnours 1. 
The literature can be confusing since various tech- 
niques are used. It is, therefore, important to briefly 
describe some of the terms used. Excitation-emission 
spectroscopy uses multiple colour illumination in se- 
qucncc, the fluorescence spectra being recorded for 
each wavclenýth, resulting in a contour type map. 
Different excitation wavelengths excite different 
chromophores in different ways giving more complex 
patterns with more biochemical information. This 
technique has been used for the diagnosis of brain and 
skin disease but most usefully for the detection of cer- 
vical cancer 'It. The technique of differential nor- 
maliscd fluorescence (DNF) is designed to amplify 
Table Il. Lascr-induced fluorescence for detection of neoplastic change in gastrointestinal tract. Joffe et al. I" used photosensi- 
tiscr fluorescence, all others depended on auto fluorescence. 
Tissue 
Oesophageal canccr/normal 
Barrat'i oesophagus High gradeflow grade dysplasia 
Colonic dysplastic adenomas/normal hyperplastic, 
Colonic neoplastic polypthyperplastic polyp 
Malignant gmaric ulccT/benign ulcer+Gastriti- 
Patients Sensitivity Specificity Reference 
32 100 98 Panjehpour et a]. 1995 
36 100 72 Panjehpour et al. 1996 
57 90 95 Cotbren 611990 
61 96 77 Schomaker 1-' 1992 
16 87.5 Joffe et al. 12 1998 
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small spectral variations and enhance differences be- 
tween normal and neoplastic fissue. " Normalisation 
is carricd out by di%iding the intenNity at each \Au%e- 
length by the integrated area under the spectrum and 
the difference between the normalised spectrum and 
the incan value from a nornialised set of spectra. A 
baselinc value can then be calculated. 
Ratio fluorescence imaging uses two excitation wave- 
lengths: the ratio of the two spectra is used to differ- 
entiate normal and malignant tissue 11. In time domain 
fluorescence spectroscopy, the short-lived back- 
ground fluorescence can be removed during time re- 
solved fluorescence spectroscopy thus enhancing the 
relative fluorescence emissions. This method has been 
very useful for study ing the uptake of photosensitisers 
such as haeniatoporphyrin derivative (HpD) and of 
alumimum phthalocyanine (AISPc) `. Fluorescence 
lifetime imaging (FIANI) can he used to differentiate 
between cndogenous and exogenous tluorophorcs, 
Such measurement% arc independent of the concentra- 
tion of fluorescence molecules (nuorophores) and 
measurement intensim but are sensitive to the mi- 
croen% ironment ". 
The most widely used method is laser-induced fluo- 
rcscence (LIF) spectroscopy. This simply informs us 
of the method of applying light to the tissue " ". A 
monochromatic laser ource illuminates the sample 
tissue, causing fluorescence, which is detected with 
fibre optic bundles and delivered to a spectral 
analyser. Low power laser illumination can induce 
auto fI uoresce nce " ithout causing tissue damage due 
to heating. Autolluorescence has spectral characteris- 
fics, due to endogenows substances in the cells. These 
are molecules such as claslin. collagen. Iryptophan, P- 
carotene, the reduced or oxidised form of nicoti- 
namide adenine dinuelcotide (NADH/NADI) and 
flaN ins. and are kno%k n its fluorophores. The fluores- 
cencc spectra of fla% ins are altered during metabolic 
changes from the oxidised to the reduced state, and 
can he good indicators of' metabolic activity. NADH has a high fluorescence yield and, as an oxidatne 
species, is important in the development of cancer. 
The ratio of NADH to NAI3* has the potential of dif- 
ferentiating norinal and precancerous tissue. 
The use of LIFS to detect autolluorcscence is prefer- 
able to the administration of an exogenous drug for 
routine screening, which is essentially an invasive 
procedure ". However. measurements of exogenous 
fluorophores have been madc and used diagnostically 
in conJunction with intrinsic fluorescence. since tu- 
mour detection potential may be increased with the 
administration oftliese oxogcnous chromophorcs. Ex- 
ogenous chroniophores have been used for in vivo 
measurements of the brain and lung and in vitro mca- 
surements of prostate and bladder ". 
Laser induced autofluorescence can discriminate be- 
tween normal and experimentally induced N-nitro- 
somethyl-benzýlamine pre-nialignant oesophageal tis- 
sue in rats ". It may also be a possible technique for the 
detection of neoplasia in the colon and oesophagus in 
patients ' 2". A distinctive laser-induced autofluores- 
cence has been reported in Barrett's adenocarchmina ". 
In Vivo results have also been publkhed for tumour flu- 
orescence detection in the urinary bladder and lungs. 
Instead of depending entirely on autolluorescence. ex- 
Fiw 1.11) ... t in"I ý11 
a'-InIcJ oc, ophagu, demon't'al'ing ; .......... lm', ýý ý, l prow- 
I. ml, hmn IX in epillicli 1, colllpý., d -11, ýn&. 1\, j; 
stroma and adjacent cclis. Fluorescence diagnosis is I-sible. High 
flumscenct: i% demonstrated by bright areas in uplwr picture conre, 
TK)nding to am-as of dysplasia shown in ihe I-ci plionnnic-graph. 
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ogcnous fluorophores have been administered in order 
to aclicive targeting of neoplastic tissue. These cxoge- 
nous fluorescence agents-often have a photodynamic 
action thus limiting the administered dose. The heme 
precursor 8-amino levulinic acid (ALA) has been ad- 
ministered topically, orally or intravenously for the 
production of the photoscnsidser protoporphyrin IX ". 
11is, selectively accumulates in dyspWtic mucosa 
(Fig. 1) and can thus be used both for diagnosis and 
photodynarnic therapy. Other studies have confirmed 
the usefulness of administering a low dose of the pho- 
toscnsitiscr Photofrin 112'". It is retained in tumours to 
a greater extent than in normal tissue with a peak dif- 
fcrcntial seen between 48 and 96 hours. This porphyrin 
fluoresces with a characteristic bimodal distribution 
with peaks at 630 and 690 mn. 
Clinical Applications 
General clinical arperience 
Laser-induccd fluorescence spectroscopy has been 
used successfully in vivo for the characterisation of 
malignant tissue 24. Ramanujam ct al. 2-12' performed 
a clinical trial using LIFS for the diagnosis of cervi- 
cal intraepithelial ncoplasia, in 115 sites in 28 pa- 
ticnts, using a nitrogen laser at 337 nm. Abnormal tis- 
sue was diagnosed with a sensitivity of 92% and 
specificity of 90% and ClN was diagnosed with a 
sensitivity of 87% and specificity of 73%. Lefell and 
Stetz 27 used a 325 nm excitation wavelength. from a 
hclium-cadmiurn laser, to study photoaging of the 
skin. A correlation was found which is believed to be 
due to differences in the collagen and clastin content. 
It was also shown that the characteristic tissue fluo- 
rcsCence spectra arc unrelated to age, pigmentation or 
skin thickness. 
Lohmann Ct al. 28 has used LIFS for the diagnosis of 
melanoma in the skin. The ratio of maximum fluores- 
ccnce outside the lesion to the minimum intensity 
within the lesion can be used to distinguish naevi and 
mclanomas, but melanomas and dysplastic naevi can- 
not be distinguished. Stercriborg ct al 1111 have done 
similar work on in vivo autofluoresccnce for the de- 
tection of skin cancer. Results. however, were not 
found to be sufficiently reliable to be used for diagno- 
sis, either in theshape of the spectra or the spatial dis- 
tribution of the fluorescence intensity. Ebert et al. 30 
carried out a study on fluorescence intensities of le- 
sions and healthy skin by recording images rather than 
excitance. However, it was found that fluorescence 
images did not reveal any fluorescence pattem spccif- 
ic to the malignancy of the lesion. 
Sartori et al. 31, Kitrell et al. 32 and Richards-Kortum ct 
al. " have used LIrS for diagnosis with arterial tissue. 
opDI 
The diagnosis of arterial plaque is important for laser 
angioplasty. Papazoglou ct al. 24 and Dcckelbaum ct 
al. 11 have tested LIFS as a guidance tool for laser ab- 
lation. Perk et al. 11 have used LIFS for the detection 
of fibrotic cndocardiurn and myocardium and study of 
conduction tissue in arrhythmia. Alfano et al. used 
LIFS for the diagnosis of cancer in breast and lung tis- 
sues 3`31. Lam ct al. used a novel bronchoscope to de- 
tect dysplasia and carcinoma in situ in the lung ". A 
total of 53 patients with known or suspected carcino- 
ma and 41 volunteers were studied. Spccificity was 
found to be 94% and sensitivity 72.5%. 
Docchio 11 covers retinal vessel imaging and other es- 
tablished uses of fluorescence in ophthalmology. 
Zuclich ct al. 42 studied the human eyes lcns with a 
view to the diagnosis of cataracts and age-related 
changes. The onset of diabetes mellitus has been in- 
vestigated by Eppstein and Bur-ell 41. Piston has used 
fluorescence spectroscopy to monitor the metabolic 
state of the cornea ". 
Andersson-Engels et al. 0 and Bottiroli ct al. 46 cite the 
presumed origin of the spectral signatures that corre- 
late with pathologies such as cancer to be the concen- 
tmtion of NADH, or the redox state of flavin co-fac- 
lots. Schomaker ct al. " and Ramanujam et al. " sug- 
gest that some of the changes in the fluorescence arc 
due to morphological changes. 
Fluorescence diagnostics cannot replace biopsies and 
histopathology but can aid the endoscopist in the se- 
Icction of biopsy sites. In addition to the classification 
of tissue as either benign or malignant in patient,; with 
cancer, the aim of LIF is to aid the detection of endo- 
scopically 'invisible' premalignant pathology, such as 
dysplasia ". 
Upper gastrointestinal endoscopy 
Lasers are ideal as endoscopic light sources to irradi- 
atc tissue since they can be passed down thin optical 
fibres. The spectra can also be collected by a similar 
or the same fibre. Usually, lascr-induced fluorescence 
spectra are measured with a probe in contact with the 
tissue or as an image of the surface. Initially, Panjc- 
pour et al. '-' showed that LIFS has great potential dif- 
ferentiating benign and malignant disease and subsc- 
quently for the detection of high-grade dysplasia in 
columnar-lined (Barrett's) ocsophagus. They used the 
DNF technique, with excitation at 410 nm. Normal 
and malignant tissues were found to have significant 
spectral differences at 480 and 660 tim, therefore, 
DNF4so and DNF6w were used to develop a discrimi- 
natory model. Using this technique, seven patients 
with high-grade dysplasia were successfully identi- 
fied. Tberc may be a problem in detecting focal areas 
of high-grade dysplasia in areas . of low-grade dyspla- 
sia. This is not a problem confined to fluorescent tech. 
A5-16 
C. l. 
niques. It is clearly a limitation of spectral analysis 
over an imaging method. Ideally, one would want to 
have acolour image with areas ofdysplasia highlight- 
ed in colour. Thus allowing clear identification and 
targeted biopsy or destruction. Tbc next stage must be 
direct incorporation into an endoscope with real-time 
imaging. 
A nitrogen laser was used to pump a dye laser with an 
output at 405 nm. The radiation passed through a 600 
jim core diameter quartz optical fibre to the tissue. 
Tissue fluorescence was collected by the same fibre 
and transmitted to a charge coupled device (CCD) 
connected to a polychromator. Broad tissue autofluo- 
rcscence was seen at 500 nm due to cndogcnous tissue 
fluorophorcs and the porphyrin fluorescence at 630 
and 690 nm. In malignant tissue, the porphyrin fluo- 
rescence is stronger and the auto-fluorescence is 
weaker. This has been exploited to examine the fluo- 
rescencc spectral characteristics of normal mucosa. 
metaplastic and dysplastic: columnar-lined (Barrctt's) 
oesophagus and invasive carcinoma 51. Fluorescence 
ratios were calculated as the quotient of the Photofrin 
fluorescence at 630 nm divided by the autofluorcs- 
cence at 500 nm. Normal ocsophageal mucosa had a 
ratio of 0.1, gastric mucosa 0.16, columnar-lined oe- 
sophagus 0.2, severe dysplasia 0.79, and adenocarci- 
noma 0.78. The important finding was that dysplasia 
was different from metaplasia. It is interesting to note 
that dysplasia and invasive cancer demonstrate similar 
fluorescence ratios, reflecting the morphological dis- 
tinction that both appear as cancer cytologically. The 
only difference is invasion beyond the mucosa. 
Ibc problem of squamous dysplasia in the upper 
acrodigestive tract is increasing with surveillance of 
patients who have had previous therapy for cancer. 
Monnicr ct al. " used the detection of abnormal fluo- 
rcscence signals for the diagnosis of superficial early 
mucosal cancers in endoscopically accessible areas. 
The early detection has allowed targeted endoscopic 
therapy avoiding the profound morbidity and mortali- 
ty of radical surgical excision. 
Early malignant ulceration of the stomach is difficult 
to di. %tingui%h from gastritis and benign disease. Chen 
et al. 11 evaluated the use of laser-induced autofluorcs- 
cence spectroscopy for the detection of prcmalignant 
lesions of the human stomach in vivo and in vitro us- 
ing a pulsed nitrogen laser. Uscr-induced fluores- 
cence detection can be improved by using an orally 
administered photosensitiser (encapsulated hypcrflav 
0.1-0.15 mg1kg body weight). Early gastric cancer and 
dysplasia was found in 87.5% of patients using endo- 
scopic laser-induced fluorescence followed by target- 
ed biopsy, compared with only 64.8% of patients hav- 
ing conventional endoscopy and biopsy 1. Macroscopý 
ically invisible lesions were found. 
W) 
Colonoscopy 
The increasing recognition of flat adcnomas and the 
need to differentiate hypcrpla. %tic from dyspla%tic adc- 
nomatous polyps with their potential for malignant 
change. means that a real-time imaging device is ur- 
gently required. Marchc. %ini' measured the emission 
spectra of neoplastic and non-neoplastic colonic mu- 
cosa with fluorescence spectroscopy in an attempt to 
evaluate the possibility of differentiating malignancy 
from prcmalignancy and neoplastic from non-neoplas- 
tic tissue in vitro. Adenomatous tissue and non-neo- 
plastic mucosa could be discriminated with a speci- 
ficity of 93.2% and a sensitivity of 88.2%. Similarly. 
Kapadia ct al. 2055 used LIF with a helium-cadmium 
laser. at 325 nm. to difrcrcntiate adcnomatous polyp,; 
from normal human colonic mucosa and hypcrplastic 
polyps in vitro. Stcpwisc multivariatc linear regres- 
sion analysis was used to create a model comprising 
35 rcsected adenomatous polyps and 35 normal hu- 
man colonic mucosa specimens. 7ben 34 normal spec- 
imens, 16 adcnomatous polyps and 16 hypcrplastic 
polyps were classified with an accuracy. respectively. 
of 100%. 100% and 94%. indicating LIF to be a use- 
ful diagnostic tool for differentiating between normal 
and pre-canccrous tissue of the gastrointestinal tract. 
Richards-Korturn et al. -1 used fluorescence spec- 
troscopy for the diagnosis of colonic adenoma. Fluo- 
rcsccnce excitation-cmission matrices were used to 
identify the optimal excitation regions for differenti- 
ating normal and pathological tissue. % 3'. The cxcita- 
tion wavelength of 370 nm was shown to be optimal 
for in vitro discrimination of adenomas from normal 
tissue, but 330 and 430 nm can also be used. Romer 
ct al. 58 used argon ion laser excitation of frozen see- 
tions of normal colonic mucosa and colonic adcno- 
mas and compared the tissue fluorescence %ith 
staincd sections (H&E. Movat pentachromc. muci- 
carmine and oil red 0). 11is was to identify the fluo- 
rophores or structures responsible for the LIF cmis- 
sion. Fluorescence in normal mucosa correlated with 
connective tissue fibres, principally collagen. Inter- 
estingly. cytoplasmic fluorescence increased with in- 
creasing grade of cpithelial dysplasia. Yukshc ct al. 
used LIF with an excitation at 325 or 337 nm for in 
vitro diagnosis of colonic adenocarcinoma and 
showed differcncc, % between carcinoma and normal 
tissue 31. 
Cothren et al. 10 used a nitrogen pumped dye laser at 
370 nm in 3 nsec at 20 Hz to examine 67 sites in 20 
patients for the diagnosis of colon cancer during 
colonoscopy. Emitted tissue fluorescence is only col- 
lected from the surface area directly illuminated. LIF 
spectra were collected from 31 adenomas. 4 hyper- 
plastic polyps and 32 samples of normal colonic mu- 
cosa. A 2D scatterplot of the fluorescence intensities 
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at 460 against 680 nm was used to distinguish prerna- 
lignant colonic adenomas from normal mucosa and 
hyperplastic polyps with a sensitivity of 100% and 
specificity of 97%. Fluorescent emission intensity is 
consistently lower in adenorna than in normal tissue, 
which may be due to levels of connective tissue. In 
1993, Cothren et al. 11 collected LIF spectra from the 
rectal mucosa of 16 patients with a history of previous 
adenomatous polyp in the last 18 months, and 16 age- 
and gender-matchcd patients with no similar history. 
Increased fluorescence was found at 680 nm for the 
polyp formers. The spectra differed only by a small ex- 
tent. Therefore, LIFS cannot be used yet to predict the 
patients at risk of developing colorectal neoplasia. 
Schomaker et al . 48 used a nitrogen laser at 337 nm 
in 
vivo and in vitro to examine 91 polyps and 86 normal 
colon tissue sites in 61 patients for the diagnosis of 
colon cancer. with a sensitivity of 86% and specificity 
or 77% for the separation of neoplastic and hypcrplas- 
tic polyps using multivariate linear regression analy- 
sis. Neoplastic tissue and non-neoplastic tissue could 
be differentiated with a sensitivity of 80% and a speci- 
ficity of 92%. In a similar study 112, looking at the 
changes in fluorescence post mortent, they showed 
that in vivo and in vitro fluorescence emissions are 
significantly different for adenomatous polyps, there- 
fore. LIF spectra should be acquired in vivo. 
Multi-photon excitation microscopy 
Scientific background 
TWo-photon excitation microscopy has potential as an 
imaging too] for in vivo examination of deep tissue 
structure at a subcellular level 63. Penetration depth 
can be optimised by using a near infrared excitation 
source. Two-pboton absorption occurs at the focal 
point enabling optical sectioning to be used. Multi- 
photon excitation microscopy offers advantages over 
fluorescence imaging in highly scattering tissues. The 
principle behind the technique is the simultaneous ab- 
sorption of two photons, which induce an electronic 
transition. Fluorophorcs generally have two photon 
absorption peaks at approximately two times their 
onc-photon absorption wavelengths. Two-photon ab- 
sorption can induce a fluorescence emission at much 
shorter wavelengths. It was first developed by Denk ct 
at. for laser scanning microscopy and for the detection 
or fluorescence imaging in 1990 61. 
Clinical studies 
Multi-photon excitation microscopy has been used to 
image human skin autofluorcscence in vivo, from the 
surface to a depth of about 100 microns 63. Results 
show the primary source of autoiluorescence to be 
N,, k-pý qx., W b ry 
NAD(P)H with 730 nm excitation. It has also been 
used to studyNAD(P)II metabolic imaging ofacomea 
in vivo ". With the use of ultraviolet light to excite 
chromophorcs, it has been observed that cell viability 
is compromised and considerable photobleaching oc- 
curs. However, this technique minimises the damaging 
effects of phototoxicity to the cells in the focal slice, 
rather than all the cells in the optical path. The two- 
photon scanning microscope, described by So ct al. us- 
es a femto second Ti-Sapphire laser at 730 nm 11-1. 
Optical coherence tomography 
Endoscopy is limited as it only visualises the superfi- 
cial mucosal layer at low magnification. Magnifica- 
tion endoscopy enables greater detail to be seen but 
only observes the mucosal surface 611. Endoscopic ul- 
trasound allows evaluation of deeper tissue structure 
and is, therefore, used in the staging ofcanccr 11, how- 
ever, the resolution is insufficient for the detection of 
subtle changes in the mucosa and sub-mucosa. Opti- 
cal coherence tomography (OCT) offers a solution for 
imaging the superficial layers and detecting early in- 
vasion into the submucosa. 
Scientific background 
OCT is a technique for high resolution, cross-section- 
al tomographic imaging, giving morphological infor- 
mation on the tissue under investigation. OCT is sim- 
ilar to B-scan ultrasound except that reflected infrared 
light from tissue structures is measured as a function 
of depth rather than acoustic backscattering. In non- 
transparent tissues, optical scattering and attenuation 
make OCT more challenging, the use of the near in- 
frared benefits from the reduced scattering at these 
wavelengths. OC`r has the advantages of being com- 
pact and easily portable. Contact is not required dur- 
ing imaging, it can be performed in air without an in- 
tervening transducing media such as required for ul- 
trasound. 
The light for OCT comes from a short coherence 
length monochromatic source. It is split between two 
fibres, one of which illuminates the tissue to be stud- 
ied and the other illuminates a miffor. On rccombina- 
tion of the signals from the tissue and the miffor, con- 
structive interference is achieved when the path 
lengths match within the coherence length of the 
light. The miffor can be displaced thus changing the 
measurement depth in the sample. The depth resolu- 
tion depends on the light sources used. 
Clinical applications 
OCr was first used for imaging the transparent struc- 
turcs in the eye. More recently, it has been used for 
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the early detection of glaucoma and to diagnose rcti- 
nal macular disimsc with 10 jim resolution 69-71. OCT 
has also been applied to the imaging of skin and blood 
Vessels 1173. 
Teamey et al. carried out a study on OCT for in situ 
imaging of the ga. %trointcstinal microstructure. Nor- 
mal and diseased tissues were measured and com- 
pared with results from histology. The different tissue 
layer% - mucosa. submucosa and muscularis - were 
identified using the technique ". 7be resolution of tis- 
suc structure down to 10 to 20 gm has the potential to 
improve the diagnostic limits of cndoscopy. 'Mis is 
essential for the early staging of disease in the mucosa 
or sub-mucosa. Improvement in the acquisition times 
is required prior to clinical use. This may be achiev- 
able by using higher power light sources. A further 
study of the oesophagus was able to identify the mi- 
croscopic structure of the mucosa and sub-mucosa, 
with crypts, blood vessels and ocsophageal glands be- 
ing clearly identifiable. OCT has the potential for the 
early detection and precise staging of small lesions ". 
As yet, OCT cannot resolve cellular and subcellular 
details. nereforc, mucosal dysplasia is only de- 
tectable once it has resulted in a gross morphological 
change, such as increase in surface thickness. 
Raman spectroscopy 
Scientific background 
Raman spectroscopy is an inelastic scattering tech- 
nique. It exploits the frequency shift, which occurs in 
the excitation light due to the excitation of vibrational 
and rotational states in illuminated molecules. The 
photons in the incident light beam undergo inelastic 
collisions with molecules, causing an exchange of en- 
crgy. Thus the wavelength of the photon is subtly 
changed. Due to the conservation of energy, the encr- 
gy gained or lost by the photon equals the energy 
change in the molecule and, therefore. molecular vi- 
brations can be probed. The vibrational spectrum of a 
molecule reflects the arrangement of atomic nuclei 
and chemical bonds in the molecule. A precise mole- 
cular fingerprint is obtained. 
Tbe technique involves irradiating a s=ple of tissue 
with a monochromatic laser beam. The scattered light 
is collected and analysed for intensity and wave- 
length. The Raman effect is very weak. typically 10-9 
to 106 of the enormous elastic (Rayleigh) scattered 
background. The interaction between the photon and 
the molecule is very fast (of the order of picosec- 
onds). It should be regarded as a perturbation rather 
than an absorption reaction. In comparison. the time 
scale of absorption and fluorescence emission by a 
molecule is of the order of 10 ns. 
The Raman shift is defined as the energy difference 
between the incoming and scattered photons. The zc- 
TO point is set at the energy of the excitation photon. 
A larger shift indicates that more energy is required to 
bring about a vibrational motion. such as a bending or 
stretching motion of the molecule. The position of the 
Raman peaks is independent of the wavelength of cx- 
citation. Raman shift frequency is independent of the 
exciting frequency used. This means that the energy 
shift is constant for a particular molecular species. 
ne units of energy used are displayed in wave num- 
bcrs (1/k cm 1). A very intense peak indicates that the 
corresponding vibrational state or the chemical bond 
or molecule is highly Raman active or more likely to 
be perturbed by incident photons. 
When the energy of the excitation photon approaches 
that required to reach the higher electron state of a 
chromophore, the intensity of the Raman scattering 
increases greatly compared with normal Raman scat- 
tering conditions. This is called pre-rcsonance Ra- 
man. Once the excitntion energy is sufficient to pro- 
mote the chromophore into the higher electron energy 
state, absorption of a photon can occur. Following the 
almost instantaneous re-cmission of a %ccand photon, 
Resonance Raman (RR) can or-cur. This phenomenon 
produces an even greater Raman scattering intensity 
arising from pre-rcsonance conditions. These reso- 
nance techniques enable the vibrational spectra of in- 
dividual chromophores to be probed in the midst of 
the myriad of others that arc found in biological tis- 
sues. However, it must be noted that high energy pho- 
tons are required to induce the Resonance Raman. 
These can have potentially damaging cffccL-. on bio- 
logical tissue. 
One of the major problems encountered in the Raman 
spectroscopy of biological tissues is that of fluores- 
cence. A fairly recent development has been the use of 
Near Infrared (NIR) laser excitation and dispersive 
spectrometers to allow rapid detection of spectra with 
low background fluorescence. NIR radiation does not 
generally induce electronic absorption so fluores- 
cence is weak relative to the Raman signal. Holo- 
graphic notch filters are used to filter the elastically 
scattercd (Rayleigh) light from the signal, combined 
with a single monochromator increases the output of 
the system compared with the triple monochromator 
used previously. The development of CCDs and diode 
lasers has enabled the development of portable NIR 
systems with short integration times 111". 
Pre-clinical applications 
Most biological molecules are Raman active with their 
own characteristic fingcrprinL Proteins, nuclcic acids, 
and cell membranes, single cells, cell cultures and tis- 
sues can all be studicd. Most data on fissue Raman spcc- 
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troscopy are in a pre-clinical stage. Raman spectroscopy 
has been used in the characterisation ofbrain. sarcomas, 
breast. colon, bladder and-ccrvical cancers '". In the 
gastrointestinal tract, spectral analysis of colonic can- 
ccr and surrounding normal colon has demonstrated 
differences 71. Tbe Raman spectra were used (with ul- 
traviolet excitation) to quantitatively measure the nu- 
c1cie acid bands and cytoplasmic proteins. 7beir ratio 
was used to distinguish cancer from adjacent normal 
tissue. This allows a good comparison with the histo- 
logical methods of identifying malignant cells by nu- 
clear enlargement and staining. Raman spectroscopy 
has the potential for approaching the gold standard of 
histological assessment 79. 
L:. - Z' u; - - -,;. - j. -- Z--- -, Fig. 2. Raman spectra of tesocted oesophageal mucosal tissue from 
one patient. Pathological diagnosis was adenocarcinoma (A). spe- 
calised Intestinal metaplasia (D), and normal squamous epithelium 
(N). A Rcnishaw Raman microspectromcicr was used to acquire 
the ýpcctra with 633 nm excitation laser light. 
Raman spectroscopy of columnar lined ocsophagus 
may offer the opportunity to distinguish inflamma- 
tion, mctaplasia, dysplasia and cancer. Spectra have 
been collcctcd (Fig. 2), but extensive work is required 
to develop this into a clinically useful model. 
Elastic scattering spectroscopy 
Scientiric background 
Light photons are most likely to interact with tissue by 
elastic scattering and absorption, therefore, the signals 
arc strong and can be acquired rapidly. The mie theory 
states that light scattering is dependent on the wave- 
length of the incident light. with greater scattering oc- 
curring in photons of a similar wavelength to the size 
of the scattering particles (320-900 nm). The elastic 
scattering spectra are a representation of tissue mor- 
phology. The scattered signal varies depending on the 
sizes and shapes of the cell nuclei, cell crowding and 
shape. It provides similar information to the morpho- 
logical analysis used in conventional histopathology, 
but can be used in vivo. The elastic scattering signal is 
sensitive to the illuminating wavelength. 
Clinical studies 
Elastic Scattering Spectroscopy has been used on the 
skin, eyes, bladder, prostate and gastrointestinal tract. 
Mourant et al. *1 " tested Elastic Scattering Spec- 
troscopy for the diagnosis of cancer in the gastroin- 
testinal tract. A total of 60 sites in the colon and rectum 
of 16 patients were investigated and a spectral metric 
was developed, which was found to have a sensitivity 
of 100% and a specificity of 98%. Samples were taken 
from the lower gastrointestinal tract of a further 32 pa- 
ticnts and from the stomach of 17 patients. The data 
suggested that elastic scattering spectroscopy was a 
promising tool for the detection of dysplasia. 
Conclusions 
Although the technology remains immature, the 
prospects for realistic optical diagnosis are clearly ap- 
parent. Ibc advantages of real-time pathological, mor- 
phological, biochemical and molecular data on a sam- 
ple of tissue is tantalising and exciting tremendous cf- 
fort and interest. The requirements for a clinical in- 
strument are demanding and set physics, optical engi- 
necring and medical instrumentation hard criteria. En- 
doscopic and histopathological diagnosis will not be a 
subjective opinion, but performed using optical instru- 
ments, mathematical algorithms and neural networks, 
leading to greater repeatability of results. 
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Abstract 
Photodynamic therapy (PDT) is a novel technique for local endoscopic treatment of gastrointestinal neoplasia. Current photosemitisers 
for PDT may cause prolonged skin phototoxicity. 5-Aminolaevuliaic acid (ALA), a precursor of the photoscrisitiser protoporphyrin IX 
(PpIX), is more acceptable because of its short half-fife and preferential accumulation in mucosa and mucosal tumour. We have treated 12 
patients, median age 73 years (range 55-88) with ocsophageal adcriocarcinorna arising from Barrett's metaplasia (two carcinomas-in-situ, 
grade 0; 10 carcinomas, grade I-UA based on endoluminal ultrasound in two and CT scanning in 10 patients). ALA (60 and 75 mg/kg body 
weight) was given orally in two or five equally divided doses. The PpTX distribution in stomach. normal oesophagus, Barrett's mucos'a and 
carcinoma was measured by quantitative fluorescence photometry. PDT was performed using laser light (630 nm) delivered via a cylindrical 
diffuser 4-6 h after the first dose of ALA. The patients received one to four sessions of PDT. PpIX accumulation in the mucosa was two to 
throe times that in the lamina propria. The differential distribution between carcinomatous and normal oesophageal mucosa was less marked 
(carcinoma: normal mucosa ratio - 1.4). Higher doses ofALA increased PpIX accumulation in all tissues but did not increase the differential 
PpIX distribution between turnout and normal ocsophageal mucosa. After PDT using ALA (ALA/PDT), all mucosashowed superficial 
white necrotic changes and the histology confirmed fibrinoid necrosis. One patient with carcinoma-in-situ had the tumour eradicated after one 
treatment with no recurrence at 28 months. Another patient with a smal ITI tumour required four ALA / PDT treatments. and died of other 
disease after 36 months. Them was no evidence of recurrence. The tumour bulk in the other carcinomas was not si gni fi cantly reduced. A LA / 
PDT has a potential for the eradication of small turnours but careful patient selection with endoltiminal ultrasound is needed when using 
ALA/PDT to treat oesophageal cancer. C 1999 Elsevier Science S. A. All rights reserved. 
Kei-ords. - Photodynainic therapy; Laser, P"oporphyrin IX*. Aminolaevulinic acid; OesophaScal cancer Adenocaminoma and floorcscence distribution 
1. Introduction 
Oesophageal adenocarcinoma carries a poor prognosis. 
Oesophagcctomy, the only potentially curative treatment, has 
an operative mortality of 5-10% 11,21. Recent data indicate 
that the incidence of this disease and of cancer of the gastric 
cardia is rising more rapidly than that of any other cancer 
[3.4]. This may be a reflection of the increase in the occur- 
rence of BarreWs metaplasia of the oesophagus. Many 
patients presenting with frank oesophageal adenocarcinoma 
are too elderly and frail for surgery. Treatment options are 
further limited by this tumoues relative insensitivity to 
*Corresponding author. Tel.: +44-1452-394679; fax: +44-1452. 
394913, e-mail: Prot. Baff@themail. co. uk 
radiotherapy. The insertion of an oesophageal endoprosthesis 
and thermal laser ablation are the most widely used pailiativc 
therapies. 
Photodynamic therapy (PDT) is a relatively new form of 
cancer treatment. It involves the administration of a MUM- 
sensitising agent and subsequent local activation of tl: __ in the tumour by application of light of appropriate 
Icngth. PDT has been shown to cure some superficial malie- 
nancies 15.10]. For gastrointestinal cancer, it off-- - 
possibility of local destruction of tumour cells. Also run 
thickness damage experimentally induced in the Tat intestine 
didnotreducc the colonicbursting pressure. Healingoccurrcd 
by regeneration and scarring was less of a problem than fol- 
lowing thermal treatment [6]. A recent expcrimcntal study 
1011-1344/99/$- see front matter 01999 Elsevier Science SA. All nghts reserved. 
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in the rat stomach has shown that PDT using 5-aminolaevu- 
linic acid (ALA/PDT) selectively causes mucosal necrosis 
without causing stenosis or perforation. Therefore it offers a 
promising technique for circumferential mucosal ablation 
[7). 
One of the main disadvantages ofPDT using conventional 
photosensitiscrs is generalised cutaneous photosensitivity. 
This can persist for 6-8 weeks, during which time the patient 
must avoid direct sunlight and strong artificial light [8]. A 
new technique using thehaern precursorALA largelyavoids 
this problem. Administration ofexogenous ALA induces the 
accumulation of protoporphyrin IX (PpIX) in a number of 
tissues, particularly epithelial surfaces 19]. PpIX, the irrune- 
diate metabolic precursor of haem, is an effective photosen- 
sitiser. Cutaneous photosensitisation is mild and completely 
resolved in 24-48 h[ 11-131 because the biological half-life 
of PpIX is short. 
We report the results of a study on the efficacy of ALA/ 
PDT in 12 patients with frank oesophagcal adenocarcinoma 
(stage ]AIA. n- 10) or carcinoma-in-situ (stage 0, n- 2) 
[ 141 associated with Barrett's metaplasia [ 15,16]. 
2. Patients and methods 
Twelve patients (seven men and five women) of median 
age 73 years (range 5548) with oesophagcal adenocarci- 
norna arising from Barrett's metaplasia were treated. They 
were either considered unfit for (n=7), or had refused 
(n-5), surgery. Informed consent from the patients and 
approval from the local ethical committees were obtained. 
Endoscopic staging was performed to assess the visual 
appearance and where possible endoscopic ultrasound was 
used. All patients underwent prclirninary endoscopicmultiple 
random biopsy; a standard protocol was not always used. 
Patients treated in later years (eight patients) were biopsied 
according to a protocol. Biopsy ofthe four quadrants ofthe 
ocsophagus at 2 cm intervals of the entire Barrett's segment 
was performed with multiple biopsy and brushing of suspi- 
cious areas. In two patients. there was only a minor abnor- 
mality in an area of BarTetts oesophagus, diagnosed as 
carrinoma-in-situ after biopsy. In six patients, the tumour 
was small, occupying I cm or less of the surface of the 
columnar lined oesophagus; two of these patients had endo- 
scopic ultrasound that demonstrated a T2 NO tumour in one 
andaTI NO lesion in the other. In the remaining four patients, 
the tumour was larger than I cm and nodular. All patients 
were free oflymph-node involvement and distant metastases 
on a combination of endoscopic ultrasound, chest X-ray and 
Cr scan of thorax and abdomen. None of the frank carcino- 
mas had invaded adjacent structures. None of the 12 patients 
had dysphagia at the time of treatment. The pathology was 
reviewedbyan experienced gastrointestinal pathologistusing 
the criteria of invasion for diagnosis ofcancer. There may be 
a considerable difference between Western pathological 
assessment and that of the Japanese 121 ]. 
ALA was dissolved in lemonade or fruit juice and given 
orally 4-6 hours before laser-light exposure. We believe that 
the uptake of ALA was predominantly systeinic although 
there may be a minimal local absorption. The contact time 
with the oesophageal mucosa is minimal and the mucosa is 
covered with mucus. ALA doses of 60 or 75 mg/kg body 
weight were given in two or five equally divided hourly doses. 
The patients were then kept in a darkened room for 24 h. 
Laser sources were an argon-pumped dye laser (Spectra- 
physics) or Laserscope KT? pumped dye laser system (600 
Series Dye Module. Laserscope (UK) Ltd. ). both emitting 
red light at 630 nm. The laser fibres were inserted into a 
cylindrical diffuser (length 1,2 or 3 cm), which was placed 
intraluminally and the area of the tumour and surrounding 
Barrett's oesophagus irradiated. The power density of the 
laser ranged from 90 to 150 mW/cm' and the total energy 
levels were 100-200 j/CM2 . Each patient received between 
one and four treatments (Table I). The patients were treated 
at cndoscopy under sedation with Midazolam. Repeat endos- 
copy and biopsy was carried out one to seven days after 
Table I 
Details of Ihe patient's age, tumoLL4 tmaumut dosimeuy and wtcom 
Patient Age Tumourtype/size Remn for not having surgery PDT ALA dose Light dose Oulcom 
(. Z/ks) (J/CM2) 
1 74 carcinorna-in-sitis ischaternic heart disease 1 75 100 complete eradication 28 months follow-up 
2 63 carcinoma-in-situ refusal 3 75 150 superficial necrosis 
3 55 >I cm refusal 3 60 70 superficial necrosis 
4 88 >I cm general frailty 2 60 100 superficiall necrosis 
5 62 >I cm refusal 4 60 70 supcificial necrosis 
6 75 >I cm general frailty 1 75 150 superficial necrosis 
7 80 <1 cm Senemlfrailty/cardiomspvatorydisme 4 60 150 turn(Alt eradicated, 36 mnths follow-up 
8 90 <1 cin general frailty 1 60 150 superficial necrosis 
9 70 <I cm respiratory disease 2 60 150 superficial necrosis 
10 73 <IC. respiratory disease 1 
60 150 superficial necrosis 
11 70 <1 cm refusal 1 60 150 superficial necrosis 
12 68 <I can refusal 2 60 150 superficial necrosis 
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PpIX fluorescence in tissue after oral administration of 60 m&1kS and 73 mg/kZ of 5-arnincilaevuhnic add 
nuorcsoeme intensity (unit/putel) 
ALA doage Nornial ocsophagus (S. D. ) Ocsophageal carrinarria (S. D. ) Bantu's ocsophagus (S. D. ) Nomal stomch (S. D. ) 
muco&s Lmnuna progirta mucciaii, Stronu Mý lAmina propina Mwm Lainim propna 
75 mglkg 16027 22271 11482 12205 5545 16535 4301 
(2674) (5623) (7863) (2433) (1644) 
60 mg/kg 8255 11112 3002 9971 3118 6500 3257 
(4440) (6365) (1531) (985) (3101) (667) 
treatment and at monthly intervals. Assessment of the treat- 
ment outcorne was based on endoscopic and histological find- 
ings. All patients were treated with a proton pump inhibitor 
(20 mg lid. of omeprazole) after treatment. 
PpIX distribution was studied in biopsies of turnour, nor- 
=1 and Barrett's oesophagus and stomach. Samples were 
taken immediately prior to treatment. snap-frozen in McIting 
iso-pcntane, and stored under liquid nitrogen until required. 
Frozen sections 10 lLm thick (at least five per biopsy) were 
cut using a cryostat and allowed to dry for 30 min in the dark 
at room temperature. The sections were then examined using 
an epifluoresccncc microscope fitted with a cryogenic charge- 
coupled device camera (Astrocarri N3200, Cambridge) and 
an XF46 fluorescence filter block (Omega Optical, VT. 
USA). Illumination was provided by aI mW belium-neon 
laser, and fluorescence was collected between 665 and 690 
nm. AU images were acquired over 5 min, using aX 40/1.40 
oil-immersion fluorescence objective. Image processing was 
performed using the Imager 2 software suite (Astrocarr4 
Cambridge). Sections were stained with haernatoxylin and 
cosin, and re-photographed using a conventional 35 min 
microscope camera. enabling correlation of the fluorescence 
distribution to histological structure. 7 issue autofluorescence 
was measured in similar prepared sections from patients not 
pre-treated with ALA. The levels of PpIX fluorescence were 
calculated after correction for autofluorescence. 
Patient% often required repeated therapy in an attempt to 
eradicate malignant tissue. We found that after two to three 
weeks the necrosis in the oesophagus had separated and fur- 
ther treatment was possible. The timing was empirical and 
there are few data to indicate the best time for repeat therapy. 
The same drug-4ight regimen was used. 
3. Results 
3.1. Fluorescence distribution 
PpIX fluorescence was higher in the tissues ofpatients who 
were given 75 mg/kg of ALA (in five divided doses) than 
in those receiving 60 kg/mg in two divided doses (Table 2). 
The PpIX fluorescence in ocsophagcal carcinoma was two to 
three times that of the surrounding lamina propria, The dif- 
ferential PpIX accumulation was no different between car- 
Table 3 
nuorcý ratio betccu caminorna and nornud oesophageal mcosa W 
between carcinom wd its surrounding strarna 
nýc= raw 
ALA dosagc 75 mg/kg 60 mglkg 
Cmiaýfuýzl ýphagu (mucow) 139 1.35 
Cucinoma mucosslaroma 1.94 3.70 
cinoma and nomial oesophageal mucosae (Table 3). Higher 
doses of ALA did not increase the differential accumulation 
of PpDC between normal mucosa and carcinoma. 
3.2. Treatment outcome 
All 12 patients showed response to the treatment with 
cndoscopic evidence of superficial necrosis. Necrosis was 
evident within 24 h of treatincrit. Biopsy of the tumour con- 
firmed fibrinoid necrosis. Assessment of the thickness of 
necrosis was not possible because of sloughing and angula- 
tion of the tissue biopsies. One patient with carcinoma-in-situ 
responded completely, repeat endoscopy and biopsy 28 
months after treatment showing no recu rrencc. In thi s patient, 
the underlying Barrett's mucosa, which extended between 35 
and 39 cm from the incisors, was replaced with pale looking 
squamous epithelium confirmed by histology, although 
unsuspected metaplastic glands remained buried under the 
neo-squanaous mucosa. The other patient with carcinoma-in- 
situ was treated three times at intervals of two weeks. At this 
point it was appropriate to consider other treatment. 7be 
Barrett's epithelium showed similar squamous re-epithelisa- 
tion but the carcinoma-in-situ was not completely eradicated. 
An elderly frail patient (unfit for surgery due to severe cardio- 
respiratory disease) with aTI NO tumour had the carcinoma 
eradicated after four PDT sessions over a period of four 
months. She died of her co-morbid disease 36 months after 
treatmentwithoutevidencc ofrecurrcntcanccr. Otherpatients 
responded with superficial necrosis ofmucosa butthc tumour 
remaincd. Repeated treatment in some patients at two- to 
four-week intervals failed to improve on the outcome. The 
remaining nine patients in the frank carcinoma group needed 
thermal laser ablation to relieve or prevent dysphagia. Fig. I 
shows the endoscopic results of the treatment. 
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Fig, 1. End-picoutconic ot patient I with , imall nodulu timactuir ttaged 
a, TI NO. Sequence., hri-rod. ), belon, treatment (upper left), auperfidal 
rmcro- at one week (upper right), the msult after two treatments (lower 
left) and the final remlt after four nssions of ALA/PDT at the 12 month 
follow-up (lower right) with va-squarrious epithelium in the astat of the 
previousturnour 
3.3. Side-effects 
Six patients had mild nausea, vomiting and retrosternal 
discomfort. Mild skin photosensitivity with erytherna 
occurred in one patient who was inadvertently exposed to 
strong sunlight sitting by the window within 24 h of ALA 
ingestion. Asparlate transaminase (AST) and bilinubin were 
elevated in five patients (less than twice the normal range). 
Elevation of the liver enzymes was more marked when 
patients were exposed to the second dose of ALA. However, 
the enzymes always returned to normal after three to four 
days. No patients had any endoscopic complications. 
3.4. Patient outcome 
The two patients who had complete eradication continued 
to have surveillance endo%copy with multiple biopsy at six- 
monthly intervals until one died ofother disease at 36 months. 
One patient remained well at 28 months follow up. The other 
patient with carcinoma-in-situ has had a successful oesopha- 
gectomy. 11iose patients with frank carcinoma received pal- 
liative thermal laser and other encloscopic therapy combined 
with chemotherapy and radiotherapy until death a mean of 
16 months (range 6-26) later. Histological examination of 
treated areas has confirmed the presence of residual Barrett's 
metaplastic glands in the surviving patients. In our study, 
biopsies that were clearly identified as coming from a treated 
have shown residual glandular epithelium. This 
emphasises the impossibility of identifying cell type at endos- 
copy in areas of treatment. We have also commonly identified 
unsuspected buned glands [ 24). 
4. Dtscinsion 
Initial attempts at treating oesophageal cancer with PDT 
relied on the use of photosensitisers such as haeMatOPOT- 
phyrin derivative (HpD) and its more purified successor Pho- 
toffin. A complete response could be obtained in patients 
with small lesions. Sibillc et al. 117 J recently published the 
outcome ofPDTof 123 patients with superficial oesophagcal 
carcinoma using these photosensitisers between 1983 and 
1991. They showed a complete response rate of 87% at six 
months. The actuarial five-year survival rate was 25%, but 
the disease specific survival rate was 74%. PDT-related corn- 
plications were oesophageal stricture (n = 43) and cutaneous 
photosensitisation (n - 16). ALA is a new agent used in PDT 
It is a 'pro-drug' and is convened in the body to PpIX, an 
effective photosensitiscr. In vivo studies have shown that it 
can be given orally and that it has a short half-life with skin 
photosensitivity lasting only 24-48 h[ 11-13 1. Other advan- 
tages ofALA are its preferential accumulation in mucosa and 
mucosal turnours. ALA/PDT has the potential benefit of 
eliminating the common complications of oesophageal PDT 
with conventional photosensitisers', i. e., prolonged cutaneous 
photosensitisation and oesophageal stricture 110.17 1. In our 
study, none of the patients developed oesophageal stncture 
and only one patient had a very transient and mild cutaneous 
photosensitivity from inadvertent exposure to sunlight less 
than 24 h after treatment. 
ALA/PDT has been used in the treatment of oral, gastro- 
intestinal and skin cancer. Tissue necrosis was noted in oral 
and gastrointestinal cancers 112,131 and some skin cancers 
have been eradicated j 18,191. Regula et al. published [ 131 
their pilot study on the efficacy ofALA/PDT and tissue PpIX 
distribution following oral administration of ALA; there were 
three oesophageal cancers among their 18 patients. They 
found that ALA/PDT was safe and tissue necrosis could be 
induced, but the disease was not eradicated. 
Our study has concentrated on clinically small and super- 
ficial oesophageal adenocarcinomas that had arisen from Bar- 
rett's metaplasia. We studied the response of both the tumour 
and the metaplasia. In retrospect, four of the patients with 
turnours larger than I cm endoscopically were unsuitable for 
PDT. However the other eight patient% were 'ideal' candi- 
dates for such treatment. Unfortunately. endoluminal ultra- 
sound was not available for tumour staging in all patient-.. In 
one patient staged with endoluminal ultrasound, the tumour 
was deeper than the cndoscopic appearance suggested. 
Clearly accurate staging is essential. A recent study of ALA/ 
PDT has demonstrated that it is very effective for the eradi- 
cation of dysplasia and for turnours that are less than 2 min 
in depth (221. It is clear that if the tumour is deeper, then 
ALA/PDT is not very effective. The alternative of photo- 
dynamic therapy with porfimer sodium (Photofnn) is very 
effective and can treat deeper turnours. This recently reported 
series is very informative, since 10 of 13 malignancies were 
ablated, but the oesophageal stricture rate was 34% [231. 
These strictures appear to be because there is destruction of 
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the muscularis mucosa through into the submucosa. We now 
only use ALA/PDT for high-grade dysplasia and will use 
porfimer sodium for malignant lesions. 
The fluorescence distribution study confirmed that PpIX 
accumulated in mucosa more flizin in the I, unina propria or 
tumourstroma. 7be accumulation of PpIX after ALA admin- 
istration by malignant oesophageal mucoss is little different 
from thatbynormal oesophageal mucosa. The lack oftumour 
selectivity may not be important, as the laser light is admin- 
istered only to the oesophageal segmentwith tumourinvolvc- 
Ment. Higherdoses ofALA increased PpIX accumulationbut 
did not increase the differential distribution between normal 
and abnormal mucosa. 
The main side-effem ofALA/PDTwcrc, nauw. % vomiting 
and transient elevation of aspaitzitc transaminase (AST) and 
bilirubin. The mechanism of the elevation of liver enzymes 
is not cl=. It is interesting to note that patients with an acute 
attack of acute intermittent porphyria (AIP) also develop 
transient elevation of AST. None of the patients given ALA 
showed other symptoms of AIR All the enzymes returned to 
normal after four to five days. 
The reason why ALA/PDTonly induced superficial necro- 
sis is not obvious. It is possible, as suggested by Regula ct al. 
[ 13), that photobleaching during PDT occurs more rapidly 
than with other photosensitisers. The alternative explanation 
is that the excitation wavelength of the light (630 nm) used 
is too far from the Soret band of PpIX. which is 405 nm. The 
reason for using longcr-wavelength light is to improve tissue 
penetration. 
Thermal laser 1201 and PDT using hacmatoporphyrin have 
been used to treat RarretC s trictapluia and its associated early 
adenocarcinoma with encouraging results. However, some 
patients have developed ocsophageal stricture afterrepeated 
treatment 110.23). Our fluorescence distribution study con- 
firmed the preferential accumulation of PpIX in the epithe- 
lium of abnormal and normal oesophagus, rather than the 
underlying stroma. This may make ALA an ideal agent for 
the treatment of widespread but very superficial lesions such 
as Barrett's dysplasia or carcinonia-in-situ. Thc surrounding 
Barrett's mucosa of our patients showed squamous re-cpi- 
thelisation but with evidence of residual metaplastic glands 
at histology. 
In conclusion. ALA/PDT can be effective in the treatment 
of oesophageal cancer confined to the mucosa. as shown in 
two patients. The adverse effects are minimal and the treat- 
ment can be repeated within a short period with no risk of 
ocsophageal stricture. It is. however, not suitable for the treat- 
ment of established ocsophageal c; ircinoma because of its 
superficial effect. 
Acknowledgments 
W. H. R. and S. B. B. are funded by the Yorkshire Cancer 
Research Campaign. 
Refertnces 
79 
(11 S. Calarubuk. Rn Herman. DM. Cm9mve. J1. Gassman. Cluster 
of the esophagus: the Cleveland Clinic expcncnm Am. Surs. 203 
(1986) 101-109. 
121 T. R. Wicester, G. Zanurou. r-F- Johanswn. Selective thcrapeunc 
approach to cancer of the lower esophagus ail cardlit, J. Thorac. 
Cardiovasc. Surg. 95 (1983) 42-54. 
E31 W. J. Blot. S. S. Devaii. R. W. Kneller. J. P. J. FraumenL Rising inci. 
denct: of of the exophogus and gastric cardia, J. Am. 
Mcd. Assoc. 265 (1991) 1287-1289. 
(4) TJL DeMecister, S. E. A. Artwood. T. C. SmyTk. D. H. Theirkildien. 
R. A. Hinder, Surgical therapy in BarreWs oesoptups. Am. Surg. 
212 (1990) 528-542. 
151 TJ. Dougherty, Yearly review - photodymmic theriipy, J. Phom- 
clients. Photobiol. B: Biol. 59 (6) (1993) 895-9W. 
161 IL Dart. C. J. Tralzu. P. B. Boulos. AJ. MacRobcrt. R. Tilly. S G. 
Down. The contrasting mochanisms of coloric collagen dionage 
between photodymnnic therapy and thermal injury. Photochem. Pho- 
tobiel. 46 (1987) 795-M. 
(7) C. S. Loh. A. J. MacRober% G. Buc-ccoinii, N. Krasner. S. C. Bo. n. 
Mucoal ablation using photodynismic therapy for the treatment of 
dysplaua: an experimental study in the normal rat stomach. Gut 38 
(1996) 71-79. 
Is] T. J. Dougherty, M. T. Cooper. T. S. Mag. Cutaneous phototoxic 
occurrences in patients receiving Photoffin, Users Surg. Med. 10 
(1990) 491-488. 
191 CS. " 13. Vernon. AJ. MacRobcn. J. Bedwell. S. G. Down. S. B. 
Brown. Endogemus porphyrin distribution induced by 5-amLitolm- 
vuhmc mid in the tissue layers of the gastrointestinal OwL J. Photo- 
chem. Photobiol. B: Biol. 20 (1993) 47-54. 
1101 B. Overholt. M. P&njcbpour. E Tcfftell". M. Rose, Photodynarn-c 
therapy for teAtount of early isdem=tneem, in barreut's oesophis- 
tua. Gastrointem E-losc. 39 (1993) 73-76. 
(III I. C. Kennedy. R. H. Ponucir. Endrigenous protoporphynn Ma clun- 
cally useful photoserisitizer for photodynamic therapy. J. Phistochem. 
Photobiol. B: Biol. 14 (1992) 273-292. 
112) WX. Gnmt. P. M. Speight. AJ. MacRobcM C. Hopper, S. G. Down. 
Photodymms: therapy of normal rat arteno aft" photosensitisatim 
using d"Plionailed alumizium phdialocyanine and 5-aminolaciria- 
bruc ac4l3r. J. Cancer 70 (1994) 72-78. 
1131 J. Rcgula. AJ. 161acRobcr% A. Gonchein, G A. Humaccorsi. S. M. 
Tborpcý G. M. Spencer. AR. Hatfield. S. C. Bown. Photosensiusaucin 
and pholodynamic therapy of oesophateal, duodenal. ad colortclal 
turnours using 5-ammolmnlinic mid induced p"oporphynn IX - 
a pilot study, Gut 36 (1995) 67-75. 
t 141 0 H. B"hrt, D. E. I lenson. R. V. Hutter (Eds. ). Manual for Staging 
of Cmicer. 3rd oil. A merkan Joint Commitoc on Cancer. J. D. Uppin- 
cot. Philadelphia. 1983, pp. 64-65. 
1151 N. Barritit, Chronic peptic uku of the oesophaguis ad tsophagnis, 
Dr. 1. Sing. 38 (1950) 175-182. 
(161 PJL Allison. A-S. Johasitunc. Thc em)phaguslinod withga4tric muc, ous 
membrneýThcxrxt 9 (1953) 97-101. 
1171 A. Sibille. R. Lambert. J. C. Souquet. C. Sabben, F. Desciss, Long- 
tam survival after photodynamic therapy for esophageal cancer. Cas- 
trocitterolotly, 108 (1995) 337-344. 
[181 J-C. Kennedy. R. H. Pottier. D. C. Press. Photodynamic therapy with 
endotmous protoporphyrus IX: basic principles and present clin. 
kal cxpeaie=, J. Phistochem. Photobiol. D: Biol. 6 (1990) 143- 
149. 
(191 F. Cairriduff. M. R. Stringer. E. J. Hudson. D. V. Ash. S. D. Brown. 
Superficial photodymmic therapy with top" 5-ammoltievulmic acid 
for Superficial primary ad secondary skin cancer. Dr. J. Cancer 69 
(1994) 605-" 
1201 M. M. Hermann. T. D. Johnson. N. R. Markowitz. K. N. Ducht. W. S. 
Samowit4 Restoralm of squarrious mucosa after ablation of 
A5-27 
WC Tan el at 1J. Phowhem Pholobiot D: Biol. 53(1999) 75-80 
Barren's esophagead epitbelluin. Gastroenterology 104 (1993) 1696- 
1691. 
RJ. Schlemper, M. Itabashi, Y. Kato, R. H. Riddell, T. Shimoda, P. 
Sippoicn, M. Stoke, H. Watanabe. H. T"ashi. R. Fujita, Differ- 
ences in diagnostic criteria for gasinc, carcinoma. between Japanese 
and Western pathologists, Lancet 349 (1997) 1725-1729. 
L Goiswr. K Stolte. R. Strolm. K. Rick, E. G. Hahn. C. E-31, Photo- 
dynamic ablation ofhigh grade dysplasia and early canceirs in Barren's 
1231 
[241 
esophaps by means of 5-arninolaevubmc acid, Gastroenterology 114 
(1998) 447455. 
B. F. Overholt, M. Pmjepmr, I. M. HAydek, Phutodynamic therupy for 
Barre, tt's esophaguslollow-up in 100patients, Castrointest. Endosc. 
49 (1999) 1-7. 
LR. DidMestone, CP. Barbaro, S. P. Wilkin, on, H. Bam, N A. 
Shepherd, Ile fustopathology of treated Barren's ewphagus. Am. J. 
Surg. Pathol. 22 (1998) 239-244. 
1211 
1221 
A5-28 
Progress in the detection of neoplastic progress and cancer 
by Raman spectroscopy 
T. C. Bakker Schut, N. Stoneb, C. Fulliamesb, H. Baffb, HA. Bruinine, G. J. Puppcis" 
'Emsmus Medical Center Rotterdam, Dr. Molewaterplein 50,3015 GE, Rotterdam, The Netherlands 
hGloucestershire Royal Hospital, Great Western Road, Gloucester, GLI 3NN, U. K. 
ABSTRACT 
Early detection ofcanrer is important because of the improved survival rates when the cancer is treated early. We study the 
application ofNIP, Raman spectroscopy for detection of dysplasia because this technique is sensitive to the small changes in 
molecular composition and conformation that occur during neoplastic progress, and because it can be used for minimally 
invasive in vivo detection using fiber-optic probes. Ile results of an in vitro study to detect neoplastic progress of 
esophageal Barrett's esophageal tissue will be presented. Using multivariate statistics, we developed three different linear 
discriminant analysis classification models to predict tissue type on the basis ofthe measured spectrum. Spectra afriormal, 
metaplastic and dysplastic tissue could be discriminated with an accuracy of up to 88%. 'Merefore Raman spectroscopy 
seems to be a very suitable technique to detect dysplasia in Barretts esophageal tissue. 
Keywords: NIR Raman spectroscopy, dysplasia, multivariate spectral analysis 
1. EMODUCTION 
A number of spectroscopic techniques is currentlybcinj investigated for in vivo detection of early cancer and especially of 
dysplasia, the first stage in the development of cancer. .2 Early detection of cancer is important because of the improved 
chances in treating the cancer successfully. Detection of dysplasia, is currently limited by the fact that it can only be done ex 
vtvo by pathological grading of tissue biopsies. Therefore, the number of samples that can be investigated is limited. Inmost 
cases, dysplastic tissue cannot be discriminated in vivo from normal tissue by visual inspection, resulting in high numbers of 
unnecessary biopsies (i. e. of normal tissue) and a significant risk of missing areas of dysplastic tissue. Fast spectroscopic in 
vivo detection of dysplasia could be ofuse as a biopsy-guiding too], enabling higher sampling rates and lower false positive 
rates by only taking biopsies from suspicious areas. Ifin vivo spectroscopy can be made specific and sensitive enough for the 
detection ofdysplasia, it could ultimately reduce the need for taking biopsies. 
in principle, Raman spectroscopy seems to be well suited for detection of dyplasia. It offers the detailed molecular 
information that is needed to detect neoplastic changes with high specificity and sensitivity, as was shown in vitro for 
detection of a number of cancers and pro-cancers! Raman spectroscopT can be applied in vivo through the use of special 
fiber optic probes, which can be optimized for a particular application. Applicability of in vtvo Raman spectroscopy in a 
clinical setting depends on development of sensitive equipment and powerful spectral analysis to enable the extraction of 
clinically relevant parameters from spectra obtained with short collection times. 
Our work focuses on detecting (pre)cancers in the Barrett's esophagus. A Barrett's esophagus is caused by gastric and 
duodenal rcfluxes, which changes the normal non-kcratinizod stratified squamous epithelium ofthe esophagus into columnar 
lined mucous producing epithelium, such as found in the intestines and stomach. This metaplastic state is now considered to 
be a pre-malignant state that increases the risk ofilevelopment ofadeno-carcinoma by a factor of5o. 
Earlier work has proven that tumor tissue could be discriminated from normal and metaplastic esophageal tissue by Raman 
spectroscopy and multivariate statistical classification techniquesý. Here we investigated the possibilities for in vitro 
classification of normal, metaplastic and dyspWtic esophageal tissue by NIR Raman spectroscopy. Using a Raman 
microspectrometer we obtained in vitro spectra ofbiopsy samples from a number ofpatients showing dysplasia in a Barrett's 
esophagus. Three different LDA models were evaluated to investigate the influence of different groupings on the 
classification results. 
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2. MATERIAL AND METHODS 
2.1 Tissuesamples 
For this in Wiro study 10 different biopsies from 3 different patients with low and high grade dysplasia were used. All 
biopsies were graded by a pathologist in 4 different classes: 3 biopsies with Normal epithelium (N), 4 biopsies with Barrett's 
epithelium (B), I biopsy with Low Grade Dysplasisa (LGD), and 2 biopsies with Iligh Grade Dysplasia QIGD). Raman 
spectra were taken from at least 20 different locations (about 100 pm apart) on the epitheliall side ofthe biopsies. 
2.2 Raman set-up 
For all measurements 100 mW of 850 nin laser light from an Argon ion laser pumped Ti-Sapph laser (Spectrii Physics, 
models 2020 and 3900S) was focused by a microscope objective (Nachet, magnification: 20 X. NA-0.4) on the sarnple. 
Raman light from the sanipIc was collected by the same objective, filtered using a holographic notch filter and focused on 
the entrance ofa fiber that was connected to the entrance ofthe spectrometer. An F12 spectrometer, built-in-house, equipped 
with a liquid nitrogen cooled deep depletion CCD (Princeton Instruments), was used to record the spectra. All spectra were 
measured with a collection time of30 seconds! 
23 Spectral analysis 
All spectra were corrected for the wavelength dependent sensitivity or the sct-up and for Raman light that was genciatcd in 
the microscope objective. All spectra were then Savitzky-Golay differentiated to reduce the Interference of slowly 
fluctuating background signal, and subsequently scaled to have zcro mean and unit variance (auto-scaling)! 
multivariate statistical classification models were built as follows: Ibc data were divided in a model set and a prediction set 
(for evaluation ofthc model). Two thirds ofthe full data set (evenly distributed) was used for modeling and I third was used 
for prediction. Clear outliers were removed from the data scL These were defined as spectra obtained from a biopsy sample 
that do not fall within a boundary of 10 times the standard deviation from the mean spectrum of that biopsy sample. 
Principal Component Analysis (PCA) was used on the model set to orthogonalisc and reduce the number of parameters 
needed to represent the variance in the spectral dataset. A two-sided t-test was used to individually select those PC's that 
show the highest signifirance in discriminating the different classes. The scores or the model spectra on these PC'sý which 
represent most ofthe useftil variance in the dataset, were used as Input for a Linear Discriminant Analysis (LDA) model. The 
number of PC's that were used as input was kept smaller tl= the number of spectrit in the smallest model group to prevent 
overrating in the LDA-model. LDA yields n-I discriminants that best separate the n groups. Prediction spectra were first 
projected on the PCA model; the scores of these prediction spectra on the PC's were subsequently projected on the LDA- 
model to yield a classification 
3. RESULTS 
3.1 Model 1: Normal, BarreiVs, Low Grade DYSPI2318 and High Grade Dysplasia 
In the I irst model all 4 tissue types were includcd as different classes. 
Figure I shows mean spectra for the 4 different tyycs of tissue: Normal, Barrm's. Low Grade Dysplasia (LGD). and High 
GTade Dysplasia (HGD). Since the diffemccs between the mean spectra are small, also the differences of the group means 
with the overall mean arc shown. 
Figure 2 shows the discriminants of this model. Since the model was developed on the basis of first derivative spectra, the 
discriminants were integrated to facilitate the interpretation of the spectral features, %hich is the subject of further analysis. 
The slowly fluctuating background in the discriminants is duc to integration, and should be ignored. The discriminants show 
combinations of positive and negative features that coincide with specific Raman bands, and can be used to identify the 
differences between the two groups. 
in figure 3 the LDA scores are shown for both the in Oro classification model (upper if= plots) and prediction spectra 
(lower three plots). Normal samples (squaw) have positive LDI scores and negative LD2 scores; Barrett' s samples (circles) 
have negative LDI scores and positive LD2 scores; LGD samples (plus signs) have ncgaivc LDI and LD3 scores and HGD 
samples (crosses) have negative LDI and LD2 scores. 
Evaluation of the model, gives a 899/6 correct classification of the model spectra, using a leave-one-out validation. 7be 
model was used to evaluate the independent test set of spectra. Table I shows the classification results for these test spýcctra. 
From these results, the sensitivity and specif icity of Raman spectroscopy as a diagnostic test for the detection or the different 
tissue types, versus the standard method (pathology). were calculated. These parametcM and the prevalence of each tissue 
type, are given in table 2. 
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Rgure 1: Above: Mean spectra of the 4 groups in model 1: 
Normal. BarrrtCs. Low Grade dysplasla (LGD) and Iligh 
Grade Dysplasia (IIGD). Below: Diff=nces (times 4) of the 
four groups compared to their overall mean 
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FIgure 2: Linear Discriminants (LD) of model I to separate 4 
groups of spectra: Normal, Baffctt'sý Low Grade Dysplasia 
and I ligh Grade Dysplasia. 
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Rgure3: Scores of the model spectra (upper 3 plots) and Pre-diction spectra (lower 3 plots) on the 3 discriminants of model 1. shown in 
figure 2. Each symbol denotes one spectrum. Symbols according to pathological grading; Squares denote normal, circles denote 
Barrctt'sý plus-signs denote low grade dysplasia. and crosses denote high grade dysplasia. The inner axes in the plots are the zero 
crossings ofthe score values. 
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Prediction set classification results for model I 
Pathology 
HGD LGD Barrett's Normal Total 
IIGD 10 02 0 12 
LGD 0 70 1 8 
Raman Barrett's 2 0 16 0 18 
Normal 0 04 19 23 
Total 12 7 22 20 61 
Table 1: 
Classification results of mcAel I for the prediction spectra shown in figure 3: Ranian classification (rows) 
versus Pathology classification (rolumns). Total number ofmisclassifications: 9 (14.75 %) 
Raman spectrascopyfor Barrett's tWue classification 
HGD LGD Barretfs Normal 
Scnsitivity 0.83 1,00 0.73 0.95 
specificity 0.96 0.98 0.95 0.90 
Prcvalence 0.20 0.11 0.36 0.33 
Table 2: 
Sensitivity and selectivity orRaman spectroscopy its a diagnostic test for classification oftissue Ows 
in Barrett's esophagus tissue using model 1. Numbers were calculated using the classification results 
of table 1. 
32 Model 2: Normal, Barrett's, Iligh Grade Dysphisla 
In the second model we left out the Low Grade Dysplasla group. This group consists of only one biopsy sample that seems 
to be contaminated with blood, as can be seen ftorn the peak at 1547 in the mean LGD spectrunt in figure I 
Figure 4 shows the mean spectra for the remaining 3 types of tissue: Normal, Barrett's and Iligh Grade Dysplasia (HGD), 
and their differences from the overall mean. 
Figure 5 shows the (integrated) discriminants of Us model. In figure 6 the LDA scores are shown for the classification (left 
plot) and prediction spectra (right plot). Normal samples (squares) have negative LDI scores and positive LD2 scores; 
Barrett's samples (circles) have positive LD I scores and I IGD samples (crosses) have negative LD I and LD2 scores. 
Evaluation ofthe model, gives a 88% correct classification ofthe model spectra, using a leave-one-out validation. The 
model was used to evaluate the independent test set ofspectra. Table 3 shows the classification results for these test spectra. 
From these results, the sensitivity and specificity ofRaman spectroscopy as a diagnostic test for the detection ofthe different 
tissue types, versus the standard method (pathology), were calculated. These parameters, and the prevalence of each tissue 
type, are given in table 4. 
3.3 Model 3: Normal, Barrett's and Dysplasla 
In the third model we added the two dysplastic groups to form a new group called dysplasia. The difference between low and 
high grade dysplasia is somewhat ambiguous, and might cause artifacts in the model. 
Figure 7 shows the mean spectra for the 3 types of tissue: Normal, Barrett's and Dysplasia, and their differences from the 
overall mean. 
Figure 8 shows the (integrated) discriminants of this model. In figure 9 the LDA scores are shown for the classi I ication (left 
plot) and prediction spectra (right plot). Normal samples (squares) have negative LDI scores and positive LD2 scores; 
Barrett's samples (circles) have positive LDI scores and Dysplasia samples (crosses) have negative LDI and LD2 scores. 
Evaluation of the model, gives a9 1% correct classification of the model spectra, using a leave-onc-out validation. The 
model was used to evaluate the independent test set of spectra. Table 5 shows the classification results for these test spectra. 
From these results, the sensitivity and specificity ofRaman spectroscopy as a diagnostic test for the detection ofthe different 
tissue types, versus the standard method (pathology), were calculated. These parameters, and the prevalence of each tissue 
type, are given in table 6. 
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Table 3: 
ClassifieWon results of model 2 for the prediction 
spectm shown in figure 6: Raman classification (rows) 
versus Pathology classification (columnsý TotAl 
number ofmiscl3ssirications: 6 (11.11 %) 
LD1 
Prediaion set clarsiflexion rmlis for model 2 
Pathology 
IlGD Barrett's Normal Total 
HGD 10 1 0 11 
Rjunan Barrett's 2 Is 0 20 
Normal 0 3 20 23 
Total 12 22 20 54 
Ta, We 4: Raman specowcop y for Barrett's lissue clatsOcation 
Sensitivity and selectivity of Raman spectroscopy as a HGD Barretfs Normal 
diagnostic test for classification of tissuc types in Bar- Sensitiviry 0.83 0.82 1.00 
rem's esophagus time using model 3. Numbers were Specificity 0.98 0.94 0.91 
calculaW using the classification results oftable 3. 
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Figure 7: Above: Mean spectra of the 3 groups in model 3: 
Normal. Barrett's and Dysplasia. Below: Differences (times 4) 
ofthe four groups compared to their overall mean 
k7gitre 9: Scores ofthc model spectra 
(left plot) and prediction spectra 
(right plot) on the two discriminants 
of model 3, shown in figure 8. Each 
symbol denotes one spectrum. 
symbols according to pathological 
grading, Squarcs denote normal, 
circles denotc Barrett's. and crosses 
dcnote dysplasia. The Inner axes in 
the plots arc the zero crossings of the 
score values. 
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Table 5: 
Dysplasia Barrctfs Normal Total 
Clas3ification results of model 3 for the prediction 
Dysplasia 17 
Raman Barrett's 2 
1 
17 
1 19 
spectra shown In figure 9: Raman classification, (rows) 0 19 
versus Pathology classificalion (columns). Total Normal 0 4 19 23 
numbcrofmisclassirications: 8(13.11 0/*) Total 19 22 20 61 
Table 6: 
Raman sPectroscomfor Barrett's tissue classification 
Sensitivity and selectivity of Rainan spectroscopy as a Dysplasia Barretrs Normal- 
diagnostic test for classification of tissue types In Bar- Sensitivity 0.89 0.77 0.95 
rctt's esophagus tissue using model 1. Numben were Specificity 0.95 0.95 0.90 
calculated using the classification results oftable 5. Prevalence 0.31 0.36 0.33 
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FIgure 8: Two Lintar Discriminants (LD) of model 3 to 
separate the three groups of spectra ; Noffnal, Barrett's and Dysplasia. 
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4. DISCUSSION 
The data presented here clearly show that it possible to discriminate in vitro between nornuil, mctaplastic and dysplastic 
tissue on the basis of their Raman spectra. The results of this in vitro study to detect dysplasia in biopsies from Barrett's 
esophagus show that there is some overlap in LDA-space between the four consecutive stages (Normal to Barrett's to LGD 
to I IGD) in the progress towards carcincima. This is probably due to problems with matching the Raman measurements with 
the pathology findings. First. it is difficult to exactly match the locations in the tissue sample where the spectra were 
measured with the location of pathological grading. Second, pathology does not give an exact composition of the tissue. but 
an overall grading. Samples &Wed as samples as I-1GD my contain some LGD and/or normal tissue. This wHI cause some 
misclassifications and overlap in the multivariate model that can only be prevented by using only samples with large areas or 
a single tissue type, %hich are hard to obtain. From figure IA, it can bc seen that the mean spectra or the four typcs of tissue 
are very similar. 7bis can partly be caused by the contaminations in the model data set, but it can also be due to sample 
volume gcomeny- the axial resolution when using the 20X, Na-0.4 objective is somewhat Larger than the thickness of the 
epithelial layer. where the main differences can be found, resulting in contributions from deeper tissue layers (lamina 
propria, muscle layer) which are similar for all tissues. 
The model spectra of the rust model, in which spectra of each type of tissue were grouped separately, were correctly 
classified in W1. of the cases using a leave-on&-out validation. therefore the model is not ideal. The classification of the 
prediction spectra with this model is correct for 85% ofthe cases, similar to the model data set. As can be seen from figure 3, 
the distribution of the prediction set is similar to that of the model &in, which indicates that there is no ovcrfining in the 
statistical model. Most ofthe misclassifications are made in the Barrett's group, which is not surprising since Bafftn's tissue 
can be very heterogeneous and may also contain patches ofnormal tissue (model data sets also gave most misclassifications 
in Barrett's group). 
In the second model we left out the LGD s=plcs., Aiiich appeared to be contaminated with blood. It can be seen from the 
discriminants ofmodel I (figure: 2) that the blood contributions do not play a mayor role in the separation ofthe LOD group. 
Elimination ofthe LGD group did not have much effect on the sensitivity and specificity for the classification of the HGD 
samples, but improved the classification ofthe normal and Barrett's samples somewhat. 11is suggests that the interference of 
the LGD samples is mainly with the Barrett's samples and the normal samples. which is also indicated by the results of the 
classification of the spectra of model I (in the classification of the model spectra. one Barren's sample and one normal 
sample but no HGD samples were classified as LGD). 
In the third model we added the two dysplastic groups to form a new group called dysplasia. *The difference between low and 
high grade dysplasia is somewhat ambiguous. and might cause artifacts in the model although the classification results of 
model I and model 2 suggest that these two groups hardly interfere. Adding LGD and IIGD does not have an effect on the 
classification of the normal samples but it improves the separation between Barrett's samples and dysplastic samples 
somewhat. The blood present in the LGD spectra does not seem to cause problems in identifying the dysplastic samples as 
one group. 
The sensitivity for detecting (high grade) dysplasia, as found by these LDA models, is not very high, but this limited study 
does indicate that it is possible to detect dysplasia in Barrett's tissue in vitro, using Raman WcuDscopy. Tic specificity for 
detecting (high grade) dysplasia for the models developed here was in all cmat higher than the sensitivity (specificity for 
detecting dysplasla >0.95). Ifa high sensitivity is required, the LDA models can easily be biased to yield a higher sensitivity, 
at the expense of having a lower specificity. 
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Raman Spectroscopy: A Diagnostic Tool for Detection of Early 
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ABSTRACr 
Ile incidence of laryngeal cancer has risen progressively over the last 25 yeam Early diagnosis and treatment of prc- 
malignant lesions ofthe larynx is vital to prevent progression to invasive squamous cell carcinoma. In the larynx, it has long 
been rccognised that histological evidence of maturation abnormality is associated with a higher risk of transformation to 
malignancy. Currently. it is extremely difficult if not impossible for the clinician to ascertain the level of abnormality 
present without removing a biopsy sample and sending it for histopathlogical analysis. Inherent risks with this technique 
include damage to vocal chords and loss ofspeech quality as well as possible selection ofunrcprcscntadve biopsy samples. 
Raman spectroscopy. incorporated into an encloscopic system. has the potential to provide a real-time, non-invasive 
diagnostic technique able to detect biochemical changes that accompany abnonnal pathology. Likely outcomes would be 
improved biopsy targeting and patient management by providing immediate results of tissue pathology. 7bis paper 
demonstrates the capacity of near, infrared Raman spectroscopy combined with statistical dam analysis techniques to 
discriminate between normal, dysplastic and cancerous laryngeal tissue. 
Keywords: Raman, Larynx, dysplasia. cancer, malignancy, biopsy, spectroscopy, dctection, endoscopy. 
1. INTRODUMON 
The incidence of laryngeal cancer has progressively risen over the last 25 years, with the most significant increase occurring 
in women'. It has been estimated that there has been no overall improvement in the mortality from laryngeal cancer over the 
last three decades. Delayed diagnosis leading to loco-regional failure and a high incidence of second primary malignancy in 
long-term survivors are the two =in reasons for this poor outcomc2. In addition, laryngeal cancer has the greatest effect on 
quality of life of any cancer, causing devastating lifestyle changes and resulting in permanent cosmetic and psychosocial 
disability. 'ller6ore, the development ofaa automated diagnostic method allowing detection oflircmalignant and malignant 
lesions earlier, at a cellular level would facilitate faster, more effective patient management and potentially further reduce 
mortality. 
The vast majority of laryngealcancers originate on the surface. The standard method ofdetection Is inspection of the organ 
with endoscopy and removal of a sample of tissue for histopathological analysis. This can be time consuming, costly and 
due to the random nature of biopsy selection stands a chance of missing any abnormal cells in the organ. In addition 
repeated biopsy procedures increase the risk ofaffecting the quaJity ofthe voice. The transformation from the normal state 
to carcinoma in the larynx involves an intermediate step, whereby the cells in the squarnous epithelia] layer begin to grow 
and mature abnormally. Ills state is called squamous dysplasia. It is known that lesions exhibiting mild dysplasia have a 
lower potential for malignant degeneration than those with severe dysplasla. If the turnout can be visually detected at 
endoscopy it may already be too late to Initiate a full cure. 
Raman spectroscopy has recently been proposed for early cancer diagnosis by a number of authors"'. Although it has 
shown potential for early diagnosis ofmalignancy in a variety oforg= (bmas4 brain, ocsophagusý, bladder, cervixý, it has 
yet to be demonstrated as a tool for detection of early laryngeal malignancies. Raman spectroscopy is the analysis of 
inelastic scattered photons following monochromatic laser excitation. It provides information about both the chemical and 
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morphological structure of tissue In near real time' and can be used as a non-invasivc optical method of tissue 
characterization. Most biological molecules are Raman active with their own characteristic fingerprint. Proteins, nucleic 
acids, cell membrancsý single cells and tissues can all be studied. The Raman spectrum is a plot of scattered intensity, as a 
function of energy difference between the incident and scattered photons. 'Me loss (or gain) in photon energies corresponds 
to the difference in the final and initial vibrational energy levels of molecules participating in the interaction. The observed 
peaks (bands) in the Raman spectrum are relatively narrow, easy to resolve and sensitive to molecular structure, 
conformation and environment. 
one of the primary obstacles encountered in the Raman spectroscopy of biological tissue is that of fluorescence. A fairly 
recent development has been the use of near infi=d (NIR) laser excitation and dispersive spectrometers to allow rapid 
detection of spectra with low background fluorcsrcncc. NIR radiation generally does not induce electronic absorption in 
tissue chromophores so fluorescence is weak relative to the Raman signal. Hologniphic notch filters are used to filter the 
elastic (Rayleigh) scattered light from the signal, combined with a single monochromator the throughput ofthe system is 
increased compared with the triple monochromator used previously. Ile development of charge coupled device (CCD) 
detectors and solid state semiconductor lasers has enabled the development of portable NIR Raman systems providing 
spectra with high signal to noise with short integration times. Compatibility with fibrc optics and the development of new 
probes Is making in vivo diagnostics with Raman spectroscopy a real possibility. 
'Me goal of this study was to assess the feasibility of using NIR Raman spectroscopy for the early diagnosis of laryngeal 
malignancy. As an initial step NIR Raman spectra of normal, dysplastic and squamous cell carcinoma were characterized 
and average spectra for each pathology were compared in order to determine its potential to differentiate between different 
pathologies. Multivariatc analysis techniques were applied to test the separation of cancers, pre-canccrs and normal tissue 
spectra by clusters. 
2. MATERLAIS AND METHODS 
2.1 Subje*cts 
Nineteen patients, ten men and nine women, participated in this preliminary study. T'heir ages ranged from 18 to 79 years, 
with a median of 53 years. Informed consent was obtained from each patient and the study was approved by the United 
Kingdom South and West Local Research Ethics Committee. 
2.2 Tissue preparation 
Biopsy specimens (5x5x5mm) were collected during routine surgical procedures (microlaryngoscoples) and snap Erozen in 
liquid nitrogen. Histological sections were cut from each ofthe samples using a freezing-microtome (Figure 1a) and stained 
with hcmatoxylin and cosin (H&E). Remaining biopsy blocks were stored at - 850C until spectroscopic studies could be 
carried OUL The larynx sections were classified by a pathologist as normal, dysplastic and squamous cell carcinoma. For the 
purpose of this study, with limited numbers of samples, mild, moderate and severe dysplasia were grouped togethe?. Only 
homogenous samples with clearly defined pathologies were used in this study, those with mixed or indeterminate 
pathologies were discarded. Twenty-one samples were retained for study with Raman spectroscopy, including twelve 
histologically normal samples, four exhibiting clysplasia and five with squamous cell carcinoma. Before spectral 
measurements, the specimens were passively warmed to room temperature and rinsed with buffered isotonic saline Solution 
(pH 7.4). No other sample pmtreatment ofany kind was performed. 
2.3 Instrumentation 
Raman scattcring measurements were obtained in vitro with a Renishaw System 1000 Raman micro-spectrometer. This 
system includes a tunable, argon ion pumped Ti. Sapphire laser (Spectra Physics 3900S), a high efficiency holographic 
spectrograph and a pelticr cooled CCD detection system. Samples were orientated in the in vivo geometry (tissue surface 
upwards) and placed between two calcium fluoride slides (Figure lb). A x8O ultra-long-working-distance leas was used to 
focus the excitation light onto the tissue and collect the scattered photons in non-confocal mode. At least four spectra were 
acquired from each sample (mean number - 7.3, range 4 to 12) with an excitation wavelength of 830nm. In this wavelength 
region, the absorption coefficients of water and tissue pigmcnts are small and the effective penetration depth is large 
(typically a few mm). There was little contribution to the Raman signal from fluorescence. The laser power at the sample 
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was 36 ± 1.1 mW, focused to a spot size of approximately 5 jun at the tissuc surface. The scattered Raman signal was 
integrated for 30 seconds and measured over a spectral range of400-1 800 crn7' with respect to the excitation frequency. 
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Figure 1. (a) Orientation of biopsy block for cutting vvith a freezing microtome. Sample was laid on acetate paper and seWoned. The 
histopathology ofthe section is studied and homogeneous samples are then investigated (b) with the Raman microspectnometer using 
an in vh(O beam geometry. 
2.4 Analysis 
The system was calibrated for wavenumber shift using a neon tamp standard and Renishaw WIRE software. Tissue spectra 
were corrected for the energy dependent response of the system using a tungsten-filament lamp with a spectral output 
calibrated by the National Physical Laboratory, UK. No further manipulation of the tissue spectra was performed prior to 
analysis. Intra-sample repeatability was evaluated and mean spectra for each tissue pathology were obtained. Variations in 
the mean spectra with pathology were assessed using multiple analysis ofvariance (MANOVA)'ý 
A large number of empirical methods have been employed in the literature to evaluate variations in the spectra with tissue 
pathologies. These usually involve absolute peak intensity or peak intensity ratio measurements. There is a disadvantage to 
this type oftnethod in that only a tiny part ofthe huge amount ofdata. obtained on the histochemistry ofthe tissue, is used 
for analysis. Biological tissue is exceedingly complex and it is likely that them am many factors influencing pathology. 
Therefore a method that incorporates as much of the data as possible in the analysis is likely to provide a more rigorous 
method of separating spectra with pathology. One such method. principle component analysis (PCA) was performed on the 
tissue spectra using the Galactic GRAMS/32 PLSIIQ software suite. Of the 181 spectra acquired, 5 were discarded due to 
extremely poor signal to noise or an unusually large fluorescence background. The remaining spectra were compiled into a 
training data sc4 which was mean-ccritered. This involved calculating the average spectrum of all the spectra in the data set 
and subtracting this result from every spectrum. The data set was then subjected to a pre-processing filter. either none, a 
Savitsky-Golay I' derivative, or a Savitsky-Golay 2*d derivative. Principle component analysis was used to describe the 
resulting spectra as a sum of a small orthogonal set (30) of linear combinations of the original variables. These are called 
principle components *and they describe over 95% of the variance from the mean spectrum across the data set. 
Multiple analysis of variance (MANOVA) was used an each principle component to identify the most diagnostically 
significant principle components for each experiment, Lc. those that show a significant difference in value for normal, 
dysplastic and cancerous larynx. The most significant components were plotted against one another to enable clustering 
with pathology to be visualized. 
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3. RESULTS 
3.1 Spectral Analysis 
The near infrared Raman spectra of normal laryngeal specimens showed little intra-sample variability (Figure 2). Visual 
inspection ofthe spectra show the peak shapes and positions to be repeatable, although overall spectral intensities can vary 
by 15% about the mean spectrum for each sample. The normal laryngeal spectra were dominated by several peaks shown in 
Figure 3. The Raman spectra have contributions from both proteins and nuclcic acids. Amide I (at 1654 cur and amide III 
(at 1244-1262 caf) bands originate from vibrations in the peptidc modes of the proteins and reflect the secondary structure 
of the proteins, their arrangement in three dimensions (a-helix, P-pleated sheet, P-turn or random coil structure). The 
position of these two peaks indicated that the majority of proteins in the normal larynx are in the cc-hel ix conformation' 1. 
The intense peak at 1336 cm"can be attributed to both collagen and nucleic acids (DNA) and more specifically to the purine 
bases guanine and adenine'2. 
600 
Counts / Raman Shift (cm4) 
Normal larynx spectra from one biopsy SOmPlO 
Mean spectrum in bold 
Figure 2. Spectra from one sample ornormall brynx, showing the intra-suWlc variation. The mean spectrum is in bold. 
Figure 4 shows the near infrared Raman spectra obtained Erom normal, dysplastic and maligriant (squamous celi carcinoma) 
laryngeal specimens. For all neoplastic laryngeal specimens the overall intensity levels of the spectra art less than that for 
the normal larynx and that for dysplastic tissue is usually intermediate. The relative intensities of the nucleic acid (DNA) / 
collagen mode at 1336 crzfl and the amide III mode at 1250 crrfl was used as a diagnostic parameter to differentiate 
neoplastic lesions from normal samples. in the majority ofmalignant spectra the intensity ratio was greater with respect to 
the normal samples (Fig. 4 and Table 1), indicating increased coilagen levels and/or cellular nuclear content in squamous 
cell carcinoma compared with that of normal laryngeal tissue. This is in agreement with the histological method of grading 
malignancy by the nucleic acid to cytoplasmatic Mtio13. in dysplastic; specimens this relative intensity ratio was between 
those of normal and malignant samples (Fig. 4 and Table 1). 
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Counts I Raman Shit (cm-1) 
Mean normal larynx spectrum korn tweKe biopsy samples (10 patients). 
Figure 3! Mean normal larynx spectrum with peak positions labeled. 
Counts I Raman Sluft (Cm-1) 
Companson of mean larynx spectra tom each pathology. 
N- normal larynx, D- dysplastic larynx, rý squamous call carcinoma of the larynx. 
Figure 4. Comparison ofmcan spectra from normaL dysplastic: and squamous cell carcinoma of the larynx. 
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Pathology No. of spectra Sum of 
Peak Ratios 
Mean Ratio of Peak 
Intensities 
Variance 
Nonnal 93 120.050 1.291 0.087 
Dysplasia 29 38.189 1.317 0.118 
Carcinoma 31 46.556 1.502 0.067 
Yable 1: summary of peak ratio analysis on raw larynx spectra 
3.11 Significance of peak ratio method of analysis 
Using multiple analysis of variance (MANOVA) to test the statistical significance of the empirical method of peak ratio 
analysis resulted in values: 17-5.90, F_j-3.06 and p-0.0034. Therefore using the intensity peak ratios at 1336 and 1250 cmi" 
the set of spectra separate into different groups with pathology with greater than 99% significance. 
31 Multivariate Analysis ofSpectra 
Multiple analysis of variance (MANOVA) was used on each principle component to identify the most diagnostically 
significant principle components for each experimen4 Le. those that show a significant difference in value for normaL 
dysplastic and cancerous larynx. These data are displayed in Table 2. ne retained components exhibit a difference with 
pathology to a 95% significance level or above. The F-value is calculated from the sum ofthe squares ofthe variance ofthe 
mean principle component value between and within pathology groups. The larger the F-value the greater the effective 
grouping with pathology. Fk is the cut-off value for 95% significance. The p-value is the probability that the principle 
components for all pathologies are statistically the same, i. e. that they do not correlate with histopathology ofthe sample. 
(a) No pre-processing. 
Principle Component 18 10 12 
F-valuc 4A6 
13* 
14 5.99 5.07 
P-Výlue 0.013 0.046 0.003 0.007 
(b) Savitsky-Golay I' derivative-using a 7-potnt filter. 
Principle Component 3 4 5 1 0 
F-value 10.86 
1 I 
366 * 112 3 1 2 
p-value 3.9xlO-' 0. 028 3 2.9xlO7 0.047 
(c) Savitsky-Golay I" derivative using a 21- intfilter. 
Principle Component 3 4 5 13 
IF-value 10.16 
1 I 
5.98 6.38 4.25 
p-value 7.3x 04 0.003 0.002 0.016 
(d) Savitsky-Golay 2ýd derivative using a 7-point filter. 
Principle Component 3 3 1 
F-value 3. 07 
1 
46 5 
P-value 0.05 0.005 
13 14 
3.863 918 
0.023 
1 
0.00016 
Tables 2(a) to 2(d) show the principle components displaying diagnostic signillcance and their comesponding MANOVA coefficients. 
Faft-3.056 is the value offfor greaterthan 95%significance that the pathological groups are diflerent. 
The principle components describing the data set pre-processed using the Savitsky-Golay 7-point I" derivative function 
were shown to be the most diagnostically significant. A two-dimensional plot of two diagnostically significant principle 
components from this data set is presented in Figure 5. 
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Figure 5 2D plot of diagnostically significant principle components derived from Larynx spectra acquired at 930nnL 
4. DISCUSSIONS 
Currently, histopathology is the gold swulaird of tissue diagnosis. However. histopathology requires tissue removal and it 
cannot provide immediate diagnostic feedback. while the accuracy of diagnosis can be limited by factors related to random 
sampling and handling of tissue. Furthermore, evaluation is based primarily on morphology rather than biochemistry. 
71creforc; the development of a non-invasive method of histocliemical analysis with immediate diagnostic feedback, thus 
enabling detection of early dysplastic changes at the cellular level will be of great importance. Raman spectroscopy seems 
to hold a grew deal of promise as it provides quantitative information about the biochemical (histochemical) differences 
between normal and neoplastic tissues. Most biological molecules arc Rantan-activc; leading to distinctive spectral 
signatures (biochemical fingerprints) that represent a true form of optical histochemistry'i. Suitable molecules for the study 
of neoplasia, as measured by Raman spectrospcopy, include proteins (hormones. oncofetall antigens, isocnzymcs, 
inuminoglobulins, carbohydrate antigcnsý kaittins), nucleic acids (DNA. RNA). nucleosomes and cell mcnibranesi. Indeed. 
recent studies have confirmed the feasibility of Raman spectroscopy for in vitro diagnosis of malignar%cy in skin, brain, 
breast. colon and cavix""'. Iliese studies relied on changes in relative protcin-to-lipid content (breast. cervix) or changes 
in protein structure and hydrogen bonding of proteins and nucleic acids (skin, colon). 
The present study is the first to demonstrate the spectral differences between normal and abnormal laryngeal tissue. Peak 
ratio analysis showed a significant difference between Raman spectm of normal, pre-mlignant and malivmt larynx. A 
possible diagnostic algorithm could be based on the relative intensities of two peaks, the nuckic acid (DNA) mode at 1336 
cm" and the amide III mode at WO crin". Our findings suggest that the relative intensity of the DNA mode and the amide 
III mode increases with progression to malignancy, indicating increased cellular nuclear content in pm-canccrous-cancerous 
lesions. compared with that of normal laryngeal tissue. Based on our current understanding of the molecular origin of these 
Raman bands, our findings raise the possibility of changes in protein secondary structures (from a-helix to random coil 
conformation) and in C-H stretching bonds in nuclcic acid bases. However, the present sample set from 19 patients is not 
large enough for a proper cross-validation study. We are currently gathering more data to increase the size of our database 
in order to enable both cross-validation and more importantly, prospective analysis. 
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Empirical methods have been employed in the literature to evaluate variations in the spectra with tissue pathologies. of 
course this is a very simple method and results obtained are easy to intcTpreL I lowever, the disadvantage is that only a tiny 
part of the histochemical data from the tissue is used for analysis. To take into account all the complexities of biological 
tissue a method incorporating as much ofthe data as possible in the analysis is likely to prove more rigorous at separating 
spectra with pathology. Principle component analysis was used in this study to reduce the data into a set of orthogonal linear 
combinations that describes the spectral variation from the mean. A statistical examination of the results show that using a 
7-point Stivitsky-Golay I' derivative function to pre-process the data set provides the most diagnostically significant set of 
principle components. The probability of the spectra, from different pathologies, being from statistically the same group is 
as low as 0.000029 for component number 5. Ibis is of the order of a hundred times less than that achieved by peak ratio 
analysis alone (11-0.0034). Principle components 3 and 5 were selected as two diagnostically significant components (Table 
2(b)) and plotted against each an example ofthe separation obtained with the current set oflarynx spectra. 
'Me principle component analysis method has been tested using MANOVA and has shown diagnostic significance by 
grouping PCs with pathology. However with only small numbers of samples, outliers can have a greater affect on results. 
Thcreforc it is proposed that this study is continued to include greater sample numbers for each pathology. It may then be 
possible to separate individual sub-groups of dysplasia. Further work will involve building and optimising sort algorithms 
and spectral libraries and development ofan in vivo Raman probe. This opens the real possibility ofearly cancer diagnosis, 
with a corresponding increased chance of cure by allowing assessment of adequacy of resection margins and directed or 
guided biopsies. This will be particularly useful in dysplasia and early glottic cancer where the repeated diagnostic biopsy 
procedures increase the risk of affecting the quality of voice. In addition, this 'real-time" diagnosis may also mean that 
second procedures could be avoided, thus reducing cost. 
ne majority of Raman studies have been performed on excised samples. However, as vadations in Raman spectra between 
fixed and fresh tissues appeared to be mialmal'9, in vitro measurements should not affect the potential diagnostic capability 
ofNear infrared Raman spectroscopy. So far successful in vivo applications have been confined to some exposed tissue 
areas sucli as in the eye"ý the nail", the artery, the skin and deeper tissues in animal modelel. 71ic most significant problem 
has been the signal generated by the fibres of the optic probes used (luminescence and Raman)P4'. The signal is 
proportional to the length of the fiben and to the excitation light intensity and can have magnitudes equal to and sometimes 
greater than that ofthe examined sample. However, new fiber optic probes are being designed to deliver and collect signal 
more efficiently in order to enable routine in vivo measurements. 
Although the spectral differences between normal and abnormal laryngeal tissue look promising, the obtained spectra are 
complex and their exact cellular and molecular basis is not completely understood yet. We believe that futum microscopic 
and chemical studies will further clarify the molecular origins ofthese signals and will lead to the development of models 
correlating them to specific tissue changes. 
Finally it must be noted that studies involving the comparison of any new diagnostic technique with the 'gold standard' 
technique have to rely on the assumption that the 'gold standard' provides diagnosis with 100% sensitivity and specificity. 
i. e. 0% false Positives and false negatives. Ifthis assumption is not valid then errors will be introduced into these studies. 
5. CONCLUSIONS 
I ligh quality fluomsccnce-fiee Raman spectra of human laryngeal tissue can be obtained using near infrared excitation. 
Normal and neoplastic laryngeal tissues have distinct biochemical features, which can be exploited spectroscopically. 'llic 
relative DNA-to-protein content could serve as possible diagnostic algorithm for spectral identification of malignancy and 
earlier dysplastic changes. However this paper has shown that multivariate analysis techniques have the ability to group 
spectra by sample pathology. With greater sample numbers it is likely that improvements in separation will be achieved. 
Therefore, the quality ofthe structural and compositional detail, which can be revealed by NIR Raman spectroscopy seems 
to make this new diagnostic modality a very attractive noninvasive tool for early detection oflaryngcal cancer and prccancer 
and could contribute significantly to understanding the underlying mechanisms ofneoplasmatic b-dwformation. 
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ABSTRACT 
The incidence of ocsophageal and laryngeal cancer has risen over past decades. 'ne early detection of diseme is vital for 
improved prognosis. The current gold standard method of tissue diagnosis is histopathology, which is invasive, costly and 
somewhat subjective. Raman spectroscopy however has potential for the non-invasive, early, in-vivo diagnosis of the 
biochemical changes associated with malignancy. Good quality Raman spectra have been measured in vitro using oesophageal 
and laryngeal tissue. Multivariate analysis has been implemented using principal component and linear discriminant analysis 
techniques. Sensitivity and specificity of more than 80% has been achieved for the discrimination of dysplasia and cancer, for 
both oesophageal and laryngeal tissue. On comparison with histopathology these results are seen to be an improvement, since 
pathology lacks sensitivity and spccificity due to the subjective nature of the diagnosis. Thus illustrating that excellent 
discrimination between normal, dysplastic and cancerous tissue can be achieved using Raman Spectroscopy. 
Keywords: Raman, larynx, oesophagus, malignancy, diagnosis, dysplasia, cancer, spectroscopy 
LINTRODUMON 
A number of spectroscopic techniques are currently being investigated for the in vivo detection of early dysplasia and canccr. 1-2 
Near infrared (NIR) Raman spectroscopy has been used to investigate Abe early detection of dysplasia in columnar and 
squamous epithelial tissue. Raman spectroscopy provides the detailed molecular information that is required to detect neoplastic 
changes with high specificity and sensitivity. It has been applied in vitro for the detection of a number of cancers and pre- 
canccrsý and can be applied in vivo through the use of special fiber optic probcs4-5-6. Previous work has shown that cancerous 
and dysplastic tissue can be distinguished from normal tissue by Raman spectroscopy in conjunction with statistical 
classification methods 7,1. 
The incidence ofoesophageal cancerhas been risingstcadily in England and Wales since the 1960's. The incidence among men 
is average for men in Western Europe, where alcohol and tobacco consumption are the main risk factors. However women in 
England and Wales have a two to three fold higher risk than women in other European countries 9. The increase of 
adenocarcinomaorthe middle and lowerthirds ofthe oesophagus has been unexplained. The survival rate ofadults diagnosed in 
England and Wales during 1986-1990 was 23% at one year and only 7% at five years. Barrett's oesophagus, a condition in 
which the normal squamous oesophagcal epithelium becomes more columnar in type, due to acid and bile rcflux, is associated 
with the development of adenocarcinoma. It is suggested that patients with Barrett's have a fifty-fold increased risk of 
developing -ndenocarcinoma. 10 
The incidence of laryngeal cancer has progressively risen over the last 25 years, with the most significant increase being in 
women 11. In England and Wales, where it is one of the more common cancers, incidence rates have been broadly stable and 
suggest a declining risk for successive generations of men ". Laryngeal cancer has the greatest effect on quality of lire of any 
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cancer, causing devastating lifestyle changes and resulting in permanent cosmetic and psychosocial dis3bility. The 
transformation from normal tissue to squamous cell carcinoma in the lar)-nx involves an intermediate step or squamous 
dysplasia, whcrc the squamous epithclial cells mature and grow abnormally. 
The majority of oesoph3geal and laryngeal cancers originate on the surface in the epithelial layer. At present diagnosis is 
undertaken in vitro by pathological grading or tissue biopsies taken at endoscopy. The number or samples that can be 
investigated is limited. so sampling is poor. In general dysplasia cannot be vi"lly distinguished from normal tissue and once a 
tumour can be seen it may be too late to enable a full cure. In the case of laryngeal cancer repeated biopsies increase the risk or 
damage to vocal cords. Spcctroscopic detection of dysplasia carried out in vivo would be fast and non-invasive, enabling mom 
cffcctivc patient management, reduced mortality and improved prognosis. Spectroscopy could initially be used as a biopsy. 
guiding tool. enabling improved selection orbicipsics, ultimately replacing the need for the excision of tissue biopsies. 
The aim of this work was to develop the use of Raman spectroscopy in conjunction with multivariatc statistical analysis for the 
early detection ofdysplasia In oesophageal and laryr4cal tissues. 
2. MATERIAIS AND bILTIIODS 
2.1 Tissue S2MPICS 
41 homogeneous samples, from 7 patients with both low acd high-grade dysplasi3, were used for the ocsophagus study. The 
pathologist graded them into 4 groups: IS biopsies with NormA epithelium (NO). 13 biopsies with Barrett's epithelium (B). 5 
biopsy with Low Grade Dysplasia (LGD), and 5 biopsies with High Grade Dysplisia (IIGD). 
32 samplcsý from 28 paticrits, were classified as homogenous and retained for the larynx study. 'Mey were graded into the 
following groups: 16 normal samples (NL). 7 dysplastic samples (DL) and 9 with squairous cell carcinoma (SCC). 
Informed consent was obtained from each patient and the studies %%crc approved by the United Kingdom South and West Local 
Research Ethics Committee. 
2.2 Tissue preparation 
Biopsy samples were collected during routine surgical procedures and map frozen in liquid nitrogen. rrozen sections were cut 
using 3 frcczin_z-tnicrotomc and the remaining biopsy b"- was stored at - 85*C until spectroscopic studies were carried out. 
The frozen sections were st3incd, with H3. -mitoxylin and Losin. for histopathologic3i diagnosis by a consultant pathologist. 
Only homogenous samples with a clearly defined pathological diagnosis were used in this study. 
2.3 Instrumentation 
Oesophagus spectra %ere measured with a home built M spearoincter. with an Argon ion pumped Ti: Sapphire laser (950 nm) 
and liquid nitrogen cooled deep depiction CCD. Tle laryngeal biopsy samples were measured using a Rcnishaw System 1000 
Raman micro-spccirornmr. with in argon ion pumped Ti: Sapphire laser (830 nnt) and a peltier cooled CCD detection system. 
Raman spectra were taken from between 4 and 20 different locations (about 100 prn apart) on the cpithcl; al side of the biopsies. 
All spectra %ere measured with a collection time of 30 seconds. oýcr a spectral range of 400- 1800 cm" with respect to the 
excitation frequency. In this wavelength region. the absorption coefficients of %hmtcr and tissue pigments are small and the 
effective penetration depth is large, typically a few mm. There was little contribution to the Raman signal from fluorescence. 
2.4 Spectral analysis 
Spectra which were seen to have an abnormally large fluorescence background or extremely poor signal to noise ratio were 
excluded from the modcl. All the remaining spectra were used as a training d3t&StL These spcam were corrected for the 
wavelength dependent sensitivity of the R=3n system. mean centered and a prc-processing filter applied. either none a 
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Savitsky-Golay I" derivative, or a Savitsky-Golay 2" derivative. MUlfivariate analysis techniques were implemented using 
principal component analysis (PCA) and linear discriminant analysis (LDA). PCA was performed using the Galactic 
GRAMS/32 PLSAQ software suite on the measured spectra. This orthogonalises and reduces the number of parameters required 
to represent the variance in the spectral dataset. Twcnty-five Principal Components (PCs) that describe over 99% of the 
variance from the mean spectrum across the data set were calculated. Multiple analysis ofvariance (MANOVA) was used on 
each principle component to identify the most diagnostically significant principle components from each model, those that show 
a significant difference in value for normal, dysplastic: and cancerous tissue. The most significant components were plotted 
against one another to enable clustering with pathology to be visualized. The twenty-five PCs were used as input for an LDA 
model. created in SPSS, which maximiscs the variation between groups while minimising the variation within groups. The 
sensitivity and specificity of the generated models was calculated for comparison. 
3. RESULTS 
3.1 Oesophagus 
Initially a four-pathology group model was investigated, the samples being classified into the following pathology groups; 
normal squamous, intestinal metaplasia. cardiac Barrett's and dysplasia. No prc-proccssing filter was used on the spectra after 
correction for the measurement sct-up. Cross validation was used in the PCA and a prior probability of all groups equal, using 
the covariancc matrix within groups gave the best results from the LDA. 
Two of the discriminant functions from the LDA model are plotted in Figure 1, which illustrates the separation of the spectra 
with pathology. 
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Figure 1. Discriminant scores from oesophagus LIDA model. 
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A breakdown or these results can be seen in Table I a, with the numbers of predicted cases in each group and the percentages 
both being displayed. Table Ib shows the sensitivity and specificity of this model for the correct diagnosis of that pathology 
group. 
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Pathology PrtdictedGroup, embenhip 
Normal Intestinal Cardiac Dysplasix Total 
Oesophaj: us Mclaplasia Barrett's 
Normal Oc3oph3gus 186 0 2 2 190 
Intestinal NlCt2ptASi2 3 17 0 0 20 
Cardiac Barrett's 3 0 54 3 60 
Dysplas12 7 0 is 88 110 
Normal Ocsophagus 97.4 05 1.1 1.1 100 
Intestinal hIctaplAsia 15.0 851 0 0.0 0.0 100 
Cardiac Barrett's 5.0 00 9(LO 5.0 100 
Dvsplasla 9.1 09 15.3 1 74.5 1 too 
90.9 % ot onpital Crouped casts -A ere cortecuy ciassiz tea usingints memoa. 
Table Ia. Classirication results of the four-patholocy Croup model for the mophacus. 
No "I Intestinal Cardiac Dysplai 
Otso: 
mh. 
i us h1timplasim, Darrell's 
ý5En,!! Lvl y 85% 9056 9 92% INA; 95% 
Table I b. Sensitivlty and speciricity of the rour-psthology group model forth e ocsophacus. 
A rivc-pathology group model %as then doclopcd with the d)-splasia samples being classified inio t"o groups, low & high- 
grade dysplasia. A brcakdo%%n ofthe rtsulu can be seen in Table 2a. wid the sensitivity JL specificity in Table 2b. 
Pathology Predicted roup blem rship 
Normal Intestinal Cardiac Low Iligh Total 
Oesophatus Mclaplasis Barrett's Grade Grade 
]USDISSIS D%Splasia 
Normal Ocsophagus 174 1 1 9 5 190 
Intestinal Slet2plasis 1 19 0 0 0 20 
Cardiac B2rrclt's 3 0 53 3 2 60 
Low Grade DyspIa%i2 0 0 0 1 30 
Iligh Grade D)splxsl3 01 0 1 13 Is 49 so 
Normal Ocsoph2gus 91.6 0.5 0.5 4.7 2.6 100 
Intestinal NIctsplAsia 5.0 95.0 0.0 0.0 0.0 too 
Cardiac Barrett's 3.3 0.0 98.3 
1 
5.0 3.3 IDO 
Low Grade DysplasI3 0.0 0.0 0.0 96.7 3.3 100 
Ilit! h Grade Dýspla b 
_ 
0.0 0.0 16.3 22.5 61.3 100 
953%ofongirul groUped Cases A ere COrrCCUY CLUSUICU UsIng MIS MCUIOU. 
Table 2a. CIASSIIIAC300n results of the fivegroup model ror the otsophaps. 
Normal 
Ocsophacus 
Intestinal 
hICt2plS%i3 
Ca rd i, 2 
Bar c t! s 
w( ýra "Displasiae , ra de ir, Ir I1Dj1%p13xs1a 
Sensitivitv 92% 95 It U 2 Z1 lu t ý 
Speciricity 97% -0 5 
; 1 'K 7 % 
Table 2b. Sens Itivity and speciricily or the five-group model for the ocsophagus. 
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3.2 Larynx 
'Me larynx provides a simplcr model than the ocsophagus in that there are only three pathology groups for classification, 
normal, dysplasia and cancerous. Itshouldbe noted that this group oflarynx spectra were acquired with a range oftneasurement 
parameters. These included one and three pixel binning and variable power levels. Spectra were shift corrected, by alignment of 
all phcnylalanine peaks at 1002 cm". and smoothed using a 2d order Savitsky-Golay filter. A I' order Savitsky-Golay 
derivative pre-proccssing filter was used on the spectra. Self-prediction was used in the PCA and a prior probability of all 
groups equal, using the covasiance matrix with separate groups gave the best results from the LIDA. Two of the discriminant 
functions from the LDA model are plotted in Figure 2, which illustrates the separation ofthe spectra with pithology. 
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Figure 2. Discriminant scores from larynx LDA model. 
A breakdown of these results can be seen in Table 3a, with the numbers of predicted cases in each group and the percentages 
both being displayed. Table 3b shows the sensitivity and specificity of this model for the correct diagnosis of that pathology 
group. 
Pathology Predl ted Group Members lp 
Normal Larynx Dysplasia Cancerous Total 
Normal Larynx 96 4 12 112 
Dysplasia 1 30 2 33 
Cancerous 4 5 45 54 
Normal Larynx 85.7 3.6 10.7 100 
Dysplasla 3.0 90.9 6.1 100 
Cancerous 1 7.4 9.3 83.3 100 
85.9 % oforiginal grouped cases were correctly classified using this method. 
Table 3a. Classification results of the larynx model. 
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Normal Dysplasia Cancerous 
Larynx 
Sensitivity 86% 91% E-83% 
Specificity 94% 95% 1 90% 
Table 3b. Sensitivity and specificity or the larynx model. 
4. DISCUSSION 
Near infrared Raman spectra with good signal to noise ratio and little fluorescence have been measured with oesophageal and 
laryngeal tissue, with little intra-sample variability seen in the measured spectra. Normal and neoplastic tissues have distinct 
biochemical features. which can be mcasured with Raman spectroscopy and analysed using statistical models. Multivariate 
analysis techniques have been shown to group the spectra by sample pathology with high sensitivity and specificity in vitro. 
The statistical models are being developed to enable the early detection of dysplasia, therefore as few false negatives as possible 
for this group in particular arc required, i. e. as high a sensitivity as possible. The fOUT-pathology group ocsophagus model 
correctly classifies over 90% of the spectra, combined with 80% sensitivity for the classification of dysplasia. Development of 
this model into the five-group model, may at first seem disappointing, with 85% of spectra being correctly classified. In 
particular the classification ofhigh-grade dysplasia in the fivc-group model is lacking at 61%. However, on close inspection of 
the classification results, in Table 2a, it is seen that many of the high-gradc dysplasia samples are misclassified as low-grade 
dysplasia. The statistical model %ill only be as good as the data it is built with, the spectra and the pathological diagnosis. We 
rely on the assumption that histopathology, as the gold standard method for tissue diagnosis, provides diagnosis with 100% 
sensitivity and specificity. However, pathological diagnosis is rccognised as being somewhat subjective, especially when 
grading dysplasia, which may account for the misclassifications in this model"- ". iiistopathology is limited in other respects in 
that it is invasive, involves the random sampling of tissue, is costly and perhaps most importantly is based on morphological 
rather than biochemical analysis. The classification results obtained with the larynx model also gave good separation of the 
spectra with pathology, with more than 85% of the spectra being correctly classified. Dysplasia and cancer were correctly 
classified with a sensitivity of91 and 83% respectively. it should be noted that the data collection parameters used with this data 
set were non-uniform. 
The models developed in this work used a limited number of spectra. It is expected that the separation of the spectra will be 
improved with greater sample numbers. However these results continue to show that Raman spectroscopy has much potential 
for the early diagnosis ofmalignant change in the development ofboth oesophageal and laryngeal cancer. 
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SUMMARY 
Photodynamic therapy involves the activation of an 
exogcncously administered. or an endogenously gen- 
crated. photoscasitizcr with fight to produce localized 
tissue destruction. It is an attractive. predominantly 
cndosopic technique forthe palliation of advanced upper 
gastrointestinal cancer and the eradication of early 
neoplastic and prL-neoplastic lesions. The nature or the 
biological responsc allowing safe healing and the 
exploitation of tissue threshold effects mean that 
adjacent tissue damage can be minimized. 
This review used a database of 368 papers. The nature 
of the photoscnsitizer is critical to the depth of tissue 
damage and the risk of adjacent tissue damage and 
stricture formation. The gcncrution of protoporphyrin 
IX following administration of 5-amlnolaevulinle acid 
has proved useful for the treatment of hIgh-gradc 
dysplasla In Barrett's ocsophagus. A double-blind 
randomized placebo controlled trial has conlirmed that 
It is a safe and effective method for the ablation of low- 
grade dysplasia. The treatment of more advanced 
lesions requires cxogcncously administered photo- 
sensitizers. flowcvcr. recent data Indicate that the 
neoplastic potential remains in some patients mod 
continued follow-up is necessary. 
Photodynamic therapy can be used to eradicate early 
neopIdsla and palliate advanced cancer. but caution is 
required before a definitive cure can be claimed. 
PHOTORIOLOGY: THE PRINCIPLES 
OF PHOTODYNAMIC THERAPY 
Photobiology Is the basis of our survival on this planet. 
Without photosynthesis and the gencration of oxidants 
and organic carbon (CI120) It Is dffxWt to see how 
complex life could have developed. ' Ught is the 
necessary agent for the generation of these essential 
molecules. Ilowcvcr. once oxygenic photosynthesis 
occurs, the organism is in u highly precarious state 
because a mechanism of protection from toxic highly 
reactive oxygen is vital. In plants photosynthesis occurs 
In highly specialized organelles. the chloroplasts. Ught 
Q)rrrsvýulmay tx Projenor H. Barr. Craqfdf PosigrAdutz Medxd 
Mimi In rLmwtstmhJre. Glomysurshirc Roval HaviLal. Great Mum 
Roa& GI. -Sler GLI JN. V. VK 
E. wl pm1. Mrj4thmwdmuk 
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is essential for their blogenesis and allows the Iniporta- 
tlon of protective oxygen quenching proteins. ' 
These Ilght activated photosynthetic mechanisms are 
catalysed by molecules (photosensitizLrs/chloropliyl6) 
within these complex photosystems. 1 The sudden and 
massive cellular destruction associated with autumnal 
senescence Is associated with a loss of protection to 
generated toxic oxygen species and Is an example of 
massive oxygenic photodestruction. Therapeutic cxplol- 
tation of these basic biological mechanisms Is the basis 
for the targeted photodestruction of photodynamlc 
therapy. 
Eukaryotic organisms, as large complex multicellular 
organisms. have a high degree of metabolic spccializa- 
tion. requiring oxygen for respiration and organic 
carbon as a fuel. The use of oxygen remains a paradox, 
because aMough necessary for life, it is reactive. 
potentially toxic and lethal to the cell. The gcnerdtion 
A5-53 
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of ruactive oxygen species is tin Initiator of apoptosts and 
Is partly responsible for bcncsccnce. It appears that the 
defining moment for eukaryotic cells to overcome this 
problem occurred with the cndosymbosis of mitochon- 
dria, it chloroplast-like energy complex derived from the 
cellular Incorporation of primitive protobactcria, 
ulthough it may have arisen tit the same time its the 
cells nuclear component. ' These organcIles arc essential 
for the safe use of oxygen during oxidative phosphory- 
lation. und mammalian survival. They are the cells' 
energy complex and manufacture all the necessary 
molecules for safe oxygen clcctron transfcr. similar to 
those in the chloroplast. 5* " These molecules are por- 
phyrins. and are necessary for cytochromc and bacin 
synthe-Nis. but tire natural endogeneous photosensitizers 
(Figure 1), able to absorb light and generate toxic 
oxygen species under certain circumstances (Figure 2). 
Mammalian cells have protective mechanisms against 
toxic oxygen damage, similar to that of the chloroplast. 
Cell death will only occur if a critical threshold of toxic 
oxygen sr"Ics Is reached and the protective mecha- 
nisms associated with the niltochondria are over- 
whclmcd. ' Metabolic disorders that lead to an excessive 
accumulation of the cndogencous porphyrin photosen- 
sitizers can result In extreme cutaneous sensitivity to 
light. This Is most evident In patients with acute 
Intermittent porphyria who are deficient in porphobflt- 
nogcn dcaminase. ' The therapeutic light activation of 
administered (exogeneous) or an endogeneously gen- 
crated photosensitizcr to destroy tissue is the basis of 
photodynamic therapy. The mechanism of cell death 
Is by the generation or toxic oxygen species to 
overwhelm the cellular defence muchanisms. This 
technique has obvious attractions for the Gastroenter- 
ologist and Gastrointestinal Surgeon. who%, - trade is to 
Illuminate and treat the dark regions of the gastroin- 
testinal tract. 
HISTORY OF CLINICAL PHOTODYNAMIC THERAPY 
The discovery that an administered substance could 
cause photosensitivity Is attributed to Oscar Raab. In 
the winter of 1887-1898. Professor von Tappeincr set 
his student Raab tostudy the toxicity of aniline dyes on 
paramecia. Raab recognized that the time to kill was 
related to the intensity of light In the laboratory. Von 
Tappeincr examined many other substances. Including 
chlorophyll, and called the phenomenon 'photodynamic 
action/photodynamische Erschelnung'. Ile dcrnonstra- 
ted that a photosensitizer. light and molecular oxygen 
were necessary. 7 He also suggested that turnourn could 
be treated and some early clinical results were reported 
in 19os. 8 
There were sporadic reports of photodynamic therapy, 
but Dr T. J. Dougherty established the modern era at the 
Division of Radiation Biology at Roswell Park Memorial 
Institute. Buffalo, USA. He reported that a systemically 
injected porphyrin (haematoporphyrin), when activated 
by red fight. caused complete eradication of transplan- 
ted experimental turnours. Ile also demonstrated the 
preferential accumulation of the photosensitizer in 
malignant tissue. 9 Endoscopists were quick to see the 
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Figure 1' The mochanism for the gcncra- 
Porphobilinogen tion of protoporphyrin IX following the de&MIIIASC 
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excess administration of 5 aminolaevulinic 
acid. 
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Figure 2. DiaWHnj to ilhLqrjlc the nuxhý- 
Lmn for the generation ofilnglet oxygen. the 
tt)xk* Photoproduct that Is the necessary for 
phouxlyminile therapy. Photoscrisitiser Ground state 
potential of photodynamic therapy for the treauncnt of 
cancens accessibIc to the endoscope. A patient at the 
Totyo Medical College with a small upper bronchial 
squamous cell tumour. treated In 1980 at bronchosopy 
with photodynaLnic therapy using a laser as the light 
source. had the tumour completely erddicated. "' Large 
obstructing m-wiphageal cancers were similarly treated 
with photodyniunic therapy with good relief of dyspha- 
giu and possib[c prolongation of survival. " 
BIOLOGY AND PHOTOPHYSICS 
OF PHOTODYNAMIC THERAPY 
The production of local tissue destruction after gener- 
ating or administering a photoscnsltizcr with the direct 
application of light fonns; the basis of photodynamic 
therapy. The most commonly used method of pbotody- 
nunfli: therapy I-; to administer it photosensitizer, 
usually Intrat, crioubly. and allow retention In the tissue 
for 48 It prior to irradiation with appropriate wave- 
length light. usually firom a laser. The exogenously 
administered photosensitizers tend to accumuldte In 
tuniour stromd and in the submucosal layer of the 
gastrointmfinal tract. This may be or little relevance If 
all the mucosa above is destroyed but does risk deeper 
damage. 
The problem of targaing the plioU)sLnsltizcr to the 
mucosa. and avoiding systemic photo. %crisitization may 
be overcome by using endogenous photosensitization. 
The metabolic activity of the mucosal cells. which have 
a rapid turnover. accumulate the endogeneotts photo- 
hensitizer to it greater degree than the underlying 
stroma. The generated photoscrultizer tends, to stay 
within the cells to whose m1lochondria It wmsynthm- 
IzeO The mechanism Is shown In Figure 1. Following 
an cxcess administration of 5-aminolaevuhnic acid 
(5-AIA). a precursor of Wein. an Intracellular accu- 
mutation of the photosensitizer protoporphyrin IX 
(PpIX) is Induced. The synthesis of S-ALA from glycine 
and succinyl-CoA is the first step In porphyrin blosyn- 
thesis and ultimately hoem. This Nthway Is tightly 
regulated by cnd-product InhIbItIon. If excess cndoge- 
neous 5-ALA is administered then this regulation Is 
bypassed and an intraccIlular accumulation of the 
photo.,; cnsiUzcr protoporphyrin IX IVpIX) is Induced. 
The level of photoscnsitization Is minimized to a 
few hours and the S-AIA can be administered orully. 
The photmcnsitIzer is activated In tissue using 
633-635 run laser light from an appropriate light 
source. such as aM pumped dye laser. The choice 
of photoscnsltlzcr Is crucial to achieve the depth of 
necrosis that Is required 
It Is important to examine the components of therapy 
and understand the photophysIcs (Figure 2) prior to 
examining the highly Important biological rmponsc. 
Each pholosensitizer has a sTccific action bpectrum. 
which Is the wavelengths of light that are absorbed to 
produce an excited electronic state. In this state the 
molecule has a higher energy and Is generally much 
more reactive. The first excited state Is normally the 
singIct and Is short lived: It may decay to Its ground 
state emitting fluorescence. This forms: the basis of laser- 
induced photosensitizer fluorescence as a method of 
cancer detection. 
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If a low dose of photosenslUzer Is given to patients with 
cancer and fluorescence is specifically excited. the 
malignant tissue can be imaged or detected using 
spcctral analysis by establishing a tumour demarcation 
function. This is calculated by dividing the photosensi- 
tizrr fluorescence by the tissues' natural autofluorcs- 
cence. For patients with oesophageal carcinoma, 
normal tissue has a fluorescence ratio of 0.1. Barrett's 
ocsophagus 0.2. dysplastic columnar-lined epithelium 
0.79 and carcinoma 0.78.1" The natural autolluorrs- 
cence occurring following Irradiation of endogenous 
photoscnsidwr/fluorphores can also be used to detect 
cancer. and forms the basis of much Instrument 
development for optical diagnosis. " 14 When the 
energy of the excited state is lost by fluorescence no 
photodynamic action occurs. However. the excited 
singlet molecule can undergo spin Inversion to a 
metastable triplet state. This has a longer lifetime and 
is usually the reactive state Involved In photodynamic 
action. Direct interaction with oxygen results In the 
generation or highly reactive sInglct oxygen. One of the 
major targets for Oils molecule are membranes. They 
become peroxldl7. ed and are iysed, resulting In cell death. 
As d6cussed previously, the cell has defences against 
oxidation and a certain threshold must be achieved for 
lethal injury to occur. The toxic photoproduct can also 
destroy the photosensitizer. a process called photode- 
gradation. Several photosensitizers are retained In 
tumours longer than In their surrounding normal 
tissues. At certain times after administration there 
exists a concentration differential of 2-3 -. I between 
the neoplastIc tissue and adjacent normal structures. 
Selective tumour destruction can be achieved If the 
photosensit1wr is admin, tered In low dosage, the 
photosLnsItIzer Is photodcgradcd by light Irradiation 
before a threshold photodynamic dose Is reached. 
However. tumours that selectively retain a higher 
concentration of photosensitscr are destroyed because 
u thrcshoia photodynamic dose is achieved and cell 
death occurs. This selective effect is restricted to very 
low dose and Is rarely clinically uscrul. 
It is noticeable that some normal tissues are very 
resistant to photodynamic therapy. This Is most appar- 
cnt In the pancreas. where the normal ceUs contain 
many mitoctiondria and are resistant to oxidative stress: 
malignant pancreatic cells arc much more sensitive to 
photodynamic therapy. Selective necrosis of tumour 
with sparing of normal pancreatic tissue can be 
dmion. %trawd In experimentally Induced tumours. " 17 
Although differential damage between normal and 
malignant tissue can be diflicult to achieve and requires 
very careful dosimetry, It Is possible to spare surround- 
Ing stromal tissues using photodynamic therapy. 
PHOTODYNAMIC THERAPY FOR ADVANCED 
UPPER GASTROINTESTINAL CANCER 
The dreadful Prognosis of oesophagcal cancer is related 
in part to the fact that It remains undetected until the 
disease Is far advanced. The patient presents with 
dysphagia and often only palliative treatment can be 
offered. The main aim of therapy is to open the 
oesopliageal lumen, allowing the patient to swallow 
until death. Endoscopic photodynamic thcrupy is only 
one option. although alternatives Including stent Inser- 
tion, NdYAG laser phototherinal therapy. thermal 
ablation and sclcrosant or cytotoxic Intruturnoural 
Injection are more frequently used. 
Various methods are used for endoscopic photody- 
namic therapy. Most groups have used various deriv- 
ativcs of haematoporphyrin and Photofrin, at a dose of 
2 mg/kg body weight. given by slow intravenous 
Injcct1on 48 h before Irradiation with laser light In the 
red at 630 nm. The light can be delivered circumferen- 
tially using cylindrical diffusing quartz fibres: the length 
of the diffuser can be varied from 2 to 7 cm to treat 
various lengths of tumour. A total light dose of 
150-300 I/cm Is required to obtain tip to 6 min dcpth 
of necrosis. The depth of necrosis Is highly dependent on 
the phoWsensitizcr uscd. The depth of necrosis using 
cxogenously administered photosensitimrs is 6 turn, 
compared to 2 min following the administration of 5 
aminolaevulinic acid to generate the photosensitizer 
protoporphyrin IX. 21 21.17 
Treatment times of 10-20 min are rLquircd to deliver 
the light at a non-thermal fluencc rate. It is Important to 
note that some patients may have temporary worsening 
of dysphagia caused by oedema and tumour necrosis 
prior to necrotic tissue separation. This usually resolves 
aftcr 5 days and may be associated with some blood 
loss. The duration or response is often quite prolonged, 
lasting for 10-15 weeks. This compares ftvourably 
with thermal ablation. which often requires monthly 
rc-trcatmcnts. A large and Important randomized 
comparison (236 patients) of Nd YAG laser therapy 
(108 patients) with photodynamic therapy (110 
patients) showed that both treatments were equally 
c5ective. in this study, photodynamic therapy was 
0 2001 BlackwcH Scimce Lid. Allonail Phanouiml Ther 15,311-321 
A5-56 
REVIEW: PHOTODYNAMIC TIIERAPY FOR IIIIIIII. R Ol DISCANH SIS 
Performed tlMng the photosensitizer. porfimcr sodium. 
The Improvement In dy%phagia and endoscopic tumour 
response %vas equal between the two groups. rhotody- 
nainle therapy was associated with tcrnporary photo. 
sensitivity but was easier 16 perform and associated with 
less perforations IphotodynamIc therapy 1%. Nd YAG 
lusL, r M. " Overall there appears to he no majorbcriclit 
for photodynamic therapy over photothermal therapy. 
NI(xlcm cxpdndable metal stents have become very easy 
to use andu5sociated with rclatively low morbidity. and 
are ut present the most widely used method or 
palliation. "' PhotodynamIc therapy is now considered 
it) inke a mvond4iry phice to other cndoscopic mcthods 
for the pdlhation of advanced ocsophageal cancer 
because It 6 less uvallabIc. more complicated Lind 
requires quite cxpcnsive equipment. It should be 
considered for high oesophageat turnours. and for 
. salvaize therapy In patients whose steMs have failed 
due it) migration. overgrowth or In-growth. Because 
photodynamic therapy is non-thermal. there Is no risk 
or damaging the stcnL11) 
PIIOTODYNA1611C THERAPY FOR EARLY UPPER 
GASTROINTESTINAL CANCER 
There has been a renewed Interest In cndoscopic: 
therapy for early gastrointestinal cancer bInce the 
utiventofprogrummes that have detected pre-malignant 
and early neoplastic changes confined to the mucosa. or 
with early Invasion uf the Idirana prcpria and submu- 
cosa. Radical surgical excision with the associated 
pniround morbidity and indeed mortality Is often a 
dialcult dilemma for clinician and patient ahke. These 
patients are often asymptomatlc. and radical 1ntcrvcn- 
tion Is limited by co-morbldity. 
SQIIA%IOITS CELL CARCINOMA 
Pdtients who have had a previous squamous cell 
carcinoma in the head and neck or the upper acro- 
digestive tract are at increased risk or developing a 
second cancer. Screening of those populations Is 
resulting In an Increased detection or early turnoum 
As many ws 15-20% of patients develop a second 
cancer. -I, The first treatment of early squamous cancers 
In the Far Etst was very successful. with 12 out of 13 
patients treated showing no detected recurrence after 
21-32 months follow-up., 15 The only complication was 
skin photoscusitizution. 
Subsequently. other Invoitigators. have confirmed the 
effectiveness or photodynuiulc therapy [or cairly 
ocsophagcal cancer (Table 2). In particular. u very 
important retrospective series Indicaud that long-term 
survival was possible after photodyntintic therapy using 
bacniatoporphyrin derivative und luscr light (610 not) 
for carly %quutnous and adenocurcinoina., 1' The 
pdtients were unsultiable for radical surgical resection 
and were staged using ctuloscople ultrasound its uTI or 
M. The 5-ycar canecrsficcific survival wits 74%. but 
was assocla" with u high incidence of oesophugeal 
stricture formation (4) out of 123 patients). The 
survival wits not Influenced by combination treatment 
with chemotherapy and rudiotherapy. 
There appears to be little difference between Pholofriti 
(rcldtcd to hacmatoporphyrin derivalive) and the 
newer photosensitizer tetra(in-hydrzyphcrtyll chlorin 
ImTHPC). Following treatment with 11hotoffin. 14 out 
or 17 patients with carly cancer had u complete 
response. whereas 12 out of 14 pjUcnts treated with 
niTIlPC had the tumour crudicated. -l" arill't- I., it very 
potent photosciisitizer that can be udministeret. 1 in lower 
dosage and requires shorter Imullation thnes. The 
serious complication rate of ot: ropliageal stricture und 
oesophagotraclical Estuld is or concern. A method of 
limiting the depth ofdaunugc Is possible by changing the 
photosensither to the endogencously gencrated proLo- 
porphyrin IX after the oral administration of S-ALN 
(Figure 1). The depth or damage or 2 min is Insufficient 
to ensure Invasive cancer crudicatlon. -" 
An alternative strategy is to limit the light penetration 
of the tissue by changing the wavelength of the 
activating light. A comparison urthe more u. %uaiiy used 
red (630nm) and green (517nm) laser light for 
Photofrin photntlynantic thcrupy has been performed 
In nine patients with early squamous cell carcinoma. "' 
Green light %vill not penetrate tissue to the saine depth 
its the more usually used red livcr light. The results 
showed that green light was as effective In the 
eradication of In situ and Intramucosal squamous cell 
carcinoma us red. The complete response rate was no 
different: some patients had oesophagcal resection 
6-36 months after photodynamic therapy. If the oaso- 
phagus had been treated using red light. there was 
trans-mural fibrosis with mar ll thinning of the wall. 
Crcca light produced only superfichil librous scarring. 
The use of green light with the photoscnslUzer mTlll'C 
may reduce the rate of serious adverse events. "' Of 19 
paticrits with early squamous tumours tnuited with red 
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light and mITIPC photodynamic therapy. there were 
three complications: two possible perforations and one 
patient developed a tracheocophagcal fistula. One 
pdtlent with a Tlb tuntour developed a recurrence 
4 months after treatment. The use of green light with 
mTHPC photodynan-dc therapy was as effective but 
there were no serious complications. J. ) 
PHOTODYNAMIC THERAPY FOR BARRETT'S 
OESOPIIAGUS AND CANCER 
Adenocarcinoma of the lower ocsophagus and the 
gastro-ocsophageal junction Is at present reaching 
epidemic proportions In the West. The rate of rise Is 
now greatmt, In the IJK. ThIs is strongly associated with 
Barrett's or columnar lined oLsophagus. Currently. 
udenocarcinoma In Barrett's oesophagus has an inci- 
denci: of 800 per 100 000. This can be compared with 
lung cancer In men over 65 years. where the incidence 
is 500 per 100 000. Cancer Incidence may be expressed 
as a percentage of it particular population developing 
cancer per year. For adults with Barrett's oesophagus 
the annual rate Is 0.8%. "' Carcinogenesis In Barrett's 
oesopliagus Is thought to foHow a sequence from 
Intestinal metaplasla through low- and high-grade 
dysplasia and finally to Invasivc cancer. The presence 
oftlysphisla Is regarded its the best marker for malignant 
transformation In the epithelium. Dysplasla Is classified 
h6tologically Into low. and high-griule, with Indefinite 
used when dysplasla cannot be clearly differcritiated 
from the reactive or regenerative changes associated 
with Inflammation. This classification Is at modification 
of histoputhological classifications used In the rest of the 
gastrointestinal tract most notably for colonic dysplasia 
associated with inflammatory bowel disease. " High- 
grade dysplasia may be a marker for coexistent cancer 
and it Is important that this 1% excluded prior to 
consideration of photodynamic ffierupy. " " 
in order to eradicate dysplasla and Barrett's metapla- 
sia. certain parameters must be understood toallow safe 
destruction and safe healing. There is one highly 
Informative study which demonstrates that columnar- 
lined epithelium is minimally thicker (0.5 nim. range 
0.39-0.59 rum) than normal squamous mucosa 
(0.49 trun, range 0.42-0.58 mm). 12 Initial measure- 
ments of snap frozen freshly excised (X--A)Pll'. IgCUI USSUC 
using optical coherence tomography have recorded a 
depth of between 0.45 an(( 0.5 mm 11 Although this Is 
the depth of metuplastic tissue, It is impowtUnt to know 
whether dysplasta Is thicker. There are no definite data 
on this but Initial observations suggest that it is slightly 
thicker and it Is certainly optically denser. " Table I 
indicates that ALA photodynamic therapy will be 
c1lective for dysplasta and metaplasia. If invasive cancer 
Is present. and the patient Is unsuitable for alternative 
treatment. cxogenous photosensitization. is necessary to 
ensure an adequate depth of nccnx%is. 
Photodynamic therapy following endogencous photo- 
sensitization with 5-AIA has been reported for the 
treatment of high-grade dysplasla and inetaplasia In 
Barrett's oesophagus. There are extensive data on the 
uptake and distribution of photosensitizem In gastroin- 
testinal mucosa. In experimental Barrat'%-likc oesopha- 
gus. protoporphyrtn IX was generated In the epithelial 
cells whether squamous or columnar. with maximum 
levels occurring 3h after oral or Intravenous Injection. 
Eradication Follow-up Table 1. Pholudyn, unic therapy for upper 
Stage M (months) Reference gastrointestinal high-grude dysplasia and 
early canccr 
AIA treatment or' 
Dysplastic Barrett's 515 (iw) 34 Bdff. 1996"' 
oesophagus 10/10(100) 9.9 Gmncr, 1998" 
7/7 28 Ackroyd. 1999' '- 
I'Airly oesoplutgeal TI 17/22(77) 9.9 - Gossncr. 1998" 
adcnocarcinorna TI-2 0/3(0) 28 Ackroyd. 1999" 
TI-2 2/12(16) 36 Tan, 1999" 
Photorrin treatment or.. 
DySpldbtIC Barrett*s 69/87(79) 19 Overholt. 1999" 
umophigus 
&-irly ocsophagcal TI-2 107/123 (87) 6 Sibille. 1995'-' 
carcinoma TI-2 9/12(75) 19 Overholt. 1999" 
TI 26/31 (84) 24 Savory, 199836 
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The maximum photodynamic effect occurred 3-6 h 
sifter ALA udiiiinistration. " The uptake in the mucusa 
was 3.5 times greater than in the muscidarls. and them 
was little difference between oral or parcritcral admin- 
Istrullon of the 5-ALA. 11, "" These experimental studies 
have also supplied Important reasons for the mucosal 
localization of PpIX The inuscularls contains more Iron 
and has is reduced activity of one of the rate-controlling 
enzymes. porphobilinogen dearninase. Clinical studies of 
the I'pIX distribution following oral 5-ALA have 
continued the mucosal accumulation rcldtIVC to sur- 
rounding tissues. 1ft' 17 
Following the accumulation of PpIX a photodynamic 
action will only occur following Lght Irradiation. 
Initially all treatment parameters were empirically 
selceted An elegant study In an experimental model of 
Barrett's-like oesophagus has confirmed that the most 
appropriate time for light Irriddidtion Is 2-3 h after 
5-ALA administration. This time Interval appears to be 
critical to achieve mucosal destruction while sparing 
ocsopliageal runctlon. "ý 
Them have been two major clinical studies of 5-ALA 
photodynamIc therapy for the ablation of high-grade 
dysishisla (Table 1). Both have demonstrated eradica- 
tion of the dysplasia and one series demonstrated the 
successful eradication ofT1 turnaurs that were less than 
2 min in dcpth. 'h, "A prospwtivc rdndomized trial of 
the treatment of low-grade dysplusla using ALA and 
Irradiation with green light rather than the usual 
6 30-nm red light has again confirmed how effectivc this 
treatment is in reversing dysplasta/metaplasia. Healing 
proceeded with the regeneration of ncosquamous 
epithelium. 19.711 
The healing of the treated epithelium and the prcvcn- 
Ilon of cancer is vitally Important. Nco-squamous 
epithelium wits restored In 70% of patients. with 
eradication of dysplasia and Intestinal metaplasla. 
However. In 10% the nex)-squarnous epithelium covered 
ructaplastic glands. 71 This Is similar to the results 
obtained when photothermall laser and argon plasma 
coagulator thermal therapy Is used to eradicate dys- 
plastic and metaplastic CpIthehUM. 7's- '-' In addition. 
following argon plasma coagulation. an Intramucosal 
adersocarcinuma has arisen under the neo-squanious 
cplthelium. 74 We have also recently reported a patient 
treated with photothermal laser therapy for low grade 
dysplasla who developed an adenocarcinoma. and a 
similar event has occurred in a patient treated with 
photodynainic thersipy. 7i 
It Is clear that continued surveillance is necessary for 
patients after mucosal abl. LtIon therapy. Intriguingly. 
the recently reported randomized trial using AIA and 
green light records u very low Incidence of residual and 
buried mclaplaslit. -'11 rollowing photodynamic therapy. 
hIgh-grade dysplasia can occur and debpItc, phenotypic 
change there may be persistent genetic abrionnulitles. h 
A variation or S-ALA photodynainic therapy Involves 
the direct endoscopic spraying of the agent combined 
with sodium b1carbonatc RS H 111UCOIY1IC onto dysplastic 
Barrett's ocsophugus. A period oftinic is allowed fur local 
absorption and then the area Is Irradiated with light. The 
response- following this technique wits variable. with two 
out of nine patients failing to show tiny response. "' 
The use ofcxogcncous photodynamic therapy ror early 
cancer and high-gradc dysplasia has been examined In 
some detail. The development of optical biopsy tech- 
niqum Including optical coherence tomography is 
making accurutc preopcrutive staging rgrNit)lc. Them 
arc now consistent data demonstrating the effectiveness 
of the Photufrin for the cradicallon of carly adenocar- 
cinomit arising from Barrett's oc. %ophagus. " The 
method or treatment has been adapted from the 
treatment of huge areas of Barrett's inetaplasla with 
or without hiph-grade dysplasla. Forty-eight hours after 
the administration of 2 mgtkg or Photnfrin. light from a 
laser at 610 nm is delivered at entloscopy to the 
oesophagus. A diffuser or a windowed centring balloon 
allows morc accurate and even light dosinictry. " The 
length oftlic light delivering device can be 3.5 or7 cin. 
At present It Is not recommended that more than 7 cm 
of Bd=tt's ocsophagus Is trLuted at one session. The 
power density used Is 400 m%V/cm, 1 to provide un 
energy density of 100-250 I1cmJ from the diffuser to 
the mucosa. Treatment can be perfunuct] on tin out. 
patient basis and patients must all receive acid suppres- 
slon with proton pump Inhibitor therapy. There Is now 
Increasing evidence that proton pump Inhibitor therapy 
only can Improve various paninictcrs of Barrett's 
oesophagus. The molecular evidence Is that effective 
acid suppression favours differentiation and dLcrcum: s 
prolificratlon. 7' There Is also a decrease In the length or 
the Barrett's segment with tin Increasc In the number 
of squimous islands. and u reduction In the proportion 
of sulphomucin-rich intestinal mctuplasla. 7" A random- 
ized double-blind study has confirmed that profound 
acid suppression with It proton pump Inhibitor. leading 
to elimination ofacid rcflux. Induces n partial regression 
of the columnar-lined seprient. . 10 
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Following photodynamic therapy, direct sunlight must 
be avoided for it period of 4-6 weeks. This Is clearly a 
more aggressive therapy than AlA photodynamic 
therapy: the level of damage Is; deeper and the 
burroanding tissims may be affected. Most patients 
develop small unilateral or bilateral pleural effusions. 
Occasionally the patient required it thoracentesis. 
Cutaneous photosensitivity can be a significant problem 
up to 2 months after phatosensitization. The major 
concern has been the Incidence ofocsophageal stricture. 
Approximately 30% developed significant stenosis 
which responded to endoscopic oesophageal dilatation. 
The result,; of Pliotufrin photodynamic therapy are 
very encouraging, with 75-80% ofthe Barrett's mucosa 
being converted to ncosquamous mucosa. Complete 
crialication of all inctaplastic epithelium occurred In 43 
out of 100 patients. Dysplasla disappeared In 78 out of 
100 patient-;. although II developed dysplasla during 
follow-up and required repeat treatment. Thirteen 
patients were treated for early cancer (T1-12 patients: 
T2-1 patient). and In 10 the tumour was eradicated. It 
is Important to emphasize that the patients must remain 
under surveillance and repeated treatment will be 
necessary In some to treat residual or recurrent areas 
ofdysplasia and inctaplasla. Usually the areas arc rather 
patchy and tire best treated using thermal ablation 
using at thermal laser. 41 
I'll OTODYNAAI IC THERAPY FOR GASTRIC CANCER 
The use or photodynamic therapy for the palliation of 
advanced gastric cancer appears to be of little udvant- 
age over alternative laser or thermal methods. 44 Early 
gastric cancer has a good prognosis but radical surgical 
excision carries signiticant morbidity. Local therapy of 
high-grade dysplasia and early cancer Is possible 
because there is a low probability of lymph-node 
metastases. For small cancers (< 2 cm) of type I to Ila, 
the 5-year survival Is between 80 and 9M" Eastern 
Castroenterologists and Surgeons have development 
methods of endoscopic mucosal resection, NdYAG laser 
therapy and photodynamic therapy to treat early gastric 
cancers after accurate staging with cndosonography. A 
major advantage of endoscopic mucosal resection Is the 
availability of a specimen for precise hIstopathological 
examination. However. thcrm. d and craloscopic muco- 
sal resection risks perforation and seeding tumour cells 
In the resection or thermal wound. Several first- and 
second-gencrallon photoscusitizers. Including Photo- 
frin, mTHPC and 5-ALA. have been assessed for 
photodynamic therapy of early gastric cancer. '" The 
major disadvantage of ALA Is that deep destruction is 
difficult, yet It is highly specific for the mucosa. 
Recently. niTHPC has been demonstrated to hate it 
high photodynanilc efficiency. Light Irradiation doses 
can be reduced to 10-20 I/cm. allowing the treatment 
times to be reduced. Light fluences; of 15G-300 I/cm tire 
required If Photofrin or ALA (PpIX) tire used. This is 
particularly important In the stomach. where the 
geometry Is difficult compared to that of the cylindrical 
ocsophagus. Variations In the distance betwcen light 
applicator and target can be reduced. allowing more 
precise dosimetry. Photodynamic therapy has proved to 
be effective for the treatment or type 1, flat and Ilb 
cancers, If less than 2 cin fit diameter. 
PHOTODYNAMIC THERAPY FOR BILIARY 
AND PANCREATIC CANCER 
Cholangiocarcinoma can lie a relatively indolent 
turnour. but treatment with surgery. radiotherapy and 
chemotherapy Is very difficult. Aggressive surgical 
therapy Is only POSSUe In at minority of patient% with 
early cancers, and the median survival Is between 13 
and 20 monthS. 49 Survival of patients with T3 and T4 
tumours Is limited to between 100 and 420 days. 9" A 
recent study of photodynarnic therapy In patients with 
non-rcscctable cholanglocarcinomat (type III and IV) 
who have failed endoprostlieses Insertion has proved to 
be highly informative. Twenty-two patients were pho- 
tosensitized with Phottifrin 2 days, prior to intraluminal 
light Irradiation of the obstructing tumour performed at 
cholangioscopy. There was no 30-day morLdlity and the 
median survival time was; 4 39 days and one patient Is 
alive at 73 9 days. ý 1ý ý' 
There are now some Initial data on clinical photody- 
nannic therapy for Inoperable pancreatic cancer using 
mT1IPC reported In abstract forna. "' The remarkable 
lack of serious complications associated with experi- 
mental photodynamic therapy to the pancreas has 
encouraged more detailed and clinical Investigation. 54 
Twelve patients have been treated with percutancously 
inserted optical fibres and up to 6.5 cm of necrosis has 
been induced without major morbidity. Two patients 
are still alive at 16 and 17 months, and live patient- 
have died of disease progression. There tire also data on 
the treatment of carcinoma of the Ampulla of Vater 
with good local control of the disease. " 
0 2001 Black"ll Science lAd. Allment Plumufawl Ther 15,311-121 
A5-60 
REVIEW: PHOTODYNAMIC THERAPY FOR UPPER Cl DISCASF 319 
PHOTODYNAMIC THERAPY AND INFECTIOUS 
DISEASE 
Helicobacter pylori Is associated with upper gastrolntes- 
(Inal disease and can on occasion be diMcult to 
eradicate. It is. however. very sensitive to photodynamic 
therapy. "' H. Pylorl on the surface of the gastric mucosa 
is accessible to topical photosensitizer application and to 
cndoscopic light delivery. This technique has not yet 
entered the clinical arcna. 
CONCLUSION 
rhotodynainic therapy is very exciting and conccplu- 
ally very attractivc. S7 It has yet to enter into widespread 
routine clinical practice. This Is partly because the 
technology has been expensive, In particular the lasers 
required are cumbersome and expensive. The newer 
diode lasers are smaller and much easier to use. The 
choice of photosensit1wr is abo Important and can be 
confusing. The most developed area ofchWcal use Is for 
the eradication of early neoplasia related to Barrett's 
oebophagus and previous squarnous cell cancer, It is 
likely that large areas of fleld cancerization can be 
successfully AIALd using photodynamic therapy. 
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